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Preface to ”Vitamin C in Health and Disease”
Vitamin C is a ubiquitous water-soluble electron donor in living organisms and an essential nutrient
in man. Having both specific and unspecific biological functions, it has been widely accepted as
the most important hydrophilic antioxidant but also as a specific cofactor in enzymatic reactions
or as a regulatory molecule. Far beyond the long accepted role in collagen biosynthesis, new
functions of vitamin C in human health are continually being unravelled. This improved mechanistic
understanding is starting to provide rationales explaining the extensive epidemiological literature
that, for decades, has consistently shown strong associations between poor vitamin C status in human
populations and increased morbidity and mortality.
The present volume encompasses both original research and literature reviews authored by experts
in the field. Covering a wide range of topics including the role and function of vitamin C in infection
and immunity, cardiovascular, skin and renal health, as well as cognition, neurodegeneration and
aging, this book provides a valuable update on present developments in the field of vitamin C in
health and disease.
Despite decades of scientific advances in understanding the role of vitamin C in human health, the
various global and governmental health authorities show very little consensus in their recommended
daily dietary intake of vitamin C that ranges from 40 to about 200 mg/day. One primary challenge
in determining the daily requirement for optimum health is the lack of established dose-response
relationships for vitamin C. This volume also presents emerging strategies to determine vitamin C
requirements and presents new evidence of associations between poor vitamin C status and diabetes.
Vitamin C continues to surprise and fascinate researchers around the world as we expand our
knowledge of this simple yet important carbohydrate. We hope this volume will inspire new
investigations into the ever expanding biology of vitamin C.
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Abstract: In the early literature, vitamin C deficiency was associated with pneumonia. After its
identification, a number of studies investigated the effects of vitamin C on diverse infections. A total
of 148 animal studies indicated that vitamin C may alleviate or prevent infections caused by bacteria,
viruses, and protozoa. The most extensively studied human infection is the common cold. Vitamin C
administration does not decrease the average incidence of colds in the general population, yet it
halved the number of colds in physically active people. Regularly administered vitamin C has
shortened the duration of colds, indicating a biological effect. However, the role of vitamin C in
common cold treatment is unclear. Two controlled trials found a statistically significant dose–response,
for the duration of common cold symptoms, with up to 6–8 g/day of vitamin C. Thus, the negative
findings of some therapeutic common cold studies might be explained by the low doses of 3–4 g/day
of vitamin C. Three controlled trials found that vitamin C prevented pneumonia. Two controlled trials
found a treatment benefit of vitamin C for pneumonia patients. One controlled trial reported treatment
benefits for tetanus patients. The effects of vitamin C against infections should be investigated further.
Keywords: ascorbic acid; bacteria; bacterial toxins; common cold; herpes zoster; pneumonia;
protozoa; respiratory tract infections; viruses; tetanus
1. Early History on Vitamin C and Infections
Vitamin C was identified in the early twentieth century in the search for a substance, the deficiency
of which would cause scurvy [1,2]. Scurvy was associated with pneumonia in the early literature,
which implies that the factor that cured scurvy might also have an effect on pneumonia.
Alfred Hess (1920) summarized a series of autopsy findings as follows: “pneumonia, lobular
or lobar, is one of the most frequent complications (of scurvy) and causes of death” and “secondary
pneumonias, usually broncho-pneumonic in type, are of common occurrence and in many (scurvy)
epidemics constitute the prevailing cause of death” [3]. He later commented that in “infantile scurvy
... a lack of the antiscorbutic factor (vitamin C) which leads to scurvy, at the same time predisposes
to infections (particularly of the respiratory tract) ... Similar susceptibility to infections goes hand in
hand with adult scurvy” [4]. In the early 1900s, Casimir Funk, who coined the word “vitamin”, noted
that an epidemic of pneumonia in the Sudan disappeared when antiscorbutic (vitamin C-containing)
treatment was given to the numerous cases of scurvy that appeared at about the same time [5].
The great majority of mammals synthesize vitamin C in their bodies, but primates and the guinea
pig cannot. Therefore, the guinea pig is a useful animal model on which to study vitamin C deficiency.
Bacteria were often found in histological sections of scorbutic guinea pigs, so much so that some
early authors assumed that scurvy might be an infectious disease. However, Hess (1920) concluded
that such results merely showed that the tissues of scorbutic animals frequently harbor bacteria, and
“there is no doubt that the invasion of the blood-stream does occur readily in the course of scurvy,
but this takes place generally after the disease has developed and must be regarded as a secondary
phenomenon and therefore unessential from an etiological standpoint. Indeed one of the striking
and important symptoms of scurvy is the marked susceptibility to infection” [3]. When summarizing
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autopsy findings of experimental scurvy in the guinea pig, Hess also noted that “Pneumonia is met
with very frequently and constitutes a common terminal infection”.
Vitamin C was considered as an explanation for scurvy, which was regarded as a disease of the
connective tissues, since many of the symptoms such as poor wound healing implied crucial effects on
the connective tissues. Therefore, the mainstream view in medicine regarded vitamin C as a vitamin
that safeguards the integrity of connective tissues [6]. The implications of the earlier research by Hess
and others were superseded. This historical background might explain the current lack of interest in
the effects of vitamin C on infections, even though firm evidence that vitamin C influences infections
has been available for decades.
Early literature on vitamin C and infections was reviewed by Clausen (1934), Robertson (1934),
and Perla and Marmorston (1937) [5,7,8]. Those reviews are thorough descriptions of the large number
of early studies on the topic of this review. Scanned versions of those reviews and English translations
of many non-English papers cited in this review are available at the home page of this author [9].
The book on scurvy by Hess (1920) is available in a digitized format [3].
2. Biology Relevant to the Effects of Vitamin C on Infections
Evidence-based medicine (EBM) emphasizes that in the evaluation of treatments researchers
should focus primarily on clinically relevant outcomes, and little weight should be put on biological
explanations. Therefore, this review focuses on infections and not on the immune system. Immune
system effects are surrogates for clinical effects and there are numerous cases when surrogates had
poor correlations with clinically relevant outcomes [10]. Nevertheless, biology provides a useful
background when we consider the plausibility of vitamin C to influence infections.
2.1. Dose–Concentration Relationship
The vitamin C level in plasma of people in good health becomes saturated at about 70 μmol/L
when the intake is about 0.2 g/day [11]. On the other hand, when vitamin C intake is below 0.1 g/day,
there is a steep relationship between plasma vitamin C level and the dose of the vitamin. Clinical
scurvy may appear when the plasma concentration falls below 11 μmol/L, which corresponds to an
intake of less than 0.01 g/day [12–14]. Thus, when healthy people have a dietary intake of about
0.2 g/day of vitamin C, there is usually no reason to expect a response to vitamin C supplementation.
This does not apply universally because certain studies have shown the benefits of supplementation,
even though the baseline intake was as high as 0.5 g/day (see below). If the initial vitamin C intake is
lower than about 0.1 g/day, effects of vitamin C supplementation may be expected on the basis of the
dose–concentration curve. Nevertheless, this argument does not apply to patients with infections since
their vitamin C metabolism is altered and they have decreased vitamin C levels (see below).
2.2. Infections Increase Oxidative Stress
Vitamin C is an antioxidant. Therefore, any effects of vitamin C may be most prominent under
conditions when oxidative stress is elevated. Many infections lead to the activation of phagocytes,
which release oxidizing agents referred to as reactive oxygen species (ROS). These play a role in the
processes that lead to the deactivation of viruses and the killing of bacteria [15]. However, many of
the ROS appear to be harmful to the host cells, and in some cases they seem to play a role in the
pathogenesis of infections [16,17]. Vitamin C is an efficient water-soluble antioxidant and may protect
host cells against the actions of ROS released by phagocytes. Phagocytes have a specific transport
system by which the oxidized form of vitamin C (dehydroascorbic acid) is imported into the cell where
it is converted into the reduced form of vitamin C [18,19].
Influenza A infection in mice resulted in a decrease in vitamin C concentration in bronchoalveolar
lavage fluid, which was concomitant with an increase in dehydroascorbic acid, the oxidized form of
vitamin C [20], and in vitamin C deficiency influenza led to greater lung pathology [21]. Respiratory
syncytial virus decreased the expression of antioxidant enzymes thereby increasing oxidative
2
Nutrients 2017, 9, 339
damage [22]. Bacterial toxins have also led to the loss of vitamin C from many tissues in animal
studies [1] (p. 6).
Increased ROS production during the immune response to pathogens can explain the decrease
in vitamin C levels seen in several infections. There is evidence that plasma, leukocyte and urinary
vitamin C levels decrease in the common cold and in other infections [1,23]. Hume and Weyers (1973)
reported that vitamin C levels in leukocytes halved when subjects contracted a cold and returned to the
original level one week after recovery [24]. Vitamin C levels are also decreased by pneumonia [25–28].
Decreases in vitamin C levels during various infections imply that vitamin C administration
might have a treatment effect on many patients with infections. There is no reason to assume that the
saturation of plasma or leukocyte vitamin C levels during infections is reached by the 0.2 g/day intake
of vitamin C that applies to healthy people (see above). In particular, Hume and Weyers (1973) showed
that supplementation at the level of 0.2 g/day was insufficient to normalize leukocyte vitamin C levels
in common cold patients, but when 6 g/day of vitamin C was administered, the decline in leukocyte
vitamin C induced by the common cold was essentially abolished [24].
2.3. Vigorous Physical Activity Increases Oxidative Stress
Heavy physical stress leads to the elevation of oxidative stress [29]. Therefore, responses to
vitamin C might be observed when people are particularly active physically. Electron spin resonance
studies have shown that vitamin C administration decreased the levels of free radicals generated
during exercise [30] and vitamin C administration attenuated the increases in oxidative stress markers
caused by exercise [31]. Therefore, vitamin C supplementation might have beneficial effects on people
who are under physical stress. In such cases there is no reason to assume that 0.2 g/day of vitamin C
might lead to maximal effects of the vitamin. Direct evidence of benefits of vitamin C supplementation
to physically active people was found in three randomized trials in which 0.5 to 2 g/day of vitamin C
prevented exercise-induced bronchoconstriction [32,33].
2.4. Vitamin C May Protect against Stress Caused by Cold and Hot Environments
Studies in animals and humans have indicated that vitamin C may protect against stress caused
by cold and hot environments [34–37]. Some common cold studies with positive results investigated
physically active participants in cold environments and other studies investigated marathon runners
in South Africa (see below). Therefore, the effects of vitamin C in the protection against cold or heat
stress might also be relevant when explaining the benefits in those studies.
2.5. Marginally Low Vitamin C Status Might Lead to Benefits of Supplementation
It seems evident that any effects of vitamin C supplementation may be more prominent when
the baseline vitamin C level is particularly low. As noted above, a profound vitamin C deficiency
was associated with pneumonia in the early literature. It seems plausible that less severe vitamin C
deficiency, which may be called “marginal vitamin C deficiency”, can also be associated with increased
risk and severity of infections, although the effects may be less pronounced than those caused by scurvy.
Low vitamin C levels are not just of historical relevance. Cases of scurvy in hospitals have been
described in several recent case reports [38,39]. One survey estimated that about 10% of hospitalized
elderly patients had scurvy [40]. Surveys have also shown that plasma vitamin C levels below
11 μmol/L were found for 14% of males and 10% of females in the USA, 19% of males and 13% of
females in India, 40% of elderly people living in institutions in the UK, 23% of children and 39% of
women in Mexico, and 79%–93% of men in Western Russia. Moreover, 45% of a cohort of pregnant
women in rural India had plasma vitamin C levels below 4 μmol/L and the mean plasma vitamin C
level fell to 10 μmol/L in a cohort of pregnant or lactating women in Gambian villages in the rainy
season [41].
The mean vitamin C intake in adults in the USA has been about 0.10 g/day, but 10% of the
population has had intake levels of less than 0.04 g/day [14]. Thus, if low intake levels of vitamin C
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have adverse effects on the incidence and severity of infections, this may be important also in
population groups in western countries, and not just in developing countries.
2.6. Vitamin C Has Effects on the Immune System
Vitamin C levels in white blood cells are tens of times higher than in plasma, which may indicate
functional roles of the vitamin in these immune system cells. Vitamin C has been shown to affect
the functions of phagocytes, production of interferon, replication of viruses, and maturation of
T-lymphocytes, etc. in laboratory studies [1,23,42–44]. Some of the effects of vitamin C on the immune
system may be non-specific and in some cases other antioxidants had similar effects.
2.7. The Diverse Biochemical, Physiological, and Psychological Effects of Vitamin C
Biochemistry textbooks usually mention the role of vitamin C in collagen hydroxylation.
However, the survival time of vitamin C deficient guinea pigs was extended by carnitine [45]
and by glutathione [46], which indicates that scurvy is not solely explained by defects in collagen
hydroxylation, and it is not clear whether hydroxylation is important at all in explaining scurvy [6].
Vitamin C participates in the enzymatic synthesis of dopamine, carnitine, a number of neuroendocrine
peptides, etc. [6,47–50]. Vitamin C is also a powerful antioxidant, as mentioned above.
Experimentally induced vitamin C deficiency leads to depression and fatigue [11,51]. Recently,
vitamin C was reported to improve the mood of acutely hospitalized patients [52,53]. Such effects
cannot be explained by collagen metabolism, and vitamin C effects on the immune system are not
plausible explanations either. Instead, the effects of vitamin C on the neuroendocrine system or
carnitine metabolism might explain such effects. Thus, if vitamin C has beneficial effects on patients
with infections, that does not unambiguously indicate that these effects are mediated by the immune
system per se.
2.8. The Effects of Antioxidants against Infections May Be Heterogeneous
It is quite a common assumption that the effects of vitamins are uniform. Thus, if there is benefit,
it is often assumed that the same benefit applies to all people. However, it seems much more likely
that the effects of vitamins, including vitamin C, vary between people depending on biology and
their lifestyle. Thus, it is possible that there are benefits (or harms) restricted to special conditions or
to particular people. In the case of vitamin E, there is very strong evidence for the heterogeneity in
its effects on pneumonia [54,55] and on the common cold [56]. Although the factors modifying the
effects of vitamin E cannot be extrapolated to vitamin C, it seems probable that there is comparable
heterogeneity in the effects of vitamin C.
3. Infections in Animals
Early research showed that severe deficiency of vitamin C increased the incidence and severity
of infections in guinea pigs. Hemilä (2006) carried out a systematic search of animal studies on
vitamin C and infections and analyzed their findings [1], which are summarized in Tables 1–3 and
discussed below.
3.1. Studies with Diets Containing Vitamin C
Many early studies with guinea pigs did not examine the effect of pure vitamin C. Instead,
“vitamin-C-deficient groups” were fed diets that contained only small amounts of vitamin C, whereas
the “vitamin C group” was administered oranges or other foods that contained high levels of vitamin C.
The findings of studies on guinea pigs with tuberculosis and other bacterial infections are shown in
Table 1.
Assuming that vitamin C containing foods do not influence infections, by pure chance only,
one positive result at the level of p < 0.01 would be expected for a group of 100 studies. However,
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20 of the reported 28 studies found significant benefits from feeding diets rich in vitamin C (Table 1).
Although these findings are consistent with the notion that low vitamin C intake may increase the
susceptibility to and the severity of infections, other substances in fruit and vegetables might also
contribute to this effect, thus confounding the differences between the study groups.
As one example of Table 1 studies, McConkey (1936) reported that the administration of
tuberculous sputum to 16 guinea pigs that were vitamin C deficient led to intestinal tuberculosis
to 15 of them, but none of the five guinea pigs that were administered tomato juice as a source of
vitamin C suffered from intestinal tuberculosis [57] (pp. 507–508).
Table 1. Effect of vitamin-C-rich foods on infections in guinea pigs.
Infection No. of Studies
No. of Studies with Benefit in Any
Infectious Disease Outcome with p ≤ 0.01
All 28 20
Tuberculosis (TB) 11 7
Bacterial infection (non-TB) a 15 11
Diphtheria toxin 2 2
One group of guinea pigs was administered a vitamin-C-poor diet, and the other group was administered oranges,
cabbage, etc. as supplements to the vitamin-C-poor diet. Based on Appendix 3 in Hemilä (2006) [1] (pp. 119–121).
See Supplementary file 1 of this review for the list of the studies. p(1-tail) is used in this table. a Bacterial infections
included pneumococcus, group C streptococcus, Staphylococcus, and Salmonella typhimurium.
3.2. Studies with Pure Vitamin C
Table 2 summarizes the animal studies in which pure vitamin C was administered to the
“vitamin C” group. Overall, 148 animal studies had been published by 2005.
Out of the 148 studies, over half found a significant benefit, p < 0.01, for at least one infectious
disease outcome. Furthermore, over a third of the studies found a benefit at the level of p < 0.001 [1].
Of the 100 studies with mammals, 58 found a significant benefit, p < 0.01, from vitamin C on some
infectious disease outcome.
A benefit of vitamin C against infections was found in all animal groups. Although rats and mice
synthesize vitamin C in their bodies, half or more of the studies with these species found significant
benefits of additional vitamin C. This implies that rats and mice do not necessarily synthesize sufficient
amounts of vitamin C to reach optimal levels that prevent or curtail infections. In addition to mammals,
vitamin C protected against infections in several studies with birds and fishes.
Vitamin C was found to be beneficial against various groups of infectious agents including
bacteria, viruses, Candida albicans, and protozoa (Table 2). Over half (n = 97) of all the studies evaluated
the effect of vitamin C on bacterial infections or bacterial toxins, and 55 out of those studies found
significant benefits of vitamin C (p < 0.01). Studies in which animals were administered diphtheria
toxin, tetanus toxin, or endotoxin are also relevant, because these toxins are essential components in
the pathogenesis of the bacterial infections. Over half of the studies on viruses, Candida albicans and
protozoa also reported significant benefits (p < 0.01).
Table 3 shows the distribution of infections in studies that reported decreases in mortality caused
by infections (p < 0.001). It is apparent that vitamin C reduced mortality in all etiological groups.
As one example of the studies in Tables 2 and 3, Dey (1966) reported that five rats administered
twice the minimal lethal dose of tetanus toxin all died, whereas 25 rats administered vitamin C either
before or after the same dose of toxin all lived [58].
In addition to the animal studies yielding quantitative data on the effect of vitamin C on infections
in Tables 1–3, a few studies reported interesting findings of vitamin C effects against infections in
studies without control groups [1] (p. 9). For example, two case-series suggested therapeutic benefit of
vitamin C on dogs afflicted by the canine distemper virus. Belfield (1967) described a series of 10 dogs
that appeared to benefit from 1–2 g/day of intravenous vitamin C over three days [59]. Leveque (1969)
noted that usually only 5%–10% of dogs recovered from canine distemper with signs of central nervous
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system (CNS) disturbance. He became interested in Belfield’s report and in a series of 16 dogs showing
CNS disturbance that were treated with vitamin C, the proportion of dogs that recovered was 44%
(95% CI: 20%–70%; based on 7/16) [60].
Table 2. Effect of pure vitamin C on infectious disease outcomes in animal studies.
Category
No. of Studies in
the Category
No. of Studies with Benefit in Any
Infectious Disease Outcome with p ≤ 0.01
All studies 148 86
Time of publication
Published in 1935–1949 40 20
Published in 1950–1989 48 32
Published in 1990–2005 60 34
Animal species
Monkey 13 4
Guinea pig 36 21
Cow, sheep, rabbit 10 8
Cat 1 1
Rat 15 10
Gerbil, hamster 7 5
Mouse 18 9




Tuberculosis (TB) 8 3
Bacteria (non-TB) 70 36
Bacterial toxins 19 16
Virus 22 12
Candida albicans 6 4
Protozoa 23 15
A shorter version of this table was published in Hemilä (2006) [1] (p. 8). This table is based on data collected and
analyzed in Appendix 2 of [1] (pp. 105–118). See Supplementary file 1 of this review for the list of the studies and
their characteristics. p(1-tail) is used in this table. a The mammals category combines all the mammal species from
the rows above.




Bacteria (non-TB) a 7




Table 3 is restricted to mortality as the outcome, and to studies in which the effect of vitamin C on mortality was
statistically significant. See Supplementary file 1 of this review for a list of the studies in which vitamin C decreased
mortality by p ≤ 0.025 (1-tail). In comparison, Table 2 includes studies with all infectious disease outcomes, such as
incidence without the animals dying, and various forms of severity of infectious diseases. a Bacterial infections
included pneumococcus and β-hemolytic streptococci; b Bacterial toxins included diphtheria toxin, tetanus toxin,
endotoxin, and a set of clostridial toxins; c Protozoa infections include Entamoeba histolytica, Leishmania donovani,
Toxoplasma gondii, and Trypanosoma brucei.
3.3. Implications of the Animal Studies
Many of the studies on vitamin C and infections summarized in Table 2 are old. However, it is
unlikely that administering a specified dose of pure vitamin C and evaluating clinical outcomes of
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infections, such as mortality, will have changed meaningfully since those early days. Furthermore,
60 studies were published in the 1990s or later, and half of these later reports also found significant
benefits of vitamin C on at least one infectious disease outcome.
The studies on guinea pigs are most interesting since that species is dependent on dietary
vitamin C as are humans. Infections in guinea pigs against which vitamin C was significantly beneficial
included Mycobacterium tuberculosis, β-hemolytic streptococci, Fusobacterium necrophorum, diphtheria
toxin, Entamoeba histolytica, Trypanosoma brucei, and Candica albicans [1].
Some of the 148 studies in Table 2 were small and did not have sufficient statistical power to test
whether vitamin C and control groups might differ. However, this problem cannot explain the large
number of reported significant benefits. In contrast, inclusion of studies with a low statistical power
biases the findings towards the opposite direction, leading to false negative findings.
Mortality and severity of infections in animals are definitive outcomes. In this respect, the animal
studies with actual infections are much more relevant to humans than studies on laboratory
determinations of the human immune system.
Given the universal nature of the effect of vitamin C against infections in diverse animal species
as seen in Table 2, it seems obvious that vitamin C also has influences on infections in humans. It seems
unlikely that human beings qualitatively differ from all of the animal species that have been used in
the experiments listed in Table 2. Nevertheless, it is not clear to what degree the animal studies can be
extrapolated to human subjects.
The fundamental question in human beings is not whether vitamin C affects the susceptibility to
and severity of infections. Instead, the relevant questions are the following: What are the population
groups who might benefit from higher vitamin C intakes? What is the dose-dependency relation
between intake and the effects on infections? How does the optimal level of intake differ between
healthy people and patients with infections?
4. The Common Cold
The term “the common cold” does not refer to any precisely defined disease, yet the set of
symptoms that is called “the common cold” is personally familiar to practically everybody [61].
Typically the symptoms consist of nasal discharge, sore throat, cough, with or without fever. Young
children typically have half a dozen colds per year, and the incidence decreases with age so that elderly
people have colds about once per year [62]. The common cold is the leading cause of acute morbidity
and of visits to a physician in high-income countries, and a major cause of absenteeism from work and
school. The economic burden of the common cold is comparable to that of hypertension or stroke [63].
The most relevant definition of the common cold is based on the symptoms; thus the “common
cold” does not always entail a viral etiology. Although the majority of common cold episodes are
caused by respiratory viruses, similar symptoms are also caused by certain bacterial infections and
by some non-infectious causes such as allergic and mechanical irritation. The cough and sore throat
after running a marathon does not necessarily imply a viral etiology, although some researchers have
assumed so. It is still reasonable to use the term the “common cold” in such a context on the grounds
of the symptom-based definition.
4.1. Vitamin C and the Common Cold
Interest in the effects of vitamin C on the common cold originated soon after purified vitamin C
became available. The first controlled trials on vitamin C were carried out as early as the 1940s.
For example, in the 1950s, a British study examined the clinical effects of vitamin C deprivation, and
reported that “the geometric mean duration of colds was 6.4 days in vitamin C-deprived subjects and
3.3 days in non-deprived subjects”, and the authors concluded that the absence of vitamin C tended to
cause colds to last longer [12].
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Figure 1 shows the number of participants in placebo-controlled studies in which ≥1 g/day of
vitamin C was administered. It also illustrates the main time points of the history of vitamin C and the
common cold.
In 1970, Linus Pauling, a Nobel laureate in chemistry and also a Nobel Peace Prize winner, wrote a
book on vitamin C and the common cold [64]. He also published two meta-analyses, which were among
the earliest meta-analyses in medicine [65,66]. Pauling identified four placebo-controlled studies from
which he calculated that there was strong evidence that vitamin C decreased the “integrated morbidity”
of colds (p = 0.00002 [65]). By integrated morbidity, Pauling meant the total burden of the common cold:
the combination of the incidence and duration of colds. In his analysis, Pauling put the greatest weight
on the study by Ritzel (1961), which was a randomized controlled trial (RCT) with double-blinded
placebo control and the subjects were schoolchildren in a skiing camp in the Swiss Alps [67]. Ritzel’s
study was methodologically the best of the four and used the highest dose of vitamin C, 1 g/day, and
therefore Pauling concluded that gram doses of vitamin C would be beneficial against colds [64–66].
Figure 1. The numbers of participants in the placebo-controlled trials for which ≥1 g/day of vitamin C
was administered. The numbers of participants in studies published over two consecutive years are
combined and plotted for the first of the two years. This figure is based on data collected by Hemilä
and Chalker (2013) [68,69]. See Supplementary file 1 of this review for the list of the studies. RCT,
randomized controlled trial.
The activity of Pauling, in turn, led to a great upsurge in interest in vitamin C among lay
people and also in academic circles in the early 1970s. From 1972 to 1979, in that eight-year
period, 29 placebo-controlled studies were published, which amounted to a total of 8409 participants
(Figure 1) [68,69]. Thus, the mean number of participants per study was 290.
In the interval from 1972 to 1975, five placebo-controlled trials were published that used ≥2 g/day
of vitamin C. Those five studies were published after Pauling’s book and therefore they formally tested
Pauling’s hypothesis. A meta-analysis by Hemilä (1996) showed that there was very strong evidence
from the five studies that colds were shorter or less severe in the vitamin C groups (p = 10−5), and
therefore those studies corroborated Pauling’s hypothesis that vitamin C was indeed effective against
colds [70].
After the mid-1970s, however, interest in the topic plummeted so much so that during the 30-year
period from 1985 to 2014, only 11 placebo-controlled trials comprising just 538 participants in total
were published, with a mean of 49 participants per study (Figure 1). Thus, the number of studies
published after 1985 is much lower than during the 1970s. In addition, the few recent studies are much
smaller than the trials published in the 1970s. Therefore, the great majority of the data on vitamin C
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and the common cold that are currently available originated within the decade after the publication of
Pauling’s book.
This sudden lack of interest after the middle of the 1970s can be explained by three papers
published in the same year by Chalmers (1975), Karlowski et al. (1975), and Dykes and Meier
(1975) [71–73] (Figure 1). Few trials were started after 1975, which indicates the great impact of these
three papers. First, the findings of the placebo controlled studies will be summarized, and then
difficulties in the interpretation of common cold studies will be considered, and finally problems in the
three papers that were published in 1975 will be discussed.
4.2. Vitamin C Does Not Decrease the Average Incidence of Colds in the General Community
Table 4 summarizes the findings of the studies on vitamin C and the common cold in the Cochrane
review by Hemilä and Chalker (2013) [68,69]. Regularly administered vitamin C has not decreased the
average number of colds among the general population (Table 4). Another meta-analysis combined
the findings of the six largest trials that had used ≥1 g/day of vitamin C and calculated that there was
no difference in the vitamin and placebo groups with RR = 0.99 (95% CI 0.93, 1.04) [74,75].






Effect of Vitamin C
(95% CI)
p
Incidence of colds b
General population 24 10,708 −3% (−6% to 0%)
People under heavy short-term physical stress 5 598 −52% (−65% to −36%) 10−6
Duration of colds No. of colds
All studies (≥0.2 g/day) 31 9745 −9.4% (−13% to −6%) 10−7
Adults (≥1 g/day) 13 7095 −8% (−12% to −4%) 10−4
Children (≥1 g/day) 10 1532 −18% (−27% to −9%) 10−5
Severity of colds No. of colds
All studies 16 7209 −0.12 (−0.17 to −0.07) c 10−6
This table summarizes the main findings of the Cochrane review by Hemilä and Chalker (2013) [68,69]. a Regular
supplementation of vitamin C means that vitamin C was administered each day over the whole study period.
Duration and severity of colds indicates the effects on colds that occurred during the study; b Incidence indicates
here the number of participants who had ≥1 cold during the study; c The unit in this comparison is the standard
deviation. Thus −0.12 means that symptoms were decreased by 0.12 times the SD of the outcome.
Thus, there is no justification for “ordinary people” to take vitamin C regularly in order to prevent
colds. However, this conclusion does not mean that regular vitamin C supplementation is ineffective
for all people. There is strong evidence that vitamin C decreases the incidence of colds under special
conditions and/or among certain population groups.
4.3. Vitamin C May Decrease Common Cold Incidence in Special Conditions
Vitamin C halved the incidence of colds in five RCTs during which the participants were under
heavy short-term physical activity (Table 4) [68,76]. Three of the studies used marathon runners in
South Africa as subjects, whereas one study used Canadian military personnel on winter exercise, and
the fifth study was on schoolchildren in a skiing camp in the Swiss Alps, i.e., the Ritzel (1961) trial [67].
Thus, three studies were conducted under conditions of a hot environment and profound physical
stress and the other two were carried out under cold environments and physical stress (see Section 2.4).
Another group in which vitamin C has prevented colds is British men [74,75,77]. Four trials found
that vitamin C decreased the incidence of colds by 30%, and in another set of four trials, the proportion
of men who had recurrent common cold infections during the study decreased by a mean of 46%.
All these studies were carried out in the 1970s or earlier, and according to surveys, the intake of
vitamin C in the United Kingdom was low when the studies were carried out, 0.03 to 0.06 g/day,
and three of the U.K. trials specifically estimated that the dietary vitamin C intake was between 0.015
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to 0.05 g/day [74]. In particular, Baird (1979) administered only 0.08 g/day of vitamin C yet they
observed 37% lower incidence of colds in the vitamin C group, indicating that it was the “marginal
deficiency” and not a high dose that explained the benefit [77,78].
In addition, the levels of vitamin C are usually lower in men than in women, which may explain
the benefit for British males, in comparison to no apparent effect in British females. Evidently, the
dietary vitamin C intake in the United Kingdom has increased since the 1970s, and therefore these
studies do not indicate that vitamin C supplementation would necessarily influence colds in ordinary
British men nowadays. However, if low dietary vitamin C intake increases the risk of respiratory
infections, then that may be currently relevant in other contexts, since there are still many population
groups that have low intakes of vitamin C. A recent small study in the USA by Johnston (2014) was
restricted to 28 males with marginally low vitamin C levels, mean 30 μmol/L, and found a decrease in
common cold incidence, RR = 0.55 (95% CI: 0.33–0.94; p = 0.04) [79], which may also be explained by
the low vitamin C levels.
4.4. Vitamin C Might Protect against the Common Cold in a Restricted Subgroup of the General Community
Although vitamin C has not influenced the average common cold incidence in the general
community trials (Table 4), some of them found that there was a subgroup of people who had obtained
benefits from vitamin C. In a Canadian trial, Anderson (1972) [80] reported that in the vitamin C group
there were 10 percentage points more participants with no “days confined to house” because of colds
(57% vs. 47%; p = 0.01, [1] (p. 44)). Thus, one in 10 benefited from vitamin C in this outcome. In a
trial with Navajo schoolchildren, Coulehan (1974) [81] found that in the vitamin C group there were
16 percentage points more children who were “never ill on active surveillance by a medically trained
clerk or the school nurse” (44% vs. 29%; p < 0.001; [1] (p. 44)). A more recent study in the UK by van
Straten (2002) reported that vitamin C decreased the number of participants who had recurrent colds
by 17 percentage points [82] (19% vs. 2%; p < 0.001, [1] (p. 47)). Thus, the statistical evidence of benefit
for a restricted subgroup in these three trials is strong.
4.5. Vitamin C Shortens and Alleviates the Common Cold
The effect of vitamin C on the duration and severity of the common cold has been studied
in regular supplementation trials and in therapeutic trials. Regular supplementation means that
vitamin C was administered each day over the whole study period, and the outcome is the duration
and severity of colds that occurred during the study. Therapeutic vitamin C trial means that vitamin C
administration was started only after the first common cold symptoms had occurred and the duration
of colds were then recorded.
In regular supplementation studies, ≥0.2 g/day of vitamin C decreased the duration of colds by
9% (Table 4). When the dosage was ≥1 g/day of vitamin C, the mean duration of colds was shortened
by 8% in adults and by 18% in children. Vitamin C also significantly alleviated the severity of the colds.
Therapeutic studies have hitherto not shown consistent benefit from vitamin C. However,
therapeutic trials are more complex to conduct and interpret than regular supplementation trials. If the
timing of the initiation of supplementation or the duration of supplementation influences the extent
of the benefit, false negative findings may result from inappropriate study protocols. For example,
four therapeutic studies used only 2–3 days of 2–4 g/day vitamin C supplementation, whereas the
mean duration of colds in these studies was about a week. None of these studies detected any benefit
from vitamin C [68,83]. On the other hand, Anderson (1974) [84] found that 8 g/day on the first day
only reduced the duration of colds significantly (Figure 2). In addition, in a five-day therapeutic trial,
Anderson (1975) [85] reported a 25% reduction in “days spent indoors per subject” because of illness
(p = 0.048) in the vitamin C group (1 to 1.5 g/day) [1] (p. 48). Finally, none of the therapeutic studies
investigated children, although the effect of regular vitamin C has been greater in children (Table 4).
Thus, although the regular supplementation trials unambiguously show that vitamin C shortens
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and alleviates the common cold, there is no consistent evidence that therapeutic supplementation
is effective.
4.6. Possible Differences in the Effects of Vitamin C between Subgroups
The regular supplementation study by Anderson (1972) is one of the largest that has been carried
out [80]. They found that the proportion of participants who were not confined to the house decreased
by 10 percentage points in the vitamin C group. In addition, they found that per episode the days
confined to the house was 21% shorter in the vitamin C group. Together these combine to a 30%
reduction in the days confined to the house per person (p = 0.001). Such a large effect gives statistical
power for subgroup comparisons.
Anderson (1972) reported that vitamin C decreased total days confined to house by 46% in
participants who had contact with young children, but just by 17% in participants who did not have
contact with young children (Table 5). Anderson (1972) also reported that vitamin C decreased total
days confined to house by 43% in participants who usually had two or more colds per winter, but just
by 13% in participants who usually had zero to one cold per winter (Table 5).
In a study with adolescent competitive swimmers, Constantini (2011) found a significant difference
between males and females in the effect of vitamin C, whereby the vitamin halved the duration and
severity of colds in males but had no effect on females [86]. In a study with British students, Baird (1979)
also found a significant difference between males and females, but the outcome was the incidence of
colds (Table 5).
Carr (1981) found that vitamin C had a beneficial effect on the duration of colds for twins living
separately, but not for twins living together [87]. This subgroup difference might be explained by
swapping of tablets by twins living together, which was not possible for twins living separately.
The significant within-trial differences in the effect of vitamin C on the common cold indicate
that there is no universal effect of vitamin C valid over the whole population. Instead, the size of the
vitamin C effect seems to depend on various characteristics of people (see Section 2.8).









Contact with young children −46% total days confined to house 0.036No contact with young children −17%
Anderson
(1972) [80]
Usually ≥2 colds per winter −43% total days confined to house 0.033Usually 0–1 colds per winter −13%
Constantini
(2011) [86]
Male adolescent competitive swimmers −47%
duration of colds 0.003Female adolescent competitive swimmers +16%
Baird
(1979) [78]
Male students in UK −37%
incidence of colds 0.0001Female students in UK +24%
Carr
(1981) [87]
Twins living separately −35%
duration of colds 0.035Twins living together +1%
Calculation of the subgroup differences for the Anderson (1972) and the Carr (1981) studies is described in
Supplementary file 2. The interactions in the Constantini (2011) and Baird (1979) trials were calculated in [77,86].
p(2-tail) is used in this table.
4.7. Dose Dependency of Vitamin C Supplementation Effect
An earlier meta-analysis of dose-dependency calculated that on average 1 g/day of vitamin C
shortened the duration of colds in adults on average by 6% and in children by 17%; and ≥2 g/day
vitamin C shortened the duration of colds in adults by 21% and in children by 26% [83]. Thus, higher
doses were associated with greater effects. In addition, children weigh less than adults and the greater
effects in children may be explained by a greater dose per weight. Nevertheless, such a comparison
suffers from numerous simultaneous differences between the trials. The most valid examination of
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dose–response is within a single study so that the virus distribution is similar in each trial arm and the
outcome definition is identical.
Coulehan (1974) [81] administered 1 g/day to children and observed a 12% reduction in common
cold duration, and in parallel they administered 2 g/day to other children and observed a 29%
reduction in cold duration. Although the point estimates suggest a dose–response, the study was small
and the 95% CIs overlap widely [68,83].
In a 2 × 2 design, Karlowski (1975) [72] randomized participants to 3 g/day regular vitamin C
and to 3 g/day vitamin C treatment for five days when the participant caught a cold. Thus, one study
arm was administered placebo, the second was administered regular vitamin C, the third therapeutic,
and the fourth arm was administered regular + therapeutic vitamin C (i.e., 6 g/day). The four arms
of the Karlowski trial are shown in Figure 2A. The 95% CIs show the comparisons with the placebo
group. The test for trend for a linear regression model gives p = 0.018.
Anderson (1974) [84] randomized participants to a placebo and two vitamin C treatment arms
which were administered vitamin C only on the first day of the cold. One treatment arm (arm #7) was
given 4 g/day of, and another (arm #8) was given 8 g/day. These arms are compared with the placebo
arm #4 in Figure 2B. The 95% CIs show the comparisons with the placebo group. The test for trend in a
linear regression model gives p = 0.013.
Finally, some case reports have proposed that vitamin C doses should be over 15 g/day for the
best treatment of colds [88,89]. Thus, it is possible that the doses used in most of the therapeutic
studies, up to just 6–8 g/day, have not been sufficiently high to properly test the effects of vitamin C
that might be achievable.
Figure 2. (A) Dose–response relationship in the Karlowski (1975) trial. The placebo arm is located at
0 g/day, the 3 g/day regular vitamin C and the 3 g/day treatment vitamin C arms are in the middle
and the regular + treatment arm is at 6 g/day [72]. The 95% CIs are shown for the comparison against
the placebo arm. With inverse-variance weighing, test for trend in a linear model gives p(2-tail) = 0.018.
The addition of the linear vitamin C effect to the statistical model containing a uniform vitamin C
effect improved the regression model by p = 0.002. Previously, analysis of variance for trend calculated
p = 0.040 for the linear trend [83]; (B) Dose–response relationship in the Anderson (1974) trial. The
placebo arm #4 is located at 0 g/day, vitamin C treatment arm #7 at 4 g/day and vitamin C treatment
arm #8 at 8 g/day [84]. In the Anderson (1974) trial, vitamin C was administered only on the first
day of the common cold. The 95% CIs are shown for the comparison against the placebo arm. With
inverse-variance weighing, test for trend in a linear model gives p(2-tail) = 0.013. See Supplementary
file 2 for the calculation of the trend for both studies.
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4.8. Vitamin C and Complications of the Common Cold
Given the strong evidence that regularly administered vitamin C shortens and alleviates common
cold symptoms, it seems plausible that vitamin C might also alleviate complications of the common
cold. One frequent complication is the exacerbation of asthma [90].
A systematic review identified three studies that provided information on the potential pulmonary
effects of vitamin C in sufferers of common cold–induced asthma [91]. A trial conducted in
Nigeria studied asthmatic patients whose asthma exacerbations resulted from respiratory infections.
A vitamin C dose of 1 g/day decreased the occurrence of severe and moderate asthma attacks by
89% [92]. Another study on patients who had infection-related asthma reported that 5 g/day vitamin
C decreased the prevalence of bronchial hypersensitivity to histamine by 52 percentage points [93].
A third study found that the administration of a single dose of 1 g vitamin C to non-asthmatic common
cold patients decreased bronchial sensitivity in a histamine challenge test [94].
It has also been proposed that vitamin C might prevent sinusitis and otitis media [95,96], but to
our knowledge there are no data from controlled studies.
A further complication of viral respiratory infections is pneumonia; this is discussed in the section
on pneumonia.
5. Problems in the Interpretation: Non-Comparability of the Vitamin C and Common Cold Trials
5.1. Vitamin C Doses in Vitamin C and Control Groups
One great problem in the interpretation of vitamin C trials arises from the fundamental difference
between vitamin C and ordinary drugs such as antibiotics. In a trial of an ordinary drug, the control
group is not given the drug, which simplifies the interpretation of the findings. In contrast, it is
impossible to select control subjects who have zero vitamin C intake and no vitamin C in their system.
Thus, all vitamin C trials de facto compare two different vitamin C levels. The lower dose is obtained
from the diet, and it has varied considerably among the controlled studies. In addition, the vitamin
C supplement doses given to the vitamin C groups have also varied extensively. Finally, the placebo
group in some trials was also given extra vitamin C, which further confuses the comparisons. Therefore,
the comparison of different vitamin C studies and the generalization of their findings is complicated.
As an illustration of these problems, Table 6 shows examples of the variations in vitamin C doses that
were used in the common cold trials.
There are 10- to 30-fold differences in the vitamin C intake in the diet of the control groups of
the Baird (1979) [78], the Glazebrook (1942) [97], and the Sabiston (1974) [98] trials compared with
the Peters (1993) [99] trial, yet all of them are labeled “control groups” of vitamin C trials (Table 6).
Evidently, we should not expect similar effects of supplemental vitamin C in such dissimilar studies.
Usually the dietary intake of vitamin C is not estimated and therefore cannot be taken into account
when comparing studies.
Vitamin C was administered to the placebo group in some studies. For example, Carr (1981) [87]
administered 0.07 g/day and some other studies administered 0.01 to 0.05 g/day to the control subjects.
This was done to refute the notion that any possible effects of high doses were due to the treatment
of marginal deficiencies. Such reasoning does not seem sound, since there are population groups
for which ordinary dietary vitamin C intake is particularly low and it would be important to know
whether vitamin C supplementation might be beneficial for them. Thus, marginal vitamin C deficiency
is also an important issue. The administration of vitamin C to the control group biases the possible
effects of vitamin C supplementation downwards.
Finally, there are up to a 240-fold difference between the lowest and highest vitamin C
supplementary dose used in the common cold trials, yet the dosage is often ignored. For example,
in his influential review (see Figure 1), Chalmers (1975) [71] presented data from the following studies
in the same table: Karlowski (1975) study administered up to 6 g/day of vitamin C to their subjects [72],
whereas the Cowan (1942) study administered only 0.025 g/day as the lowest dose [100]. Chalmers
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(1975) did not list the vitamin C dosages in his table and therefore his readers were unable to consider
whether the comparison of such different studies was reasonable or not. Still, Chalmers’ review has
been widely cited as evidence that vitamin C is not effective against colds [1] (pp. 36–38).
Finally, combinations of the above variations lead to paradoxes. The “vitamin C group” of the
Baird (1979) study received about 0.05 g/day of vitamin C from food and 0.08 g/day from supplements,
which amounted to 0.13 g/day of total vitamin C [78]. In contrast, the “placebo group” in the study
by Peters (1994) received about four times as much, 0.5 g/day, of vitamin C from their usual diet [99].
Furthermore, Baird (1979) administered 0.08 g/day of vitamin C to their vitamin C group [78], whereas
Carr (1981) administered 0.07 g/day vitamin C to their placebo group [87]. Thus, the dosages of
vitamin C were essentially the same, but the groups were on the opposite sides in the evaluation of
vitamin C effects.
High dietary vitamin C intake, and vitamin C supplementation of the placebo group, cannot lead
to false positive findings about the efficacy of vitamin C against colds. In contrast, they can lead to
false negative findings or estimates biased towards the null effect.
Table 6. Variations in vitamin C dose in the control and vitamin C groups.
Vitamin C Level (g/Day)
Trial Country, Participants
Dietary Intake Level






USA, schoolchildren ? 0.025–0.05
Baird (1979) [78] UK, students 0.05 0.08
Glazebrook (1942) [97]
UK, boarding school boys 0.015 0.05–0.3
Peters (1993) [99]
South Africa, marathon runners 0.5 0.6
Sabiston (1974) [98]
Canada, military recruits 0.04 1
Carr (1981) [87]




Modified from Table 12 from Hemilä (2006) [1] (p. 34). a In addition to Carr (1981), a few studies administered 0.01
to 0.05 g/day of vitamin C to the placebo group, but they are not listed here; b In the 1970s, the average vitamin C
intake in the USA was approximately 0.1 g/day. The participants of the Karlowski (1975) study were employees of
the National Institutes of Health and therefore their mean dietary intake of vitamin C probably was higher than the
national average, but intake of vitamin C was not estimated.
5.2. Non-Compliance of Participants
Carr (1981) studied twins, some of whom lived together, whereas others lived apart [87]. Vitamin C
had a significant effect on the duration and severity of colds in twins living apart, but no effect in twins
living together (Table 5). Furthermore, the duration of colds among twins living together (5.4 days
in vitamin C and placebo groups) was in the middle of the duration of colds among the vitamin C
group (4.9 days) and placebo group (7.5 days) of twins living apart. An evident explanation for such
a difference between twins living together and twins living apart, is that twins who lived together
exchanged their tablets to some extent, whereas the twins who lived apart could not do so. Two studies
on children found an increase in vitamin C levels in the plasma of boys and in the urine of boys of the
placebo (sic) groups [81,101], which indicates tablet swapping among the children on vitamin C and
placebo. Thus, non-compliance may have confounded the results and the true effects of vitamin C
might be greater than those reported.
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5.3. Implications of the Common Cold Studies
Given the great variations in the vitamin C dosage levels in the vitamin C and control groups, and
the apparent problem of non-compliance in some studies, it is obvious that the comparison of different
“vitamin C trials” can be complicated. The generalization of the findings of any particular trial is
limited irrespective of its methodological quality and statistical power. However, the large variations
in vitamin C levels in the vitamin C and control groups, and the non-compliance in some studies,
both predispose against a false positive differences between the study groups. In contrast, they make
it more difficult to detect true differences, and therefore the findings on common cold duration and
severity shown in Table 4 may be biased downwards and might camouflage even stronger true effects.
6. Evaporation of Interest in Vitamin C and the Common Cold after 1975
Given the strong evidence from studies published before 1970 that vitamin C has beneficial effects
against the common cold [65], and from the ≥2 g/day vitamin C studies published between 1972 and
1975 [70], it is puzzling that the interest in vitamin C and the common cold collapsed after 1975 so that
few small trials on vitamin C and the common cold have been conducted thereafter (Figure 1).
This sudden loss of interest can be explained by the publication of the three highly important
papers in 1975 (Figure 1). These papers are particularly influential because of their authors and the
publication forums. Two of the papers were published in JAMA [72,73], and the third paper was
published in the American Journal of Medicine [71]. Both of these journals are highly influential medical
journals with extensive circulations. Two of the papers were authored by Thomas Chalmers [71,72],
who was a highly respected and influential pioneer of RCTs [1,102,103], and the third paper was
authored by Paul Meier [73], who was a highly influential statistician, e.g., one of the authors of the
widely used Kaplan–Meier method [1,104,105].
Karlowski, Chalmers, et al. (1975) [72] published the results of a RCT in JAMA, in which 6 g/day
of vitamin C significantly shortened the duration of colds (Figure 2A). However, these authors claimed
that the observed benefit was not caused by the physiological effects of vitamin C, but by the placebo
effect. However, the “placebo-effect explanation” was shown afterwards to be erroneous. For example,
Karlowski et al. had excluded 42% of common cold episodes from the subgroup analysis that was the
basis for their conclusion, without giving any explanation of why so many participants were excluded.
The numerous problems of the placebo explanation are detailed in a critique by Hemilä [1,106,107].
Chalmers wrote a response [108], but did not answer the specific issues raised [109].
In the same year (1975), Chalmers published a review of the vitamin C and common cold studies.
He pooled the results of seven studies and calculated that vitamin C would shorten colds only by
0.11 (SE 0.24) days [71]. Such a small difference has no clinical importance and the SE indicates that it
is simply explained by random variation. However, there were errors in the extraction of data, studies
that used very low doses of vitamin C (down to 0.025 g/day) were included, and there were errors
in the calculations [1,110]. Pauling had proposed that vitamin C doses should be ≥1 g/day. When
Hemilä and Herman (1995) included only those studies that had used ≥1 g/day of vitamin C and
extracted data correctly, they calculated that colds were 0.93 (SE 0.22) days shorter, which is over eight
times that calculated by Chalmers, and highly significant (p = 0.01) [110].
The third paper was a review published in JAMA by Michael Dykes and Paul Meier (1975). They
analyzed selected studies and concluded that there was no convincing evidence that vitamin C has
effects on colds [73]. However, they did not calculate the estimates of the effect nor any p-values,
and many comments in their analysis were misleading. Pauling wrote a manuscript in which he
commented upon the review by Dykes and Meier and submitted it to JAMA. Pauling stated afterwards
that his paper was rejected even after he twice made revisions to meet the suggestions of the referees
and the manuscript was finally published in a minor journal [111,112]. The rejection of Pauling’s
papers was strange since the readers of JAMA were effectively prevented from seeing the other side
of an important controversy. There were also other problems that were not pointed out by Pauling;
see [1,70].
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Although the three papers have serious biases, they have been used singly or in the combinations
of two as references in nutritional recommendations, in medical textbooks, in texts on infectious
diseases and on nutrition, when the authors claimed that vitamin C had been shown to be ineffective
for colds [1] (pp. 21–23, 36–38, 42–45). The American Medical Association, for example, officially
stated that “One of the most widely misused vitamins is ascorbic acid. There is no reliable evidence
that large doses of ascorbic acid prevent colds or shorten their duration” [113], a statement that was
based entirely on Chalmers’s 1975 review.
These three papers are the most manifest explanation for the collapse in the interest in vitamin C
and the common cold after 1975, despite the strong evidence that had emerged by that time that
≥2 g/day vitamin C shortens and alleviates colds [70].
7. Pneumonia
Pneumonia is the most common severe infection, which is usually caused by bacteria and viruses.
As recounted at the beginning of this review, the association between frank vitamin C deficiency
and pneumonia was noted by Alfred Hess and other early authors, when the chemical identity of
vitamin C was not yet known. Vitamin C was purified in the early 1930s and soon thereafter a
few German and U.S. physicians proposed that vitamin C might be beneficial in the treatment of
pneumonia. For example, Gander and Niederberger (1936) concluded from a series of 15 cases that
“the general condition is always favorably influenced (by vitamin C) to a noticeable extent, as is the
convalescence, which proceeds better and more quickly than in cases of pneumonia, which are not
treated with vitamin C” [114] and other German physicians also claimed benefits of vitamin C [115,116].
Translations of these papers are available [9]. Case reports from the USA also suggested that vitamin C
was beneficial against pneumonia [117–119].
A Cochrane review on vitamin C and pneumonia identified three controlled trials that reported
the number of pneumonia cases in participants who were administered vitamin C and two therapeutic
trials in which pneumonia patients were given vitamin C [27,28].
7.1. Vitamin C and the Incidence of Pneumonia
Table 7 shows the findings of the three vitamin C and pneumonia trials. Each of them found a
≥80% lower incidence of pneumonia for their vitamin C group [27,28,120].
Glazebrook (1942) studied male students (15–20 years) in a boarding school in Scotland during
World War II [97]. No formal placebo was used; however, 0.05 to 0.3 g/day of vitamin C was added to
the morning cocoa and to an evening glass of milk in the kitchen. Thus, the placebo effect does not
seem to be a relevant concern in the dining hall. The ordinary diet of the schoolboys contained only
0.015 g/day vitamin C so that their intake was particularly low.
Kimbarowski (1967) studied the effect of 0.3 g/day of vitamin C on military recruits who had been
hospitalized because of influenza type-A in the former Soviet Union [121]. Thus, these pneumonia
cases were complications of the viral respiratory infection. Vitamin C also shortened the mean stay in
hospital for pneumonia treatment (9 vs. 12 days).
The latest of the three pneumonia prevention trials was carried out during a two-month recruit
training period with U.S. Marine recruits by Pitt (1979) [122]. The dose of vitamin C was 2 g/day. This
was a randomized double-blind placebo-controlled trial, whereas the two earlier studies were not.
The findings of the three studies are consistent with the notion that the level of vitamin C intake
may influence the risk of pneumonia. However, all the three studies were carried out using special
participants under particular conditions, and their findings cannot be generalized to the ordinary
current Western population. Dietary vitamin C intake was particularly low in the oldest study, and
may also have been low in the second study. Thus, the benefit of vitamin C supplementation may be
explained by the correction of marginal deficiency in these two older studies. However, in the study
by Pitt (1979), the baseline plasma level of vitamin C, 57 μmol/L, corresponds to the dietary vitamin C
intake of about 0.1 g/day [11]. Furthermore, although the dose of 2 g/day was high, the plasma
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level of vitamin C increased only by 36% for the vitamin C group. This also indicates that the basal
dietary intake vitamin C was high. Thus, treating marginal vitamin C deficiency is not a reasonable
explanation for that latest study.
It is also worth noting that two of these trials used military recruits, and the third used young
males who were accommodated in a boarding school [123]. Therefore, the exposure to viruses and
bacteria causing pneumonia may have been much higher compared to children and young adults
living at home. In each of the three trials, the incidence of pneumonia in the control group was very
high when compared with the incidence in the ordinary population [124,125]. A high incidence of
pneumonia has been reported in military recruits [126], but the incidence of pneumonia has been even
higher in some child populations of the developing countries [127] (Table 7).
It seems reasonable to consider that these three studies observed a true effect of vitamin C against
pneumonia in their specific circumstances. However, these findings should not be extrapolated to
different circumstances. It would seem worthwhile to examine the effect of vitamin C in population
groups that have a high incidence of pneumonia concomitantly with a low intake of vitamin C [27,41].
Table 7. Effect of vitamin C on the incidence of pneumonia.
Study Pneumonia Cases/Total p a
Incidence of Pneumonia
in the Control Group
(1/1000 Person-Years)
Vitamin C Control
Glazebrook (1942) [97] 0/335 17/1100 0.006 30
Kimbarowski (1967) [121] 2/114 10/112 0.022 9% b
Pitt (1979) [122] 1/331 7/343 0.009 120
Incidence of pneumonia in selected populations:
Merchant (2004) [124] Middle-aged males in the USA 3
Hemilä (2004) [125] Middle-aged males in Finland 5
Pazzaglia (1983) [126] Military recruits in the USA 60
Paynter (2010) [127] Children in developing countries, up to 400
Modified from Hemilä (2006) [1] (p. 51). a Mid-p (1-tail); combined test for all three sets of data: p = 0.00002 [120];
b 9% of the hospitalized influenza A patients contracted pneumonia.
7.2. Vitamin C in the Treatment of Pneumonia
Two studies have reported on the therapeutic effect of vitamin C for pneumonia patients [27,28].
Hunt (1994) carried out a randomized, double-blind placebo controlled trial with elderly people
in the UK (mean age 81 years), who were hospitalized because of acute bronchitis or pneumonia [26].
The mean plasma vitamin C level at baseline was 23 μmol/L and one third of the patients had a
vitamin C level of just ≤11 μmol/L. There was a significant difference in the effect of 0.2 g/day of
vitamin C between patients who were more ill and those who were less ill when admitted to the
hospital. Vitamin C reduced the respiratory symptom score in the more ill patients but not in their less
ill counterparts. There were also six deaths during the study, all among the more ill participants: five
in the placebo group, but only one in the vitamin C group.
Mochalkin (1970) examined the effect of vitamin C on pneumonia patients in the former Soviet
Union [25]. Although a placebo was not administered to the control group, two different doses of
vitamin C were used and the observed difference between the low and high dosage cannot be explained
by the placebo effect. The high-dose regime administered on average twice the quantity of vitamin C
of the low dose, but both of them were related to the dosage of antibiotics so that the low dose vitamin
C ranged from 0.25 to 0.8 g/day, and the high dose ranged from 0.5 to 1.6 g/day. The duration of
hospital stay in the control group (no vitamin C supplementation) was 23.7 days. In the low dose
vitamin C group the hospital stay was 19% shorter and in the high dose vitamin C group it was 36%
shorter. A benefit was also reported on the normalization of chest X-ray, temperature, and erythrocyte
sedimentation rate.
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Although both of these therapeutic studies give support to the old case reports stating that
vitamin C is beneficial for pneumonia patients, the findings cannot be directly generalized to typical
pneumonia patients of Western countries.
8. Tetanus
Tetanus is a disease caused by the toxin of Clostridium tetani, which may contaminate wounds.
An early case report claimed that vitamin C was beneficial against tetanus in an unvaccinated
six-year-old boy in the USA [128]. A Cochrane review identified one controlled trial in which the effect
of vitamin C on tetanus patients was examined [129,130].
Jahan (1984) studied the effect of 1 g/day of intravenous vitamin C on tetanus patients in
Bangladesh [131]. In children aged one to 12 years, there were no deaths in the vitamin C group,
whereas there were 23 deaths in the control group (p = 10−9) [1] (p. 17). In tetanus patients aged
13 to 30 years, there were 10 deaths in the vitamin C group compared with 19 deaths in the control
group (p = 0.03). The significant difference between the above-described age groups may be caused by
the difference in the body weights of the patients. In the young children the same dose of vitamin C
corresponds to a substantially higher dose per unit of weight. Although there were methodological
weaknesses in the trial, they are unlikely explanations for the dramatic difference in the younger
participants [129].
9. Other Infections
The effect of vitamin C supplementation on the common cold has been most extensively studied.
One important reason for extensive research on vitamin C and the common cold seems to be the wide
publicity given to it by Pauling [1,132]. Probably some researchers wanted to show that Pauling was
either right or wrong, whereas others just wanted to study a topic about which a Nobel Prize winner
had put his credibility on the line. Another reason for the large number of studies on the common
cold is that it is a non-severe ubiquitous infection, and it is very easy to find common cold patients in
schools and work places. It is much more difficult to study more serious infections.
The three infections discussed above, the common cold, pneumonia, and tetanus, were selected
on the basis that the effects of vitamin C have been evaluated in Cochrane reviews, which entails a
thorough literature search and a careful analysis of the identified trials. However, the selection of these
three infections does not imply that the effects of vitamin C are limited to them.
Table 2 indicates that vitamin C may have effects on various infections caused by viruses, bacteria,
Candida albicans and protozoa. Vitamin C might have similar effects in humans. However, it also
seems evident that the role of additional vitamin C depends on various factors such as the initial
dietary intake level, other nutritional status, the exposure level to pathogens, the level of exercise and
temperature stress, etc.
Three extensive searches of the older literature on vitamin C and infections have been published,
and they give an extensive list of references, but none of these publications gave a balanced discussion
of the findings [133–135]. A few studies on the possible effects of vitamin C on other infections are
outlined below, but this selection is not systematic.
Terezhalmy (1978) [136] used a double-blind placebo-controlled RCT and found that the duration
of pain caused by herpes labialis was shortened by 51%, from 3.5 to 1.3 days (p = 10−8), when patients
were administered 1 g/day of vitamin C together with bioflavonoids [1] (pp. 15–17). Furthermore,
when vitamin C treatment was initiated within 24 hours of the onset of the symptoms, only six out of
26 patients (23%) developed herpes vesicles, whereas with later initiation of vitamin C, eight out of
12 patients (67%) developed vesicles (p = 0.003 in the test of interaction). Vitamin C was administered
with bioflavonoids, so the study was not specific to vitamin C, but there is no compelling evidence to
indicate that bioflavonoids affect infections.
Herpes zoster (reactivation of varicella zoster virus) can cause long lasting post-herpetic neuralgia
(PHN). Chen (2009) found that patients with PHN had significantly lower plasma vitamin C plasma
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than healthy volunteers, and their RCT showed that vitamin C administration significantly decreased
the pain level of PHN [137]. A number of other reports have also suggested that vitamin C may be
effective against the pain caused by herpes zoster [138–142].
Patrone (1982) and Levy (1996) reported that vitamin C administration was beneficial to patients
who had recurrent infections, mainly of the skin [143,144]. Many of the patients had impaired
neutrophil functions and therefore the findings cannot be generalized to the ordinary population.
Galley (1997) reported that vitamin C increased the cardiac index in patients with septic
shock [145]. Pleiner (2002) reported that intravenous vitamin C administration preserved vascular
reactivity to acetylcholine in study participants who had been experimentally administered
Escherichia coli endotoxin [146].
It seems unlikely that the effects of vitamin C on herpetic pain, cardiac index and the vascular
system are mediated through effects on the immune system. Such effects are probably caused by other
mechanisms instead. The question of the possible benefits of vitamin C against infections is therefore
not just a question about the immune system effects of the vitamin, as was discussed earlier in this
review (see Section 2.7).
Some physicians used vitamin C for a large set of infectious disease patients and described their
experiences in case reports that are worth reading [89,147].
10. Observational Studies on Vitamin C and Infections
Cohort studies on vitamins are often unreliable because diet is strongly associated with numerous
lifestyle factors that cannot be fully adjusted for in statistical models. Therefore, there may always
remain an unknown level of residual confounding [148]. The main source of vitamin C in the diet
is fruit, and high dietary vitamin C intake essentially always means a high fruit intake [149]. Thus,
any substantial correlations between vitamin C intake and infections could also reflect some other
substances in fruit. Only two observational studies are commented upon in this section.
Merchant (2004) studied men whose ages ranged from 40 to 75 years in the USA and found no
association between their vitamin C intake and community-acquired pneumonia [124]. These males
were U.S. health professionals; thus they were of a population that has a great interest in factors
that affect health. The incidence of pneumonia was only three cases per 1000 person-years (Table 7).
The median vitamin C intake of the lowest quintile was 0.095 g/day and of the highest quintile it
was 1.1 g/day. In contrast, the overall median of the adult U.S. population is about 0.1 g/day, and
10% of the U.S. population has an intake level of less than 0.04 g/day [14]. Thus, Merchant and
colleagues’ cohort study indicates that increasing the vitamin C intake upwards from the median level
in the USA will not lead to any further decline in the already low pneumonia incidence among male
health professionals. However, the study is uninformative about whether decreasing vitamin C level
downwards from 0.1 g/day might increase pneumonia risk, or about whether vitamin C might have
effects in populations that have particularly high incidences of pneumonia (Table 7). Even though we
must be cautious about interpreting observational studies, it seems that biological differences, rather
than methodological differences, are most reasonable explanations for the divergence between the
findings in the Merchant et al. cohort study and the three controlled trials shown in Table 7.
A cohort analysis of Finnish male smokers that is part of the Alpha-Tocopherol Beta-Carotene
Cancer prevention (ATBC) Study found a significant inverse association between dietary vitamin C
intake and tuberculosis risk in participants who were not administered vitamin E supplements [150,151].
The highest quartile had the median dietary vitamin C intake level of 0.15 g/day, whereas the lowest
quartile had an intake level of only 0.052 g/day. The adjusted risk of tuberculosis in the lowest vitamin
C intake quartile was 150% higher than that of the highest intake quartile. This is consistent with the
animal studies that found that low vitamin C intake increases the susceptibility to, and severity of,
tuberculosis (Tables 1–3).
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11. Potentially Harmful Interactions between Vitamins C and E
Vitamin C and vitamin E are both antioxidants and they protect against ROS. Therefore, these
substances are of parallel interest as water-soluble vitamin C regenerates the lipid-soluble vitamin
E in vitro [152]. Dietary vitamin C intake modified the effect of vitamin E on mortality in the ATBC
Study, which indicates that these substances may also have clinically important interactions [153].
However, the major sources of the vitamin C in this subgroup were fruit, vegetables and berries and
other substances in these foods might also have explained the modification of the vitamin E effect.
Such a possibility was refuted by calculating the residual intake of fruit, vegetables and berries, and
showing that the residual did not modify the effect of vitamin E. Vitamin C was thus indicated as the
specific modifying factor. A similar approach was used to show that vitamin C specifically modified
the effect of vitamin E on pneumonia [154].
Two subgroups of the ATBC Study were identified in which the combination of high dietary
vitamin C intake and vitamin E supplementation increased the risk of pneumonia by 248% and 1350%
when compared with high vitamin C intake without vitamin E (Table 8). In the former subgroup,
one extra case of pneumonia was caused for every 13 participants and in the latter subgroup, for every
28 participants. In both subgroups, the residual intake of fruit, vegetables and berries did not modify
the effect of vitamin E, indicating specificity of vitamin C. The total number of participants in the
ATBC Study was 29,133 and in that respect the identified subgroups were relatively small and at
1081 individuals only amounted to 4% of all the ATBC participants. However, in these two subgroups
the harm arising from the combination of vitamins C and E was substantial [154].
Another subgroup analysis of the ATBC Study found that the combination of high vitamin C
intake together with vitamin E supplementation increased the risk of tuberculosis in heavy smokers by
125% compared with high vitamin C alone subgroup (Table 8). Thus, one extra case of tuberculosis
arose in every 240 participants who had high intakes of vitamins C and E [150,151].
ROS have been implicated in the pathogenesis of diverse diseases, including infections.
Antioxidants have been assumed to be beneficial since they react with ROS. However, given the
suggestions that people should take vitamins C and E to improve their immune system, the subgroup
findings in Table 8 are somewhat alarming. Nevertheless, the harm in the three subgroups is limited to
the combination of vitamins C and E. This author does not know of any findings that indicate that
similar doses of vitamin C alone might cause harm.
Table 8. Increase in pneumonia and tuberculosis risk with the combination of vitamins C and E.








Body weight < 60 kg
who started smoking at ≤20 years
Dietary vitamin C
<median 467 0.98 (0.48 to 2.0)
0.026≥median (75 mg/day) 468 3.48 (1.61 to 7.5) 13
Pneumonia
Body weight ≥ 100 kg
who started smoking at ≤20 years
Dietary vitamin C
<median 613 1.37 (0.46 to 4.0)
0.019≥median (95 mg/day) 613 14.5 (1.84 to 114) 28
Tuberculosis
Smoking ≥ 20 cigarettes/day
Dietary vitamin C
<median 9073 0.82 (0.50 to 1.33)
0.011 a≥median (90 mg/day) 8172 2.25 (1.19 to 4.23) 240
Subgroups of the ATBC Study in which vitamin C increased the risk of pneumonia and tuberculosis [150,151,154].
ATBC Study, Alpha-Tocopherol Beta-Carotene Cancer prevention Study. NNH, number needed to harm: how many
people in the particular subgroup need to be exposed to the treatment to cause harm to one person. RR, relative risk.
a Interaction test was calculated for this review.
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12. Misconceptions and Prejudices about Vitamin C and Infections
In the first half of the 20th century, a large number of papers were published in the medical
literature on vitamin C and infections and several physicians were enthusiastic about vitamin C.
The topic was not dismissed because of large-scale controlled trials showing that vitamin C was
ineffective. Instead, many rather large trials found benefits of vitamin C. There seem to be four
particular reasons why the interest in vitamin C and infections disappeared.
First, antibiotics were introduced in the mid-20th century. They have specific and sometimes
very dramatic effects on bacterial infections and therefore are much more rational first line drugs for
patients with serious infections than vitamin C. Secondly, vitamin C was identified as the explanation
for scurvy, which was considered a disease of the connective tissues. Evidently it seemed irrational
to consider that a substance that “only” participates in collagen metabolism might also have effects
on infections. However, the biochemistry and actions of vitamin C are complex and not limited to
collagen metabolism. Thirdly, the three papers published in 1975 appeared to herald the loss of interest
in vitamin C and the common cold (Figure 1) and it seems likely that they increased the negative
attitude towards vitamin C for other infections as well. Fourthly, “if a treatment bypasses the medical
establishment and is sold directly to the public ... the temptation in the medical community is to accept
uncritically the first bad news that comes along” [155].
The belief that vitamin C is “ineffective” has been widely spread. For example, a survey of general
practitioners in the Netherlands revealed that 47% of respondents considered that homeopathy is
efficacious for the treatment of the common cold, whereas only 20% of those respondents considered
that vitamin C was [156]. Prejudices against vitamin C are not limited to the common cold. Richards
compared the attitudes and arguments of physicians to three putative cancer medicines, 5-fluorouracil,
interferon and vitamin C, and documented unambiguous bias against vitamin C [157–159]. Goodwin
and Tangum gave several examples to support the conclusion that there has been a systematic bias
against the concept that vitamins may yield benefits in levels higher than the minimum needed to
avoid the classic deficiency diseases [160].
The use of vitamin C for preventing and treating colds falls into the category of alternative
medicine under the classifications used by the National Institutes of Health in the USA and of the
Cochrane collaboration. However, such categorization does not reflect the level of evidence for vitamin
C, but reflects the low level of acceptance amongst the medical community, and may further amplify
the inertia and prejudices against vitamin C [161].
13. Conclusions
From a large series of animal studies we may conclude that vitamin C plays a role in preventing,
shortening, and alleviating diverse infections. It seems evident that vitamin C has similar effects in
humans. Controlled studies have shown that vitamin C shortens and alleviates the common cold and
prevents colds under specific conditions and in restricted population subgroups. Five controlled trials
found significant effects of vitamin C against pneumonia. There is some evidence that vitamin C may
also have effects on other infections, but there is a paucity of such data. The practical importance and
optimally efficacious doses of vitamin C for preventing and treating infections are unknown. Vitamin
C is safe and costs only pennies per gram, and therefore even modest effects may be worth exploiting.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/9/4/339/s1,
Supplementary file 1 and Supplementary file 2.
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Abstract: Vitamin C is an essential micronutrient for humans, with pleiotropic functions related to
its ability to donate electrons. It is a potent antioxidant and a cofactor for a family of biosynthetic
and gene regulatory enzymes. Vitamin C contributes to immune defense by supporting various
cellular functions of both the innate and adaptive immune system. Vitamin C supports epithelial
barrier function against pathogens and promotes the oxidant scavenging activity of the skin, thereby
potentially protecting against environmental oxidative stress. Vitamin C accumulates in phagocytic
cells, such as neutrophils, and can enhance chemotaxis, phagocytosis, generation of reactive oxygen
species, and ultimately microbial killing. It is also needed for apoptosis and clearance of the spent
neutrophils from sites of infection by macrophages, thereby decreasing necrosis/NETosis and
potential tissue damage. The role of vitamin C in lymphocytes is less clear, but it has been shown to
enhance differentiation and proliferation of B- and T-cells, likely due to its gene regulating effects.
Vitamin C deficiency results in impaired immunity and higher susceptibility to infections. In turn,
infections significantly impact on vitamin C levels due to enhanced inflammation and metabolic
requirements. Furthermore, supplementation with vitamin C appears to be able to both prevent and
treat respiratory and systemic infections. Prophylactic prevention of infection requires dietary vitamin
C intakes that provide at least adequate, if not saturating plasma levels (i.e., 100–200 mg/day), which
optimize cell and tissue levels. In contrast, treatment of established infections requires significantly
higher (gram) doses of the vitamin to compensate for the increased inflammatory response and
metabolic demand.
Keywords: ascorbate; ascorbic acid; immunity; immune system; neutrophil function; microbial
killing; lymphocytes; infection; vitamin C
1. Introduction
The immune system is a multifaceted and sophisticated network of specialized organs, tissues,
cells, proteins, and chemicals, which has evolved in order to protect the host from a range of pathogens,
such as bacteria, viruses, fungi, and parasites, as well as cancer cells [1]. It can be divided into epithelial
barriers, and cellular and humoral constituents of either innate (non-specific) and acquired (specific)
immunity [1]. These constituents interact in multiple and highly complex ways. More than half
a century of research has shown vitamin C to be a crucial player in various aspects of the immune
system, particularly immune cell function [2,3].
Vitamin C is an essential nutrient which cannot be synthesized by humans due to loss of a key
enzyme in the biosynthetic pathway [4,5]. Severe vitamin C deficiency results in the potentially fatal
disease scurvy [6]. Scurvy is characterized by weakening of collagenous structures, resulting in poor
wound healing, and impaired immunity. Individuals with scurvy are highly susceptible to potentially
fatal infections such as pneumonia [7]. In turn, infections can significantly impact on vitamin C levels
due to enhanced inflammation and metabolic requirements. Early on, it was noted that scurvy often
followed infectious epidemics in populations [7], and cases of scurvy have been reported following
respiratory infection [8]. This is particularly apparent for individuals who are already malnourished.
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Although the amount of vitamin C required to prevent scurvy is relatively low (i.e.,
~10 mg/day) [9], the recommended dietary intakes for vitamin C are up to one hundred-fold
higher than that for many other vitamins [10]. A diet that supplies 100–200 mg/day of vitamin C
provides adequate to saturating plasma concentrations in healthy individuals and should cover
general requirements for the reduction of chronic disease risk [11,12]. Due to the low storage capacity
of the body for the water-soluble vitamin, a regular and adequate intake is required to prevent
hypovitaminosis C. Epidemiological studies have indicated that hypovitaminosis C (plasma vitamin C
< 23 μmol/L) is relatively common in Western populations, and vitamin C deficiency (<11 μmol/L)
is the fourth leading nutrient deficiency in the United States [13,14]. There are several reasons why
vitamin C dietary recommendations are not met, even in countries where food availability and supply
would be expected to be sufficient. These include poor dietary habits, life-stages and/or lifestyles
either limiting intakes or increasing micronutrient requirements (e.g., smoking and alcohol or drug
abuse), various diseases, exposure to pollutants and smoke (both active and passive), and economic
reasons (poor socioeconomic status and limited access to nutritious food) [15,16]. Even otherwise
‘healthy’ individuals in industrialized countries can be at risk due to lifestyle-related factors, such
as those on a diet or eating an unbalanced diet, and people facing periods of excessive physical or
psychological stress [15,16].
Vitamin C has a number of activities that could conceivably contribute to its immune-modulating
effects. It is a highly effective antioxidant, due to its ability to readily donate electrons, thus protecting
important biomolecules (proteins, lipids, carbohydrates, and nucleic acids) from damage by oxidants
generated during normal cell metabolism and through exposure to toxins and pollutants (e.g.,
cigarette smoke) [17]. Vitamin C is also a cofactor for a family of biosynthetic and gene regulatory
monooxygenase and dioxygenase enzymes [18,19]. The vitamin has long been known as a cofactor
for the lysyl and prolyl hydroxylases required for stabilization of the tertiary structure of collagen,
and is a cofactor for the two hydroxylases involved in carnitine biosynthesis, a molecule required for
transport of fatty acids into mitochondria for generation of metabolic energy (Figure 1) [19].
Figure 1. The enzyme cofactor activities of vitamin C. Vitamin C is a cofactor of a family of
biosynthetic and gene regulatory monooxygenase and dioxygenase enzymes. These enzymes are
involved in the synthesis of collagen, carnitine, catecholamine hormones, e.g., norepinephrine, and
amidated peptide hormones, e.g., vasopressin. These enzymes also hydroxylate transcription factors,
e.g., hypoxia-inducible factor 1α, and methylated DNA and histones, thus playing a role in gene
transcription and epigenetic regulation. ↑ indicates an increase and ↓ indicates a decrease.
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Vitamin C is also a cofactor for the hydroxylase enzymes involved in the synthesis of catecholamine
hormones, e.g., norepinephrine, and amidated peptide hormones e.g., vasopressin, which are central
to the cardiovascular response to severe infection [20]. Furthermore, research over the past 15 years
or so has uncovered new roles for vitamin C in the regulation of gene transcription and cell signaling
pathways through regulation of transcription factor activity and epigenetic marks (Figure 1) [21,22].
For example, the asparagyl and prolyl hydroylases required for the downregulation of the pleiotropic
transcription factor hypoxia-inducible factor-1α (HIF-1α) utilize vitamin C as a cofactor [21]. Recent
research has also indicated an important role for vitamin C in regulation of DNA and histone
methylation by acting as a cofactor for enzymes which hydoxylate these epigenetic marks [22].
Our review explores the various roles of vitamin C in the immune system, including barrier
integrity and leukocyte function, and discusses potential mechanisms of action. We discuss
the relevance of the immune-modulating effects of vitamin C in the context of infections and conditions
leading to vitamin C insufficiency.
2. Barrier Integrity and Wound Healing
The skin has numerous essential functions, the primary of which is to act as a barrier against
external insults, including pathogens. The epidermal layer is highly cellular, comprising primarily
keratinocytes, whilst the dermal layer comprises fibroblasts which secrete collagen fibers, the major
component of the dermis [23]. Skin contains millimolar concentrations of vitamin C, with higher levels
found in the epidermis than the dermis [24–26]. Vitamin C is actively accumulated into the epidermal
and dermal cells via the two sodium-dependent vitamin C transporter (SVCT) isoforms 1 and 2 [27],
suggesting that the vitamin has crucial functions within the skin. Clues to the role of vitamin C in
the skin come from the symptoms of the vitamin C deficiency disease scurvy, which is characterized
by bleeding gums, bruising, and impaired wound healing [28,29]. These symptoms are thought to
be a result of the role of vitamin C as a co-factor for the prolyl and lysyl hydroxylase enzymes that
stabilize the tertiary structure of collagen (Table 1) [30]. Further research has shown that vitamin C can
also increase collagen gene expression in fibroblasts [31–35].
Table 1. Role of vitamin C in immune defense.
Immune System Function of Vitamin C Refs.
Epithelial barriers
Enhances collagen synthesis and stabilization [30–35]
Protects against ROS-induced damage 1 [36–40]
Enhances keratinocyte differentiation and lipid synthesis [41–45]
Enhances fibroblast proliferation and migration [46,47]
Shortens time to wound healing in patients [48,49]
Phagocytes (neutrophils,
macrophages)
Acts as an antioxidant/electron donor [50–53]
Enhances motility/chemotaxis [54–63]
Enhances phagocytosis and ROS generation [64–71]
Enhances microbial killing [54,55,57,58,70,72]
Facilitates apoptosis and clearance [71,73,74]
Decreases necrosis/NETosis [73,75]
B- and T-lymphocytes Enhances differentiation and proliferation [62,63,76–82]
Enhances antibody levels [78,83–85]
Inflammatory mediators Modulates cytokine production [75,77,86–94]
Decreases histamine levels [56,61,95–101]
1 ROS, reactive oxygen species; NET, neutrophil extracellular trap. Note that many of these studies comprised
marginal or deficient vitamin C status at baseline. Supplementation in situations of adequate vitamin C status may
not have comparable effects.
Vitamin C intervention studies in humans (using both dietary and gram doses of vitamin C) have
shown enhanced vitamin C uptake into skin cells [26,36] and enhanced oxidant scavenging activity
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of the skin [36,37]. The elevated antioxidant status of the skin following vitamin C supplementation
could potentially protect against oxidative stress induced by environmental pollutants [38,39].
The antioxidant effects of vitamin C are likely to be enhanced in combination with vitamin E [40,102].
Cell culture and preclinical studies have indicated that vitamin C can enhance epithelial barrier
functions via a number of different mechanisms. Vitamin C supplementation of keratinocytes in
culture enhances differentiation and barrier function via modulating signaling and biosynthetic
pathways, with resultant elevations in barrier lipid synthesis [41–45]. Dysfunctional epithelial
barrier function in the lungs of animals with serious infection can be restored by administration
of vitamin C [74]. This was attributed to enhanced expression of tight junction proteins and prevention
of cytoskeletal rearrangements.
Animal studies using the vitamin C-dependent Gulo knockout mouse indicated that deficiency
did not affect the formation of collagen in the skin of unchallenged mice [103]; however,
following full thickness excisional wounding there was significantly decreased collagen formation
in vitamin C-deficient mice [46]. This finding is in agreement with an earlier study carried out with
scorbutic guinea pigs [104]. Thus, vitamin C appears to be particularly essential during wound healing,
also decreasing the expression of pro-inflammatory mediators and enhancing the expression of various
wound healing mediators [46]. Fibroblast cell culture experiments have also indicated that vitamin C
can alter gene expression profiles within dermal fibroblasts, promoting fibroblast proliferation and
migration which is essential for tissue remodeling and wound healing [46,47]. Following surgery,
patients require relatively high intakes of vitamin C in order to normalize their plasma vitamin C status
(e.g., ≥500 mg/day) [105], and administration of antioxidant micronutrients, including vitamin C, to
patients with disorders in wound healing can shorten the time to wound closure [48,49,106,107].
Leukocytes, particularly neutrophils and monocyte-derived macrophages, are major players in
wound healing [108]. During the initial inflammatory stage, neutrophils migrate to the wound site in
order to sterilize it via the release of reactive oxygen species (ROS) and antimicrobial proteins [109].
The neutrophils eventually undergo apoptosis and are cleared by macrophages, resulting in resolution
of the inflammatory response. However, in chronic, non-healing wounds, such as those observed
in diabetics, the neutrophils persist and instead undergo necrotic cell death which can perpetuate
the inflammatory response and hinder wound healing [109,110]. Vitamin C is thought to influence
several important aspects of neutrophil function: migration in response to inflammatory mediators
(chemotaxis), phagocytosis and killing of microbes, and apoptosis and clearance by macrophages
(see below).
3. Vitamin C and Leukocyte Function
Leukocytes, such as neutrophils and monocytes, actively accumulate vitamin C against a concentration
gradient, resulting in values that are 50- to 100-fold higher than plasma concentrations [111–113]. These cells
accumulate maximal vitamin C concentrations at dietary intakes of ~100 mg/day [114,115], although
other body tissues likely require higher intakes for saturation [116,117]. Neutrophils accumulate
vitamin C via SVCT2 and typically contain intracellular levels of at least 1 mM [111,118]. Following
stimulation of their oxidative burst neutrophils can further increase their intracellular concentration of
vitamin C through the non-specific uptake of the oxidized form, dehydroascorbate (DHA), via glucose
transporters (GLUT) [118,119]. DHA is then rapidly reduced to ascorbate intracellularly, to give levels
of about 10 mM [119]. It is believed that the accumulation of such high vitamin C concentrations
indicates important functions within these cells.
Accumulation of millimolar concentrations of vitamin C into neutrophils, particularly following
activation of their oxidative burst, is thought to protect these cells from oxidative damage [119].
Vitamin C is a potent water-soluble antioxidant that can scavenge numerous reactive oxidants and can
also regenerate the important cellular and membrane antioxidants glutathione and vitamin E [120].
Upon phagocytosis or activation with soluble stimulants, vitamin C is depleted from neutrophils in
an oxidant-dependent manner [50–53]. An alteration in the balance between oxidant generation and
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antioxidant defenses can lead to alterations in multiple signaling pathways, with the pro-inflammatory
transcription factor nuclear factor κB (NFκB) playing a central role [121]. Oxidants can activate
NFκB, which triggers a signaling cascade leading to continued synthesis of oxidative species and other
inflammatory mediators [122,123]. Vitamin C has been shown to attenuate both oxidant generation and
NFκB activation in dendritic cells in vitro, and NFκB activation in neutrophils isolated from septic Gulo
knockout mice [75,124]. Thiol-containing proteins can be particularly sensitive to redox alterations
within cells and are often central to the regulation of redox-related cell signaling pathways [125].
Vitamin C-dependent modulation of thiol-dependent cell signaling and gene expression pathways has
been reported in T-cells [126,127].
Thus, vitamin C could modulate immune function through modulation of redox-sensitive cell
signaling pathways or by directly protecting important cell structural components. For example,
exposure of neutrophils to oxidants can inhibit motility of the cells, which is thought to be due to
oxidation of membrane lipids and resultant effects on cell membrane fluidity [63]. Neutrophils contain
high levels of polyunsaturated fatty acids in their plasma membranes, and thus improvements in
neutrophil motility observed following vitamin C administration (see below) could conceivably be
attributed to oxidant scavenging as well as regeneration of vitamin E [120].
3.1. Neutrophil Chemotaxis
Neutrophil infiltration into infected tissues is an early step in innate immunity. In response
to pathogen- or host-derived inflammatory signals (e.g., N-formylmethionyl-leucyl-phenylalanine
(fMLP), interleukin (IL)-8, leukotriene B4, and complement component C5a), marginated neutrophils
literally swarm to the site of infection [128]. Migration of neutrophils in response to chemical stimuli is
termed chemotaxis, while random migration is termed chemokinesis (Figure 2). Neutrophils express
more than 30 different chemokine and chemoattractant receptors in order to sense and rapidly respond
to tissue damage signals [128]. Early studies carried out in scorbutic guinea pigs indicated impaired
leukocyte chemotactic response compared with leukocytes isolated from guinea pigs supplemented
with adequate vitamin C in their diet (Table 1) [54–56,64]. These findings suggest that vitamin C
deficiency may impact on the ability of phagocytes to migrate to sites of infection.
Patients with severe infection exhibit compromised neutrophil chemotactic ability [129–132].
This neutrophil ‘paralysis’ is believed to be partly due to enhanced levels of anti-inflammatory and
immune-suppressive mediators (e.g., IL-4 and IL-10) during the compensatory anti-inflammatory
response observed following initial hyper-stimulation of the immune system [133]. However, it is also
possible that vitamin C depletion, which is prevalent during severe infection [20], may contribute.
Studies in the 1980s and 1990s indicated that patients with recurrent infections had impaired
leukocyte chemotaxis, which could be restored in response to supplementation with gram doses
of vitamin C [57–60,65–67]. Furthermore, supplementation of neonates with suspected sepsis with
400 mg/day vitamin C dramatically improved neutrophil chemotaxis [134].
Recurrent infections can also result from genetic disorders of neutrophil function, such as
chronic granulomatous disease (CGD), an immunodeficiency disease resulting in defective leukocyte
generation of ROS [135], and Chediak-Higashi syndrome (CHS), a rare autosomal recessive disorder
affecting vesicle trafficking [136]. Although vitamin C administration would not be expected to
affect the underlying defects of these genetic disorders, it may support the function of redundant
antimicrobial mechanisms in these cells. For example, patients with CGD showed improved
leukocyte chemotaxis following supplementation with gram doses of vitamin C administered either
enterally or parenterally [137–139]. This was associated with decreased infections and clinical
improvement [137,138]. A mouse model of CHS showed improved neutrophil chemotaxis following
vitamin C supplementation [140], and neutrophils isolated from two children with CHS showed
improved chemotaxis following supplementation with 200–500 mg/day vitamin C [141,142], although
this effect has not been observed in all cases [140,143]. The vitamin C-dependent enhancement of
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chemotaxis was thought to be mediated in part via effects on microtubule assembly [144,145], and
more recent research has indicated that intracellular vitamin C can stabilize microtubules [146].
Figure 2. Role of vitamin C in phagocyte function. Vitamin C has been shown to: (a) enhance neutrophil
migration in response to chemoattractants (chemotaxis), (b) enhance engulfment (phagocytosis)
of microbes, and (c) stimulate reactive oxygen species (ROS) generation and killing of microbes.
(d) Vitamin C supports caspase-dependent apoptosis, enhancing uptake and clearance by macrophages,
and inhibits necrosis, including NETosis, thus supporting resolution of the inflammatory response and
attenuating tissue damage.
Supplementation of healthy volunteers with dietary or gram doses of vitamin C has also
been shown to enhance neutrophil chemotactic ability [61–63,147]. Johnston et al., proposed that
the antihistamine effect of vitamin C correlated with enhanced chemotaxis [61]. In participants who
had inadequate vitamin C status (i.e., <50 μM), supplementation with a dietary source of vitamin C
(providing ~250 mg/day) resulted in a 20% increase in neutrophil chemotaxis [147]. Furthermore,
supplementation of elderly women with 1 g/day vitamin C, in combination with vitamin E, enhanced
neutrophil functions, including chemotaxis [148]. Thus, members of the general population may
benefit from improved immune cell function through enhanced vitamin C intake, particularly if they
have inadequate vitamin C status, which can be more prevalent in the elderly. However, it should be
noted that it is not yet certain to what extent improved ex vivo leukocyte chemotaxis translates into
improved in vivo immune function.
3.2. Phagocytosis and Microbial Killing
Once neutrophils have migrated to the site of infection, they proceed to engulf the invading
pathogens (Figure 2). Various intracellular granules are mobilized and fuse with the phagosome,
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emptying their arsenal of antimicrobial peptides and proteins into the phagosome [149]. Components
of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase assemble in the phagosomal
membrane and generate superoxide, the first in a long line of ROS generated by neutrophils to kill
pathogens. The enzyme superoxide dismutase converts superoxide to hydrogen peroxide, which
can then be utilized to form the oxidant hypochlorous acid via the azurophilic granule enzyme
myeloperoxidase [149]. Hypochlorous acid can further react with amines to form secondary oxidants
known as chloramines. These various neutrophil-derived oxidants have different reactivities and
specificities for biological targets, with protein thiol groups being particularly susceptible.
Neutrophils isolated from scorbutic guinea pigs exhibit a severely impaired ability to kill
microbes [54,55,70], and studies have indicated impaired phagocytosis and/or ROS generation in
neutrophils from scorbutic compared with ascorbate replete animals [68–70]. Generation of ROS by
neutrophils from volunteers with inadequate vitamin C status can be enhanced by 20% following
supplementation with a dietary source of vitamin C [147], and increases in both phagocytosis
and oxidant generation were observed following supplementation of elderly participants with
a combination of vitamins C and E [148]. Patients with recurrent infections [57,58,66,67,72], or the
genetic conditions CGD or CHS [138,139,141,143,150], have impaired neutrophil bacterial killing
and/or phagocytosis, which can be significantly improved following supplementation with gram
doses of vitamin C, resulting in long lasting clinical improvement. A couple of studies, however,
showed no improvement of ex vivo anti-fungal or anti-bacterial activity in neutrophils isolated from
CGD or CHS patients supplemented with vitamin C [140,151]. The reason for these differences
is not clear, although it may depend on the baseline vitamin C level of the patients, which is not
assessed in most cases. Furthermore, different microbes have variable susceptibility to the oxidative
and non-oxidative anti-microbial mechanisms of neutrophils. For example, Staphylococcus aureus
is susceptible to oxidative mechanisms, whereas other microorganisms are more susceptible to
non-oxidative mechanisms [152]. Therefore, the type of microbe used to assess the ex vivo neutrophil
functions could influence the findings.
Patients with severe infection (sepsis) exhibit a decreased ability to phagocytose microbes and
a diminished ability to generate ROS [153]. Decreased neutrophil phagocytosis was associated with
enhanced patient mortality [154]. Interestingly, Stephan et al. [155] observed impaired neutrophil
killing activity in critically ill patients prior to acquiring nosocomial infections, suggesting that
critical illness itself, without prior infection, can also impair neutrophil function. This resulted in
subsequent susceptibility to hospital-acquired infections. Impaired phagocytic and oxidant-generating
capacity of leukocytes in patients with severe infection has been attributed to the compensatory
anti-inflammatory response, resulting in enhanced levels of immunosuppressive mediators such as
IL-10 [133], as well as to the hypoxic conditions of inflammatory sites, which diminishes substrate for
ROS generation [156]. Another explanation is the larger numbers of immature neutrophils released
from the bone marrow due to increased demands during severe infection. These immature ‘band’
cells have decreased functionality compared with differentiated neutrophils [157]. Thus, conflicting
findings in severe infection could be due to variability in the total numbers of underactive immature
neutrophils compared with activated fully-differentiated neutrophils [158,159]. Despite displaying
an activated basal state, the mature neutrophils from patients with severe infection do not generate
ROS to the same extent as healthy neutrophils following ex vivo stimulation [160]. The effect of
vitamin C supplementation on phagocytosis, oxidant generation, and microbial killing by leukocytes
from septic patients has not yet been explored.
3.3. Neutrophil Apoptosis and Clearance
Following microbial phagocytosis and killing, neutrophils undergo a process of programmed
cell death called apoptosis [161]. This process facilitates subsequent phagocytosis and clearance of
the spent neutrophils from sites of inflammation by macrophages, thus supporting resolution of
inflammation and preventing excessive tissue damage (Figure 2). Caspases are key effector enzymes
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in the apoptotic process, culminating in phosphatidyl serine exposure, thus marking the cells for
uptake and clearance by macrophages [162]. Interestingly, caspases are thiol-dependent enzymes,
making them very sensitive to inactivation by ROS generated by activated neutrophils [163,164].
Thus, vitamin C may be expected to protect the oxidant-sensitive caspase-dependent apoptotic process
following activation of neutrophils. In support of this premise, in vitro studies have shown that loading
human neutrophils with vitamin C can enhance Escherichia coli-mediated apoptosis of the neutrophils
(Table 1) [71]. Peritoneal neutrophils isolated from vitamin C-deficient Gulo mice exhibited attenuated
apoptosis [75], and instead underwent necrotic cell death [73]. These vitamin C-deficient neutrophils
were not phagocytosed by macrophages in vitro, and persisted at inflammatory loci in vivo [73].
Furthermore, administration of vitamin C to septic animals decreased the numbers of neutrophils in
the lungs of these animals [74].
Numerous studies have reported attenuated neutrophil apoptosis in patients with severe infection
compared with control participants [165–172]. The delayed apoptosis appears to be related to
disease severity and is thought to be associated with enhanced tissue damage observed in patients
with sepsis [173,174]. Immature ‘band’ neutrophils released during severe infection were also
found to be resistant to apoptosis and had longer life spans [157]. Plasma from septic patients
has been found to suppress apoptosis in healthy neutrophils, suggesting that pro-inflammatory
cytokines were responsible for the increased in vivo survival of neutrophils during inflammatory
conditions [165,174–176]. Interestingly, high-dose vitamin C administration has been shown to
modulate cytokine levels in patients with cancer [177] and, although this has not yet been assessed
in patients with severe infection, could conceivably be another mechanism by which vitamin C
may modulate neutrophil function in these patients. To date, only one study has investigated
the effect of vitamin C supplementation on neutrophil apoptosis in septic patients [178]. Intravenous
supplementation of septic abdominal surgery patients with 450 mg/day vitamin C was found to
decrease caspase-3 protein levels and, thus was presumed to have an anti-apoptotic effect on peripheral
blood neutrophils. However, caspase activity and apoptosis of the neutrophils following activation was
not assessed. Furthermore, circulating neutrophils may not reflect the activation status of neutrophils
at inflammatory tissue loci. Clearly, more studies need to be undertaken to tease out the role of
vitamin C in neutrophil apoptosis and clearance from inflammatory loci.
3.4. Neutrophil Necrosis and NETosis
Neutrophils that fail to undergo apoptosis instead undergo necrotic cell death (Figure 2).
The subsequent release of toxic intracellular components, such as proteases, can cause extensive
tissue damage [179,180]. One recently discovered form of neutrophil death has been termed
NETosis. This results from the release of ‘neutrophil extracellular traps’ (NETs) comprising neutrophil
DNA, histones, and enzymes [181]. Although NETs have been proposed to comprise a unique
method of microbial killing [182,183], they have also been implicated in tissue damage and organ
failure [184,185]. NET-associated histones can act as damage-associated molecular pattern proteins,
activating the immune system and causing further damage [186]. Patients with sepsis, or who go on
to develop sepsis, have significantly elevated levels of circulating cell-free DNA, which is thought to
indicate NET formation [184,187].
Pre-clinical studies in vitamin C-deficient Gulo knockout mice indicated enhanced NETosis
in the lungs of septic animals and increased circulating cell-free DNA [75]. The levels of these
markers were attenuated in vitamin C sufficient animals or in deficient animals that were administered
vitamin C (Table 1). The same investigators showed that in vitro supplementation of human
neutrophils with vitamin C attenuated phorbol ester-induced NETosis [75]. Administration of
gram doses of vitamin C to septic patients over four days, however, did not appear to decrease
circulating cell-free DNA levels [188], although the duration of treatment may have been too short to
see a sustained effect. It should be noted that cell-free DNA is not specific for neutrophil-derived DNA,
as it may also derive from necrotic tissue; however, the association of neutrophil-specific proteins
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or enzymes, such as myeloperoxidase, with the DNA can potentially provide an indication of its
source [184].
The transcription factor HIF-1α facilitates neutrophil survival at hypoxic loci through delaying
apoptosis [189]. Interestingly, vitamin C is a cofactor for the iron-containing dioxygenase enzymes
that regulate the levels and activity of HIF-1α [190]. These hydroxylase enzymes downregulate
HIF-1α activity by facilitating degradation of constitutively expressed HIF-1α and decreasing
binding of transcription coactivators. In vitamin C-deficient Gulo knockout mice, up-regulation
of HIF-1α was observed under normoxic conditions, along with attenuated neutrophil apoptosis and
clearance by macrophages [73]. HIF-1α has also been proposed as a regulator of NET generation by
neutrophils [191], hence providing a potential mechanism by which vitamin C could downregulate
NET generation by these cells [75].
3.5. Lymphocyte Function
Like phagocytes, B- and T-lymphocytes accumulate vitamin C to high levels via SVCT [192,193].
The role of vitamin C within these cells is less clear, although antioxidant protection has been
suggested [194]. In vitro studies have indicated that incubation of vitamin C with lymphocytes
promotes proliferation [76,77], resulting in enhanced antibody generation [78], and also provides
resistance to various cell death stimuli [195]. Furthermore, vitamin C appears to have an important
role in developmental differentiation and maturation of immature T-cells (Table 1) [76,79]. Similar
proliferative and differentiation/maturation effects have been observed with mature and immature
natural killer cells, respectively [196].
Early studies in guinea pigs showed enhanced mitotic activity of isolated peripheral blood
lymphocytes following intraperitoneal vitamin C treatment, and enhanced humoral antibody
levels during immunization [82–85]. Although one human intervention study has reported
positive associations between antibody levels (immunoglobulin (Ig)M, (Ig)G, (Ig)A) and vitamin C
supplementation [85], another has not [62]. Instead, Anderson and coworkers showed that oral
and intravenous supplementation of low gram doses of vitamin C to children with asthma and
healthy volunteers enhanced lymphocyte transformation, an ex vivo measure of mitogen-induced
proliferation and enlargement of T-lymphocytes (Table 1) [62,63,81]. Administration of vitamin C to
elderly people was also shown to enhance ex vivo lymphocyte proliferation [80], a finding confirmed
using combinations of vitamin C with vitamins A and/or E [148,197]. Exposure to toxic chemicals can
affect lymphocyte function, and both natural killer cell activity and lymphocyte blastogenic responses
to T- and B-cell mitogens were restored to normal levels following vitamin C supplementation [198].
Although the human studies mentioned above are encouraging, it is apparent that more human
intervention studies are needed to confirm these findings.
Recent research in wild-type and Gulo knockout mice indicated that parenteral administration
of 200 mg/kg vitamin C modulated the immunosuppression of regulatory T-cells (Tregs) observed
in sepsis [89]. Vitamin C administration enhanced Treg proliferation and inhibited the negative
immunoregulation of Tregs by inhibiting the expression of specific transcription factors, antigens,
and cytokines [89]. The mechanisms involved likely rely on the gene regulatory effects of
vitamin C [79,89,199,200]. For example, recent research has implicated vitamin C in epigenetic
regulation through its action as a cofactor for the iron-containing dioxygenases which hydroxylate
methylated DNA and histones [22,201]. The ten-eleven translocation (TET) enzymes hydroxylate
methylcytosine residues, which may act as epigenetic marks in their own right, and also facilitate
removal of the methylated residues, an important process in epigenetic regulation [202]. Preliminary
evidence indicates that vitamin C can regulate T-cell maturation via epigenetic mechanisms involving
the TETs and histone demethylation [79,199,200]. It is likely that the cell signaling and gene regulatory
functions of vitamin C, via regulation of transcription factors and epigenetic marks, play major roles in
its immune-regulating functions.
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3.6. Inflammatory Mediators
Cytokines are important cell signaling molecules secreted by a variety of immune cells, both innate
and adaptive, in response to infection and inflammation [1]. They comprise a broad range of molecules,
including chemokines, interferons (IFNs), ILs, lymphokines, and TNFs, which modulate both humoral
and cell-based immune responses, and regulate the maturation, growth, and responsiveness of specific
cell populations. Cytokines can elicit pro-inflammatory or anti-inflammatory responses, and vitamin C
appears to modulate systemic and leukocyte-derived cytokines in a complex manner.
Incubation of vitamin C with peripheral blood lymphocytes decreased lipopolysaccharide
(LPS)-induced generation of the pro-inflammatory cytokines TNF-α and IFN-γ, and increased
anti-inflammatory IL-10 production, while having no effect on IL-1β levels [77]. Furthermore, in vitro
addition of vitamin C to peripheral blood monocytes isolated from pneumonia patients decreased
the generation of the pro-inflammatory cytokines TNF-α and IL-6 [86]. However, another study found
that in vitro treatment of peripheral blood monocytes with vitamin C and/or vitamin E enhanced
LPS-stimulated TNF-α generation, but did not affect IL-1β generation [87]. Furthermore, incubation
of vitamin C with virus-infected human and murine fibroblasts enhanced generation of antiviral
IFN [91–93]. Supplementation of healthy human volunteers with 1 g/day vitamin C (with and without
vitamin E) was shown to enhance peripheral blood mononuclear cell-derived IL-10, IL-1, and TNF-α
following stimulation with LPS [87,94]. Thus, the effect of vitamin C on cytokine generation appears
to depend on the cell type and/or the inflammatory stimulant. Recent research has indicated that
vitamin C treatment of microglia, resident myeloid-derived macrophages in the central nervous
system, attenuates activation of the cells and synthesis of the pro-inflammatory cytokines TNF, IL-6,
and IL-1β [90]. This is indicative of an anti-inflammatory phenotype.
Preclinical studies using Gluo knockout mice have highlighted the cytokine-modulating effects of
vitamin C. Vitamin C-deficient Gulo knockout mice infected with influenza virus showed enhanced
synthesis of the pro-inflammatory cytokines TNF-α and IL-1α/β in their lungs, and decreased
production of the anti-viral cytokine IFN-α/β [88]. Administration of vitamin C to Gulo mice with
polymicrobial peritonitis resulted in decreased synthesis of the pro-inflammatory cytokines TNF-α
and IL-1β by isolated neutrophils [75]. Another study in septic Gulo mice administered 200 mg/kg
parenteral vitamin C has shown decreased secretion of the inhibitory cytokines TGF-β and IL-10 by
Tregs [89]. In this study, attenuated IL-4 secretion and augmented IFN-γ secretion was also observed,
suggesting immune-modulating effects of vitamin C in sepsis. Overall, vitamin C appears to normalize
cytokine generation, likely through its gene-regulating effects.
Histamine is an immune mediator produced by basophils, eosinophils, and mast cells during
the immune response to pathogens and stress. Histamine stimulates vasodilation and increased
capillary permeability, resulting in the classic allergic symptoms of runny nose and eyes. Studies
using guinea pigs, a vitamin C-requiring animal model, have indicated that vitamin C depletion is
associated with enhanced circulating histamine levels, and that supplementation of the animals with
vitamin C resulted in decreased histamine levels [56,95–98]. Enhanced histamine generation was found
to increase the utilization of vitamin C in these animals [96]. Consistent with the animal studies, human
intervention studies with oral vitamin C (125 mg/day to 2 g/day) and intravenous vitamin C (7.5 g
infusion) have reported decreased histamine levels [61,99–101], which was more apparent in patients
with allergic compared with infectious diseases [101]. Although vitamin C has been proposed to
‘detoxify’ histamine [96,97], the precise mechanisms responsible for the in vivo decrease in histamine
levels following vitamin C administration are currently unknown. Furthermore, effects of vitamin C
supplementation on histamine levels are not observed in all studies [203].
4. Vitamin C Insufficiency Conditions
Numerous environmental and health conditions can have an impact on vitamin C status.
In this section we discuss examples which also have a link with impaired immunity and increased
susceptibility to infection. For example, exposure to air pollution containing oxidants, such as ozone
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and nitrogen dioxide, can upset the oxidant-antioxidant balance within the body and cause oxidative
stress [204]. Oxidative stress can also occur if antioxidant defenses are impaired, which may be the case
when vitamin C levels are insufficient [205]. Air pollution can damage respiratory tract lining fluid
and increase the risk of respiratory disease, particularly in children and the elderly [204,206] who are
at risk of both impaired immunity and vitamin C insufficiency [14,204]. Vitamin C is a free-radical
scavenger that can scavenge superoxide and peroxyl radicals, hydrogen peroxide, hypochlorous acid,
and oxidant air pollutants [207,208]. The antioxidant properties of vitamin C enable it to protect lung
cells exposed to oxidants and oxidant-mediated damage caused by various pollutants, heavy metals,
pesticides, and xenobiotics [204,209].
Tobacco smoke is an underestimated pollutant in many parts of the world. Both smokers and
passive smokers have lower plasma and leukocyte vitamin C levels than non-smokers [10,210,211],
partly due to increased oxidative stress and to both a lower intake and a higher metabolic turnover
of vitamin C compared to non-smokers [10,211–213]. Mean serum concentrations of vitamin C in
adults who smoke have been found to be one-third lower than those of non-smokers, and it has been
recommended that smokers should consume an additional 35 mg/day of vitamin C to ensure there is
sufficient ascorbic acid to repair oxidant damage [10,14]. Vitamin C levels are also lower in children
and adolescents exposed to environmental tobacco smoke [214]. Research in vitamin C-deficient
guinea pigs exposed to tobacco smoke has indicated that vitamin C can protect against protein
damage and lipid peroxidation [213,215]. In passive smokers exposed to environmental tobacco smoke,
vitamin C supplementation significantly reduced plasma F2-isoprostane concentrations, a measure of
oxidative stress [216]. Tobacco use increases susceptibility to bacterial and viral infections [217,218], in
which vitamin C may play a role. For example, in a population-based study the risk of developing
obstructive airways disease was significantly higher in those with the lowest plasma vitamin C
concentrations (26 μmol/L) compared to never smokers, a risk that decreased with increasing vitamin C
concentration [219].
Individuals with diabetes are at greater risk of common infections, including influenza,
pneumonia, and foot infections, which are associated with increased morbidity and mortality [220,221].
Several immune-related changes are observed in obesity that contribute towards the development
of type 2 diabetes. A major factor is persistent low-grade inflammation of adipose tissue in obese
subjects, which plays a role in the progression to insulin resistance and type 2 diabetes, and which
is not present in the adipose tissue of lean subjects [222,223]. The adipose tissue is infiltrated by
pro-inflammatory macrophages and T-cells, leading to the accumulation of pro-inflammatory cytokines
such as interleukins and TNF-α [224,225]. A decrease in plasma vitamin C levels has been observed
in studies of type 2 diabetes [18,226], and a major cause of increased need for vitamin C in type 2
diabetes is thought to be the high level of oxidative stress caused by hyperglycemia [10,227,228].
Inverse correlations have been reported between plasma vitamin C concentrations and the risk of
diabetes, hemoglobin A1c concentrations (an index of glucose tolerance), fasting and postprandial
blood glucose, and oxidative stress [219,229–232]. Meta-analysis of interventional studies has indicted
that supplementation with vitamin C can improve glycemic control in type 2 diabetes [233].
Elderly people are particularly susceptible to infections due to immunosenescence and decreased
immune cell function [234]. For example, common viral infections such as respiratory illnesses, that
are usually self-limiting in healthy young people, can lead to the development of complications such as
pneumonia, resulting in increased morbidity and mortality in elderly people. A lower mean vitamin C
status has been observed in free-living or institutionalized elderly people, indicated by lowered plasma
and leukocyte concentrations [10,235,236], which is of concern because low vitamin C concentrations
(<17 μmol/L) in older people (aged 75–82 years) are strongly predictive of all-cause mortality [237].
Acute and chronic diseases that are prevalent in this age group may also play an important part in
the reduction of vitamin C reserves [238–240]. Institutionalization in particular is an aggravating
factor in this age group, resulting in even lower plasma vitamin C levels than in non-institutionalized
elderly people. It is noteworthy that elderly hospitalized patients with acute respiratory infections
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have been shown to fare significantly better with vitamin C supplementation than those not receiving
the vitamin [241]. Decreased immunological surveillance in individuals older than 60 years also results
in greater risk of cancer, and patients with cancer, particularly those undergoing cancer treatments,
have compromised immune systems, decreased vitamin C status, and enhanced risk of developing
sepsis [242,243]. Hospitalized patients, in general, have lower vitamin C status than the general
population [244].
5. Vitamin C and Infection
A major symptom of the vitamin C deficiency disease scurvy is the marked susceptibility to
infections, particularly of the respiratory tract, with pneumonia being one of the most frequent
complications of scurvy and a major cause of death [7]. Patients with acute respiratory infections, such
as pulmonary tuberculosis and pneumonia, have decreased plasma vitamin C concentrations relative to
control subjects [245]. Administration of vitamin C to patients with acute respiratory infections returns
their plasma vitamin C levels to normal and ameliorates the severity of the respiratory symptoms [246].
Cases of acute lung infections have shown rapid clearance of chest X-rays following administration of
intravenous vitamin C [247,248]. This vitamin C-dependent clearance of neutrophils from infected
lungs could conceivably be due to enhanced apoptosis and subsequent phagocytosis and clearance of
the spent neutrophils by macrophages [73]. Pre-clinical studies of animals with sepsis-induced lung
injury have indicated that vitamin C administration can increase alveolar fluid clearance, enhance
bronchoalveolar epithelial barrier function, and attenuate sequestration of neutrophils [74], all essential
factors for normal lung function.
Meta-analysis has indicated that vitamin C supplementation with doses of 200 mg or more
daily is effective in ameliorating the severity and duration of the common cold, and the incidence
of the common cold if also exposed to physical stress [249]. Supplementation of individuals who
had an inadequate vitamin C status (i.e., <45 μmol/L) also decreased the incidence of the common
cold [203]. Surprisingly, few studies have assessed vitamin C status during the common cold [250].
Significant decreases in both leukocyte vitamin C levels, and urinary excretion of the vitamin, have
been reported to occur during common cold episodes, with levels returning to normal following
the infection [251–254]. These changes indicate that vitamin C is utilized during the common cold
infection. Administration of gram doses of vitamin C during the common cold episode ameliorated
the decline in leukocyte vitamin C levels, suggesting that administration of vitamin C may be beneficial
for the recovery process [251].
Beneficial effects of vitamin C on recovery have been noted in pneumonia. In elderly people
hospitalized because of pneumonia, who were determined to have very low vitamin C levels,
administration of vitamin C reduced the respiratory symptom score in the more severe patients [246].
In other pneumonia patients, low-dose vitamin C (0.25–0.8 g/day) reduced the hospital stay by
19% compared with no vitamin C supplementation, whereas the higher-dose group (0.5–1.6 g/day)
reduced the duration by 36% [255]. There was also a positive effect on the normalization of
chest X-ray, temperature, and erythrocyte sedimentation rate [255]. Since prophylactic vitamin C
administration also appears to decrease the risk of developing more serious respiratory infections, such
as pneumonia [256], it is likely that the low vitamin C levels observed during respiratory infections are
both a cause and a consequence of the disease.
6. Conclusions
Overall, vitamin C appears to exert a multitude of beneficial effects on cellular functions of
both the innate and adaptive immune system. Although vitamin C is a potent antioxidant protecting
the body against endogenous and exogenous oxidative challenges, it is likely that its action as a cofactor
for numerous biosynthetic and gene regulatory enzymes plays a key role in its immune-modulating
effects. Vitamin C stimulates neutrophil migration to the site of infection, enhances phagocytosis and
oxidant generation, and microbial killing. At the same time, it protects host tissue from excessive
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damage by enhancing neutrophil apoptosis and clearance by macrophages, and decreasing neutrophil
necrosis and NETosis. Thus, it is apparent that vitamin C is necessary for the immune system to mount
and sustain an adequate response against pathogens, whilst avoiding excessive damage to the host.
Vitamin C appears to be able to both prevent and treat respiratory and systemic infections by
enhancing various immune cell functions. Prophylactic prevention of infection requires dietary vitamin C
intakes that provide at least adequate, if not saturating plasma levels (i.e., 100–200 mg/day), which
optimize cell and tissue levels. In contrast, treatment of established infections requires significantly
higher (gram) doses of the vitamin to compensate for the increased metabolic demand.
Epidemiological studies indicate that hypovitaminosis C is still relatively common in Western
populations, and vitamin C deficiency is the fourth leading nutrient deficiency in the United
States. Reasons include reduced intake combined with limited body stores. Increased needs occur
due to pollution and smoking, fighting infections, and diseases with oxidative and inflammatory
components, e.g., type 2 diabetes, etc. Ensuring adequate intake of vitamin C through the diet or via
supplementation, especially in groups such as the elderly or in individuals exposed to risk factors for
vitamin C insufficiency, is required for proper immune function and resistance to infections.
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Abstract: Observational studies have found a protective effect of vitamin C on cardiovascular health.
However, results are inconsistent, and residual confounding by fiber might be present. The aim of
this study was to assess the association of vitamin C with the incidence of cardiovascular disease
(CVD) and cardiovascular mortality (CVM) while accounting for fiber intake and adherence to the
Mediterranean dietary pattern. We followed up 13,421 participants in the Seguimiento Universidad
de Navarra (University of Navarra follow-up) (SUN) cohort for a mean time of 11 years. Information
was collected at baseline and every two years through mailed questionnaires. Diet was assessed with
a validated semi-quantitative food frequency questionnaire. Incident CVD was defined as incident
fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, or death due to any cardiovascular
cause. CVM was defined as death due to cardiovascular causes. Events were confirmed by physicians
in the study team after revision of medical records. Cox proportional hazard models were fitted
to assess the associations of (a) energy-adjusted and (b) fiber-adjusted vitamin C intake with CVD
and CVM. We found energy-adjusted vitamin C was inversely associated with CVD and CVM after
adjusting for several confounding factors, including fiber from foods other than fruits and vegetables,
and adherence to the Mediterranean dietary pattern. On the other hand, when vitamin C was adjusted
for total fiber intake using the residuals method, we found a significant inverse association with CVM
(HR (95% confidence interval (CI)) for the third tertile compared to the first tertile, 0.30 (0.12–0.72),
but not with CVD in the fully adjusted model.
Keywords: vitamin C; cardiovascular disease; cardiovascular mortality; fiber
1. Introduction
Vitamin C, also known as L-ascorbic acid, is a water-soluble vitamin naturally present in some
foods, added to others, and available as dietary supplement. Vitamin C is an essential dietary
component, since humans, unlike most animals, are unable to synthetize it. Vitamin C is required for
the synthesis of collagen, L-carnitine and some neurotransmitters. Based on vitamin C’s antioxidant
capacity, there is growing interest in assessing whether vitamin C intake might help prevent or delay
some type of cancer, cardiovascular disease (CVD) or other diseases in which oxidative stress plays an
important role.
Recommended dietary allowances (RDA) for vitamin C—75 mg/day for women and 90 mg/day
for men [1]—are based on its known physiological and antioxidant functions in white blood cells and
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are higher than the amount required to prevent deficiency. Nevertheless, given that vitamin C may
relate to cancer, CVD, or other diseases through different mechanisms, whether classical RDAs are
optimal to obtain maximum benefits is unclear [2].
The belief that vitamin C relates to cardiovascular health stemmed from the benefits observed
from fruit and vegetable consumption [3–5]. Observational studies have found an inverse association
of dietary vitamin C [6] and ascorbic acid plasma levels [6–8] with cardiovascular risk factors, CVD,
and cardiovascular mortality (CVM). Nevertheless, those studies showed some limitations, including
suboptimal adjustment for potential confounders such as fiber intake.
Vitamin C from foods and supplements seemed to be equally bioavailable [9]. However,
observational studies [6] and clinical trials [10–13] concluded that supplementation with vitamin C
(500 to 1000 mg/day) had no effect on different cardiovascular endpoints. Moreover, higher CVM
and total mortality has been reported among participants under vitamin C supplementation in both
observational [14] and interventional studies [15]. On the other hand, two meta-analyses reported
that high dose supplementation with vitamin C ((500 to 2000 mg/day) and (500 to 4000 mg/day)
respectively) was associated to endothelial function improvements [16] and reduced blood pressure [17].
The aim of this study was to assess whether vitamin C intake was independently associated
with lower CVD and CVM risk among participants in the Seguimiento Universidad de Navarra
(University of Navarra follow-up) (SUN) cohort.
2. Materials and Methods
2.1. Study Population
The SUN project is an ongoing, prospective and multipurpose cohort of Spanish university
graduates. As a dynamic cohort, enrolment is permanently open, and follow-up information is
gathered by mailed questionnaires every two years. Regarding the obtention of informed consent of
potential participants, we duly informed these potential candidates of their right to refuse to participate
in the SUN study or to withdraw their consent to participate at any time without reprisal, according to
the principles of the Declaration of Helsinki. Special attention was given to the specific information
needs of individual potential candidates as well as to the methods used to deliver their information
and the feedback that may receive in the future from the research team. After ensuring that the
candidate had understood the information, we sought their potential freely-given informed consent,
and their voluntary completion of the baseline questionnaire. These methods were accepted by our
Institutional Review Board as to imply an appropriately-obtained informed consent. A more detailed
description of the SUN methodology can be found elsewhere [18]. The study protocol was approved
by the Institutional Review Board of the University of Navarra (approval code 010830).
We assessed 22,280 participants recruited before March 2014 to ensure they completed at least
the two-year follow-up questionnaire. We excluded 308 participants due to prevalent cardiovascular
disease, 7384 participants younger than 40 years old who were considered too young to present
a cardiovascular event during the follow-up, 290 participants with energy intake out of the sex-specific
limits (under p1 or above p99), and 284 participants with vitamin C intake out of the sex-specific limits
(under p1 or above p99). Out of the rest of the participants, 593 were lost to follow-up (retention in the
cohort: 96%), leading to a final sample of 13,421 participants (Figure 1).
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Figure 1. Flow chart of participants for the assessment of the association of cardiovascular disease
and cardiovascular mortality with vitamin C intake in the Seguimiento Universidad de Navarra
(University of Navarra follow-up) (SUN) cohort (follow-up 1999–2016).
2.2. Exposure Assessment
Participants were asked to complete a previously validated semi-quantitative food frequency
questionnaire (FFQ) [19,20] and report how often on average they had consumed 136 foods and
beverages during the past year. The FFQ had nine categories for intake frequency, from never to two
or more servings per day. Multivitamin and supplements users were asked to specify the brand of
multivitamin or supplement, the dose, and frequency of use. The nutritional content of each food
was obtained from Spanish food composition guides [21,22] and supplemented with information
from food and supplement manufacturers when needed. The nutrient contribution of each food item
was calculated by multiplying the frequency of food consumption by the nutrient composition of the
specified portion size. Dietary vitamin C intake was adjusted for energy intake using the residuals
method, and categorized into tertiles. Total vitamin C intake was estimated by summing the vitamin C
contribution of food items and supplements. In ancillary analyses, we assessed the independent effect
of vitamin C from foods additionally adjusted for supplement intake (dichotomous variable).
In further analyses, to nullify the correlation between vitamin C and fiber, dietary vitamin C was
alternatively adjusted for total fiber intake using the residuals method.
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2.3. Outcome Assessment
Incident CVD was defined as either incident fatal or non-fatal myocardial infarction (with or
without ST elevation), or fatal or non-fatal stroke and death due to other cardiovascular causes.
CVM was defined as death due to cardiovascular causes.
Information about the events was initially gathered from follow-up questionnaires.
When participants reported any of the previously mentioned events, they were asked for their medical
reports, which were evaluated by physicians in the study team who were blinded to the nutritional
information. Myocardial infarction was diagnosed using universal criteria. Non-fatal stroke was
defined as sudden onset focal-neurological lack with a vascular mechanism that last more than 24 h.
Confirmed events were classified according to the International Classification of Diseases (ICD-10).
I21 and I63 codes were considered to define cardiovascular events [23]. The National Death Index is
checked at least once a year to confirm the vital status of participants during follow-up. Deaths were
reported by either participant’s next of kin, work associates, or postal authorities.
Participants were followed-up from enrollment until December 2016, the diagnosis of the event,
or death, whichever came first.
2.4. Covariates
Information about socio-demographic and anthropometric characteristics, lifestyle (physical activity,
television watching, smoking status), classical cardiovascular risk factors (hypertension,
hypercholesterolemia, hypertriglyceridemia and diabetes), prevalent diseases (cancer and cardiovascular
related diseases), and family history of stroke and cardiovascular-related medication was collected
at baseline.
Age was calculated as the difference between the date of recruitment and the date of birth.
Body mass index (BMI) was calculated by dividing participants’ weight (kg) by their squared height
(m). A validation study in a subset of the SUN cohort showed that self-reported weight and height
were highly reproducible and specific [24].
Dietary information was obtained from the baseline FFQ. Energy (kcal/day) and fiber (mg/day)
intakes were calculated by multiplying the frequency of each food item consumed by the energy and
fiber contribution of its specified portion size. Total energy and fiber intakes were calculated as the sum
of energy and fiber provided by each food item. We also calculated the adherence to the Mediterranean
dietary pattern based on the information from the FFQ using the classical Mediterranean Dietary
Score (MDS) [25] without the fruit- and vegetable-related items (total seven items). We defined three
categories of adherence to the MDS: Low (from 0 to 2 points), medium (from 3 to 4 points), and high
(from 5 to 7 points).
Physical activity was collected at baseline with a previously validated questionnaire [26] that
included 17 activities and 10 categories of response, from never to eleven or more hours per week.
METs-h/week for each activity were calculated by multiplying the number of Metabolic Equivalent of
Task (METs) of each activity [27] by the weekly participation in that activity, weighted according to
the number of months dedicated to each activity. Total physical activity was quantified by summing
the METs-h/week dedicated to all activities performed during leisure time. Time spent watching
television was used as a proxy of sedentary behavior [28]. Hours per week of television watching were
calculated as the mean of hours spent watching television during weekdays and hours spent watching
television during weekends. Missing data were imputed based on the values of other covariates.
Cardiovascular-related diseases at baseline (coronary heart disease, tachycardia, atrial fibrillation,
aortic aneurism, heart failure, venous thrombosis, and claudication) were grouped in a single
quantitative variable (number of cardiovascular-related diseases) included in the multivariable
adjustment. Validation studies in the SUN cohort showed self-reported information about
cardiovascular risk factors was valid as to be used in epidemiological studies [29,30].
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2.5. Statistical Analysis
Baseline characteristics of participants were presented by tertiles of total vitamin C intake as mean
(standard deviation) for quantitative variables, and as proportions for qualitative variables. A p value
for trend across tertiles was calculated using simple linear or logistic regressions.
We fitted Cox proportional hazard models to assess the association of energy-adjusted vitamin C
intake with CVD and CVM. We estimated the hazard ratios (HR) and their 95% confidence intervals
(CI) for second and third tertile of vitamin C intake compare to the lowest tertile (category of reference).
Age was used as the underlying time variable in all the models. We fitted five multivariable adjusted
models: (1) adjusted for age and sex; (2) additionally adjusted for body mass index (continuous),
total energy intake (continuous), physical activity (continuous), television watching (continuous),
smoking (never, current, or former), family history of stroke (dichotomus) and treatment with aspirin
(dichotomus); (3) additionally adjusted for number of cardiovascular-related diseases at baseline
(discrete), prevalent cancer (dichotomus), prevalent hypertension (dichotomus), prevalent diabetes
(dichotomus), prevalent hypercholesterolemia (dichotomus) and prevalent hypertriglyceridemia
(dichotomus); (4) additionally adjusted for dietary fiber (fiber from foods other than fruits and
vegetables) (continuous); and (5) additionally adjusted for adherence to the MDS (without the fruit- and
vegetable-related items (low, medium or high).
Interactions with vitamin C supplements intake, total fiber intake and age at the end of follow-up
were assessed for both CVD and CVM by adding an interaction product term to the model and
calculating the maximum likelihood ratio test.
In ancillary analyses, we evaluated the association of tertiles of dietary vitamin C with CVD and
CVM fitting a model additionally adjusted for vitamin C supplements intake (dichotomus).
In further analyses, we re-ran the multivariable adjusted models for fiber-adjusted vitamin C
intake categorized into tertiles.
Analyses were performed with STATA version 12.0 (StataCorp, College Station, TX, USA).
3. Results
We followed-up 13,421 participants for a mean time of 10.9 years (the standard deviation
(SD) = 3.82). Baseline characteristics of participants by tertiles of vitamin C intake are described
in Table 1. Participants in the highest tertile of vitamin C intake (from 320 to 1110 mg/day) were
older, more likely to be women, and less likely to be current smokers. They were also more physically
active and spent less time watching television. Moreover, they reported higher fiber intake and
greater adherence to the Mediterranean dietary patter (MDP). We found total vitamin C intake showed
a modest correlation with energy intake (r = 0.33), but it was highly correlated with total fiber intake
(r = 0.72). Similar results were found for dietary vitamin C.
Aortic aneurism, heart failure, and hypertriglyceridemia at baseline were less prevalent among
participants with higher vitamin C intake. However, cancer, venous thrombosis, diabetes, hypertension,
and family history of stroke at baseline were more prevalent, probably due to the older age of
participants with higher intake of vitamin C. Participants in the highest tertile of vitamin C intake were
more likely to be under treatment with diuretics, antihypertensives, aspirin, and other cardiovascular
treatment drugs.
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Table 1. Baseline characteristics of participants over 40 years old in the SUN cohort by tertiles of total
vitamin C intake. Numbers are means (SD) or percentages.
Baseline Characteristics
Tertiles of Vitamin C Intake
Q1 Q2 Q3 p
N 4474 4474 4473
Vitamin C intake (mg/day) 148 (44.2) 257 (33.0) 445 (114) <0.001
Fiber intake (g/day) 23.0 (10.0) 27.8 (9.8) 38.3 (14.1) <0.001
Vittamin C range (mg/day) 0–205 206–319 320–1110
Vittamin C from supplements (mg/day) 0.56 (4.2) 2.0 (10.0) 9.6 (33.4) <0.001
Sex (female) 41.6 55.8 67.9 <0.001
Age (years) 41.2 (10.3) 42.8 (10.7) 43.7 (10.8) <0.001
BMI (kg/m2) 24.3 (3.6) 24.1 (3.5) 23.8 (3.5) <0.001
Mediterranean Dietary Score § <0.001
Low (0–2 points) 39.0 29.6 21.4
Medium (3–4 points) 47.3 50.9 51.1
High (5–7 points) 13.7 19.5 27.5
Energy intake (kcal/day) 2548 (804) 2346 (710) 2530 (755) 0.26
Physical activity (MET-h/week) 23.4 (20.6) 25.8 (21.6) 29.2 (25.3) <0.001
Television time (h/week) 1.63 (1.1) 1.57 (1.1) 1.51 (1.1) <0.001
Family history of myocardial infarction 15.8 18.3 17.1 0.09
Smoking 0.03
Never 43 44 44
Current 29 23 22
Former 28 33 34
Prevalent diseases
Cancer 3.7 4.6 5.6 <0.001
Coronary heart disease 0.38 0.47 0.27 0.39
Tachycardia 1.9 1.6 2.3 0.12
Atrial fibrillation 0.65 0.72 0.69 0.80
Aortic aneurism 0.25 0.11 0.02 0.01
Heart failure 0.42 0.56 0.38 0.75
Pulmonary embolism 0.13 0.09 0.11 0.75
Venous thrombosis 0.51 0.92 0.92 0.03
Claudication 0.31 0.31 0.56 0.07
Diabetes 1.4 2.2 3.0 <0.001
Hypertension 9.7 11.3 10.9 0.07
Hypercholesterolemia 20.0 21.9 20.7 0.42
Hypertriglyceridemia 8.5 8.9 7.3 0.04
Drugs
Digoxin 0.11 0.13 0.13 0.77
Diuretics 1.0 1.6 1.7 0.01
Beta blockers 1.7 2.3 1.9 0.40
Calcium antagonists 0.40 0.45 0.63 0.13
Nitrite 0.13 0.11 0.18 0.57
Antihypertensives 2.8 4.1 3.7 0.03
Aspirin 3.4 5.2 4.9 0.001
Other CV treatment drug 5.2 6.9 6.6 0.01
§ Mediterranean Diet Score without the fruit- and vegetable-related items. N = 13,421.
Multivariable-adjusted associations of total vitamin C intake with both CVD and CVM are showed
in Figure 2.
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Figure 2. Restricted Cubic Splines for the Hazard Ratio (HR) and 95% Confidence Interval (CI) for
cardiovascular disease and cardiovascular mortality associated with total vitamin C intake in the SUN
cohort (follow-up 1999–2016). Age strata as underlying time variable. Multivariable model adjusted
for sex, body mass index (continuous), total energy intake (continuous), physical activity (continuous),
television watching (continuous), smoking (never, current or former), family history of stroke, treatment
with aspirin, number of cardiovascular-related diseases at baseline, prevalent cancer, prevalent
hypertension, prevalent diabetes, prevalent hypercholesterolemia, prevalent hypertriglyceridemia,
fiber (from foods other than fruits and vegetables) (continuous), and Mediterranean Dietary Score
(MDS) without fruit- and vegetable-related items (low, medium, high).
3.1. Cardiovascular Disease
A total of 134 cases of CVD were identified over 146,973 person-years at risk. The cumulative
risk of a cardiovascular event was 0.07% in the highest tertile versus 0.12% in the lowest tertile of
vitamin C intake.
We found that higher vitamin C intake was associated with a lower risk of CVD in the age-adjusted
analysis (Table 2). Moreover, this association remained significant in the age and sex-adjusted model,
in the model adjusted for demographic, metabolic, and lifestyle risk factors (multivariable adjusted
model 1), and in the model additionally adjusted for prevalent diseases at baseline (multivariable
adjusted model 2). Further adjustment for fiber intake (multivariable adjusted model 3) did not change
the results. In the fully adjusted model (multivariable adjusted model 4), we found that, compared
with participants in the first tertile of vitamin C intake, those in the second and third tertiles showed
significant lower risk of CVD (HR (95% CI): 0.60 (0.40–0.91) and 0.62 (0.40–0.97), respectively).
High vitamin C intake showed no significant association with CVD when fiber from fruits
and vegetables was also considered. HRs (95% CI) for the third tertile in models 3 and 4 were
0.66 (0.39–1.10) and 0.68 (0.40–1.13), respectively. Nevertheless, the association was still significant
when the second and third tertiles were considered together (HR (95% CI): 0.63 (0.41–0.94) for model 3
and 0.64 (0.43–0.88) for model 4).
Neither age at the end of follow-up (p = 0.79) nor fiber intake (p = 0.15) resulted in effect
modification. Marginally significant interaction was found between total vitamin C and vitamin
C supplementation (p = 0.05).
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Table 2. Hazard Ratio (HR) and 95% Confidence Interval (CI) for cardiovascular disease (CVD)
associated with total vitamin C intake for participants over 40 years old in the SUN cohort (follow-up
1999–2016).
Main Analyses §
Tertiles of Vitamin C Intake
Q1 (N = 4474) Q2 (N = 4474) Q3 (N = 4473)
Incident CVD (person-years at risk) 61 (50,792) 38 (48,765) 35 (47,415)
Age-adjusted 1.00 (Ref.) 0.52 (0.35–0.78) 0.44 (0.29–0.67)
Sex- and age-adjusted 1.00 (Ref.) 0.59 (0.39–0.89) 0.56 (0.37–0.86)
Multivariable adjusted model 1 1.00 (Ref.) 0.59 (0.39–0.90) 0.60 (0.39–0.93)
T2 + T3 vs. T1 1.00 (Ref.) 0.60 (0.42–0.85)
Multivariable adjusted model 2 1.00 (Ref.) 0.58 (0.38–0.88) 0.58 (0.37–0.90)
T2 + T3 vs. T1 1.00 (Ref.) 0.58 (0.41–0.83)
Multivariable adjusted model 3 1.00 (Ref.) 0.58 (0.38–0.88) 0.58 (0.37–0.90)
T2 + T3 vs. T1 1.00 (Ref.) 0.58 (0.41–0.83)
Multivariable adjusted model 4 1.00 (Ref.) 0.60 (0.40–0.91) 0.62 (0.40–0.97)
T2 + T3 vs. T1 1.00 (Ref.) 0.61 (0.43–0.88)
§ Age strata as underlying time variable in all the models; N = 13,421; Ref: reference category. Multivariable
adjusted model 1: Additionally adjusted for sex, body mass index (continuous), total energy intake (continuous),
physical activity (continuous), television watching (continuous), smoking (never, current or former), family history
of stroke, and treatment with aspirin. Multivariable adjusted model 2: Additionally adjusted for the number
of cardiovascular-related diseases at baseline, prevalent cancer, prevalent hypertension, prevalent diabetes,
prevalent hypercholesterolemia and prevalent hypertrygliceridemia. Multivariable adjusted model 3: Additionally
adjusted for dietary fiber (fiber from foods other than fruits and vegetables) (continuous). Multivariable adjusted
model 4: Additionally adjusted for the MDS without fruit and vegetable intake related items (low, medium, or high).
3.2. Cardiovascular Mortality
A total of 48 cases of CVM occurred over 147,495 person-years at risk during the follow up.
The cumulative risk was 0.02% in the third tertile versus 0.04% in the first tertile of vitamin C intake.
Compare to the category of reference, we found a significant inverse association for the highest
tertile of vitamin C intake and CVM in the age-adjusted analysis (Table 3). Results were similar in the
age and sex-adjusted model; the models adjusted for demographic, metabolic and lifestyle risk factors;
(multivariable adjusted model 1); and in the model additionally adjusted for prevalent diseases at
baseline (multivariable adjusted model 2). Additional adjustment for fiber from foods other than fruits
and vegetables did not change the results, but they became non-significant when total fiber intake
was considered (HR (95% CI): 0.48 (0.19–1.20)). No significant results were found in the fully-adjusted
model that included the MDS.
Neither age at the end of follow-up (p = 0.70), fiber intake (p = 0.42), nor vitamin C supplements
intake (p = 0.12) modified the association between total vitamin C intake and CVM.
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Table 3. Hazard Ratios (HR) and 95% Confidence Intervals (CI) for cardiovascular mortality associated
with total vitamin C intake for participants over 40 years old in the SUN cohort (follow-up 1999–2016).
Main Analyses §
Tertiles of Vitamin C Intake
Q1 (N = 4474) Q2 (N = 4474) Q3 (N = 4473)
Cardiovascular deaths
(person-years at risk) 22 (51,016) 15 (48,901) 11 (47,577)
Age-adjusted 1.00 (Ref.) 0.55 (0.28–1.06) 0.34 (0.17–0.73)
Sex- and age-adjusted 1.00 (Ref.) 0.56 (0.29–1.10) 0.37 (0.17–0.79)
Multivariable adjusted model 1 1.00 (Ref.) 0.57 (0.29–1.12) 0.39 (0.18–0.86)
Multivariable adjusted model 2 1.00 (Ref.) 0.54 (0.27–1.08) 0.40 (0.18–0.89)
Multivariable adjusted model 3 1.00 (Ref.) 0.54 (0.27–1.09) 0.41 (0.19–0.92)
Multivariable adjusted model 4 1.00 (Ref.) 0.56 (0.28–1.12) 0.45 (0.20–1.01)
§ Age strata as underlying time variable in all the models; N = 13,421; Ref: reference category. Multivariable adjusted
model 1: Additionally adjusted for sex, body mass index (continuous), total energy intake (continuous), physical
activity (continuous), television watching (continuous), smoking (never, current or former), family history of
stroke, and treatment with aspirin. Multivariable adjusted model 2: Additionally adjusted for the number of
cardiovascular-related diseases at baseline, prevalent cancer, prevalent hypertension, prevalent diabetes, prevalent
hypercholesterolemia, and prevalent hypertrygliceridemia. Multivariable adjusted model 3: Additionally adjusted
for dietary fiber (fiber from foods other than fruits and vegetables) (continuous). Multivariable adjusted
model 4: Additionally adjusted for the MDS without fruit and vegetable intake related items (low, medium, or high).
3.3. Fiber-Adjusted Vitamin C Intake
In further analyses, dietary vitamin C was adjusted for total fiber intake using the residuals
method to nullify the correlation between vitamin C and fiber (Table 4). We found a cumulative risk
for CVD of 0.07% in the third versus 0.12% in the first tertile. However, no significant association was
found for vitamin C intake and CVD.
On the other hand, the cumulative risk for CVM was 0.01% in the third tertile versus 0.05% in
the first one. Compared with participants in the first tertile, those in the highest tertile of vitamin
C intake showed significant lower risk of CVM in multivariable adjusted analyses (HR (95% CI):
0.30 (0.13–0.73)). Further adjustment for the MDS did not change the results.
Neither CVD nor CVM were significantly associated with dietary vitamin C, independently of
vitamin C supplement intake (Figure S1).
Table 4. Hazard Ratio (HR) and 95% Confidence Interval (CI) for the association of total vitamin C
intake, adjusted for fiber intake using the residuals method with both cardiovascular disease (CVD)
and cardiovascular mortality (CVM) for participants over 40 years old in the SUN cohort (follow-up
1999–2016).
Main Analyses §
Tertiles of Vitamin C Intake
Q1 (N = 4474) Q2 (N = 4474) Q3 (N = 4473)
Incident CVD (person-time-1 at risk) 58 (49,706) 44 (49,080) 32 (48,186)
Multivariable adjusted § ‡ 1.00 (Ref.) 0.86 (0.57–1.29) 0.74 (0.47–1.15)
Additionally adjusted for MDS 1.00 (Ref.) 0.86 (0.57–1.29) 0.74 (0.47–1.15)
Cardiovascular deaths (person-years at risk) 27 (49,879) 14 (49,247) 7 (48,368)
Multivariable adjusted § ‡ 1.00 (Ref.) 0.52 (0.26–1.02) 0.30 (0.13–0.73)
Additionally adjusted for MDS 1.00 (Ref.) 0.52 (0.26–1.04) 0.30 (0.12–0.72)
MDS: Mediterranean Dietary Score without fruit and vegetable intake related items (low, medium, or high);
§ Age as underlying time variable in all the models; ‡ Adjusted for sex, body mass index (continuous), total energy
intake (continuous), total fiber intake (continuous), physical activity (continuous), television watching (continuous),
smoking (never, current or former), number of cardiovascular-related diseases at baseline, prevalent cancer, prevalent
hypertension, prevalent diabetes, prevalent hypercholesterolemia, prevalent hypertriglyceridemia, family history of
stroke, and treatment with aspirin. N = 13,421; Ref: reference category.
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4. Discussion
In this large cohort of Spanish university graduates followed-up over a mean time of 11 years,
we found that, compared with the lowest category, the third tertile of total vitamin C intake was
associated with 70% (95% CI 18%–88%) lower risk of CVM, but not with CVD. This analysis was based
on a multivariable adjusted model that thoroughly controlled potential confounding by fiber and
accounted for the adherence to the Mediterranean dietary pattern.
The belief that vitamin C benefits cardiovascular health is based on its antioxidant capability.
Vitamin C may prevent oxidative changes to low-density lipoprotein (LDL)-cholesterol [31] and
reduce monocyte adhesion [32], which are key in reducing the risk of atherosclerosis. Moreover,
vitamin C prevents vascular smooth muscle cells apoptosis, which keeps atheroma plaques stables [33].
In addition, vitamin C improves the nitric oxide production of the endothelium [34], which in turn
contributes to reduced blood pressure. This evidence, when added to the results found in the analyses
to account for confounding by fiber and dietary variables included in the MDS, suggests that the
associations of vitamin C intake with CVM may not be due to confounding factors, but may instead
represent a true biological effect.
Observational studies had reported inverse associations of vitamin C with cardiovascular
outcomes, particularly on hypertension [6] and heart failure [7]. However, those studies did not
account for fiber intake. Due to the high correlation between vitamin C and fiber intakes found in
this study, it was difficult to assess the effect of vitamin C on cardiovascular health independently of
fiber intake in a multivariable adjusted model. In order to nullify that correlation, dietary vitamin C
was adjusted for total fiber intake using the residuals method. On the other hand, reduced CVM risk
associated to vitamin C intake had been previously reported in observational studies [8]. However,
this association has not been confirmed in randomized controlled trials [10,11].
We found that energy-adjusted total vitamin C intake was associated with a lower risk of CVD.
We obtained similar estimates in the comparisons of the second and the third tertiles, which suggests
a threshold effect or L-shaped association between total vitamin C and CVD. However, in further
analyses, we found the association of fiber-adjusted vitamin C with CVD was not significant.
We also found that high energy-adjusted total vitamin C intake was associated with lower risk of
CVM after multivariable adjustment for demographic, metabolic, and lifestyle risk factors, prevalent
diseases at baseline, and fiber from foods other than fruits and vegetables. However, results became
non-significant when the model was additionally adjusted for the MDS. Nevertheless, further analyses
showed that, compared to the first tertile, the highest category of fiber-adjusted vitamin C intake was
associated with lower CVM risk in the fully adjusted model (HR: 0.30, 95% CI (0.12–0.72)).
These results suggest that most of the confounding effect by fiber was due to fiber from fruits and
vegetables. Since vitamin C and fiber were highly correlated (r = 0.72) it was difficult to assess the effect
of one of them while keeping the other one constant (Tables 2 and 3). When vitamin C was adjusted
for fiber using the residuals method (Table 4), the correlation was nullified (r = 0), which allowed for
the assessment of the effect of vitamin C on cardiovascular health independently of fiber. Nevertheless,
given that vitamin C is a single nutrient and may not represent the whole dietary pattern, these
results must be taken with caution. Several reasons support the hypothesis that attributing all of
the observed effect to a single nutrient or food may be too simplistic and that when assessing the
association of dietary variables with non-communicable diseases, the whole dietary pattern should be
considered [35].
None significant associations with either CVD or CVM were found when vitamin C from food
was considered alone. Importantly, means (SD) (mg/day) of fiber-adjusted dietary vitamin C intake
across successive tertiles were 184 (57), 266.7 (20.5), and 387.7 (75.6) respectively. Therefore, the absence
of significant results might be explained by the low variability in the exposure.
Regarding vitamin C supplements, our results parallel previous intervention studies that reported
no effect of vitamin C supplementation on cardiovascular health [10–13]. It must be acknowledged that
some clinical trials permitted the control group to an intake of vitamin C and multivitamin supplements,
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which made it harder to find significant differences between groups. Vitamin C supplementation
in our study ranged from 3.4 to 440 mg/day, which is much lower than the doses assessed in the
available clinical trials. We found the effect of total vitamin C on CVD may depend on vitamin C
supplementation (p for interaction 0.05). However, among the 1055 participants undertaking vitamin C
supplementation (8%), we found two cases of CVD and one single case of CVM; thus, stratified
analyses were not possible.
Some limitations of this study must be acknowledged. First, because information about exposure
was self-reported, some degree of misclassification is possible. Nevertheless, information bias would
more likely be non-differential with respect to the outcomes, resulting in an attenuation of the observed
associations. Moreover, little variability observed in the exposure might have reduced the possibility of
significant findings. Second, the SUN cohort is not a representative sample of the general population,
and therefore generalization of these results must be based on biological mechanisms rather than
on statistical representativeness. Third, given the observational design of the study, the possibility
of residual confounding for factors that were not considered (such as vitamin E) must be taken
into account. Thus, before causality is implied, these results must be confirmed in well-designed
randomized controlled trials. Finally, because participants in the SUN cohort are relatively young and
health conscious, few incident cases of CVM were observed during follow-up. Further studies are
need to determine if the magnitude of the association we observed represents the upper bound of the
association between vitamin C and CVM. Despite these limitations, our study has several strengths.
The sample size is large, the follow-up period is long, and the retention rate is high. Dietary information
was collected with a validated FFQ, and outcomes were confirmed by physicians checking participant’s
medical records. Finally, participants in the SUN cohort are highly educated, and more than half are
health professionals themselves, which reduces potential confounding by educational level, leads to
better quality in self-reported data, and increases the internal validity of the study.
5. Conclusions
Energy-adjusted analyses suggest a threshold effect in the association of vitamin C intake with
CVD, but not with CVM. Nevertheless, the model fitted to thoroughly control potential confounding
for fiber showed that compared with the category of reference, the highest tertile of total vitamin C
intake was associated with a significantly lower risk of CVM, but not CVD, after adjusting for several
confounding factors, including adherence to the Mediterranean dietary pattern. Further research
is needed in order to fully understand the biological mechanisms explaining these associations.
Moreover, these results must be reproduced in different populations before clinical implications can
be assessed.
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Abstract: Vitamin C (vitC) deficiency is associated with increased cardiovascular disease risk, but its
specific interplay with arteriolar function is unclear. This study investigates the effect of vitC
deficiency in guinea pigs on plasma biopterin status and the vasomotor responses in coronary
arteries exposed to vasoconstrictor/-dilator agents. Dunkin Hartley female guinea pigs (n = 32)
were randomized to high (1500 mg/kg diet) or low (0 to 50 mg/kg diet) vitC for 10–12 weeks.
At euthanasia, coronary artery segments were dissected and mounted in a wire-myograph. Vasomotor
responses to potassium, carbachol, sodium nitroprusside (SNP), U46619, sarafotoxin 6c (S6c) and
endothelin-1 (ET-1) were recorded. Plasma vitC and tetrahydrobiopterin were measured by HPLC.
Plasma vitC status reflected the diets with deficient animals displaying reduced tetrahydrobiopterin.
Vasoconstrictor responses to carbachol were significantly decreased in vitC deficient coronary
arteries independent of their general vasoconstrictor/vasodilator capacity (p < 0.001). Moreover,
in vitC deficient animals, carbachol-induced vasodilator responses correlated with coronary artery
diameter (p < 0.001). Inhibition of cyclooxygenases with indomethacin increased carbachol-induced
vasoconstriction, suggesting an augmented carbachol-induced release of vasodilator prostanoids.
Atropine abolished carbachol-induced vasomotion, supporting a specific muscarinic receptor effect.
Arterial responses to SNP, potassium, S6c, U46619 and ET-1 were unaffected by vitC status. The study
shows that vitC deficiency decreases tetrahydrobiopterin concentrations and muscarinic receptor
mediated contraction in coronary arteries. This attenuated vasoconstrictor response may be linked
to altered production of vasoactive arachidonic acid metabolites and reduced muscarinic receptor
expression/signaling.
Keywords: Vitamin C; ascorbic acid; vascular responses; biopterins
1. Introduction
The association between vitamin C (vitC) deficiency and an increased risk of cardiovascular
disease (CVD) in humans is well-established [1–6], though a mechanistic link is yet to be elucidated.
VitC is an essential nutrient for humans and an estimated 10–15% of adults in the Western populations
suffer from hypovitaminosis C (plasma concentration <23 μM) [7]. Pathologies of vascular diseases
are characterized by changed vasomotion as a consequence of an imbalance in vasodilation and
vasoconstriction, leading to abnormal blood flow regulation and organ dysfunction. In the vasculature,
vitC is a key component in maintaining collagen integrity of blood vessels; prolonged severe deficiency
ultimately leads to the development of bleedings and haematoma hallmarking scurvy. However, little
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is known about how non-scorbutic vitC deficiency affects the function of the vascular cells and the
vasomotion of arterioles proximal to the capillaries.
In human endothelial cells in vitro, vitC has been shown to act as specific redox modulator in
the nitric oxide (NO) synthesis essential for vasodilation [8]. Furthermore, vitC provides reducing
equivalents in the conversion of dihydrobiopterin (BH2) to tetrahydrobiopterin (BH4) [9,10], which in
turn acts as co-factor for endothelial nitric oxide syntase (eNOS) to ensure the generation of NO [11].
Reduced BH4 levels lead to eNOS uncoupling, and generation of superoxide rather than NO [12], likely
to form the strong oxidant peroxynitrite and decreasing NO bioavailability [9]. We have previously
shown that vitC deficiency in guinea pigs leads to decreased BH4 plasma concentration in vivo [13],
potentially weakening the vasodilator capacity.
Another important aspect of vitC is its antioxidant function, serving as a scavenger of reactive
oxygen species (ROS) [14]. ROS play key roles in signal transduction related to both vasodilation
and vasoconstiction [15] and can inhibit the two major endothelium-derived relaxing factors, NO and
prostacyclin [15]. While eNOS uncoupling reduces NO bioavailability, peroxynitrite can inactivate
prostacyclin synthase by tyrosin nitration of its active site [16,17]. Thus, as the primary vascular
antioxidant, vitC protects the endothelium from oxidative stress [18].
A third mechanism of vitC-associated action could be on the cholinergic response of vascular
smooth muscle cells (VSMCs). Increased oxidative stress has been found to reduce muscarinic receptor
function in smooth muscle cells of the urinary bladder [19], and studies have shown an attenuated
parasympathetic response [20] and muscarinic-cholinergic receptor density [21] in submandibular
gland acinar cells in vitC deficient guinea pigs. As coronary arteries express muscarinic receptors in
the endothelium and VSMCs, and an extensive network of cholinergic perivascular nerve fibres in the
coronary artery tree is present in guinea pigs [22], the acetylcholine analogue carbachol was applied to
study both vasodilator and vasoconstrictor responses.
In contrast to rats and mice, guinea pigs and humans share a requirement for dietary vitC. This
makes the guinea pig an excellent in vivo model for studying effects of diet-imposed vitC deficiency.
In this study, we examined a causal relationship between chronic vitC deficiency and plasma biopterin
redox status, and putative consequences on the vasodilator and vasoconstrictor responses in isolated
coronary arteries.
2. Materials and Methods
2.1. Animal Study
All experimental animal procedures were performed following protocols approved by the Danish
Animal Experimental Inspectorate under the Ministry of Environment and Food of Denmark (No.
2012-15-2934-00205). Group sizes were determined by power analysis of sample size, applying a power
of 80% and a 5% significance level. A difference of 30% was considered biologically relevant and
variations of the chosen end-points were based on our previous experience with the model [23,24].
Animals were selected by randomization from a larger, extensive, study of diet imposed vitC deficiency
in guinea pigs intended to investigate vitC transport to the brain (unpublished results). Thus, the
current data-set depicts findings from a randomly defined subset of animals, representing high vitC
intake (control) and low (deficient), thereby, reflecting the extremes of the imposed interventions of the
main study.
Seven-day old, Dunkin Hartley female guinea pigs (Envigo, Horst, The Netherlands) were
equipped with subcutaneous microchip implant for identification (Uno Pico Transponder, Zevenaar,
The Netherlands) upon arrival to the facility. Animals were randomized into weight stratified groups
and subjected to either high (n = 16; 1500 mg vitC/kg feed; Controls) or low vitC (n = 16, 0 mg vitC/kg
feed for 3 weeks, followed by 50 mg vitC/kg feed until study termination; Deficient). All diets were
chow based standard guinea pig diets for growing animals (Ssniff Spezialdiäten, Soesst, Germany),
differing only in vitC levels as confirmed by post production analysis. Animals were group-housed
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in identical floor pens and allowed free access to feed, dried hay (devoid of vitC by analysis) and
drinking water. Body-weight was monitored throughout the study period, and though vitC deficient
animals experienced a brief period (1–3 days) of weight stagnation immediately prior to changing
from 0 mg to 50 mg vitC/kg feed, clinical signs of vitC deficiency were absent and body weight was
comparable between groups at the time of euthanasia, 10–12 weeks after study start.
2.2. Euthanasia
Guinea pigs were sedated with Torbugesic Vet (2 mL/kg) (Butorphanol 10 mg/mL; ScanVet
Animal Health, Fredernsborg, Denmark) and anesthetized with 5% isofluorane (Isoba Vet 100%,
Intervet International, Boxmeer, The Netherlands) in oxygen (Conoxia® 100%, AGA A/S, Copenhagen,
Denmark) until cessation of voluntary reflexes. Blood was collected by cardiac puncture through the
apex using a 18 G needle fitted onto a 1 mL syringe previously flushed with 15% tripotassium EDTA.
Immediately hereafter, the guinea pig was euthanized by decapitation.
2.3. Wire Myography and Tissue Preparation
Immediately following euthanasia, the heart was isolated and placed into cold physiological
buffer (in mM: 117.8 NaCl, 4.0 KCl, 2.0 CaCl2, 0.9 MgCl2, 1.25 NaH2PO4, 20 NaHCO3, and 5.0 glucose).
The left anterior descending (LAD) coronary artery was dissected from surrounding myocardial tissue,
cut into 2 mm segments and directly mounted in a wire myograph (Danish Myo Technology, Aarhus,
Denmark). The anatomical localization of the LAD coronary artery is illustrated in Supplemental
Figure S1. Wire myography experiments were initiated by normalisation to an internal circumference
corresponding to 0.9 of the circumference at 13.3 kPa. Following a 15 min equilibration period in
physiological buffer the artery segments were contracted 2–3 times using 60 mM potassium (similar
composition as the above physiological buffer, except that NaCl was exchanged with KCl on equimolar
basis) to measure the vasoconstrictor reactivity of the arteries. Only segments with potassium induced
contraction >0.5 mN/mm were included in the study. After washing to obtain baseline relaxation,
the ETB receptor agonist, Sarafotoxin 6c (S6c) was added in a cumulative fashion (10−12 to 10−7 M).
Carbachol induced vasodilation and vasoconstriction (10−12 to 3 × 10−4 M) was tested following
pre-constriction with potassium (40 mM). In order to elucidate the carbachol vasomotor responses,
carbachol concentration-response curves were acquired either in absence (controls) or in presence of
the muscarinic receptor antagonist, atropine (10−5 M), the COX-inhibitor indomethacin (10−4 M) or
the eNOS inhibitor L-NAME (10−5 M). Endothelium-independent vasodilation was tested by sodium
nitroprusside (10−9 to 10−5 M) following pre-constriction with 40 mM potassium. U46619 (10−12
to 10−5 M) and endothelin-1 (ET-1)-induced (10−12 to 10−7 M) vasoconstriction were tested using
cumulative additions.
2.4. Biochemical Analysis
EDTA-stabilized blood samples were centrifuged (16,000× g, 1 min, 4 ◦C). Plasma for ascorbate
and dehydroascorbic acid (DHA) analysis was stabilized with meta-phosphoric acid prior to storage at
−80 ◦C. Previous studies have shown that both ascorbate and DHA are stable under these conditions
for at least five years [23]. Concentrations were measured by HPLC with colorimetric detection as
previously described [25,26]. The remaining plasma aliquots were stored neat at −80 ◦C until further
analysis, except for samples for BH2 and BH4 determination, where the blood was stabilized in 0.1%
dithioerythritol prior to centrifugation (2000× g, 4 min, 4 ◦C), yielding a plasma fraction, which was
analyzed by HPLC, as previously described [13].
2.5. Data and Statistical Analysis
Force data (mN) were transformed to tension (Nm−1) by dividing by twice the artery segment
length and subtracting the baseline tension values [24]. Active tension was calculated by subtracting the
passive tension from the potassium-induced active tension. Agonist-induced tension was normalized
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to the potassium induced active tension. Carachol-induced relaxation was calculated by subtracting the
active tensions from the potassium-induced (40 mM) active tension. All statistical analysis and graphs
were performed in GraphPad Prism 7.00 (GraphPad Software, La Jolla, CA, USA). Differences between
two groups were evaluated by a two-sided Student’s t-test. For multiple comparisons (in functional
myography data), two-way ANOVA repeated-measures with Sidak’s multiple comparisons was
applied. Correlations between specific outcomes were evaluated by Pearson correlation (r) coefficient
with two-tailed p-values.
2.6. Materials
Endothelin-1, human, porcine (Catalogue No. SC324, PolyPeptide Group, Strassbourg, France),
Sarafotoxin S6c (SC457, PolyPeptide Group, Strassbourg, France), 9,11-dideoxy-11α,9α-epoxy-
methanoprostaglandin F2α (BML-PG023-0001, Enzo Life Sciences, Exeter, UK). Carbamoylcholine
chloride (C4382-1G SIGMA, Sigma-Aldrich, St. Louis, MO, USA), indomethacin (I7378-5G SIGMA,
Sigma-Aldrich, St. Louis, MO, USA), Nω-nitro-L-arginine methylester hydrochloride (N5751 Sigma,
Sigma-Aldrich, St. Louis, MO, USA), atropine (A0132 SIGMA, Sigma-Aldrich, St. Louis, MO, USA),
meta-phosphoric acid (239275, Sigma, Sigma-Aldrich, St. Louis, MO, USA), 1,4-dithioerythritol (D9680,
Sigma, Sigma-Aldrich, St. Louis, MO, USA).
3. Results
3.1. Effects of Vitamin C Deficiency on Weight Gain of Animals, Plasma Ascorbate Concentration and Plasma
BH4 Concentration
Plasma vitC concentrations were measured at euthanasia, following 11 weeks on the experimental
diets. The dietary regimen was reflected in plasma ascorbate and DHA concentrations, with marked
(p < 0.001) reduction in plasma ascorbate concentration in the deficient group compared to the control
group (Table 1). VitC deficiency also led to a significant reduction in plasma BH4 concentration
(p < 0.0001) (Figure 1).
Table 1. Animal weight and plasma analyses. Data are expressed as means ± SEM, N is number of
animals, **** Different from controls, p < 0.0001, unpaired t-test.
N Controls N VitC Deficient
Weight (g) 16 625 ± 14 16 602 ± 16
Ascorbate concentration, (μM) 16 60.2 ± 5.1 16 2.3 ± 0.1 ****
Ascorbate total, (μM) 16 61.5 ± 5.3 16 2.3 ± 0.1 ****
% DHA 16 1.9 ± 0.5 16 2.2 ± 1.0
Figure 1. (a) Plasma concentrations of BH4; (b) plasma BH2:BH4-ratio. Means ± SEM, *** p < 0.0001
(n = 8).
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3.2. Contractile Reactivity
The potency and efficacy of ET-1 was significantly higher than that of U46619 (p < 0.05), and
the selective ETB receptor agonist, S6c, induced only a negligible contraction in the coronary artery
segments (Table 2). VitC status did not have a significant effect on the potassium, ET-1, U46619 or S6c
vasoconstrictor responses (Figure 2a,b). In contrast to the other vasoconstrictors, potassium induced a
long-lasting vasocontractile response persisting for at least 10 min and potassium was therefore used
as a pre-constrictor in the studies of the relaxation-inducing agonists. Coronary arteries from vitC
deficient guinea pigs were significantly smaller than the controls (p < 0.05, Table 2). Additionally, we
found that for the vitC deficient group, the animal weight was positively correlated with the coronary
artery diameter (p < 0.002, Table 3 and Figure 3a).
Table 2. Artery segment properties, diameter (μm), potassium tension (Nm−1), agonist induced
contraction (% of potassium contraction). Data are expressed as means ± SEM, N is number of animals,
n is number of artery segments, NC = not calculated. * Different from controls, p < 0.05, unpaired t-test.
N, n Controls N, n VitC Deficient
Diameter 16, 35 366 ± 16 16, 35 312 ± 12 *
Potassium, tension 16, 35 3.2 ± 0.2 16, 35 3.1 ± 0.3
Endothelin-1 12, 17
Emax 116 ± 16
12, 17
Emax 108 ± 8
pEC50 8.2 ± 0.1 pEC50 8.3 ± 0.1
Sarafotoxin 6c 8, 20
Emax NC
8, 20
Emax 3 ± 1.6
pEC50 NC pEC50 8.5 ± 0.7
U46619 16, 35
Emax 58 ± 9
16, 35
Emax 64 ± 13
pEC50 6.6 ± 0.1 pEC50 6.7 ± 0.2
Figure 2. Contractile responses in coronary arteries. (a) Contractile responses to 60 mM extracellular
potassium; (b) contractile responses to cumulative concentrations of ET-1 and U46610 in coronary
arteries from control guinea pigs (green) and vitC deficient (red). Means ± SEM (K+, n = 16; ET-1,
n = 12; U46619, n = 16).
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Table 3. Correlation analyses of specific outcomes in the control and vitC deficient groups. Pearson
correlation analyses, N is number of animals, n is number of artery segments, r is Pearson correlation
coefficient, ** p <0.002, *** p < 0.001.
Controls VitC Deficient
N, n Pearson r p Values N, n Pearson r p Values
Diameter vs. weight 16, 35 0.182 0.500 16, 35 0.729 0.001 **
Diameter vs. carb induced dilatation 16, 35 0.010 0.954 16, 35 0.555 0.0005 ***
Diameter vs. carb induced contraction 16, 35 −0.174 0.518 16, 35 −0.286 0.284
BH4 vs. carb induced dilatation 8, 15 0.403 0.105 8, 15 0.057 0.840
BH4 vs. carb induced contraction 8, 15 −0.372 0.172 8, 15 0.232 0.406
Figure 3. Scatter plots of coronary artery diameter vs. guinea pig body weight (a) and
carbachol-induced vasorelaxation compared with coronary artery diameter (b). Control guinea pigs
(green squares) and VitC deficient (red triangles).
3.3. Vascular Responses to Carbachol
Cumulative concentrations of carbachol in the range of 1 nM to 1 μM markedly relaxed coronary
artery segments pre-contracted with 40 mM potassium (Figure 4a) and higher concentrations (1 μM to
0.3 mM) caused a rise in the isometric tension in a concentration-dependent fashion. Carbachol-induced
relaxation and sensitivity was not significantly different in coronary arteries from vitC deficient guinea
pigs compared to controls (Figure 3a); however, a significantly positive correlation between coronary
artery diameter and carbachol-induced relaxation was found in coronary arteries from vitC deficient
guinea pigs, but not in controls (p < 0.001), Table 3 and Figure 3b). The maximal carbachol-induced
contraction response was significantly lower in segments from vitC deficient compared to controls
(p < 0.001; Figure 4a) and in both vitC deficient and control animals the contractions were independent
on coronary artery diameter (p > 0.05, Table 3). The muscarinic receptor antagonist, atropine
(10 μM), blocked both the carbachol-induced vasodilation and vasoconstriction from both diet groups
(Figure 2b). To evaluate the contribution of NO and prostanoids to carbachol-induced vasodilation
and vasoconstriction, carbachol concentration- response curves were recorded during pre-contraction
induced by potassium and in the presence of the COX inhibitor, indomethacin (10 μM), NOS inhibitor,
L-NAME (100 μM) or in the presence of both indomethacin (10 μM) and L-NAME (100 μM). The
presences of inhibitors alone or in combination revealed no differences in the vasodilator responses
in control compared with vitC deficient animals, and the augmented vasoconstrictor responses in
arteries from control animals compared to segments from vitC deficient animals were maintained in
the presence of the inhibitors (Figure 4b–d).
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Figure 4. Log-concentration-response curves of coronary artery segments from vitC versus control
guinea pigs. (a) Vasomotor responses to carbachol in coronary artery segments pre-constricted with
40 mM extracellular potassium; (b) in presence of L-NAME; (c) indomethacin; (d) both L-NAME
and indomethacin; (e) atropine. (f) Vasodilator responses to sodium nitroprusside (SNP) in coronary
arteries pre-constricted with 40 mM extracellular potassium. Control guinea pigs (green) and VitC
deficient (red). Means ± SEM (n = 8–16), * p < 0.05, ** p < 0.01, *** p < 0.001.
L-NAME significantly inhibited the vasodilatory response to carbachol in segments from both
control and vitC deficient guinea pigs (p < 0.001; Figure 5a,b); however L-NAME alone had no effect
on the subsequent vasoconstrictor response compared to non-treated segments. In the presence
of indomethacin alone, both carbachol-induced vasodilatation and vasoconstriction were restored
(Figure 5c,d) in arteries from both groups compared to non-treated segments.
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Figure 5. Log-concentration-response curves of coronary artery segments after treatment with L-NAME
and/or indomethacin. The figures illustrate how the combination of inhibitors in artery segments from
the same animal modulates the carbachol-induced vasodilator and constrictor responses. Vasomotor
responses to carbachol in artery segments pre-constricted with 40 mM extracellular potassium: in
absence versus presence of L-NAME in (a) control guinea pigs; (b) vitC deficient. In absence versus
presence of indomethacin in (c) control; and (d) vitC deficient, in absence of L-NAME versus presence
both L-NAME and indomethacin in (e) control guinea pigs; (f) VitC deficient, and in absence of
indomethacin versus presence both L-NAME and indomethacin in (g) control guinea pigs; (h) VitC
deficient. Means ± SEM (n = 8–16), * p < 0.05, ** p < 0.01, *** p < 0.001.
In the presence of L-NAME, indomethacin amplified the carbachol-induced vasoconstriction only
in segments from vitC deficient guinea pigs, suggesting a potential effect arachidonic acid metabolites
74
Nutrients 2017, 9, 691
e.g., vasodilator prostanoids counteracting the vasoconstrictor effect of carbachol in coronary arteries
from vitC deficient guinea pigs or increased production of vasoconstrictor leukotrienes, which is
unmasked in the presence of indomethacine. This effect was not recorded for control animals.
In summary, we found that carbachol-induced vasodilator and constrictor responses were
mediated by muscarinic receptors. In vitC deficient guinea pigs, the diameter of the coronary
arteries were significantly and positively correlated with the weight of the animals and the
endothelium-dependent vasorelaxation. These correlations were not present in the control group. In
vitC deficient guinea pigs the muscarinic receptor-induced vasoconstrictor responses were significantly
attenuated compared to controls and partly restored by COX-inhibition.
3.4. Relaxing Responses to SNP
To evaluate the endothelium-independent response to NO, relaxing response to the NO donor
SNP (1 nM to 30 μM) was measured in potassium pre-contracted arteries. SNP induced a concentration
dependent relaxation and the maximal relaxation and the sensitivity to SNP were not affected by the
vitC status in the animals (Figure 4f).
4. Discussion
The present study shows that vasoconstrictor responses to carbachol are significantly decreased
in arteries from vitC deficient guinea pigs as compared to arteries from control animals, proposing a
link between vitC deficiency and compromised vascular function in vivo. Interestingly, contractions
induced by other constrictors: potassium, S6c, U46619 and ET-1 were not affected by vitC status,
suggesting that the contractile apparatus per se is not affected. Although vitC deficiency decreased
plasma BH4 levels, there was no significantly decreased vasodilator capacity compared to controls.
However, vitC deficient guinea pigs had significantly smaller coronary artery diameters than controls,
and in vitC deficient guinea pigs, the decreased diameter correlated with decreased carbachol-induced
vasodilatation. Consequently, it appears that impaired vitC status affects the diameter of the
coronary arteries and the endothelial function; furthermore vitC status induces a specific effect on the
parasympathetic muscarinic receptor system, as measured by attenuated vasoconstrictor responses.
The parasympathetic neurotransmitter, acetylcholine and its analogue carbachol are widely used
to study endothelial dependent/independent vasodilation and vasoconstriction, and the agonist
is relevant since guinea pigs have an extensive network of cholinergic perivascular nerve fibres in
the coronary artery tree [22]. In isolated coronary artery segments, carbachol induced a biphasic
concentration-response pattern with an initial vasodilator response at low concentrations (from
10 nM to 1 μM) followed by a vasoconstrictor response at higher concentrations (from 1 μM to
0.3 mM). Carbachol-responses in the presence of atropine, indomethacin and/or L-NAME in the
organ bath were assessed, revealing that atropine blocked both the carbachol-induced vasodilatation
and vasoconstriction over the entire carbachol concentration interval. This suggests that carbachol
elicits its effect via muscarinic receptors on guinea pig coronary arteries. This is consistent with
previous studies showing that acetylcholine-induced vasodilator responses in bovine [25], simian [26]
and mice [27] coronary arteries are mediated predominantly by endothelial muscarinic M3 receptors,
and that acetylcholine induced vasoconstrictor responses are mediated by vascular M3 receptors in
bovine [28,29] and porcine [30,31] coronary arteries.
In this study, we found that in vitC deficient guinea pigs, the endothelial-dependent vasodilation
was significantly correlated with coronary artery diameter; a correlation that was not present in
controls. Furthermore, we found coronary artery diameters were significantly smaller in vitC deficient
guinea pigs as compared to control guinea pigs, despite sampling at uniform, anatomically defined,
orientation. These results suggest that vitC deficiency potentially impair coronary artery growth and
endothelial function of young guinea pigs. Hence, those guinea pigs that responded most sensitively
to vitC restriction further developed more overall growth retardation with consequently impaired
coronary artery growth and endothelial function. In the control group, in contrast, the variation in
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artery diameter did not reflect a pathophysiological response, but rather, a random variation in growth.
Previously, degenerative changes in the capillary endothelium have been found in scorbutic guinea pigs
whereas the larger arteries showed no abnormalities [32]. However, although we found this correlation
between artery diameter and endothelial function in vitC deficient animals and not in controls;
we found no overall effect of vitC deficiency when comparing the two groups. Treatment of the
coronary artery segments with L-NAME abolished the initial carbachol-induced vasodilator response
in both diet groups. In contrast, indomethacin did not significantly affect the vasodilator response
between groups, suggesting that carbachol-induced vasodilator response was predominantly driven by
endothelial-dependent NO release. Importantly, the vasodilator responses were investigated in arteries
preconstricted with high extracellular concentration of potassium. High potassium concentrations
depolarize VSMC and endothelial cells [33] which consequently hide a putative endothelium-derived
hyperpolarizing factor (EDHF) mediated vasodilator effect [34]. Therefore, blocking the contribution
of EDHF to vasodilation allowed the isolation of the effects of NO and prostaglandins on carbachol
induced vasodilation.
Muscarinic receptors are widely expressed in smooth muscle cells in several organs,
and diet-induced ascorbate deficiency in guinea pigs has previously been shown to reduce
muscarinic-cholinergic receptor density [21]. Increased oxidative stress has been found to
acutely reduce muscarinic receptor-mediated smooth muscle cell constriction in guinea pigs [19],
and increased ROS production in ischemia/reperfusion reduce efficacy and sensitivity to
cholinergic stimulation [35,36], linking redox imbalance to functional consequences mediated via
muscarinic receptors.
Stimulating the arteries with the NO donor sodium nitroprussid revealed vasodilation with
similar sensitivity and maximal effect in arteries from vitC deficient and control guinea pigs (Figure 4f).
NO mediates a vasodilator effect by binding to soluble guanylyl cyclase (sGC) in VSMC. Guanylyl
then catalyses the production of cGMP, which activates protein kinase G that via dephosphorylation of
myosin light chain leads to vasorelaxation [37]. Oxidative stress has been showed to down-regulate
soluble guanylyl cyclase expression and activity [38]. In present study, we found no effect of vitC
deficiency on the NO-mediated vasodilation, indicating that the sGC activity was unaltered by the
vitC status.
When coronary artery segments were treated with L-NAME and/or indomethacin, the
carbachol-induced vasoconstrictor response remained reduced in arteries from vitC deficient compared
to control animals. However, indomethacin increased the carbachol-induced vasoconstrictor response
in eNOS blocked segments from vitC deficient animals, which was not present in arteries from control
animals. This suggests that vitC deficiency promotes the release of vasodilator prostanoids in coronary
arteries when stimulated with carbachol. Vasodilator prostanoids have previously been found to
negate the effect of coronary vasoconstrictors after myocardial infarction [39], a condition known to
induce oxidative stress [40] and be detrimental to cellular function and survival. In contrast, inhibition
of prostanoid production has been found to have little effect in healthy humans [41] and dogs [42].
In this study, prostanoid-induced suppression of carbachol vasoconstrictor responses in coronary
arteries were increased in vitC deficient guinea pigs, suggesting a compensatory role in the regulation
of coronary vascular tone under vitC and BH4 deficiency. The contractile responses induced by either
extracellular potassium, U46619, S6c or ET-1 were not affected by vitC status, supporting the idea that
the general vasoconstrictor capacity is not affected by vitC deficiency.
VitC deficiency (defined as plasma concentrations <23 μM) is surprisingly common, affecting
~15% of adults in the Western World with even higher prevalence among individuals who smoke, have
high BMI, low socioeconomic status [7] as well as children with underlying medical conditions [43,44].
Epidemiological studies have shown an association between vitC deficiency and an increased risk
of cardiovascular disease; however, the mechanistic link has not been elucidated [45,46]. Altered
vasomotion and reactivity of coronary arteries plays an important role in pathophysiologic mechanisms
involved in heart disease. The parasympathetic nervous system is known to provide a modulating
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influence on the response of coronary arteries to local metabolic requirements in the heart [47].
Moreover, muscarinic receptors are known to be expressed in human coronary arteries [48]. Patients
with variant angina or coronary stenosis have been found to have altered coronary vasoconstriction
after injection of acetylcholine, pointing toward a causal relationship with altered muscarinic receptor
response and disease [49,50]. The observation that muscarinic receptor mediated contraction is
impaired as a result of vitC deficiency is of potential importance, not only in regulation of coronary
artery vasomotion, but also in other tissues that are highly dependent on parasympathetic-muscarinic
receptor-mediated contraction (bladder, esophagus, intestines, pancreas, and salivary glands). For
obvious ethical reasons, it is impossible to perform long-term controlled trials on humans to establish
the consequence of vitC deficiency on vasculature and present knowledge is therefore restricted
to indirect evidence. Applying the guinea pig as a unique and validated model of diet-induced
vitC deficiency, this study shows that chronic vitC deficiency in vivo alters the response of the
coronary arteries to parasympathetic stimuli. This provides a link between vitC deficiency and
cardiovascular disease, proposing a yet undisclosed, specific, effect of vitC in the modulation
of muscarinic receptor-modulated response within the vascular wall. Though requiring further
investigation, the apparent association between vitC status and coronary artery contraction may prove
relevant in the prevention and treatment of cardiovascular diseases in humans with poor vitC status.
The present study has several limitations. Based on existing literature, we expected that
vitC deficiency reduced NO-mediated vasodilation as a consequence of the decreased BH4 plasma
concentration. The potential reason for the lack of correlation between the BH4 plasma concentrations
and endothelial function could be that we determined biopterines and vitC in the plasma, rather than
in the arteries, which could potentially more adequately have reflected the vessel status. Interestingly,
a correlation between animal weight, artery diameter and endothelial function in vitC deficient guinea
pigs was found. Future studies are needed to elaborate on a causal relationship and putative functional
consequences e.g., clarifying if vitC deficiency induces morphological changes of the heart muscle
and vessels. Furthermore, measurements of intracellular calcium concentrations would be highly
relevant to determine if vitC deficiency alters cytosolic calcium levels and handling, which can lead
to increased tone and decreased vessel diameter. Here, the effect of vitC deficiency was evaluated
in young guinea pigs—reproductive maturity is reached at around 10 weeks of age—with no other
underlying pathophysiological condition. We found that the coronary arteries were highly resistant to
mechanically endothelial denudation, suggesting that the animals, despite vitC deficiency, retained a
high NO capacity and/or sensitivity in the coronary arteries. However, it could be speculated that in the
presence of an additional vascular disease, such as atherosclerosis, left ventricular hypertension [51] or
even age-related reductions in compensatory abilities, a decreased vitC concentration and consequently,
a reduced capacity to recycle BH4, may be crucial in preserving an adequate vasodilator capacity [52].
Our finding, that the muscarinic receptor system is highly sensitive to vitC deficiency, is a novel
and so far unrecognized effect of in vivo vitC deficiency. Future studies are needed to elucidate the
mechanisms underlying the impaired muscarinic receptor mediated contraction observed here and to
study other tissues with highly dependent parasympathetic-muscarinic receptor-mediated contraction
(e.g., bladder, esophagus, intestines, pancreas, and salivary glands).
5. Conclusions
The present study shows that chronic vitC deficiency impairs vasomotor function of coronary
arteries. During vitC deficiency, the endothelial function is reduced, with decreasing vessel diameter
and carbachol-induced vasoconstrictor responses being significantly impaired. The carbachol-induced
effects are apparently mediated by altered muscarinic receptor activity. Although further studies
are required to evaluate the underlying mechanisms and the potential clinical implications, these
findings may provide a link between chronic vitC deficiency and increased risk of cardiovascular
disease reported in numerous epidemiological studies.
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Abstract: Accumulating evidence in mice models of accelerated senescence indicates a rescuing
role of ascorbic acid in premature aging. Supplementation of ascorbic acid appeared to halt cell
growth, oxidative stress, telomere attrition, disorganization of chromatin, and excessive secretion
of inflammatory factors, and extend lifespan. Interestingly, ascorbic acid (AA) was also found
to positively modulate inflamm-aging and immunosenescence, two hallmarks of biological aging.
Moreover, ascorbic acid has been shown to epigenetically regulate genome integrity and stability,
indicating a key role of targeted nutrition in healthy aging. Growing in vivo evidence supports
the role of ascorbic acid in ameliorating factors linked to Alzheimer’s disease (AD) pathogenesis,
although evidence in humans yielded equivocal results. The neuroprotective role of ascorbic acid not
only relies on the general free radical trapping, but also on the suppression of pro-inflammatory genes,
mitigating neuroinflammation, on the chelation of iron, copper, and zinc, and on the suppression of
amyloid-beta peptide (Aβ) fibrillogenesis. Epidemiological evidence linking diet, one of the most
important modifiable lifestyle factors, and risk of Alzheimer's disease is rapidly increasing. Thus,
dietary interventions, as a way to epigenetically modulate the human genome, may play a role in
the prevention of AD. The present review is aimed at providing an up to date overview of the main
biological mechanisms that are associated with ascorbic acid supplementation/bioavailability in the
process of aging and Alzheimer’s disease. In addition, we will address new fields of research and
future directions.
Keywords: ascorbic acid; aging process; Alzheimer’s disease
1. Ascorbic Acid and Its Relevance to the Aging Process
Due to the aging population and the increased life-expectancy [1] in developed and developing
countries, a growing area of interest concerns the understanding of the mechanisms that regulate
aging and that differentiate successful aging from pathological aging. Prolonged exposure to antigens
throughout life produces a progressive modification of the individual homeostasis [2].
The free radical theory of aging allows an explanation of the molecular mechanisms underlying
the aging process, at least partially, and the pathogenesis of age-related diseases, such as
atherosclerosis, cardiovascular diseases, dementia, diabetes, and osteoporosis [3,4]. From a biological
perspective, the process of aging is characterized by immunosenescence: this may be defined as
the reduced ability to respond to foreign antigens and to tolerate self-antigens, leading to increased
susceptibility to infections, cancer, and autoimmune diseases [5]. The most accredited molecular
mechanisms for immunosenescence include redox-mediated and mitochondria-dependent oxidative
pathways. High levels of free radicals and peroxidation products of lipid membranes, such as
malondialdehyde (MDA), are able to modulate the activation of nuclear transcription factors,
associated with cell aging and longevity, such as tumor protein p53, transcriptional protein AP-1
and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB). In addition, these same
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mechanisms are responsible for altered T cell expression and the altered phenotype of immunological
subpopulations [6].
Oxidative stress is increasingly considered to be the major epigenetic factor for aging and also
plays an important role in inducing the low-grade inflammation, as the two processes are strictly
intertwined. This pro-inflammatory phenotype, defined ‘inflamm-aging’, is characterized by an
increased expression of genes related to inflammation and to the immune response. Indeed, it is
known that the increased serum levels of C reactive protein (CRP) and pro-inflammatory cytokines,
such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) induce the activation of NF-KB
mediated superoxide production in mitochondria, promoting the release of oxygen reactive species
(ROS) [2,6].
Inflamm-aging is also associated with decreased nitric oxide (NO) bioavailability in the endothelial
layer, which induces endothelial dysfunction. Inflamm-aging may be considered a biological
background for both the aging process and the pathophysiological process of frailty in humans [7].
The endogenous antioxidant enzymatic defense system superoxide dismutase (SOD), catalase
and glutathione peroxidase (GSH) counteracts oxidative exogenous agents from diet and may undergo
substantial decrease related to the aging process [8]. Accumulating evidence indicates that nutrition is
a key relevant factor for inflamm-aging and an important modulator of the aging process as well [9–11].
Ascorbic acid (AA) is a powerful first-line antioxidant that mediates several beneficial effects on
redox oxidative pathways and mitochondrial pathways on the immune system, on inflamm-aging,
on endothelial integrity, and on lipoprotein metabolism [12,13]. AA, a lactone with six carbon atoms,
is synthesized from glucose in the liver of many species of mammals. Humans have evolutionarily
lost the gulonolactone oxidase enzyme, essential for the synthesis of 2-keto-L-gulonolactone, its direct
precursor. As a result, people absorb AA exclusively from the diet. AA enters the cells through the
sodium-dependent vitamin C transporters SVCT1 and SVCT2, a process favored by the electrochemical
sodium gradient: due to its high capacity and low affinity, SVCT1 assures the intestinal and renal
absorption and reabsorption [14].
All of the physiological and biochemical actions of AA are due to its ability to donate electrons
(as a reducing agent). AA undergoes two consecutive and reversible oxidations: from the first electron
loss, it generates an intermediate product, the ascorbate free radical (AFR), which is converted into
dehydroascorbate (DHA) after the loss of the second electron. At physiological concentrations, AA is
a powerful antioxidant and scavenger of free radicals in plasma and different tissues, including the
central nervous system (CNS) [15,16].
AA is also implicated in the endothelial integrity associated with NO bioavailability [17]. The
molecular mechanisms that induce endothelial dysfunction affect the enzyme NO synthase (eNOS)
by impairing Gi- dependent signaling, decreasing mRNA stability for eNOS, and blocking eNOS
translocation from the plasma membrane to the Golgi membranes. The reduced bioavailability of its
substrate (L-arginine) or its co-factor (tetrahydrobiopterin BH4) was also observed [18]. Low levels of
BH4 compromise eNOS function by promoting the transfer of electrons to oxygen molecules instead of
L-arginine: in turn, eNOS produces a superoxide anion instead of generating NO [19].
2. Ascorbic Acid, Epigenetic Modulation and Nutrigenomics
In the last decades, the understanding of AA properties has undergone a major revolution, ranging
from a simple antioxidant to a micronutrient, capable of epigenetic regulation [20,21].
Recent advances in epigenetics have identified a series of di-oxygenases Fe2+ and 2 oxoglutarate
(2OG-dependent) enzymes that catalyze the epigenetic modifications of DNA and histones. Some
of these enzymes require ascorbate to maintain their catalytic activity. Therefore, the availability of
ascorbate might affect the epigenome, with a potential impact on health and age-related diseases.
Methylation in the C5 position of cytosine (5-methylcytosine, 5mC) is the most important and
well-studied epigenetic mark of mammalian DNA, which plays an essential role in the transcriptional
and in the maintenance of genome stability.
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DNA methyltransferase (DNMTs) is responsible for the transfer of a methyl group from the
universal methyl donor, S-adenosyl-L-methionine (SAM), to the 5-position of cytosine residues in
DNA. The presence of an unusual nucleotide, 5-hydroxymethylcytosine (5hmC) in mammalian DNA
has been reported. Although 5hmC represents less than 1% of total nucleotides, high levels have
been observed in the cerebellar Purkinje cells and in the granule neurons, suggesting a potential role
for neuronal functions in epigenetic regulation. This nucleotide (5hmC) is formed by the activity of
a group of enzymes, ten-eleven translocation methylcytosine dioxygenas (TET: TET1, TET2, TET3),
that catalyze the ten-eleven translocation and oxidize 5mC to generate 5hmC. TET enzymes were
shown to further oxidize 5hmC into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). Ascorbic
acid is known to increase 5hmC production in a TET-dependent way, probably by reactivating the
catalytic site of TET enzyme, reducing Fe3+ to Fe2+. Namely, AA induced a significant demethylation
of 5-methylcytosine (5mC) to 5-hydroxymethyl cytosine (5hmC) [22,23].
Variation in ascorbate bioavailability can influence the demethylation of DNA and histones: in
addition, ascorbate deficiency can present at different stages of aging and could be involved in the
development of different age-related diseases. In particular, if additional ascorbate is not provided by
supplementation or improved uptake, there would be progressive AA decline in the brain, which might
be associated with neurodegeneration. So far, there is inconsistent data on epigenetic modifications in
the human brain. Further studies could unravel the potential impact of age-related ascorbate decline
on the epigenome and on neurodegeneration.
So far, AA seems to increasingly have beneficial effects on the aging processes and on
the prevention of age-related diseases as atherosclerosis, cardiovascular diseases, cancer, and
neurodegenerative diseases.
Nutrigenomics is a young area of research, but meaningful studies indicated a role for AA on gene
expression. A previous study found that, although no diet-gene interactions were observed, genetic
variation of SVCT1 can influence serum ascorbic acid concentrations. Moreover, both AA transporter
genotypes modify the strength of the correlation between dietary AA and serum levels [24].
Recently, genetic variations of haptoglobin, polymorphisms in the transporters of AA, and deleted
polymorphisms of glutathione-S-transferase have provided genetic information regarding possible
relative AA levels [25–27].
Intriguingly, AA functions at the interface of different molecular pathways associated with aging,
as illustrated by Figure 1.
Figure 1. AA is at the crossroads of biological aging, intercepting immunosenescence, inflamm-aging,
and oxidative stress (free radical theory of aging), with a potential role in the onset of age-related
diseases and frailty trajectories.
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3. Ascorbic Acid and the Aging Process: In Vitro Models
Several lines of research have increasingly accredited the role of AA in the aging process. The
in vitro and in vivo evidence is reported herein and illustrated in Table 1.
Table 1. In vitro and in vivo evidence for a role of AA in the aging process.
Species Model Design and Methods Conclusion References
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A mouse model of senescence showed that AA promotes proliferation of bone marrow
mesenchymal cells derived from aging mice. The senescence-accelerated mouse prone 6 (SAMP6) mice
and senescence-accelerated mouse resistant 1 (SAMR1) mice were used as the test group and the control
group, respectively. Bone marrow mesenchymal stem cells (BMMSCs) derived from SAMP6 mice were
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treated with increasing concentrations of AA [44]. The treatment significantly improved the BMMSCs
proliferation in a dose-dependent manner by increasing telomerase activity and TERT expression.
The AA concentration of 100 μg/mL induced the strongest effect in promoting the proliferation of
BMMSCs in SAMP6 mice, while at a concentration of 1.000 mg/mL, AA suppressed the cell growth.
AA can promote the proliferation of BMMSCs from aging mice, possibly by increasing the cellular
telomerase activity.
Interestingly, it is known that bone marrow (BM) plays a key role in immunological memory and
surveillance, through inflamm-aging. Overexpression of IL-15 and IL-6 was stimulated by IFN-y and
correlated with ROS. The plasma-cell survival factor a proliferation- inducing ligand (APRIL) was also
reduced. AA was effective in counteracting inflammatory- and oxidative stress-related changes in the
aging bone marrow, improving immunological memory in old age. This study is of key relevance in
assessing the protective role for AA in immunosenescence [35].
The positive effects of AA on premature cellular events was confirmed by treatment with
AA on Werner’s syndrome protein (WRN-deficient) human mesenchymal stem cells (MSCs) [33].
In this model, the analysis of mRNA levels showed that AA altered gene expression was involved
in chromatin condensation, the regulation of the cell cycle, and DNA replication and repair. AA
promoted heterochromatin remodeling to a younger state (as demonstrated from the upregulation
of heterochromatin Protein 1 (HP1α) markers and histone H3K9me3 by Western blotting). AA
slowed down cellular senescence in mesenchymal WRN-deficient cells (as demonstrated by the
SA-β-gal staining) restoring mesenchymal stem cells’ vitality and proliferative potential. AA repressed
telomere shortening, decreased the production of pro-inflammatory cytokines, such as IL-6 and IL-8,
downregulated the expression of markers of aging, such as cyclin-dependent kinase inhibitor 2A,
multiple tumor suppressor 1 p16Ink4a and zinc finger transcriptional GATA4, and repressed the SASP
(elevated senescence-associated secretory phenotype). AA was effective at alleviating aging defects by
reducing cell cycle regulation, telomere attrition, ROS burst, and nuclear laminin disorganization.
AA was also reported to stimulate/inhibit the differentiation of mesoderm-derived embryonic
stem cells (ES) through the involvement of p38 mitogen activated protein kinase/cAMP response
element binding (CREB) nuclear transcription factor activation (p38 MAPK/CREB pathway) and
increased expression of the SVCT2 transporter. More precisely, AA was found to promote ES
differentiation by regulating chromatin domain overlapping. These in vitro models have important
implications for the aging process. The effect of AA in the context of body weight could be at
least partially related to stem cell differentiation towards myogeneis and osteogenesis, inhibiting
adipogenesis. Since aging is associated with sarcopenia and defects in body weight, the current
observations suggest that AA-mediated stem cell effects could play a role in the aging process [36,37].
Furthermore, the same results were replicated in human bone marrow mesenchymal stromal cells
(hBM-MSCs) undergoing replicative senescence to investigate the relationship between ROS levels and
stem cell potential differentiation after AA treatment. Interestingly, AA supplementation eliminated
ROS excess and restored the endogenous antioxidant enzymatic activity (catalase, SOD) by influencing
phosphorylated fox head box O protein 1 (p-FOXO) and p53. Moreover, differentiation into adipocytes
and osteocytes was significantly increased [38].
Thus, AA seems to be implicated in the regulation and differentiation of stem cells. Current
knowledge on MSC cell surface biomarkers and molecular mechanisms of MSC differentiation
emphasizes the role of Wnt/β-catenin signaling, the Notch signaling pathway, bone morphogenesis
proteins, various growth factors, and oncogene and immunosuppressive activities of MSCs. Therefore,
further investigations are needed to establish a role for AA in such targeting regulation of cell
differentiation, which may have important clinical implications for the prevention of age-related
disease [45].
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Ascorbic Acid and the Aging Process: In Vivo Evidence
Murine models of Werner’s syndrome (WS) (Wrn Δhel/Δhel mutants) exhibit many phenotypic
characteristics similar to accelerated human aging. The supplementation with AA for nine months was
found to reduce oxidative stress in hepatocytes and cardiomyocytes, and decrease hypertriglyceridemia
and hyperglycemia. A significant improvement of the metabolic profile, including insulin resistance
and the body fat in WrnΔhel/Δhel mutant mice was also observed.
Similarly, other Werner syndrome-like in vivo models have confirmed that AA supplementation
rescued the shorter lifespan, reversing age-related abnormalities in adipose tissue, the liver, and
genome integrity. In the metabolic profile, inflammatory status was improved and, at a molecular
level, the normalization of the phosphorylation of AKT kinase, transcriptional levels of NF-kappa B,
protein kinase delta (PKC delta), peroxisome proliferator-activated receptor alpha (PPAR-alpha) and
hypoxia-inducible factor-1 alpha (HIF1-alpha), were observed [45].
A further study of WrnΔhel/Δhel mutant mouse models showed that the pro-oxidant and
inflammatory state produced a premature defenestration of sinusoidal endothelium in liver tissue with
consequent hepatic dysfunction and impaired hepatic lipoprotein metabolism. Long-term treatment
with AA restored physiological levels of GSH and the fenestrated sinusoidal endothelium by quenching
oxidative stress. It is noteworthy that in healthy mice, the beneficial effects of AA on health and lifespan
were not significant and the supplementation significantly reduced the oxidative damage only in
WrnΔhel/Δhel mouse liver [30,34].
AA had a positive impact on the cardiometabolic and inflammatory profiles of mice lacking
the functional Werner syndrome protein helicase. AA reversed changes in the expression levels of
plasminogen activator-1 (PAI-1) and improved, at a transcriptional level, fatty acid degradation. In
addition, AA increased glutathione metabolism and reversed the oxidative stress. This study suggested
that AA could be a potential cardiometabolic biomarker in patients with WS [39].
Caenorhabdilis elegans worm models, with a non-functional wrn-1 DNA helicase ortholog, exhibited
a shorter lifespan. The supplementation with AA increased lifespan in the mutant strain, compared
with the wild-type strain possibly by altering the expression of genes regulating the metabolism of
lipids, ketones, organic acids, and carboxylic acids. AA modified the expression of genes involved in
locomotion and development of the anatomical structure. Conversely, in the wild-type worms, AA
only influenced the biological process of proteolysis [32].
Knockout (Gulo−/−) mice represent an interesting in vivo model that mimics human physiology,
lacking the gulonolactone oxidase (Gulo) gene. Accumulating evidence from this in vivo model
yielded additional information on the role of ascorbate in aging. Knockout (Gulo−/−) mice developed
high oxidative stress, sensorimotor deficits, and behavior abnormalities. The lifespan of Gulo−/−
mice appeared to inversely correlate with the phosphorylation levels of IRE1α and IF2α, in response
to endoplasmic reticulum stress. In this model, AA supplementation reduced phosphorylated IRE1α,
implicating its protective effect on endoplasmic reticulum stress and extended lifespan. In addition, in
the same in vivo model, AA supplementation was shown to improve T cell-mediated acute response
after liver injury, suggesting a modulation of the immune system [31].
Uchio et al. demonstrated the influence of long-term high-dose AA intake on the number and
function of immune cells in SMP30KO mice. The total counts of leucocytes, lymphocytes, granulocytes,
and monocytes in the peripheral blood, as well as the number of splenocytes and thymocytes, were all
significantly higher in the treated group. In addition, the number of naive T cells in peripheral blood
lymphocytes, the number of memory T-cell populations in splenocytes, and the number of clusters of
differentiated CD4+ and CD8+ T cells in thymocytes were all remarkably elevated. High dietary AA
intake was associated with the improvement of age-related thymic atrophy. The study indicated a role
for AA in immunosenescence by targeting CD4+ and CD8+ cells. Further, AA was found to modulate
immune cell surveillance in SMP30 knockout mice [40].
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In line with these data, Sato and colleagues suggested that AA plays an important role in
preventing protein oxidation in the liver of SM30/gluconolactonase knockout mice, with potential
implications in overall health and aging [41].
4. Ascorbic Acid and the Aging Process: Oxidative Stress and Antioxidant Defense
Oxidative stress is considered noxious for lifespan and AA, and, as a first line antioxidant, has
been thought to potentially increase longevity. These notions have recently been challenged by
findings in model organisms that show beneficial effects on lifespan of increased ROS generation
produced by mutations or pro-oxidant treatments [46,47]. Such a relationship would arise from a
combination of beneficial effects from a moderate increase in ROS levels and their dose-dependent
toxicity. Intriguingly, the small elevation of ROS levels that increase lifespan seems not to be stressful,
nor do they induce an increased resistance to oxidative stress. In particular, in a Caenorhabdilis elegans
model, [48] AA displayed an inverted U-shaped dose–response relationship between ROS levels
and lifespan; both high and low levels of ROS were detrimental for longevity. This evidence further
complicated the role of AA in aging. The fact that both antioxidant and pro-oxidant treatments reveal
such a different behavior suggests that temporal administration of AA is of key relevance to obtain
beneficial effects. Moreover, ROS levels still need to be optimized for lifespan in different cells, and the
net balance between antioxidant and oxidant defense and their concentrations plays a relevant role in
the aging process.
From a clinical perspective, AA functions at a true interface between aging, life span and
age-related diseases. It is able to modulate telomeres activity, bioenergetics, DNA repair and oxidative
stress, indicating a nutrigenomic role in the process of aging as well [49].
During aging, the antioxidant capacity of AA is finely regulated by the redox balance of
DHA/ascorbate and the ability of the endogenous antioxidant enzymatic defense system (glutathione
and nicotinamide adenine dinucleotide phosphate; NADPH) to recycle DHA back to AA. An increased
ratio of DHA/AA becomes an indicator of a pro-oxidative ability of AA to mediate biological processes
and may play a role in age-related diseases, intercepting different aging trajectories.
Similarly, cellular antioxidant enzymatic capacity declines during the aging process and oxidation
of glutathione and NADPH may also explain different results in studies targeting aging and disease
prevention. Recently, it has been shown that elderly people with lower peripheral antioxidant
parameters, including AA and a decreased antioxidant capacity, are more prone to clinical vulnerability,
disability, frailty and higher mortality over a 5-year follow up [50].
Conversely, two studies in healthy elderly subjects showed that daily intake of star fruit
juice (Averrhoa Carambola, a fruit with high content of AA) acted as a scavenger of free
radicals, and maintained low levels of lipoperoxidative stress (MDA), restoring GSH levels. The
associated AA antioxidant capacity also mediated anti-inflammatory effects by the reduction of
pro-inflammatory cytokine secretion, especially TNF-alpha and interleukin-23 (IL-23) excluding
interleukin-2 (IL-2) [51,52].
Kim et al. investigated the effects of high-dose AA supplementation (1250 mg daily) in humans.
After eight weeks, the analysis of serum lipoproteins showed a reduction of advanced glycation end
products (AGEs). The anti-glycoxidative effect was significantly higher, especially in non-smoking
men, and was associated with net improvement of plasma HDL levels. The quantitative analysis of the
LDL fractions also showed an improvement of LDL lipid composition. Therefore, the supplementation
with AA could exert protective effects against atherosclerosis and related systemic inflammation by
reducing the oxidized LDL and macrophage phagocytosis, with reduced conversion to foam cells [42].
Interestingly, this study demonstrated that AA induced changes in gene expression of
some microRNAs that negatively regulate target genes’ post-transcriptional expression. After AA
consumption, miR155 levels decreased by 90%, suggesting that high doses of AA may significantly
modulate miRNA levels and the anti-inflammatory response [42]. Thus, AA may be considered an
epigenetic key to personalized nutrition.
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5. Evidence for Ascorbic Acid in Brain Aging
In the central nervous system, AA plays a complex role that is still only partially established.
Cerebrospinal fluid (CSF) ascorbic acid concentrations (200–400 mM) are higher compared to those in
cerebral parenchyma and in plasma (30–60 nM) [43].
AA is secreted into the CSF across the apical membrane of choroid plexus cells by an active
and saturable transporter for AA, the sodium-dependent vitamin C transporter 2 (SVCT2). In turn,
dehydroascorbate (DHA) can cross the blood-brain barrier (BBB) more efficiently through the GLUT1
transporter present in the BBB endothelial cells. SVCT2 mediates AA uptake through neurons
or astrocytes in the brain while GLUT receptors (In particular GLUT1 and GLUT3) are primarily
responsible for the DHA absorption from the central nervous system cells. Neurons likely use both
mechanisms to maintain intracellular ascorbate, although SVCT2 transport mostly contributes to
maintaining the ascorbate concentration gradient from CSF to neurons [43]. Moreover, AA recycling
acts through a bystander effect by GLUT receptors mediated cellular uptake in pro-oxidative conditions.
It favors the intracellular conversion from DHA to AA with increased intracellular accumulation. This
bystander effect is responsible for AA recycling activity between neurons and astrocytes and plays a
role in the fine balance between pro-oxidative and anti-oxidative status [53].
Recently, it has been shown that AA release mediated by neurons is linked to glutamate
metabolism and kinetics in the brain. In particular, Wilson et al. [53] demonstrated that AA extracellular
release is the direct consequence of astrocyte swelling mediated by glutamate receptors’ increased
sodium uptake. Heightened AA release in the brain and CSF is considered responsible for its
antioxidant and neuroprotective mechanism against glutamate excitotoxicity [53].
Several in vivo studies documented that AA plays an antioxidative role, especially after an
ischemic event or cerebral reperfusion. AA, at millimolar concentrations, was able to scavenge the
superoxide anion, recycling the α-tocopherol within the lipid layers of the cellular membrane [54].
This, in turn, impeded the lipoperoxidation process. In addition, in the CNS, AA participated in
several hydroxylation reactions that include the redox activity of Fe3+ and Cu2+ at dioxigenase
sites. In vitro studies on cultured stem cells showed that AA is also implicated in neuronal
developmental maturation and in neurotransmission. Lee et al. [55] further demonstrated that AA (at
a 200 millimolar concentration) was effective in differentiating neuronal and astrocytes precursors,
promoting synaptic maturation.
Using SVTC knockout mice as an in vivo model showed that AA, at lower doses, was able to
mediate dendrite formation, increasing post-synaptic electrical potential [56].
AA is essential for the biosynthesis of catecholamines, peptide amination, myelin formation,
synaptic function enhancement, along with the neuroprotective activity against glutamate
toxicity [53,57]. In particular, AA plays an essential role in neurotransmission, because it is a co-factor of
the dopamine beta–hydroxylase enzyme that catalyzes the conversion from dopamine to noradrenaline.
AA is considered to modulate cerebral plasticity by orchestrating neurotransmitter balancing in
the brain. The main AA-mediated mechanisms impacting neurotransmission could relate to redox
modulating activity of the NMDA receptor, supporting a role for AA in counteracting glutamate
excitotoxicity [57,58].
It is expected that better understanding of the physiological and molecular mechanisms associated
with AA brain recycling and the differential expression of SVCT2 and GLUT receptors could contribute
to disentangling the pathogenesis of complex neurodegenerative diseases, such as Alzheimer’s disease
and Huntington’s disease.
6. Ascorbic Acid and Its Relevance to Alzheimer’s Disease
Over the years, L-ascorbic acid (AA) has been increasingly found to promote several beneficial
effects on neurodegeneration, with particular regard to Alzheimer’s disease (AD) [59]. The increasing
burden of this life-threatening condition [60] and the lack of disease-modifying drugs have guided the
research towards preventive strategies, targeting AD modifiable risk factors [12]. Mounting evidence
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indicates a role for L-ascorbic acid in ameliorating specific factors linked to AD pathogenesis [61].
Namely, the main mechanisms associated with AA neuroprotection involve the scavenging activity
against ROS, the modulation of neuroinflammation, the suppression of the fibrillation of amyloid-beta
peptide (Aβ), and the chelation of iron, copper and zinc [62]. The amyloid cascade hypothesis is
considered the primary event of AD pathogenesis [63]. The sequential cleavage by gamma and β
secretase (BACE1) of the β-amyloid precursor protein (APP) results in the production of the β-amyloid
species with neurotoxic oligomer accumulation. Brain accumulation of Aβ1-42 oligomers results in
increased neuronal vulnerability to oxidative stress [64,65] neuroinflammation with impairment of
synaptic plasticity [66], and neuronal death. Extracellular amyloid plaques are also responsible for the
hyperphosphorylation of the cytoskeletal Tau protein [67]. In addition, Aβ oligomers interfere with
mitochondrial dynamics [68,69].
Copper, zinc, and iron are present in Aβ plaques due to the presence of metal binding sites [70].
Metals can affect the morphology of Aβ, accelerating fibrillation and cytotoxicity of Aβ [71]. Therefore,
redox active copper and iron linked to Aβ can generate hydroxyl radicals via the Fenton reaction,
increasing protein and DNA oxidation and lipid peroxidation (MDA) in the AD brain. Metal redox
activity also induces the production of AGEs, carbonyls, peroxynitrites, and increased levels of heme
oxygenase-1 (HO-1), with decreased cytochrome c oxidase activity [61]. AGEs, through their interaction
with receptors for advanced glycation end products (RAGEs), further activate pro-inflammatory
pathways with the induction of pro-inflammatory cytokines, such as IL-6 [72]. In addition, lower
concentrations of the fluorescent AGE pentosidine were observed in the CSF of AD patients, compared
to healthy subjects, in support of a role for altered AGE metabolism in AD pathogenesis [73].
Oxidative stress is generally associated with chronological aging, while aging is the major
epigenetic risk factor for AD. Recent evidence has found that oxidative stress plays an essential
role in the pre-phase of AD, including mild cognitive impairment [74]. The brain is vulnerable to ROS
damage due to neurons’ post-mitotic state with higher oxygen consumption. With respect to lipid
peroxidation products, oxidized proteins, and DNA damage, peroxynitrites have been increasingly
detected in the AD temporal cortex, as well as oxidation of mitochondrial DNA and nuclear DNA
in the parietal cortex [75]. In AD hippocampal neurons and astrocytes, a redox imbalance has been
observed with an overexpression of heme oxygenase-1 and increased levels of Cu/Zn superoxide
dismutase [76]. The conjugated aromatic ring of tyrosine residues is also a target for free-radical
attack, and accumulation of dityrosine and 3-nitrotyrosine has also been reported in the AD brain [77].
Therefore, oxidative stress can directly activate glia with the priming of astrocytes and microglia at
the injury site. In turn, the direct contact of activated glial cells with neurons may generate immune
mediators (nitric oxide, ROS, pro-inflammatory cytokines, and chemokines) that are neurotoxins,
spreading inflammation in the central nervous system [78,79]. Thus, extensive oxidative damage
may act as a driver of brain aging, and early accumulation of oxidatively modified biomolecules may
constitute the initial steps of AD neurodegeneration.
All of these findings could provide a mechanistic role for oxidative stress as a direct effect of
aging and a consequence of the toxic effect of Aβ. Oxidative stress interacts with multiple features
associated with AD pathogenesis, such as APP processing, mitochondrial dysfunction, and metal
accumulation [80]. The main AA mediated neuroprotective effects on AD pathogenesis are reported








Table 2. In vitro and in vivo evidence for a role of AA in Alzheimer’s disease.
Species Model Design and Methods Conclusion References
Mouse TASTPM Evaluation of carbonyls, glutathione, Aβ, APP Decreased oxidative stress markers, Nrf2, GSH, APP, solubleAβ1-42. No increase of BACE 1, PS1and AB plaque Choundhry, F. 2012 [58]
Mouse Model with human APP695 anddouble mutation (K670N, M671L)
Evaluation of Aβ, BACE1, antioxidant system and
IL-1β
Increased antioxidant system, reduced activity of BACE, IL-1β
and NO levels, Aβ deposition Apelt, J. 2004 [60]
Mouse APP/PS1 transgenic ROS scavengers and inhibitors effects on Aβ-inducedimpairments in LTP
Reversal of Aβ- deposition by mitochondria-targeted
ROS scavenging Ma, T. 2011 [62]
Mouse HAPP/Sod1−/− Anti-Aβ1-16 antibody Inhibition of amyloid plaques (Aβ hexamers/BACE1 modulation) Murakami, K. 2012 [65]
Mouse Tg2576 Aβ levels brain deposition
Suppressed brain inflammatory and oxidative stress responses in
mice, significant reduction of soluble and insoluble Aβ1-40 and
Aβ1-42
Yao, Y. 2004 [57]
Mouse APPS we/PSEN1ΔE9 MDA, Aβ levels, AChE activity. Learning and memory Improvement of learning and memory Beneficial effects againstMDA, and Beneficial effects on AChE function Harrison, F.E. 2009 [50]
Mouse APPSWE/PSEN1ΔE9 mice,SVCT2+/− Behavioural test, GSH, MDA, isoprostanes
Decreased Aβ deposition (senile plaque formation
and accumulation) Dixit, S. 2015 [81]
Rat F-344 Aβ deposition Decreased-amyloid immunoreactive fibrils Hauss-Wegrzyniak, B. 2002 [82]
Rat and Mouse Charles-Foster, Swiss Albino mouse Cognitive test, cytokines, ROS CytotoxicActivity Assay Enhancement of anti-oxidative pathway Sil, S. 2016 [83]
Mouse Gulo−/−5XFAD Identification modification of cerebral capillaries Reduction of Aβ accumulation Kook, S.Y. 2014 [84]
In Vitro neuroblastoma cell line SH-SY5Y Apoptosis (phosphatidylserine, TUNEL assay,caspase-3 activity) Prevention of toxicity induced by Aβ Huang, J. 2006 [85]
Mouse Tg2576, 3xTg-AD Aβ staining, investigation APP andHS oligosaccharides Modulation of Aβ fibrillogenesis Cheng, F. 2011 [86]
Mouse AD model Fibrillogenesis: senile plaques Modulation of synaptophysin and the phosphorylation of tau atSer396 Murakami, K. 2011 [87]
Rat Wistar Lipoperoxidation, oxidation, Inflammation, nitrites Reduction of pro-inflammatory cytokine Inhibition ofAβ deposition Rosales-Corral, S. 2003 [88]
Human In Vitro NT2 undifferentiated cells
Measurement levels of Aβx-40 and Aβx-42, HNE,
expression of BACE-1. Evaluation apoptotic cell death
induced by HNE
Increased anti-oxidative pathways against SAPK pathways and
BACE-1 that regulate AβPP processing Tamagno, E. 2005 [74]
Human In Vitro Neuroblastoma cell line SH-SY5Y Glutathione, superoxide dismutase, and catalase Neuroprotection anti-oxidative pathways Improvement ofantioxidant defense system Ballaz, S. 2013 [80]
Rat PND7 Induction of ROS, apoptotic markers. Quantificationof Bax/Bcl-2 ratio, cytochrome c and caspases
Reduction of oxidation, neuroinflammation (both activated
microglia and astrocytes). reduced ethanol-induced activation of
PARP-1 and neurodegeneration
Ahmad, A. 2016 [89]









Species Model Design and Methods Conclusion References
In Vitro EA. hy926 cells Quantification LDL-enriched lipoproteins, GSH, andlipid peroxidation Endothelial integrity May, J.M. 2010 [91]
Rat Cortical neuron/glia co-cultures ofneonatal
Measuring nitrites IL-6 and MIP-2, LDH. p38 and ERK
MAPKs
Suppression of the LPS-stimulated production of inflammatory
mediators Huang, Y.N. 2014 [92]
Rat Sprague–Dawley Behavioural test BBB components Modulation of cortical compression and/or BBB dysfunction Lin, J.L. 2010 [12]
Rat MCAO
Measurement of infarct and edema brain,
measurement of serum MMP-9 levels, behavioural
testing
decreased MMP-9 levels, Improvement of the vascular insult
(BBB disruption and brain edema) Allahtavakoli, M. 2015 [93]
Rat Brains Assessment the role of nanocapsulated ascorbic acid(NAA)
NAA exerted protection to brain mitochondria by preventing
oxidative damage in ROS mediated CIR injury Sarkar, S. 2016 [94]
Rat Hippocampal neurons Incubation with Aβ Os or 4-CMC ± NAC NAC prevention of Aβ O-induced mitochondrial Fragmentationby anti-oxidative pathways Sanmartin, C.D. 2012 [61]
Rat Cortical neuronsNeuroblastoma cells Oxidative stress and DHA uptake, analysis of GLUTs Improvement of anti-oxidative defense of neurons García-Krauss, A. 2016 [75]
Rat Primary neurons Incubation with H2O2, ratio GSH/GSSG Increased glutathione system of peroxide detoxification Dringen, R. 1999 [78]
Rat Astroglial cells Treatment with H2O2 or hydro peroxide, NO release,Lipid Peroxidation, ROS Reduction of neuroinflammation (microglial-astroglial cells) Röhl, C. 2010 [79]
Rat SD Induction of transient focal cerebral ischemia,treatment with DHA
DHA reduced brain edema and vascular permeability formation
following cerebral ischemia Song, J. 2015 [95]
Human Endothelial cell (HBMEC) andastrocyte co-colture BBB after hyperglycaemic insult
Improvement of BBB permeability by reducing oxidative stress
associated with glucose normalization Allen, C.L. 2009 [96]
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6.1. Ascorbic Acid and Oxidative Stress in Alzheimer’s Disease
AA is suggested to play a major role in the pathogenesis of AD by direct neuroprotection
against oxidative stress. Imbalance of AA homeostasis has been extensively demonstrated in
neurodegeneration [58]. AA is a key antioxidant of the CNS, released from glial cells to the synaptic
cleft, and taken up by neurons as an antioxidant defense to maintain neuronal metabolism and synaptic
function. The astrocyte-neuron interaction was found to function as an essential mechanism for AA
recycling, participating in the anti- oxidative defense of the brain [97].
It is well documented that AA is a first-line antioxidant defense to neutralize ROS reactivity,
promoting the regeneration of endogenous antioxidants (GSH, catalase, vitamin E) [98].
Interestingly, it is also presumed that AA moderates the oxidative stress mediated by glutamate,
protecting from excitotoxicity in the brain [56,88]. A previous study in APP/PSEN 1 transgenic mice
showed that parenteral administration of AA possessed nootropic properties, without altering the
AD-like features of plaque deposition, oxidative stress and acetylcholinesterase activity [85]. Therefore,
several in vitro and in vivo studies underpin the therapeutic role of AA in AD, bolstering oxidative
defense [99].
In rat hippocampal brains, oral administration of AA reduced oxidative stress and
neuroinflammation mediated by Aβ fibrils [100]. Additionally, AA was shown to protect SH-SY5Y
neuroblastoma cells from apoptosis mediated by Aβ [86], decreasing the rate of endogenous amyloid
generation. Further, AA was reported to decrease acetylcholinesterase activity in mice [101] and to
positively restore presynaptic acetylcholine release [102].
More recently, the NO-catalyzed release of anhydromannose in the presence of AA was
detected [103] with an associated decreased formation of toxic Aβ oligomers. APP/PSEN 1
mice lacking the SVCT2 transporter and having AA mild deficiency showed accelerated amyloid
pathogenesis, linked to oxidative stress pathways, compared to control mice with normal brain ascorbic
acid [81]. Further, orally-administered AA reduced oxidative stress and pro-inflammatory cytokines
induced by Aβ peptide injections in the CA1 area of the hippocampus in rat brains [99].
6.2. Metals, Oxidative Stress and Ascorbic Acid in Alzheimer’s Disease: The AA Oxidative Balance in the Brain
The main features of enhanced oxidative stress in the AD brain are also related to the increased
content of Cu and Fe, capable of stimulating free radical generation, lipid peroxidation, reactive
nitrogen species (NRS) release, and stress-sensitive proteins [104]. In turn, the interaction of the
redox-active copper ions with misfolded Aβ aggregates and oligomers may favor AD pathogenesis.
It is well known that at higher concentrations, AA acts as a pro-oxidant, either by generating
reactive oxygen species or by inhibiting the antioxidant systems in the presence of iron, which, in
turn, induces lipid peroxidation [105]. A pro-oxidant or antioxidant effect of AA mainly relies on the
concentration gradient and redox state of a cell [106]. Evidence from a mouse model that selectively
over-expressed the AA transporter SVCT2 in the eye [107] implicated AA in age-related damage to
crystalline proteins in the lens. All of these experimental data contribute to heightening the debate on
the potential pro-oxidant role of AA via the Fenton reaction.
A previous study undermined the protective role of AA in dementia, indicating that the interaction
of AA with ‘free’ catalytically-active metal ions could contribute to oxidative damage through the
production of hydroxyl and alkoxyl radicals [108]. Interestingly, some in vitro studies investigated the
pro-oxidant properties of ascorbate [109], which were mainly attributed to the release of metal ions
from damaged cells. It has been reported that neurotoxic forms of amyloid β, Aβ (1–42), Aβ (1–40),
and also Aβ (25–35) induced copper-mediated oxidation of ascorbate, whereas non-toxic Aβ (40–1)
did not [110,111]. It was concluded that toxic Aβ peptides mediated copper-oxidation of ascorbate
with the generation of hydroxyl radicals, indicating a role for cupric-amyloid peptide’s free radical
generation in the pathogenesis of AD. In line with these last findings, Aβ was not found to silence
the redox activity of Cu2+/+ via chelation, but rather hydroxyl radicals were produced as a result
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of Fenton-Haber Weiss reactions of ascorbate and Cu2+, rapidly quenching harmful radicals [112].
Moreover, reaction rates and mechanisms of AA oxidation resulted in greater biological relevance in
the presence of Cu(II)-containing Aβ oligomers and fibrils, given the close proximity of ROS to cell
membranes [104]. Further evidence indicated a pro-oxidative role for AA in the interaction of the
redox-active copper ions with misfolded amyloid β and AD pathogenesis, with particular relevance to
catalytic sites for Cu+ present in full-length Aβ instead of in any particular Aβ conformation [82].
However, to complicate the issue, AA was observed to reduce in vivo oxidative damage in the
presence of iron, despite its well-known in vitro pro-oxidant properties in buffer systems containing
iron [83]. In addition, a recent report evaluated the in vitro effects of different food constituents
on brain metal chelation, oxidative stress, and fibrillogenesis [89]. The results did not support the
currently hypothesized AA neuroprotective mechanisms of action. Indeed, AA was found to be a good
antioxidant with poor metal chelating activity. Strikingly, the study did not show any AA-mediated
inhibiting effect on Aβ fibrillogenesis, compared to the multifunctional food abilities of epigallocatechin
gallate (EGCG), gallic acid, and curcumin. Hence, due to good AA brain uptake, further investigation
is needed to address the role of ascorbic acid in counteracting oxidative stress in an AD brain.
6.3. Ascorbic Acid and Neuroinflammation in Alzheimer’s Disease
A previous study demonstrated that chronic administration of AA in the brain chronically
infused with lipopolysaccharide and tiorphan was associated with increased deposition of Aβ amyloid
plaques and increased Aβ neuronal immunoreactivity [92]. However, a body of evidence implicated
AA in the suppression of glia-mediated inflammation. In particular, a colchicine-induced oxidative
stress/neuroinflammation AD rat model [84] showed that administration of AA was effective in
preventive memory impairment, and reducing inflammatory markers (TNF alpha, IL 1 beta), ROS,
and nitrite levels in the hippocampus of AD rats. AA also significantly reduced amyloid plaque
formation. Peripheral immune response (increased phagocytic activity of blood WBC and splenic
PMN) was also recovered after AA administration and the observed changes were associated with the
higher efflux of inflammatory mediators from the brain to peripheral circulation. The same results
also addressed a pro-oxidant role of AA at higher doses (600 mg diet), supporting the dual role of
AA in addressing the oxidative stress. In addition, a rat model of ethanol-induced oxidative stress
showed that AA was effective in counteracting ethanol-induced oxidative stress, neuroinflammation,
and apoptotic neuronal loss with beneficial effects against ethanol damage to brain development [87].
Even if the model is not a true AD model, the current findings add knowledge to the role of AA against
oxidative stress and neuroinflammation in the brain. In particular, due to its free radical scavenging
properties, AA treatment reduced the production of ROS and suppressed both activated microglia and
astrocytes. AA also demonstrated mitigation of apoptosis and neurotoxicity by decreasing levels of
the Bax/Bcl-2 ratio, cytochrome C, and different caspases, such as caspase-9 and caspase-3. Moreover,
AA treatment reduced ethanol-induced activation of poly [ADP-ribose] polymerase 1 (PARP-1) and
neurodegeneration. In line with these data, AA was also observed to suppress the lipopolysaccharide
(LPS)-stimulated production of inflammatory mediators in neuron/glia co-cultures by inhibiting the
MAPK and NF-κB signaling pathways [113].
6.4. Ascorbic Acid and Amyloid Plaque Accumulation in Alzheimer’s Disease
Accumulating evidence indicates a role for AA on the toxic fibrillogenesis of Aβ. High doses of
AA supplementation reduced the amyloid plaque burden in a 5 familial Alzheimer’s disease mutation
(5XFAD) AD mouse model. To better identify the pathogenetic importance of AA in an AD mouse
model, the cross-breeding of 5XFAD mice with gulono-gamma-lactone oxidase (Gulo) knockout mice
was performed (KO-Tg mice). The higher supplementation of AA in KO-Tg mice resulted in the
amelioration of BBB disruption and mitochondrial alteration, with substantial reduction of amyloid
plaque burden [114].
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The APPSWE/PSEN1deltaE9 mouse model of AD, created by crossing APP/PSEN1(+)
bigenic mice with SVCT2(+/−) heterozygous knockout mice, also showed interesting results [81].
By 14 months of age, increased oxidative stress was observed (malondialdehyde, protein carbonyls,
F2-isoprostanes) with decreased total glutathione, compared to wild-type controls. In addition,
increased amounts of both soluble and insoluble Aβ1-42, and a higher Aβ1-42/1-40 ratio with increased
hippocampal and cortical amyloid-β plaque deposits were observed, compared to APP/PSEN1(+)
mice with normal AA brains. These data suggested that AA deficiency plays an important role in
accelerating amyloid accumulation, particularly during early stages of disease, and that these effects
are likely modulated by oxidative stress pathways. Huang et al. showed that pre-loading cells with
ascorbate substantially prevented apoptosis and death of SH-SY5Y cells, while also decreasing basal
rates of endogenous beta-amyloid generation [86]. Cheng et al. demonstrated, in an in vitro model,
that an inadequate supply of AA could contribute to the increased formation of toxic Aβ oligomers.
In the absence of AA, the temporary interaction between the Aβ domain and small NO-catalyzed
release of anhydromannose (anMan)-containing oligosaccharides is prevented, with the increased
induction of neurotoxic fibrillogenesis [103]. Murakami et al. [91], in APP transgenic mice, showed
that AA administration attenuated oligomerization, but not the total amyloid plaque volume. The
authors concluded that the ability of mice to retain de novo synthesis of AA is possible, and a longer
study duration is needed to appreciate the significant changes in amyloid plaque accumulation. These
last findings are original and indicate the need to test the “sink hypothesis” through the systematic
assessment of cerebrospinal fluid AA levels in order to support the role of AA in promoting healthy
brain aging. Indeed, it is hypothesized that there is some form of equilibrium for the Aβ in the brain
and the periphery such that Aβ can be transported across the blood-brain barrier. By modulating
the peripheral Aβ levels, it is predicted that the brain Aβ levels will undergo concomitant changes,
forming the basis of the “sink hypothesis” for Aβ lowering strategies.
6.5. Acid Ascorbic and Vascular Disease Associated with Alzheimer’s Disease
Recently, a pathophysiological role of the vascular component in the pathogenesis of AD has
been demonstrated [115]. Again, oxidative stress is considered a key relevant mediator, confirming
the pathogenetic link between AD and vascular disease [116]. Oxidative stress may affect the
neurovascular unit, by impairing the endothelial integrity with increased Aβ42 production. This series
of pathological events resulted in automatically maintaining the cycle between ROS overproduction
and new extracellular Aβ42 deposition. It was ascertained that AA mediates a series of protective
effects on brain neurodegeneration by reducing intima-media thickness, lipid peroxidation, and
endothelial dysfunction [90,116–119]. In keeping with this, it has been recently documented that
the integrity of the endothelial lining in the blood-brain barrier is essential to prevent the onset
of AD [120–122]. Each of these vascular risk factors may represent a biological target for AA and
contribute to the preventative role of AA in the development of AD pathogenesis, associated with the
vascular component.
Growing evidence indicates a role for AA in reducing cardiovascular related mortality and overall
mortality, according to higher quartile plasma AA concentrations in humans [123]. Interestingly, it
should be noted that the higher risk of carotid intima thickness >1.2 mm was exclusively associated
with the lowest plasma AA tertile. This same increased risk was not observed with uric acid, vitamin
A, or enzymatic antioxidant load (superoxide dismutase and glutathione oxidase activity). Similarly,
dietetic interventions in elderly subjects showed that carotid intima thickness progression was reduced
only in those subjects taking AA daily.
The risk of either AD or vascular dementia is higher in patients with elevated blood pressure,
which suggests how arterial stiffness and atherosclerosis play important pathogenetic roles [123].
Endothelial dysfunction is associated with arterial stiffness which, in turn, is a strong predictor for
cognitive decline [124]. All of these data support the role for AA in modifying vascular risk factors
associated with Alzheimer’s-type dementia.
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Endothelial dysfunction is a crucial factor associated with AD pathogenesis. Aβ aggregates are
cleared from the brain across the BBB, as the transport is finely regulated by RAGE receptors and LDL
receptor-related protein (LRP-1). In patients with AD, brain endothelial LRP-1 expression throughout
the BBB is reduced [125]. These data suggested an essential role of the endothelial cell integrity
lining in the onset and progression of AD. The efficacy of AA against BBB breakdown due to cortical
compression was reported [90]. A model of ischemic-reperfusion [126] and BBB breakdown with
reduced NO bioavailability may be considered a prototypical model to understand the pleiotropic roles
of AA on endothelial function. AA regulates endothelial integrity via oxidative pathways; superoxide
generated by endothelial cells reacts with NO to form cytotoxic peroxynitrites and AA could decrease
NO consumption by scavenging superoxide. In addition, AA was found to play a role in the function of
endothelial nitric oxide synthase (eNOS) by recycling the eNOS co-factor, tetrahydrobiopterin, which is
relevant for arterial elasticity and blood pressure regulation [18]. AA also favored the restoration of NO
metabolism from S-nitrosothiols in plasma [127], reducing nitrite (NO2) to NO, which may preserve
NO in tissues or plasma. AA was reported to reverse the generation and metabolism of NO [94], and
to prevent endothelial dysfunction by inhibiting LDL oxidation. An oxidized endothelium is known to
increase BBB permeability [117] and the AA-associated protective mechanism on lipid metabolism
was found to improve BBB endothelial disruption. In addition, AA prevented the impaired response
to the vasodilator acetylcholine (endothelium-dependent agonist) and reduced ROS (e.g., superoxide)
produced by neutrophils [93]. Thus, a series of studies have suggested that AA may protect from AD
onset, by protecting BBB integrity.
So far, scant investigations have explored the effects of anti-oxidative vitamins on dementia
through the cerebrovascular axis [95]. The study of Kook et al. [87] recently reported that high-dose
supplementation of AA reduced amyloidosis in AD mice (5XFAD) via the reduction of BBB disruption
and mitochondrial alteration [96]. Additionally, AA was also reported to prevent the disruption of
BBB by upregulating the expression of tight junction proteins, occludin and claudin-5.
In a model of stroke with substantial BBB disruption, AA significantly reduced BBB
permeability [128]. Similarly, in a mouse model of cerebral ischemia, AA ameliorated BBB dysfunction
by reversing tight junction claudin-5 and attenuated edema and neuronal loss [129]. Moreover, an
in vitro study provided evidence that AA reversed hyperglycemia-mediated BBB disruption [130]. To
date, AA seems to offer neuroprotection by restoring BBB integrity. However, further investigations
should focus on simultaneously testing brain neuroprotective effects and BBB protective effects of
antioxidants [95]. AA seems to possess both types of neuroprotection and could be further tested as a
targeted dual agent for preventing cognitive decline.
Several cross-sectional studies have demonstrated a lower CSF-to-plasma AA ratio in AD
patients compared to controls. In particular, recent findings [95] suggest that maintenance of a high
CSF-to-plasma AA ratio is important in preventing cognitive decline in AD and that BBB impairment
unfavorably affects this ratio. However, whether the AA transport carrier dysfunction (SVCT2) or the
disturbed BBB integrity is responsible for it, is still a matter of debate.
Indeed, the loss of BBB integrity seen in elderly people with dementia may hamper the brain’s
ability to retain CNS AA regardless of the successful transport [131–133]. Genetic variations of the
SVCT2 carrier at the choroid plexus and in neurons may also play a significant role. In line with
these data, a recent review has concluded that CSF levels within the normal range for AA indicate
the preservation of choroid plexus function and AA transport into the CSF [134], despite lower
plasma levels.
7. From Bench to Bedside
Ascorbic acid levels in plasma are decreased in AD patients [135] and the association between
cognitive impairment and low antioxidant status is accumulating. Indeed, it has been suggested
that increased dietary intake may reduce the risk of developing AD. So far, whether oxidative stress
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associated with the disease is responsible for the reduction of antioxidants, or whether the low
antioxidants contribute to the progression of the disease has not been ascertained.
However, plasma levels of AA were found to be lower both in patients with mild cognitive
impairment and AD, compared to controls [136].
A further difference existed between undernourished patients with dementia and patients taking
any antioxidant supplement.
From bench to bedside, eight large population studies [57] have investigated the association
between AA intake and Alzheimer’s-type dementia in both European countries and the US. However,
the neuroprotection associated with AA has not yet been established. According to the CHAP
study [137], none of the elderly dementia-free participants longitudinally developed dementia, due to
AA supplementation. In contrast, a synergistic association between AA and vitamin E supplementation
was shown in reducing the risk of AD [138]. Another large population study has shown a protective
role for AA in vascular dementia and cognitively-intact subjects, but no protective role of AA was
shown for Alzheimer’s disease [139].
The Rotterdam study showed the most consistent association between higher AA intake and
reduced relative risk for AD in the largest population study [140] with the higher magnitude of
association in people most depleted of AA (e.g., smokers). The same study found an association
for lower levels of vitamin E in AD patients at follow up an average of 9.6 years later, but not for
AA intake.
Additionally, eleven studies have examined the relationship between plasma AA and cognitive
decline, including AD, and four of them examined CSF AA and CSF-to-plasma AA ratios. An early
study of Goodwin [29] assigned patients to AA plasmatic deficiency according to tertiles. The main
findings suggested a significant association between AA deficiency below 20 μM, mild cognitive
impairment, and AD patients compared to healthy controls, even after correction for co- morbidities,
age, and fruit/vegetables intake.
The study of Quinn [141] showed that the mean CSF-to-plasma AA ratio was significantly lower
in AD compared with controls. A further prospective analysis of CSF AA, rates of cognitive decline,
and BBB did not draw final conclusions, but a higher CSF-to-plasma AA ratio was associated with a
slower rate of decline [57].
Conversely, several clinical studies did not show any beneficial effect of AA on cognition in
patients with AD. In a population study of North Carolina, 616 elders aged over 75 years and
long-term supplement users of AA did not show any neuroprotection against developing AD [142].
However, no record was made of dietary intake, and the results outlined that less healthy behaviors
and socioeconomic status were associated with the poorer cognitive outcomes. Vitamin E levels
were significantly lower in the AD group than controls while AA levels did not differ significantly
between groups.
A series of limitations may count for interpreting the clinical results. There is substantial
inconsistency among the observational studies on AA intake, plasma levels, beneficial effects on
aging and cognition.
It is noteworthy that a great deal of clinical studies usually excluded elderly people if they had
polypharmacy or comorbidity. These exclusion criteria critically undermine the validity of results,
leaving out the populations most at risk for AA deficiency.
Approximately 17% of the elderly population did not meet the RDA for AA intake, which critically
suggests that large elderly population groups show depleted levels of AA; this determinant may count
for the disparate conclusions of different clinical studies. In particular, as accurately summarized by
Harrison F et al. [143], the classification of groups according to AA status differs greatly among studies.
The deficiency levels of AA are lower than 11 μmol/L, with suboptimal concentrations between
11–38 μmol/L, adequate plasmatic concentrations of AA above 28 μmol/L and optimal concentrations
between 50–60 μmol/L (μmol/L: conversion factor 56.78 from mg/dL concentrations of AA).
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Moreover, the range of AA supplements greatly vary from 27 to 230–270 mg/day, introducing
another element of variability.
Not least, the higher intakes of AA were associated with beneficial effects on cognition if not
exceeding 500 mg/day; higher plasmatic values (1 g/day) of AA were associated with poorer
cognitive performance.
The beneficial effects of AA need reliable plasmatic determinations with repeated points of
measurement. The lack of accuracy in study designs and methodologies may also affect the reliability
of the findings [57]. In addition, the lack of standardization between single nutrient consumption or
multivitamins and the lack of systematic detection of plasmatic levels of AA also affect the accuracy
of outcomes.
Moreover, the missing consideration of specific AA metabolism, the inaccurate daily estimate
of AA consumption, and the erroneous intestine-to-bloodstream absorption due to saturable AA
transporters being critical determinants for drawing appropriate conclusions [57]. The variability of the
results may also be ascribed to difference of plasma AA concentrations according to polymorphisms of
SVCT2 and SVCT1 despite equivalent AA intake. This difference indicates that SVCT1/2 genotype may
play an important role in the association between AA intake and circulating AA levels. Furthermore,
the difference between food intake and synthetic supplements and the mean of their bioavailability
need to be clearly defined.
It should also be noted that the current intake of AA may not accurately reflect the subjects’
lifetime habits; this, in turn, may substantially affect the biological trajectory of Alzheimer’s disease
with particular regard to early mid-life deposition of amyloid plaque. Thus, the stratification of
different aging populations according to their clinical vulnerability, cognitive reserve, comorbidity and
specific risk profile could add knowledge to this field [95]. Similarly, a greater understanding of the
modulation between pro-oxidative AA status and antioxidative capacity during aging and age-related
specific conditions, including dementia, is warranted.
Currently, the clinical data yield inconsistent results. AA supplementation showed beneficial
effects when restoring a nutritional deficit or preventing vitamin deficiency; thus, it seems more
plausible that avoiding AA deficiency is likely to be more beneficial than taking supplements on top of
a normal healthy diet.
So far, the levels of AA needed to beneficially modify brain aging are largely unknown. A causal
association between AA deficiency and cognitive decline, including dementia, is still debated and two
main issues are unanswered. Namely, the co-causal role of AA deficiency versus its epiphenomenal role
in AD neurodegeneration has not yet been established. However, AA’s strong free radical scavenging
properties, the well-characterized kinetics of transport, and the good bioavailability in the CNS provide
a favorable background for further exploring its role in promoting brain function and healthy aging.
With testing by neuroimaging, recent research has demonstrated that it is possible to detect
brain levels of AA by using a MEGA-PRESS mediated spectra (MEGA-PRESS, MEGA-point-resolved
spectroscopy) [144]. The study indicated a relationship between brain and blood AA levels and
provides a new conceptual framework for future studies, further exploring the role of AA in the brain.
8. Conclusions
In conclusion, randomized clinical trials have failed to demonstrate any association between
AA-mediated antioxidant therapeutic activity and a delay in AD neurodegeneration.
However, the assessment of the “sink hypothesis” could substantiate a crucial role for AA in
promoting healthy aging of the brain. The analysis of AA concentration in plasma, CSF, and the ratio
of AA/glutamate, along with the role of AA-related carriers (SVCT2 SNPs) and barriers to its brain
transport (BBB) could significantly spur this research field by directly analyzing the AA concentrations
in the brain.
Neuroimaging measures also hold promise in offering deeper insights on the structural, metabolic,
and connective role that AA plays in the brain [144], contributing to the larger picture.
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Additionally, animal models need to be further investigated with a particular focus on
gulonolactone oxidase knockout models that mimic human physiology, and may help identify novel
AA mechanisms of action to promote healthy aging of the brain.
Another intriguing area of research could address the protective association between AA and
glutamate transport/NMDA receptors to critically evaluate the AA role in neurodegeneration.
Finally, the field of epigenetics has recently answered the question as to why AA is
disproportionally concentrated in CSF and brain parenchyma compared to plasma [28]. Nutrition
represents one of the most powerful environmental modifications of the genome. Recent research has
assessed a peculiar epigenetic role for AA. Namely, the oxidation of 5-mc (5-methylcytosine) to 5-hmc
(5-hydroxymethylcytosine), as part of dynamic DNA demethylation, is catalyzed by TET (ten-eleven
translocation) dioxygenase enzymes, for which AA is a critical co-factor [23,145]. Interestingly, no
other antioxidant displayed such an epigenetic mechanism. Thus, AA can be considered vital for
neuronal repair and offers new molecular mechanisms to understand the true neuroprotective role of
AA in brain aging and neurodegeneration.
In addition, it has been recently documented that 75% of ascorbic acid degradation is due to
Maillard degradation pathways (amide-AGEs) [146]. Knowledge of the mechanisms of Maillard model
systems could help understand the changes occurring during storage and processing of AA-containing
food, as well as in vivo modifications.
Thus, all of these lines of research could improve the understanding of the role of AA in brain
aging and, hopefully, provide a new conceptual framework for AD in the near future.
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Abstract: Vitamin C (Vit C) is considered to be a vital antioxidant molecule in the brain. Intracellular
Vit C helps maintain integrity and function of several processes in the central nervous system (CNS),
including neuronal maturation and differentiation, myelin formation, synthesis of catecholamine,
modulation of neurotransmission and antioxidant protection. The importance of Vit C for CNS
function has been proven by the fact that targeted deletion of the sodium-vitamin C co-transporter in
mice results in widespread cerebral hemorrhage and death on post-natal day one. Since neurological
diseases are characterized by increased free radical generation and the highest concentrations of
Vit C in the body are found in the brain and neuroendocrine tissues, it is suggested that Vit C may
change the course of neurological diseases and display potential therapeutic roles. The aim of this
review is to update the current state of knowledge of the role of vitamin C on neurodegenerative
diseases including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, multiple sclerosis
and amyotrophic sclerosis, as well as psychiatric disorders including depression, anxiety and
schizophrenia. The particular attention is attributed to understanding of the mechanisms underlying
possible therapeutic properties of ascorbic acid in the presented disorders.
Keywords: vitamin C; Alzheimer’s disease; Parkinson’s disease; Huntington’s disease; multiple
sclerosis; amyotrophic sclerosis; depression; anxiety; schizophrenia
1. Introduction
Vitamin C (Vit C, ascorbic acid) belongs to a group of water-soluble vitamins. In organisms, Vit C
can exist in two forms: reduced—the exact ascorbic acid (AA) which in physiological pH occurs in
its anion form of an ascorbate—and oxidized one—dehydroascorbic acid (DHA), which is a product
of two-electron oxidation of AA (Figure 1). In the course of metabolic processes an ascorbate free
radical can be produced as a result of one-electron oxidation. This variety may subsequently undergo
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Figure 1. Forms of vitamin C occurring in organisms.
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Mammalian organisms are generally capable of synthesizing Vit C themselves. However, some
species like fruit bats, guinea pigs, other primates and humans are deprived of this ability due
to the lack of L-gulono-1,4-lactone oxidase enzyme which is an element of the metabolic pathway
responsible for synthesis of ascorbic acid from glucose [1,2]. Moreover, Vit C is not produced by
intestinal microflora [3]. The above facts make these organisms strictly dependent on dietary intake.
The recommended Vit C daily intake was established as 60 mg with the reservation that in smokers
this value should be increased up to 140 mg [4]. According to the later recommendations, Vit C
consumption should be 75 (women) and 90 (men) mg per day, whereas in smokers this value ought to
be increased by 35 mg per day [3,5,6].
Vit C is a nutrient of greatest importance for proper functioning of nervous system and its
main role in the brain is its participation in the antioxidant defense. Apart from this role, it is
involved in numerous non-oxidant processes like biosynthesis of collagen, carnitine, tyrosine and
peptide hormones as well as of myelin. It plays the crucial role in neurotransmission and neuronal
maturation and functions [7]. For instance, its ability to alleviate seizure severity as well as reduction of
seizure-induced damage have been proved [8,9]. On the other hand, disruption of vitamin C transport
has been shown to contribute to brain damage in premature infants [10]. Furthermore, Vit C treatment
has been reported to ameliorate neuropathological alterations as well as memory impairments and the
neurodegenerative changes in rats exposed to neurotoxic substances like aluminum or colchicine [11,12].
Consequently, the growing interest in the issue of vitamin C deficiency, as well as vitamin
C treatment in the nervous system diseases, was observed for many years. These facts made us
decide to update the current state of knowledge of the role of Vit C in neurodegenerative diseases
including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, multiple sclerosis as well
as amyotrophic sclerosis, as well as in psychiatric disorders including depression, anxiety disorders
and schizophrenia.
2. Methods
To review the literature on brain Vit C transport/distribution and its function in central nervous
system, PubMed and Scopus databases were searched using the following search terms: (vitamin
C OR ascorbic acid) AND (central nervous system OR CNS) or (vitamin OR ascorbic acid) AND
brain, separately.
To review the literature on the role of Vit C in neurodegenerative diseases and psychiatric
disorders, PubMed and Scopus databases were searched using the following search terms: (vitamin
C OR ascorbic acid) AND Alzheimer, (vitamin C OR ascorbic acid) AND Parkinson, (vitamin C OR
ascorbic acid) AND Huntington, (vitamin C OR ascorbic acid) AND multiple sclerosis, (vitamin C OR
ascorbic acid) AND amyotrophic sclerosis, (vitamin C OR ascorbic acid) AND depression, (vitamin
C OR ascorbic acid) AND anxiety and (vitamin C OR ascorbic acid) AND schizophrenia, separately.
The searching was limited to the last 10 years and human studies, but if none or a few human studies
were found the criteria were expanded then to include in vitro or animal studies.
The final search was conducted in April 2017. The titles and abstracts of the articles identified
through the initial search were reviewed, and the irrelevant articles were excluded. The full texts of
the remaining articles were reviewed to detect studies that did were not suitable for this review.
3. Vitamin C Transport Systems and Distribution in the Brain
Two basic barriers limit the entry of Vit C (being a hydrophilic molecule) into the central nervous
system: the blood-brain barrier and the blood-cerebrospinal fluid barrier (CSF) [13]. Considering the
whole body, ascorbic acid uptake is mainly conditioned by two sodium-dependent transporters from
the SLC23 family, the sodium-dependent Vit C transporter type 1 (SVCT1) and type 2 (SVCT2). These
possess similar structure and amino acid sequence, but have different tissue distribution. SVCT1 is
found predominantly in apical brush-border membranes of intestinal and renal tubular cells, whereas
SVCT2 occurs in most tissue cells [14,15]. SVCT2 is especially important for the transport of Vit
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C in the brain—it mediates the transport of ascorbate from plasma across choroid plexus to the
cerebrospinal fluid and across the neuronal cell plasma membrane to neuronal cytosol [16]. Although
dehydroascorbic acid (DHA) enters the central nervous system more rapidly than the ascorbate, the
latter one readily penetrates CNS after oral administration. DHA is taken up by the omnipresent
glucose transporters (GLUT), which have affinity to this form of Vit C [17,18]. GLUT1 and GLUT3
are mainly responsible for DHA uptake in the CNS [13]. Transport of DHA by GLUT transporter is
bidirectional—each molecule of DHA formed inside the cells by oxidation of the ascorbate could be
effluxed and lost. This phenomenon is prevented by efficient cellular mechanisms of DHA reduction
and recycling in ascorbate [19]. Neurons can take up ascorbic acid using both described ways [20],
whereas astrocytes acquire Vit C utilizing only GLUT transporters [21].
The brain has been found to belong to the organs of the highest ascorbate content, with neurons
displaying the highest concentration of all the human organism and reaching 10 mmol/L [1,22].
Mefford et al. [23] and Milby et al. [24] showed high concentrations of Vit C in neuron-rich areas
of hippocampus and neocortex in the human brain. Authors suggested that ascorbate content in
above brain areas is as much as two-fold higher than in other regions. The difference in ascorbate
content between neurons and glia appears to be significant [25]. It is postulated that in astrocytes
and glial supported cells lacking the SVCT2, the uptake and reduction of DHA may be the only
mechanism of ascorbate retention [26]. In addition to ascorbate motion in neurons and glial cells, it is
also released from both types of cells. This release contributes to a certain extent to the homeostatic
mechanism of extracellular ascorbate maintenance in the brain [15,19]. Moreover, the extracellular
ascorbate concentration is regulated dynamically by glutamate release—increase in extracellular Vit C
concentration causes heteroexchange with glutamate [27,28].
4. Vitamin C Function in Central Nervous System
It is well known that the main function of intracellular ascorbic acid in the brain is the antioxidant
defense of the cells. However, vitamin C in the central nervous system (CNS) has also many
non-antioxidant functions—it plays a role of an enzymatic co-factor participating in biosynthesis
of such substances as collagen, carnitine, tyrosine and peptide hormones. It has also been indicated
that myelin formation in Schwann cells could be stimulated by ascorbic acid [7,29].
The brain is an organ particularly exposed to oxidative stress and free radicals’ activity, which is
associated with high levels of unsaturated fatty acids and high cell metabolism rate [16]. Ascorbic acid,
being an antioxidant, acts directly by scavenging reactive oxygen and nitrogen species produced during
normal cell metabolism [30,31]. In vivo studies demonstrated that the ascorbate had the ability to
inactivate superoxide radicals—the major byproduct of fast metabolism of mitochondrial neurons [32].
Moreover, the ascorbate is a key factor in the recycling of other antioxidants, e.g., alpha-tocopherol
(Vitamin E). Alpha-tocopherol, found in all biological membranes, is involved in preventing lipid
peroxidation by removing peroxyl radicals. During this process α-tocopherol is oxidized to the
α-tocopheroxyl radical, which can result in a very harmful effect. The ascorbate could reduce the
tocopheroxyl radical back to tocopherol and then its oxidized form is recycled by enzymatic systems
with using NADH or NADPH [33]. Regarding these facts, vitamin C is considered to be an important
neuroprotective agent.
One non-antioxidant function of vitamin C is its participation in CNS signal transduction through
neurotransmitters [16]. Vit C is suggested to influence this process via modulating of binding of
neurotransmitters to receptors as well as regulating their release [34–37]. In addition, ascorbic acid
acts as a co-factor in the synthesis of neurotransmitters, particularly of catecholamines—dopamine
and norepinephrine [26,38]. Seitz et al. [39] suggested that the modulating effect of the ascorbate
could be divided into short- and long-term ones. The short-term effect refers to ascorbate role as
a substrate for dopamine-β-hydroxylase. Vit C supplies electrons for this enzyme catalyzing the
formation of norepinephrine from dopamine. Moreover, it may exert neuroprotective influence
against ROS and quinones generated by dopamine metabolism [16]. On the other hand, the long-term
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effect could be connected with increased expression of the tyrosine hydroxylase gene, probably via a
mechanism that entails the increase of intracellular cAMP [39]. It has been stated that the function of
ascorbic acid as a neuromodulator of neural transmission may be also associated with amino acidic
residues reduction [40] or scavenging of ROS generated in response to neurotransmitter receptor
activation [34,41]. Moreover, some have studies showed that ascorbic acid modulates the activity
of some receptors such as glutamate as well as γ-aminobutyric acid (GABA) ones [22,40,42–44].
Vit C has been shown to prevent excitotoxic damage caused by excessive extracellular glutamate
leading to hyperpolarization of the N-methyl-D-aspartate (NMDA) receptor and therefore to neuronal
damage [45]. Vit C inhibits the binding of glutamate to the NMDA receptor, thus demonstrating a
direct effect in preventing excessive nerve stimulation exerted by the glutamate [26]. The effect of
ascorbic acid on GABA receptors can be explained by a decrease in the energy barrier for GABA
activation induced by this agent. Ascorbic acid could bind to or modify one or more sites capable
of allosterically modulating single-channel properties. In addition, it is possible that ascorbic acid
acts through supporting the conversion from the last GABA-bound closed state to the open state.
Alternatively, ascorbic acid could induce the transition of channels towards additional open states in
which the receptor adopts lower energy conformations with higher open probabilities [40,44].
There have also been reports concerning the effect of Vit C on cognitive processes such as learning,
memory and locomotion, although the exact mechanism of this impact is still being investigated [26].
However, animal studies have shown a clear association between the ascorbate and the cholinergic
and dopaminergic systems, they also suggested that the ascorbate can act as a dopamine receptor
antagonist. This was also confirmed by Tolbert et al. [46], who showed that the ascorbate inhibits the
binding of specific dopamine D1 and D2 receptor agonists.
Another non-antioxidant function of Vit C includes modulation of neuronal metabolism by
changing the preference for lactate over glucose as an energy substrate to sustain synaptic activity.
During ascorbic acid metabolic switch, this vitamin is released from glial cells and is taken up by
neurons where it restraints glucose transport and its utilization. This allows lactate uptake and its
usage as the primary energy source in neurons [47]. It was observed that intracellular ascorbic acid
inhibited neuronal glucose usage via a mechanism involving GLUT3 [48].
Vit C is involved in collagen synthesis, which also occurs in the brain [26]. There is no doubt that
collagen is needed for blood vessels and neural sheath formation. It is well recognized that vitamin
C takes part in the final step of the formation of mature triple helix collagen. In this stage, ascorbic
acid acts as an electron donor in the hydroxylation of procollagen propyl and lysyl residues [16]. The
role of Vit C in collagen synthesis in the brain was confirmed by Sotiriou et al. [49]. According to
these authors in mice deficient in SVCT2 ascorbate transporter, the concentration of ascorbate in the
brain was below detection level. The animals died due to capillary hemorrhage in the penetrating
vessels of the brain. Ascorbate-dependent collagen synthesis is also linked to the formation of the
myelin sheath that surrounds many nerve fibers [26]. In vitro studies showed that ascorbate, added to
a mixed culture of rat Schwann cells and dorsal root ganglion neurons, promoted myelin formation
and differentiation of Schwann cells during formation of the basal lamina of the myelin sheath [7,29].
5. Role of Vitamin C in Neurodegenerative Diseases
Vit C is important for proper nervous system function and its abnormal concentration in nervous
tissue is thought to be accompanied with neurological disorders. Studies have shown that disruption
of vitamin C transport may cause brain damage in premature infants. Vit C was found to show
alleviating effect on seizures severity as well as reducing influence on seizure-induced damage of
hippocampus [8,9]. One of the recent studies also revealed that glutamate-induced negative changes
in immature brain of rats were reduced by Vit C treatment [50]. Moreover, Vit C administration
was shown to recover the colchicine-induced neuroinflammation-mediated neurodegeneration and
memory impairments in rats [12] as well as ameliorate behavioral deficits and neuropathological
alterations in rats exposed to aluminum chloride [11].
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The fact that Vit C can neutralize superoxide radicals, which are generated in large amount during
neurodegenerative processes, seems to support its role in neurodegeneration. Moreover, plasma and
cellular Vit C levels decline steadily with age and neurodegenerative diseases are often associated
with aging. An association of Vit C release with motor activity in central nervous system regions,
glutamate-uptake-dependent release of Vit C, its possible role in modulation of N-methyl-D-aspartate
receptor activity as well as ability to prevent peroxynitrite anion formation constitute further evidence
pointing to the role of Vit C in neurodegenerative processes.
5.1. Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia, an incurable and progressive
neurodegenerative disease, leading to far-reaching memory loss, cognitive decline and eventually
death. There are two major forms of the AD disease: early onset (familial) and late onset (sporadic).
Early-onset one is rare, accounting for less than 5% of all AD cases. Mutations in three genes, mainly
amyloid precursor protein (21q21.3), presenilin-1 (14q24.3) and presenilin-2 (1q42.13), have been
identified to be involved in the development of this form. Late-onset AD (LOAD) is common among
individuals over 65 years of age. Although heritability of LOAD is high (79%), its etiology is considered
to be polygenic and multifactorial. The apolipoprotein E ε4 allele (19q13.2) is the major known genetic
risk factor for this form of AD. The E4/E4 genotype does not determine the occurrence of LOAD, but is
a factor that increases susceptibility to this disease and lowers the age of disease onset. Moreover,
a large number of genes have been suggested to be implicated in risk of late-onset Alzheimer’s,
e.g., clusterin (8p21), complement receptor 1 (1q32), phosphatidylinositol binding clathrin assembly
protein (11q14.2), myc box-dependent-interacting protein 1 (2q14.3), ATP binding cassette transporter
7 (19p13.3), membrane-spanning 4-domains, subfamily A (11q12.2), ephrin type-A receptor 1 (7q34),
CD33 antigen (19q13.3), CD2 associated protein (6p12.3), sortilin-related receptor 1 (11q24.1), GRB2
associated-binding protein 2 (11q13.4–13.5), insulin-degrading enzyme (10q24), death-associated
protein kinase 1 (DAPK1) or gene encoding ubiquilin-1 (UBQLN1) [51,52]. The list of genes associated
with AD is still growing. For instance, in the recent study, Lee et al. revealed that single-nucleotide
polymorphisms in six genes, including 3-hydroxybutyrate dehydrogenase, type 1 (BDH1), ST6
beta-galactosamide alpha-2,6-sialyltranferase 1 (ST6GAL1), RAB20, member RAS oncogene family
(RAB20), PDS5 cohesin associated factor B (PDS5B), adenosine deaminase, RNA-specific, B2 (ADARB2),
and SplA/ryanodine receptor domain and SOCS box containing 1 (SPSB1), were directly or indirectly
related to conversion of mild cognitive impairment to AD [53].
A neuropathological lesions characteristic of AD include neurofibrillary tangles (composed of
hyperphosphorylated and aggregated tau protein) accumulated in the neuronal cytosol as well as the
extracellular plaque deposits of the β-amyloid peptide (Aβ), with their frequency correlating with
declining cognitive measures [54]. Proteolytic cleavage of amyloid precursor polypeptide chain by
secretases (mainly β- and γ-secretase) produces Aβ40 and Aβ42 peptides, which consist of 40 and
42 amino acids, respectively. The latter one, due to its hydrophobicity, is characterized by a greater
tendency to form fibrils and is believed to be the main factor responsible for the formation of amyloid
deposits [55]. However, Nagababu et al. suggested that the enhanced toxic effect observed for Aβ42
could be attributed to a greater toxicity of the 1–42 aggregates than the 1–40 ones of a comparable size
distribution and not to the formation of larger fibrils [56]. According to Ott et al. [54] pre-aggregated
Aβ42 peptide induces hyperphosphorylation and pathological structural changes of tau protein and
thereby directly links the “amyloid hypothesis” to tau pathology observed in AD [54]. Although
the pathogenesis of AD has not been fully understood yet, many studies have demonstrated that
ROS and oxidative stress are implicated in disease progression. Aβ peptide was found to enhance
the neuronal vulnerability to oxidative stress and cause an impairment of electron transport chain,
whereas oxidative stress was shown to induce accumulation of Aβ peptide which subsequently
promotes ROS production [16,22,57]. Bartzokis et al. in turn [58] suggested that myelin breakdown
in vulnerable late-myelinating regions released oligodendrocyte- and myelin-associated iron that
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promoted the development of the toxic amyloid oligomers and plaques. There is also the “amyloid
cascade-inflammatory hypothesis” which assumes that AD probably results from the inflammatory
response induced by extracellular β-amyloid protein deposits, which subsequently become enhanced
by aggregates of tau protein [59]. Moreover, recent research has suggested that AD might be a prion-like
disease [60,61].
The role of Vit C in AD disease was studied in APP/PSEN1 mice carrying human AD mutations
in the amyloid precursor protein (APP) and presenilin (PSEN1) genes (transgenic mouse model of
Alzheimer’s disease) with partial ablation of vitamin C transport in the brain [9,62,63].
Warner et al. [9] demonstrated that decreased brain Vit C level in the 6-month-old SVCT2+/−
APP/PSEN1 mice (obtained by crossing APP/PSEN1 bigenic mice with SVCT2+/− heterozygous
knockout mice, which have the lower number of the sodium-dependent Vit C transporter) was
associated with enhanced oxidative stress in brain, increased mortality, a shorter latency to seizure
onset after kainic acid administration (10 mg/kg i.p.), and more ictal events following treatment
with pentylenetetrazol (50 mg/kg i.p.). Furthermore, the authors reported that Vit C deficiency
alone in SVCT2+/− mice increased the severity of kainic acid- and pentylenetetrazol-induced
seizures [62]. According to another study even moderate intracellular Vit C deficiency displayed an
important role in accelerating amyloid aggregation and brain oxidative stress formation, particularly
during early stages of disease development. In 6-month-old SVCT2+/− APP/PSEN1 mice increased
brain cortex oxidative stress (enhanced malondialdehyde, protein carbonyls, F2-isoprostanes) and
decreased level of total glutathione as compared to wild-type controls were observed. Moreover,
SVCT2+/− mice had elevated levels of both soluble and insoluble Aβ1-42 and a higher Aβ1-42/Aβ1-40
ratio. In 14-month old mice there were more amyloid-β plaque deposits in both hippocampus and
cortex of SVCT2+/−APP/PSEN1+ mice as compared to APP/PSEN+ mice with normal brain Vit
C level, whereas oxidative stress levels were similar between groups [62]. Ward et al. [63], in turn,
showed that severe Vit C deficiency in Gulo−/− mice (lacking L-gulono-1,4-lactone oxidase (Gulo)
responsible for the last step in Vit C synthesis) resulted in decreased blood glucose levels, oxidative
damage to lipids and proteins in the cortex, and reduction in dopamine and serotonin metabolites
in both the cortex and striatum. Moreover, Gulo−/− mice displayed a significant decrease in
voluntary locomotor activity, reduced physical strength and elevated sucrose preference. All the
above-mentioned behaviors were restored to control levels after treatment with Vit C (250 mg/kg,
i.p.). The role of Vit C in preventing the brain against oxidative stress damage seems to be also
proved by the recent study performed by Sarkar et al. [64]. The researchers share a view that cerebral
ischemia-reperfusion-induced oxidative stress may initiate the pathogenic cascade leading eventually
to neuronal loss, especially in hippocampus, with amyloid accumulation, tau protein pathology and
irreversible Alzheimer’s dementia. Being the prime source of ROS generation, neuronal mitochondria
are the most susceptible to damage caused by oxidative stress. The study proved it that L-ascorbic acid
loaded polylactide nanocapsules exerted a protective effect on brain mitochondria against cerebral
ischemia-reperfusion-induced oxidative injury [64]. Kennard and Harrison, in turn, evaluated the
effects of a single intravenous dose of Vit C on spatial memory (using the modified Y-maze test) in
APP/PSEN1 mice. The study was performed on APP/PSEN1 and wild-type (WT) mice of three age
spans (3, 9 or 20 months). It was shown that APP/PSEN1 mice displayed no behavioral impairment as
compared to WT controls, but memory impairment along with aging was observed in both groups.
Vit C treatment (125 mg/kg, i.v.) improved performance in 9-month old APP/PSEN1 and WT mice,
but improvements in short-term spatial memory did not result from changes in the neuropathological
features of AD or monoamine signaling, as acute Vit C administration did not alter monoamine
levels in the nucleus accumbens [65]. Cognitive-enhancing effects of acute intraperitoneal (i.p.) Vit C
treatment in APP/PSEN1 mice (12- and 24-month-old) were investigated by Harrison et al. Vit C
treatment (125 mg/kg i.p.) improved Y-maze alternation rates and swim accuracy in the water maze
in both APP/PSEN1 and wild-type mice; but like in the previous study had no significant effect on the
age-associated increase in Aβ deposits and oxidative stress, and did not also affect acetylcholinesterase
112
Nutrients 2017, 9, 659
(AChE) activity either, which was significantly reduced in APP/PSEN1 mice [66]. Murakami et al. [67]
in turn reported that 6-month-treatment with Vit C resulted in reduced Aβ oligomer formation
without affecting plaque formation, a significant decrease in brain oxidative damage and Aβ42/Aβ40
ratio as well as behavioral decline in an AD mouse model. Furthermore, this restored the declined
synaptophysin and reduced the phosphorylation of tau protein at Ser396.
Besides the presented roles, Vit C has also been suggested to prevent neurodegenerative changes
and cognitive decline by protecting blood–brain barrier (BBB) integrity [68].
Kook et al., in the study performed on KO-Tg mice (generating by crossing 5 familial Alzheimer’s
disease mutation (5XFAD) mice with mice lacking Gulo), found that oral Vit C supplementation (3.3 g/L
of drinking water) reduced amyloid plaque burden in the cortex and hippocampus by ameliorating
BBB disruption (via preventing tight junction structural changes) and morphological changes in the
mitochondria [69]. This seems to be confirmed by other studies that proved that Vit C might affect
levels of proteins responsible for the tightness of BBB, like tight junction-specific integral membrane
proteins (occludin and claudin-5) as well as matrix metalloproteinase 9 (MMP-9). Allahtavakoli et al.
demonstrated that in a rat stroke model Vit C administration (500 mg/kg; 5 h after stroke) significantly
reduced BBB permeability by reducing serum levels of matrix metalloproteinase 9 [70]. Song et al.
reported that Vit C (100 mg/kg i.p.) protected cerebral ischemia-induced BBB disruption by preserving
the expression of claudin 5 [71], whereas Lin et al. observed that Vit C (500 mg/kg i.p.) prevented
compression-induced BBB disruption and sensory deficit by upregulating the expression of both
occludin and claudin-5 [72].
In the available literature, there were only few studies investigating the role of Vit C in AD disease
in human and the existing ones have yielded equivocal results.
Some studies have shown significantly lower plasma/serum Vit C level in AD patients as
compared to healthy individuals, whereas others have found no difference [73,74]. However,
meta-analysis performed by Lopes da Silva et al. proved significantly lower plasma levels of Vit
C in AD patients [75]. It seems that the above discrepancies may result from the fact that not plasma
but rather intracellular Vit C may be associated with AD.
Generally, studies involving human participants are limited to assessing the effect of Vit C
supplementation administrated with other antioxidants on AD course.
Arlt et al. [76] found that 1-month and 1-year co-supplementation of Vit C (1000 mg/day) with
vitamin E (400 IU/day) increased their concentrations not only in plasma but also in cerebrospinal
fluid (which reflects the Vit C status of the brain), while cerebrospinal fluid lipid oxidation was
significantly reduced only after 1 year. However, vitamins’ supplementation did not have a significant
effect on the course of AD [76]. These findings were aslo confirmed by the randomized clinical trial
of Galasko et al. [77], which showed that treatment of AD patients for 16 weeks with vitamin E
(800 IU/day) plus Vit C (500 mg/day) plus α-lipoic acid (900 mg/day) did not influence cerebrospinal
fluid levels of Aβ42, tau and p181tau (widely accepted biomarkers related to amyloid or tau pathology),
but decreased F2-isoprostane level (a validated biomarker of oxidative stress). Moreover, is should
be emphasized that the above treatment increased risk of faster cognitive decline. This seems to be
consistent with results of the recent study which revealed it that Vit C was a potent antioxidant within
the AD brain, but it was not able to ameliorate other factors linked to AD pathogenesis as it was
proved to be a poor metal chelator and did not inhibit Aβ42 fibrillation [78]. In the study considering
an association between nutrient patterns and three brain AD-biomarkers, namely Aβ load, glucose
metabolism and gray matter volumes (a marker of brain atrophy) in AD-vulnerable regions, it was
found that the higher intake of carotenoids, vitamin A, vitamin C and dietary fibers was positively
associated only with glucose metabolism [79].
On the other hand, a randomized control trial involving 276 elderly participants demonstrated
that 16-week-co-supplementation of vitamin E and C with β-carotene significantly improved cognitive
function (particularly with higher doses of β-carotene). Furthermore, the authors suggested that such
a treatment markedly reduced plasma Aβ levels and elevated plasma estradiol levels [80]. Vit C and E
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co-supplementation for more than 3 years was also shown to be associated with a reduced prevalence
and incidence of AD [81]. Moreover, an adequate Vit C plasma level seems to be associated with
less progression in carotid intima-media thickness (C-IMT)—the greater C-IMT is suggested to be a
risk factor in predicting cognitive decline in the general population, in the elderly population and in
patients with Alzheimer’s disease. Polidori et al. showed significant decrease (with a linear slope)
in Vit C level among old individuals with no or very mild cognitive impairment from the first to the
fourth C-IMT quartile [82].
5.2. Parkinson’s Disease
Parkinson’s disease (PD) is a common long-term neurodegenerative movement disorder
characterized by the progressive loss of substantia nigra dopaminergic neurons and consequent
depletion of dopamine in the striatum. Dementia, depression and behavioral deficiencies are
common symptoms in the advanced stages of the disease [22]. PD is pathologically heterogeneous,
but abnormal aggregation of α-synuclein (α-syn) within neuronal perikarya (Lewy bodies) and
neurites (Lewy neurites) are neuropathological (but not pathognomonic) hallmarks of this disease [83].
The primary cause of the neurodegenerative process underlying PD is still unknown. Only about
10% of PD cases have shown to be hereditary, whereas the rest are sporadic and result from
complex interactions between environmental and common genetic risk factors. Monogenic PD with
autosomal-dominant inheritance is caused by mutation in α-synuclein gene (SNCA) or leucine-rich
repeat kinase 2 gene (LRRK2), whereas the form with autosomal recessive inheritance by mutations in
the genes encoding Parkin 2 (PARK2), PTEN-induced putative kinase 1 (PINK1), protein deglycase
DJ-1 (PARK7), and protein ATP13A2 (PARK9). However, many diverse genetic defects in other
loci have been suggested to be associated with PD. Candidate genes which have been reported
to be associated with PD include e.g., β-glucocerebrosidase (GBA), diacylglycerol kinase θ, 110kD
(GAK-DGKQ), SNCA, human leukocyte antigen (HLA), RAD51B, DYRK1A, CHCHD2, VPS35, RAB39B
or TMEM230 [84,85]. Different mechanisms, including genomic factors, epigenetic changes, toxic
factors, mitochondrial dysfunction, oxidative stress, neuroimmune/neuroinflammatory reactions,
hypoxic-ischemic conditions, metabolic deficiencies and ubiquitin–proteasome system dysfunction,
seem to be involved in PD pathogenesis [84,86–92]. Mitochondrial dysfunction has been shown to be
linked to mutations in PINK1 and DJ1 genes [87,88]. Moreover, it is known that dopamine metabolism
produces oxidant species, whereas oxidative stress participates in protein aggregation in PD [22,90,93].
Glutamate-mediated excitotoxicity has been proposed to be a further PD factor. It is also suggested
that, like in the case of AD, PD might be a prion-like disease [94–96]. Olanow et al. [94] proposed the
hypothesis that α-synuclein is a prion-like protein that can adopt a self-propagating conformation and
thereby cause neurodegeneration. Scheffold et al. [97], in turn, reported that telomere shortening (one
of the hallmarks of ageing) led to an acceleration of synucleinopathy and impaired microglia response
and thereby might contribute to PD pathology. It is likely that not the above factors per se, but rather
their synergistic interactions result in the development of the nigrostriatal damage in PD.
Vit C is believed to play a role in dopaminergic neuron differentiation. He et al. [98] in in vitro
study found that Vit C enhanced the differentiation of midbrain derived neural stem cell towards
dopaminergic neurons by increasing 5-hydroxymethylcytosine (5hmC) and decreasing histone H3
lysine 27 tri-methylation (H3K27m3) generation in dopamine phenotype gene promoters, which
are catalyzed by ten-eleven-translocation 1 methylcytosine dioxygenase 1 (Tet1) and histone H3K27
demethylase (Jmjd3), respectively [98,99]. It seems that Vit C acts through regulation of Tet1 and
Jmjd3 activities (it acts as a co-factor), since Tet1 and Jmjd3 knockdown/inhibition resulted in no
effect of Vit C on either 5hmC or H3K27m3 in the progenitor cells [98]. In another in vitro study, it
was shown that mouse embryonic fibroblasts cultured in Vit C-free medium displayed extremely low
content of 5hmC, whereas treatment with Vit C resulted in a dose- and time-dependent increase in
5-hmC generation, which was not associated with any change in Tet genes expression. Additionally,
it was found that treatment with another reducing agent as glutathione did not affect 5-hmC, whereas
114
Nutrients 2017, 9, 659
blocking Vit C entry into cells or knocking down Tet expression significantly reduced the effect of Vit C
on 5-hmC [100].
Vit C is also believed to play an indirect role in α-syn oligomerization. Posttranslational α-syn
modifications caused by oxidative stress, including modification by 4-hydroxy-2-nonenal, nitration
and oxidation, have been implicated to promote oligomerization of α-syn, whereas Vit C as an
antioxidant prevents this effect [22,101]. Jinsmaa et al. [102] found that treatment with Vit C
attenuated Cu2+-mediated augmentation of 3,4-dihydroxyphenylacetaldehyde (DOPAL)-induced
α-syn oligomerization in rat pheochromocytoma PC12 cells, but alone (without Cu2+) did not exert
such an effect. Khan et al. showed, in turn, that Vit C supplementation (227.1 μM, 454.2 μM or
681.3 μM in diet, 21 days) caused a significant dose-dependent delay in the loss of climbing ability of
PD Drosophila model expressing normal human α-syn in the neurons [103].
Moreover, Vit C is thought to be involved in neuroprotection against glutamate-mediated
excitotoxicity occurring in PD. Ballaz et al. [104] in in vitro study performed on dopaminergic
neurons of human origin showed that Vit C prevented cell death following prolonged exposure
to glutamate. Glutamate induced toxicity in a dose-dependent way via the stimulation of
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and metabotropic receptors and to
a lesser degree by N-methyl-D-aspartate (NMDA) and kainate receptors, whereas Vit C (25–300 μM)
administration protected cells against glutamate excitotoxity. The authors emphasized the fact that
such a neuroprotection effect was dependent on the inhibition of oxidative stress, as Vit C prevented
the pro-oxidant action of quercetin occurred over the course of prolonged exposure [104]. Vit C
neuroprotection effect against dose-dependent glutamate-induced neurodegeneration in the postnatal
brain was also confirmed by Shah et al. [50].
The effect of Vit C on dopamine system has also been observed. Izumi et al. [105] showed that
PC12 cells treated with paraquat (50 μM, 24 h) displayed increased levels of cytosolic and vesicular
dopamine, whereas pretreatment with Vit C (0.3–10 μM, 24 h) suppressed the elevations of intracellular
dopamine and almost completely prevented paraquat toxicity.
Human studies have shown that Vit C deficiency among PD patients is widespread [106,107].
However, similarly like in the case of AD, not plasma but rather intracellular Vit C seems to be
associated with PD. This could to be confirmed by the study performed by Ide et al. [108] who
investigated the association between both lymphocyte and plasma Vit C levels in various stages of PD.
Lymphocyte Vit C levels in patients with severe PD was significantly lower compared to those at less
severe stages, whereas plasma Vit C levels showed a decreasing tendency; however that effect was not
significant [108].
Although in the newest literature data, there are only a few human studies considering the role of
Vit C treatment in PD, the existing ones give some evidences that Vit C treatment may have beneficial
effect in PD course. A cohort study involving 1036 PD patients showed that dietary Vit C intake
was significantly associated with reduced PD risk. However, it was not significant in a 4-year lagged
analysis [109]. Quiroga et al., in turn, reported a case of a 66-year-old man with PD, pleural effusion
and bipolar disorder who was found to have low serum Vit C and zinc levels. Intravenous replacement
of both Vit C and zinc resulted in resolution of the movement disorder in less than 24 h [107]. The other
case report concerned 83-year-old men with dementia, diabetes mellitus, hypertension, benign prostatic
hypertension, paroxysmal atrial fibrillation, congestive heart failure and suspected PD. The man was
treated with Vit C (200 mg) and zinc (4 mg), which resulted in complete resolution of periungual and
gingival bleeding as well as palatal petechiae. Moreover, the man’s orientation and mental status were
found to be markedly improved and no further delusions or agitations were observed [110].
Vit C was shown to increase L-dopa (3,4-dihydroxy-L-phenylalanine, one of the main drugs used
in PD therapy) absorption in elderly PD patients. However, this effect was not observed in all patients
but only in those with poor baseline L-dopa bioavailability [111]. Moreover, in vitro study performed
by Mariam et al. revealed that Vit C is a strong inducer of L-dopa production from pre-grown mycelia
of Aspergillus oryzae NRRL-1560 [112].
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5.3. Huntington’s Disease
Huntington’s disease (HD) is a genetic, autosomal dominant disorder characterized by general
neurodegeneration in brain with marked deterioration of medium-sized spiny neurons (MSNs) in the
striatum [17,113]. HD is caused by a mutation (a CAG expansion) in the huntingtin gene (HTT), which
results in an abnormal polyglutamine expansion in the huntingtin (HTT) protein and consequently
HTT aggregation [113]. The mutant HTT alters intracellular Ca2+ homeostasis, induces mitochondrial
dysfunction, disrupts intracellular trafficking and impairs gene transcription [114].
Clinically, HD is characterized by tripartite clinical features, namely progressive motor
dysfunction (so-called choreic movements), neuropsychiatric symptoms and a variety of cognitive
deficits [115,116]. Neuropathologically, HD is associated with a progressive, selective neuronal
dysfunction and degeneration, especially in the both part of striatum (caudate and putamen) [117,118].
HD is known to be associated with a failure in energy metabolism, impaired mitochondrial ATP
production and oxidative damage [113,119–121]. Other mechanisms, such as excitotoxicity, aberrant
glutamatergic, dopaminergic and Ca2+ signaling mechanisms, metabolic damage, immune response,
apoptosis as well as autophagy are also suggested to be involved in HD pathology [119,121–124].
Vit C flux from astrocytes to neurons during synaptic activity is regarded to be essential for
protecting neurons against oxidative damage and modulation of neuronal metabolism, thus permitting
optimal ATP production [119]. Under physiological conditions, Vit C is released from astrocytes to
striatal extracellular fluid during increased synaptic activity. The enhancement of Vit C concentration
in striatal extracellular fluid results in SVCT2 translocation to the plasma membrane and consequently
Vit C uptake by neurons [119]. In neurons, Vit C is able to scavenge reactive oxygen species generated
during synaptic activity and neuronal metabolism. As a result, Vit C is oxidized to dihydroascorbate,
which is then released into the extracellular fluid and uptaken by neighboring astrocytes, where
is subsequently turned back to a reduced form, which can be used again by neurons. Vit C can
interact directly with reactive oxygen species but can also act as a co-factor in the reduction of other
antioxidants as glutathione and α-tocopherol. Moreover, Vit C may function as a neuronal metabolic
switch, which means that it is capable to inhibit glucose consumption and permit lactate uptake/use
as a substrate to sustain synaptic activity. This function is not dependent on antioxidant activity of
Vit C [47] and seems to be of great importance, taking into account that decreased expression of GLUT3
in both STHdhQ cells (striatal neurons derived from knock-in mice expressing mutant huntingtin; cell
model of HD) and R6/2 mice (mouse model of HD) as well as impaired GLUT3 localization at the
plasma membrane in HD cells were observed [125].
Unfortunately, the mechanism mentioned above does not work properly in HD. Abnormal Vit
C flux from astrocytes to neurons was found both in R6/2 mice and STHdhQ cells. Acuña et al.
proved that SVCT2 failed to reach the plasma membrane in cells expressing mutant Htt, which
resulted in disturbed Vit C uptake by neurons [119]. Additionally, there is some evidence that altered
glutamate transporter activity (GLT1—the protein primarily found on astrocytes and responsible for
removing most extracellular glutamate), observed in HD, is related to deficient striatal Vit C release
into extracellular fluid [126–128]. Miller et al. performed the study on R6/2 mice receiving ceftriaxone
(200 mg/kg, once daily injection per 5 days)—a β-lactam antibiotic that selectively increases the
expression of GLT1. To evaluate Vit C release in vivo voltammetry combined with corticostriatal
afferent stimulation was used. R6/2 mice treated with saline displayed a marked decrease in striatal
extracellular Vit C level compared to control group, whereas treatment with ceftriaxone restored striatal
Vit C in R6/2 mice to control level and also improved the HD behavioral phenotype. It was also shown
that intra-striatal infusion of GLT1 inhibitor (dihydrokainic acid or DL-threo-β-benzyloxyaspartate)
blocked evoked striatal Vit C release [126]. Dorner et al., in turn, observed that cortical stimulation
resulted in a rapid increase in Vit C release in both R6/2 and wild-type mice, but the response had a
significantly shorter duration and smaller magnitude in R6/2 group. The researchers also measured
striatal Vit C release in response to treatment with d-amphetamine (5 mg/kg)—a psychomotor
stimulant known to release Vit C from corticostriatal terminals independently of dopamine. Both
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Vit C release and behavioral activation were diminished in R6/2 mice compared to wild-type ones.
The authors concluded that the corticostriatal pathway was directly involved in behavior-related Vit C
release and that this system was dysfunctional in HD [127]. It is thought that Vit C is released into
striatal extracellular fluid as glutamate is uptaken—glutamate/Vit C heteroexchange. Consequently,
Vit C level decreases while glutamate level increases in extracellular fluid of HD striatum owing to
a downregulation of GLT1 [127,128]. Elevated glutamate level in synaptic gaps leads to abnormal
signal transmission.
In addition, it is also believed that long-term oxidative stress (one of the key players in HD
progression) eliminates the ability of Vit C to modulate glucose utilization [125].
The effect of Vit C treatment on behavior-related neuronal activity was studied by Rebec et al. [129].
The authors showed that in the striatum of R6/2 mice impulse activity was consistently elevated
compared to wild-type mice, whereas restoring extracellular Vit C to the wild-type level by Vit C
treatment (300 mg/kg, 3 days) reversed this effect. This suggests Vit C involvement in normalization
of neuronal function in HD striatum. In another study, the same researchers reported that regular
injections of Vit C (300 mg/kg/day, 4 days/week) restored the behavior-related release of Vit C in
striatum, which was associated with improved behavioral responding. Vit C treatment significantly
attenuated the neurological motor signs of HD without altering overall motor activity [130].
Although studies performed on cell and animal models of HD appear to indicate the role of Vit
C in HD course, to the best of our knowledge, in the newest literature there exists a lack of studies
considering the role of Vit C or the effect of its supplementation in HD human subjects.
5.4. Multiple Sclerosis
Multiple sclerosis (MS) is a progressive demyelinating process considered as an autoimmune
disease of unknown etiology. MS is characterized by infiltration of immune cells (in particular T cells
and macrophages), demyelination (loss of myelin sheath that surrounds and protects nerve fibers
allowing them to conduct electrical impulses) and axonal pathology resulting in multiple neurological
deficits, which range from motor and sensory deficits to cognitive and psychological impairment [131,132].
The etiology of MS is still unknown, but it is suggested that genetic predisposition associated with
environmental factors can lead to expression of the envelope protein of MS-associated retrovirus
(MSRV) and thus trigger the disease [133]. Although pathogenesis of MS has not been fully clarified
yet, either destruction by the immune system or a significant extent apoptosis, particularly apoptosis
of oligodendroglia cells, are believed to be underlying mechanism. Oxidative/nitrosative stress and
mitochondrial dysfunction are believed to contribute to the pathophysiology of MS [131,134–137].
Having regarded the presented facts, it seems to be justified that Vit C, being a very important
brain antioxidant, may affect MS course. Vit C is known to affect numerous metabolic processes
directly associated with immune system. Furthermore, Vit C-dependent collagen synthesis has also
been linked to formation of the myelin sheath [7].
In the literature data, there are only a few studies considering association between MS and Vit
C. However, the existing ones showed that MS patients displayed significantly lower Vit C level
as compared to healthy individuals [135,136,138]. Besler et al. [138], in turn, observed an inverse
correlation between the serum levels of Vit C and lipid peroxidation in MS patients. The authors
concluded that decreased Vit C level, observed in MS patients during relapse of the disease,
might be dependent on the elevated oxidative burden as reflected by increased lipid peroxidation.
Hejazi et al. [139], in turn, found no significant difference between daily intake of Vit C (recorded
from a 24-h dietary recall questionnaire for 3 days) in MS patients (n = 37) in comparison with healthy
subjects. The intake of Vit C in both groups was below dietary reference intake (DRI), however in
control group it was near the DRI value.
An efficiency of antioxidant therapy in relapsing-remitting multiple sclerosis patients (n = 14)
treated with complex of antioxidants and neuroprotectors with various mechanisms of action (oc-lipoic
acid, nicotinamide, acetylcysteine, triovit beta-carotine, alpha-tocopheryl acetate, ascorbic acid,
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selenium, pentoxifylline, cerebrolysin, amantadine hydrochloride) during 1 month, 2 times a year
was investigated by Odinak et al. [140]. The treatment resulted in significant reduction of relapse
frequency, decrease of required corticosteroid courses and significantly reduced content of lipid
peroxide products [140]. However, it should be underlined that Vit C was only one element of
multicomponent treatment. However, in another study it was shown that intrahippocampal injection
of Vit C (0.2, 1, 5 mg/kg, 7 days) improved memory acquisition of passive avoidance learning (PAL)
in ethidium bromide-induced MS in rats. The injection of ethidium bromide caused significant
deterioration of PAL, whereas treatment with Vit C at a dose of 5 mg/kg resulted in significant
improvement in PAL [141].
Summing up, the possible role of Vit C in MS course remains to be explored.
5.5. Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is an incurable, chronic progressive neurodegenerative
disease characterized by the degeneration of upper motor neurons in the motor cortex and lower
motor neurons in the spinal cord and the brain stem [142]; the reason why only motor neurons are
targeted remains unknown. ALS results in loss of power and function of skeletal muscles, which is
reflected by difficulties in walking, using the arms, speaking and swallowing. ALS occurs in two forms:
hereditary one, which is called familial (5–10% of ALS cases) and not hereditary one, called sporadic.
Familial ALS is indistinguishable from the much more common sporadic form, but usually it begins
at a slightly younger age. It is assumed that about 2% of all cases of ALS are caused by mutations in
the gene encoding copper/zinc superoxide dismutase (SOD1) on chromosome 21, but the etiology of
the remaining ALS cases is not fully understood. The course of ALS is variable, but usually relatively
rapid. Most patients die, usually due to respiratory failure (respiratory muscles paralysis), within
3–5 years from the onset of symptoms [143].
Although the underlying causes of motor neuron degeneration remain still unknown, researchers
have suggested a contribution of oxidative stress, mitochondrial dysfunction, glutamate-mediated
excitotoxicity, cytoskeletal abnormalities, and protein aggregation [144]. Because of the
above-presented facts and its activity-dependent release in the brain, it seems to be possible that
Vit C may be involved in ALS pathogenesis. It appears to be confirmed by Blasco et al. who compared
1 H-NMR spectra of cerebrospinal fluid (CSF) samples collected from ALS patients (n = 44) and
patients without a neurodegenerative disease. The authors found significantly higher Vit C level in
the ALS group. Vit C, apart from being free radical scavenger, was suggested to modulate neuronal
metabolism by reducing glucose consumption during episodes of glutamatergic synaptic activity and
stimulating lactate uptake in neurons, which is consistent with lower lactate/pyruvate ratio seen in
ALS patients [144].
However, in the available literature data, there are only a few studies evaluating an association
between Vit C and ALS, and the existing ones have not proved its role in the course of this disease.
Nagano et al. [145] investigated the efficacy of Vit C treatment (0.8% w/w in the diet) in familiar
ALS mice, administered before or after the onset of the disease. The mice treated with Vit C before
disease onset survived significantly longer by 62% than the control. However, that treatment did
not affect the mean age of onset appearance and administration after disease onset did not prolong
survival. Netzahualcoyotzi and Tapia [146] found that the infusion of Vit C (20 mM), alone or in
combination with glutathione ethylester, did not prevent the AMPA-induced motor alterations of the
rear limbs and motor neuron degradation in rats. The pooled analysis of 5 large prospective studies of
about 1100 ALS patients performed by Fitzgerald et al. showed that neither supplementation (even
long-term) nor high dietary intake of Vit C affected risk of ALS [147]. Okamoto et al. [148] investigated
the relationship between dietary intake of vegetables, fruit and antioxidants and the risk of ALS (153
ALS patients aged 18–81 years with disease duration of 3 years) in Japan. The study showed that a
higher consumption of fruits and/or vegetables was associated with a significantly reduced risk of ALS.
However, no significant dose-response relationship was observed between intake of beta-carotene,
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Vit C and vitamin E and the risk of ALS. Spasojević et al. [149], in turn, suggested that the use of
Vit C could have an unfavorable effect in ALS patients. The researchers examined the effect of Vit C
on the production of hydroxyl radicals in CSF obtained from sporadic ALS patients. Using electron
paramagnetic resonance spectroscopy, the authors detected ascorbyl radicals in CSF of ALS patients,
whereas in control CSF they were undetectable. Moreover, the addition of hydrogen peroxide to the
CSF of ALS patients provoked further formation of ascorbyl as well as hydroxyl radicals ex vivo. Thus,
it seems that herein Vit C may paradoxically induce pro-oxidative effects. This may result from the
fact that Vit C is an excellent one-electron reducing agent that can reduce ferric (Fe3+) ion to ferrous
(Fe2+) one, while being oxidized to ascorbate radical. In a Fenton reaction, Fe2+ reacts with H2O2
generating Fe3+ and a very strong oxidizing agent—hydroxyl radical. The presence of Vit C allows the
recycling of Fe3+ back to Fe2+, which can subsequently catalyze the successive formation of hydroxyl
radicals [1,150]. Moreover, it has also been shown that high concentrations of ascorbyl radical can
reduce SOD activity.
6. Role of Vitamin C in Psychiatric Disorders
Vit C is also believed to be involved in anxiety, stress, depression, fatigue and mood state in
humans. It has been hypothesized that oral Vit C supplementation can elevate mood as well as reduce
distress and anxiety.
6.1. Depression
Depression (DP) is a mental disorder characterized by a number of basic symptoms like low
mood, biological rhythm disorders, psychomotor slowdown, anxiety, somatic disorders as well
other nonspecific symptoms [151]. It has a multifactorial etiology, with biological, psychological,
social and lifestyle factors of important roles [152]. Several hypotheses have been proposed to
explain the mechanisms underlying depression. Firstly, it is believed that depression is associated
with disturbances of serotonin, norepinephrine and dopamine neurotransmission. Moreover, many
observations have supported the involvement of GABAergic system in the pathomechanism of
depression [153]. GABA level in plasma and CSF of patients suffering from depression was shown to
be reduced [154,155] which points to its decreased synthesis in the brain. Recent data have suggested
that chronic stress, via initiating changes in the hypothalamic-pituitary-adrenal axis and the immune
system, acts as a trigger for the above-mentioned disturbance. For example, glucocorticoids and
proinflammatory cytokines enhance the conversion of tryptophan to kynurenine thus leading to a
decrease in the synthesis of brain serotonin (because less tryptophan is available for conversion to
serotonin) and an increase in the formation of neurotoxic metabolites, e.g., glutamate antagonist
quinolinic acid. The activity of the dopaminergic systems was also found to be reduced in response to
inflammation [156]. Secondly, some genetic factors have been suggested to be implicated in depression
etiology [157]. Thirdly, apoptosis of the brain cells seems to be involved in depression development,
since a numerical and morphological alterations of astrocytes in patients with major depressive
disorder were observed [158–161]. This may also be dependent, at least partially, on proinflammatory
cytokine actions since quinolinic acid was shown to contribute to the increase in apoptosis of astrocytes
or neurons [162,163].
Basing on several animal studies [153,155,164–166], there is preliminary evidence that Vit C exerts
an antidepressant-like effect via:
1. modulation of monoaminergic systems [167] (e.g., Vit C was shown to activate the serotonin 1A
(5-HT1A) receptor, this activation is a mechanism of action of many antidepressant, anxiolytic
and antipsychotic drugs);
2. modulation of GABAergic systems (via activation of GABAA receptors and a possible inhibition
of GABAB receptors) [155];
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3. inhibition of N-methyl-D-aspartate (NMDA) receptors and L-arginine-nitric oxide (NO)-cyclic
guanosine 3,5-monophosphate (cGMP) pathway—the blockade of NMDA receptor is associated
with reduced levels of NO and cGMP, whereas reduction of NO levels within the hippocampus
was shown to induce antidepressant-like effects [119];
4. blocking potassium (K+) channels—Vit C administration was shown to produce an antidepressant-like
effect in the tail suspension test via K+ channel inhibition [119]; as K+ channels were reported
to belong to the physiological targets of NO and cGMP in the brain, their inhibition plays a
significant role in the treatment of depression;
5. activation of phosphatidylinositol-3-kinase (PI3K) and inhibition of glycogen synthase kinase
3 beta (GSK-3β) activity [112,119];
6. induction of heme oxygenase 1 expression—it is a candidate depression biomarker which may
be a link factor between inflammation, oxidative stress and the biological as well functional
changes in brain activity in depression; its decreased expression is associated with depressive
symptoms [166,168];
7. since depression is well known to be associated with altered anti- and prooxidant profiles, Vit C
may play antidepressant function also by its antioxidant properties [118,119].
The available literature data indicate that Vit C deficiency is very common in patients with
depressive disorders. Gariballa [169] in a randomized, double blind, placebo-controlled trial observed
that low Vit C status was associated with increased depression symptoms following acute illness in
older people. Parameters were measured at baseline as well as after 6 weeks and 6 months. Patients
with Vit C depletion had significantly increased symptoms of depression as compared to those with its
higher concentrations both at baseline and at 6 weeks. Significantly lower serum Vit C level in patients
with depression vs. healthy controls was also shown by Bajpai et al. [170] and Gautam et al. [171].
Moreover, in the latter study dietary supplementation of Vit C (1000 mg/day) along with vitamins A
and E for a period of 6 weeks resulted in a significant reduction in depression scores [171]. Furthermore,
a case-control study carried out on 60 male university students showed that subjects diagnosed
with depression had significantly lower intake of Vit C than the healthy ones [172]. Similarly, in
another case-control study involving 116 girls identified as having depressive symptoms, depression
was negatively associated with Vit C intake, even after adjusting for confounding variables [173].
Rubio-López et al. [174], in turn, examined the relationship between nutritional intake and depressive
symptoms in 710 Valencian schoolchildren aged 6–9 years and also observed that nutrient intake
of Vit C was significantly lower in children with depressive symptoms. Additionally, prevalence
of Vit C inadequacy (below dietary recommended intakes) was significantly higher in subjects with
depressive symptoms.
The efficacy of Vit C as an adjuvant agent in the treatment of pediatric major depressive disorder
in a double-blind, placebo-controlled pilot trial was evaluated by Amr et al. [175]. Patients (n = 12)
treated for six months with fluoxetine (10–20 mg/day) and Vit C (1000 mg/day) showed a significant
decrease in depressive symptoms in comparison with the fluoxetine plus placebo group as measured
by the Children’s Depression Rating Scale and Children’s Depression Inventory. No serious adverse
effects were shown. Zhang et al. [176] in double-blind clinical trial investigated the effect of Vit C
(500 mg twice daily) on mood in non-depressed acutely hospitalized patients. The applied therapy
increased plasma and mononuclear leukocyte Vit C concentrations and was associated with a 34%
reduction in mood disturbance (assessed with Profile of Mood States) [176]. Similarly, Wang et al.
found that short-term Vit C (500 mg twice daily) treatment was associated with a 71% reduction
in mood disturbance (assessed with Profile of Mood States) and a 51% reduction in psychological
distress (assessed with Distress Thermometer) in acutely hospitalized patients with a high prevalence
of hypovitaminosis C [177]. Khajehnasiri et al. [178] in a randomized, double-blind, placebo-controlled
trial involving 136 depressed male shift workers observed, in turn, that Vit C administration (250 mg
twice daily for 2 months) alone and in combination with omega-3 fatty acids significantly reduced the
Beck Depression Inventory (BDI) score, however omega-3 fatty acid supplementation alone was more
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effective. Moreover, Vit C and omega-3 fatty acids supplementation alone (but not in combination)
decreased significantly serum MDA levels. Fritz et al. [179] conducted a systematic review of human
and observational studies assessing the efficiency of interventional Vit C as a contentious adjunctive
cancer therapy and reported that it could improve quality of life, physical function, as well as prevent
some side effects of chemotherapy, including fatigue, nausea, insomnia, constipation and depression.
6.2. Anxiety
Anxiety is an adaptive response to uncertain threat, but it becomes pathological when is
disproportionate to the threat, persists beyond the presence of the stressor, or is triggered by
innocuous stimuli or situations. Similarly like in the case of depression, neurotransmitter system
disruptions (namely GABA, serotonin and noradrenalin) as well as an impaired regulation of the
hypothalamic-pituitary-adrenal axis are involved in anxiety disorders [180]. Furthermore, several
studies have suggested a positive correlation between oxidative stress and anxiety-like behavior.
The growing evidence, which has been recently emerged, suggests that anxiety is associated with
Vit C deficit, whereas Vit C supplementation could help reduce feeling of anxiety. The underlying
mechanism is not fully understood yet, but Vit C seems to play this role by: regulating
neurotransmitters’ activity, attenuating cortisol activity, preventing stress-induced oxidative damage
and antioxidant defense in brain or some as yet undetermined effects on anxiety-related brain
structures [181].
Kori et al. [182] observed that rats subjected to restrained stress (by placing in a wire mesh
restrainer for 6 h per day for 21 days) displayed a significant increase in serum cortisol level with
concomitant decrease in serum Vit C and E levels. Boufleur et al. [183], in turn, found decreased plasma
Vit C levels in rats exposed to chronic mild stress. Interestingly, neonatal handling could prevent Vit C
reduction in rats exposed to chronic mild stress in adulthood. Koizumi et al. [184] showed that Vit C
status was critical for determining vulnerability to anxiety in a sex-specific manner. The study was
performed on senescence marker protein–30/gluconolactones knockout mice (unable to synthesize
Vit C) whose Vit C status was continuously shifted from adequate to depleted one (by providing a
water with or without Vit C). It was observed that anxiety responses in the novelty-suppressed feeding
paradigm were worse during Vit C depletion conditions, especially in females. Hughes et al. [181],
in turn, reported that prolonged treatment with Vit C (approximately 80 mg/kg/day in drinking
water, 83 days) markedly decreased anxiety-related behavior in the open field test in hooded rats.
In another study, the same researchers examined the effect of Vit C treatment with three doses (61,
114 or 160 mg/kg/day in drinking water, 8 weeks) and observed that an anxiolytic effects of Vit C
were displayed in higher frequencies of walking (with doses of 114 mg/kg/day and 160 mg/kg/day),
higher frequencies of rearing (with dose of 61 mg/kg/day) and lower frequencies of grooming (with
dose of 61 mg/kg/day) in the open-field as well as more frequent occupation of the open arms in the
elevated plus-maze (with dose of 61 mg/kg/day). The authors concluded that anxiolytic effects of Vit
C were more typical of the lowest dose and it was to some extent dependent on anxiety intensity [185].
The effect of Vit C on adrenal gland function (an element of the stress response system) was investigated
by Choi et al. [186]. An adrenalectomized (ADX) and non-ADX rats were treated with Vit C (25 or
100 m/kg, 7 days) and subsequently subjected to both Vit C treatment and electroshock stress for next
5 days. Vit C supplementation reduced corticosterone level in non-ADX rats. Stress decreased the
mean value of rearing frequency in both non-ADX and ADX rats, whereas Vit C partially attenuated
this effect in non-ADX group. Moreover, Vit C treatment decreased adrenocorticotropic hormone
in both groups and significantly reduced freezing time increased by stress. The authors suggested
that the alleviating effect of Vit C on stress-related rearing behavior was exerted via modulation
of corticosterone, whereas the effect on freezing behavior via modulation of corticotropin-releasing
hormone or adrenocorticotropin-releasing hormone [186]. Puty et al. [187] in turn suggested that
Vit C plays anxiolytic-like effect via affecting serotonergic system. The researchers evaluated the
protective effect of Vit C against methylmercury (MeHg)-induced anxiogenic-like effect in zebrafish.
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MeHg produced a marked anxiogenic effects in the light/dark box test, which was accompanied
by a decrease in the extracellular levels of serotonin as well an increase in its oxidized metabolite
tryptamine-4,5-dione, whereas pretreatment with Vit C (2 mg/g, i.p.) prevented such alterations.
Furthermore, Angrini and Leslie [188] found that pretreatment with Vit C (100 mg or 200 mg/kg)
could attenuate, especially the higher dose, behavioral and anxiogenic effects of prolonged exposure
to noise (100 dB for 2 months, 5 days/week, 4 h daily) on male laboratory mice.
Although there are only a few studies considering the effects of vitamin C on anxiety and stress
responses in humans, the existing ones seem to provide promising results.
De Oliveira et al. [189] examined the effects of short-term oral Vit C supplementation (500 mg/day,
14 days) in high school students (n = 42) in a randomized, double-blind, placebo-controlled trial.
The treatment led to higher plasma Vit C concentration that was associated with reduced anxiety
levels evaluated with BIA (Beck Anxiety Inventory). Moreover, the Vit C supplementation had
positive effect on the heart rate. Gautam et al. [171] observed that patients with generalized anxiety
disorder had significantly lower Vit C levels in comparison with healthy controls, whereas 6-week
vitamins supplementation (vitamin C accompanied with A and E) led to a significant reduction in
anxiety scores [171]. Mazloom et al. [190], in turn, showed that short-term supplementation of Vit C
(1000 mg/day) reduced anxiety levels (evaluated basing on Depression Anxiety Stress Scales 21-item)
in diabetic patients. This effect was exerted through alleviating oxidative damage. Furthermore,
recently performed a systematic review also showed that high-dose Vit C supplementation was
effective in reducing anxiety as well as stress-induced blood pressure increase [191].
6.3. Schizophrenia
Schizophrenia is a severe and complex neuropsychiatric disorder that affects 1% of the population
worldwide [192–194]. Symptoms of schizophrenia are described as “positive” (also so-called
productive) and “negative” ones: the first include hallucinations, paranoia and delusions, while
negative examples are: limited motivation, impaired speech, weakening and social withdrawal. These
symptoms usually appear in early adulthood and often persist in about three-fourths of patients
despite optimum treatment [192]. Some authors have suggested that insufficient dopamine level due
to the loss of dopamine producing cells may lead to schizophrenia [195]. On the other hand, it has
been postulated that schizophrenia has been linked to hyperactivity of brain dopaminergic systems
that may reflect an underlying dysfunction of NMDA receptor-mediated neurotransmission [194].
Furthermore, there is the increasing evidence that several physiological mechanisms such as oxidative
stress, altered one carbon metabolism and atypical immune-mediated responses may be involved in
schizophrenia pathomechanism [192,196].
Hoffer [197] summarized in the review study the evidence showing that among others Vit C
deficiency could worsen the symptoms of schizophrenia and that large doses of this vitamin could
improve the core metabolic abnormalities predisposing some people to development of this disease.
According to the author, it is probable that the pathologic process responsible for schizophrenia
could increase ascorbic acid utilization. Sarandol et al. [198] also noted lower levels of serum Vit
C as compared to control group, but this was not regarded as a statistically significant difference.
Moreover, a 6-week-long antipsychotic treatment did not modify the concentration of this vitamin.
The authors explained that other factors, such as nutrition, physical activity, etc., might be the reason
for the discrepancy between the results of their research and other studies. Similarly, Young et al. [199]
observed only a slight decrease in Vit C levels in schizophrenic group vs. control one; but interestingly,
a highly significant increase in Vit C level in the control female group as compared to both control as
well as schizophrenic male group was observed. The authors pointed out that this information might
be relevant particularly in the light of recent reports that the risk of schizophrenia is higher in men
than women. The reduced supply of Vit C with the diet in patients with schizophrenia was noted by
Konarzewska et al. [200].
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The review of Magalhães et al. revealed that the implementation of Vit C as a low-molecular-weight
antioxidant alleviated the effects of free radicals in the treatment of schizophrenia [201]. According
to Bentsen et al. [202] membrane lipid metabolism and redox regulation may be disturbed in
schizophrenia. These authors conducted a study aiming at examination of the clinical effect of adding
vitamins E + C to antipsychotics (D2 receptor antagonists). Patients with schizophrenia or related
psychoses received Vit C (1000 mg/day) along with vitamin E (364 mg/day) for 16 weeks. Vitamins
impaired the course of psychotic symptoms, especially of persecutory delusions. The authors pointed
to the usefulness of supplementation of antioxidant vitamins as agents alleviating some side effects
of antipsychotic drugs. This was also confirmed by the next study involving schizophrenia patients
treated with haloperidol [203]. Classical antipsychotics like haloperidol are suggested to increase
oxidative stress and oxidative cell injury in brain, which may influence the course as well as treatment
effects of schizophrenia. In this study, chronic haloperidol treatment connected with supplementation
of a combination of ω-3 fatty acids and vitamins E and C showed a significant beneficial effect on
schizophrenia treatment as measured by SANS (Simpson Angus Scale) and BPRS (Brief Psychiatric
Rating Scale) scales. BPRS total score and subscale scores as well as SANS scores were significantly
improved starting from the 4th week of treatment. Moreover, in patients with schizophrenia after
16 weeks of treatment, serum Vit C levels were almost twice as high as at the beginning of the study.
These results supported the hypothesis of a beneficial effect of the applied supplementation both on
positive and negative symptoms of schizophrenia as well as the severity of side effects induced by
haloperidol [203]. Heiser et al. [204] also stated that reactive oxygen species (ROS) were involved in
the pathophysiology of psychiatric disorders such as schizophrenia. Their research demonstrated
that antipsychotics induced ROS formation in the whole blood of rats, which could be reduced by
the application of vitamin C. The aim of their study was to demonstrate the effects of clozapine,
olanzapine and haloperidol at different doses (18, 90 and 180 μg/mL) on the formation of ROS in the
whole blood by using electron spin resonance spectroscopy. To demonstrate the protective capacity
of Vit C the blood samples were incubated the highest concentration of each drug with Vit C (1 mM)
for 30 min. Olanzapine caused significantly greater ROS formation vs. control under all treatment
conditions, while in the case of haloperidol and clozapine only two higher concentrations resulted in
significantly increased ROS formation. Vitamin C reduced the ROS production of all tested drugs, but
for olanzapine the attenuating effect did not reach a significant level.
A relatively novel approach as for the role of Vit C in etiology and treatment of schizophrenia
was presented by Sershen et al. [193]. According to the researchers, deficits in N-methyl-D-aspartate
receptor (NMDAR) function are linked to persistent negative symptoms and cognitive deficits in
schizophrenia. This hypothesis is supported by the fact that the flavoprotein D-amino acid oxidase
(DAO) was shown to degrade the gliotransmitter D-Ser, a potent activator of N-methyl-D-aspartate-type
glutamate receptors, while a lot of evidence has suggested that DAO, together with its activator,
G72 protein, may play a key role in the pathophysiology of schizophrenia. Furthermore, in a
postmortem study the activity of DAO was found to be two-fold higher in schizophrenia subjects [205].
Sershen et al. [193] showed that acute ascorbic acid dose (300 mg/kg i.p.) inhibited PCP-induced
and amphetamine-induced locomotor activity in mouse model, which was further attenuated in the
presence of D-serine (600 mg/kg). The authors suggested that this effect could result from the Vit
C-depended changes in dopamine carrier-membrane translocation and/or altered redox mechanisms
that modulate NMDARs. However, this issue needs to be further investigated.
7. Conclusions
The crucial role of Vit C in neuronal maturation and functions, neurotransmitter action as well as
responses to oxidative stress is well supported by the evidences presented in this review (Figure 2).
The aforementioned animal studies confirmed the usefulness of using of Vit C in the treatment
of neurological diseases, both neurodegenerative and psychiatric ones. Only in the case of ALS,
the possible unfavorable effects were suggested. However, studies on the role of Vit C in the course of
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neurological disorders in human are limited and the existing ones have aimed mostly at evaluating the
effect of Vit C supplementation (often co-supplementation with other agents). Recently, a tendency
toward using administration of large doses of Vit C as an adjuvant in curing of many diseases was
observed. Unfortunately, in the available literature there is a lack of studies considering this issue in
the context of neurological disorders.
Figure 2. The main potential consequences of brain Vit C deficiency in the course and pathogenesis of
neurological disorders.
In conclusion, the future studies concerning the question if Vit C could be a promising adjuvant
in therapy of neurodegenerative and/or psychiatric disorders in humans, seem to be advisable.
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Abstract: Vitamin C plays a role in neuronal differentiation, maturation, myelin formation and
modulation of the cholinergic, catecholinergic, and glutaminergic systems. This review evaluates the
link between vitamin C status and cognitive performance, in both cognitively intact and impaired
individuals. We searched the PUBMED, SCOPUS, SciSearch and the Cochrane Library from 1980
to January 2017, finding 50 studies, with randomised controlled trials (RCTs, n = 5), prospective
(n = 24), cross-sectional (n = 17) and case-control (n = 4) studies. Of these, 36 studies were conducted
in healthy participants and 14 on cognitively impaired individuals (including Alzheimer’s and
dementia). Vitamin C status was measured using food frequency questionnaires or plasma vitamin C.
Cognition was assessed using a variety of tests, mostly the Mini-Mental-State-Examination (MMSE).
In summary, studies demonstrated higher mean vitamin C concentrations in the cognitively intact
groups of participants compared to cognitively impaired groups. No correlation between vitamin C
concentrations and MMSE cognitive function was apparent in the cognitively impaired individuals.
The MMSE was not suitable to detect a variance in cognition in the healthy group. Analysis of the
studies that used a variety of cognitive assessments in the cognitively intact was beyond the scope of
this review; however, qualitative assessment revealed a potential association between plasma vitamin
C concentrations and cognition. Due to a number of limitations in these studies, further research
is needed, utilizing plasma vitamin C concentrations and sensitive cognitive assessments that are
suitable for cognitively intact adults.
Keywords: vitamin C; ascorbic acid; central nervous system; cognition; Alzheimer’s;
dementia; MMSE
1. Introduction
The biological benefits of the water soluble molecule vitamin C (L-ascorbic acid or ascorbate)
have been well documented [1–5]. Based on its unique chemistry, the biological role of ascorbate is
to act as a reducing agent, donating electrons in various enzymatic and non-enzymatic reactions [6].
It is a cofactor for at least eight enzymatic reactions involved in key bodily processes including the
production of collagen, preventing harmful genetic mutations, protecting white blood cells [7] and
the production of carnitine, vital for energy [8]. Ascorbate is reversibly oxidized with the loss of two
electrons to form dehydroascorbic acid (DHAA).
Despite the extensive research into its enzymatic roles and antioxidant properties, the biological
roles of vitamin C on the brain have only recently been described in detail. Animal studies have
explored this biological link. In particular, research has focused on guinea pigs, due to their inability
to biosynthesize vitamin C from glucose, similar to humans [9]. As a result of this biological
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limitation, the human brain relies on dietary sources of vitamin C. Animal studies have shown
that vitamin C plays a vital role in neurodevelopment by influencing neuronal differentiation and
the general development of neurons and myelin formation [9]. Additional, specific neurotransmitter
functions include modulation of the cholinergic, catecholinergic, and glutaminergic systems of the
brain. Ascorbic acid affects synaptic neurotransmission by preventing neurotransmitter binding
to receptors [10], by modulating their release and reuptake [11], and also acting as a cofactor in
neurotransmitter synthesis [12]. Another neuromodulatory role of Vitamin C appears to be its
involvement in presynaptic re-uptake of glutamate [13], exhibiting a direct effect in the prevention of
neuronal over-stimulation by glutamate [14].
Less research has been conducted on ascorbate in collagen synthesis in brain than in other organs,
but minimal amounts are essential for blood vessel formation (angiogenesis). Vitamin C is essential for
the formation of procollagen which then acts as an intracellular “glue” that gives support, shape and
bulk to blood vessels [15]. Studies indicate that vitamin C deficiency in the brain is associated with
a reduction in angiogenesis and vascular dysfunction [16,17] and the production of nitric oxide,
responsible for vasodilation.
Neurons are especially sensitive to ascorbate deficiency, possibly due to 10-fold higher rates of
oxidative metabolism than supporting glia [18]. Ascorbate at the concentrations present in CSF and
neurons in vivo has been shown to effectively scavenge superoxide [19]. Once a superoxide radical is
formed in the mitochondria of neurons, ascorbate catalyses its conversion to H2O2 and is oxidised in
the process to an ascorbate free radical and DHAA. Ascorbate also supports the regeneration of other
antioxidants, such as vitamin E and glutathione [19].
Indicative of its vital role in the brain is its recycling, homeostatic mechanism [20] which maintains
vitamin C concentrations in the brain and neuronal tissues relative to other bodily organs and tissues.
In the healthy brain, the content of vitamin C in cerebrospinal fluid (CSF) is highly concentrated
compared to plasma (2–4 times more, 150–400 μmol/L) [21]. In whole brain, 1 to 2 mM of ascorbic
acid has been detected, while intracellular neuronal concentrations are much higher, reaching up to
10 mM [22]. These high concentrations are the result of DHAA being recycled into ascorbate within
astrocytes, which consist of glutathione [23]. The most saturated vitamin C brain regions include the
cerebral cortex, hippocampus and amygdala [24,25].
Although higher plasma ascorbic acid concentrations generally result in higher CSF
concentrations, these concentrations start to reach a steady state. As plasma concentrations decline,
relatively more ascorbate is pumped into the CSF in order to maintain homeostasis [26]. Studies have
demonstrated a higher CSF: plasma ratio in those with lower plasma vitamin C [26,27]. This could be
a reflection of the increased “consumption” of ascorbate by the oxidative stressed brain, leading to
lower plasma concentrations [26].
Thus, not only is it difficult to deplete brain ascorbate, it is also difficult to increase levels above
those set by uptake and recycling mechanisms. In neuronal cells, the apparent Michaelis–Menten
transport kinetics (Km) for ascorbate appears to be somewhat high (113 μmol/L); this affinity
corresponds well to plasma ascorbate concentrations of 30–60 μmol/L [28]. Thus, plasma vitamin C
can only relate to brain vitamin C status in a narrow window, likely levels below 30 μmol/L.
Duration of deficiency has shown to influence brain ascorbate concentrations to a higher
degree than the amount of depletion. This is exemplified by observations in acute scurvy
where brain concentrations of ascorbate are relatively maintained through depletion of peripheral
tissues [29], whereas marginal deficiency for longer periods of time resulted in greater brain ascorbate
depletions [30].
Given the various biological roles on the central nervous system, a number of studies have been
conducted with the intention of exploring whether vitamin C status is associated with cognitive
performance in cognitively intact participants as well as those diagnosed with a neurodegenerative
condition. This systematic review is the first to explore the effects of blood vitamin C status and
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cognitive performance in both cognitively impaired and intact groups of participants. This systematic
review summarises current knowledge and provides recommendations for future studies.
2. Methods
2.1. Search Strategy
We searched the PUBMED, SCOPUS, SciSearch and the Cochrane Library for publications from
1980 to January 2017. Keywords used were vitamin C, ascorbic acid, antioxidant, cognition, memory,
Alzheimer’s and dementia. Additional published reports were obtained by checking references of
screened articles. Studies only examining cognitive function and vitamin C status were included.
2.2. Selection of Trials
Study designs included randomised controlled trials, prospective cohort, cross-sectional,
and case-control, restricted to those in the English language. This selection included adult participants
who were either cognitively intact or diagnosed with a neurodegenerative condition such as
Alzheimer’s or dementia. Studies that administered some form of vitamin C measure and quantitative
cognitive assessment were accepted.
2.3. Quality Assessment
Quality of studies was independently assessed by two investigators (NT and KR). Appraisal was
determined using established guidelines for randomised, controlled trials (RCT), and observational
studies (prospective and cohort) established from the Cochrane collaboration [31]. Quality was
assessed on selection bias, allocation bias, attrition bias, methods to control confounding factors,
and conflict of interest. Compliance was further assessed in RCTs. Higher-quality trials (score ≥4 of
8 points for RCT, ≥3 of 4 points for prospective and ≥2 of 3 for cross-sectional and case control) were
compared with lower-quality studies.
2.4. Analysis of Trials Using Comparable Methods
An initial survey of the literature revealed that many studies used comparable cognitive and
vitamin C measures—The Mini Mental State Examination (MMSE) and blood plasma vitamin C
concentrations. Given this consistency in measurement we decided to further explore these trends
across studies. A brief summary of these inclusions and methods is presented below. We contacted
authors for mean values and standard deviations of studies which did not report numerical mean
vitamin C concentrations or MMSE scores (0–30) but instead placed the means into categories
(e.g., MMSE score of over/under 27, vitamin C concentrations into deficient/adequate ranges).
2.5. Blood Plasma Vitamin C
Given the practicality and accuracy of measuring absorbed vitamin C status through blood
plasma, plasma vitamin C has been considered the ideal measure of vitamin C status [32]. A number
of investigated studies have used this measure to determine vitamin C status. vitamin C blood
concentrations, based on population studies, indicate that a plasma concentration of <11 μmol/L
is considered to be deficient, 11–28 μmol/L is depleted or marginally deficient, 28–40 μmol/L is
adequate, and >40 μmol/L is optimal [33]. Other studies measured CSF vitamin C concentrations
or incorporated a variety of FFQs and supplementation questionnaires, measuring daily intake in
milligrams. A recommended daily intake of 200 mg/day has been suggested, as this corresponds with
optimal vitamin C blood concentrations [34].
2.6. Measure of Cognition
The MMSE is a simple validated and reliable paper and pen questionnaire designed to estimate
the severity and progression of cognitive impairment and used to follow the course of cognitive
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changes in an individual over time [35]. Any score greater than or equal to 24 points (out of 30)
indicates normal cognition. Below this, scores can indicate severe (≤9 points), moderate (10–18 points)
or mild (19–23 points) cognitive impairment [36]. The cognitive domains measured include attention
and calculation, recall, language, ability to follow simple commands and orientation. Descriptive
analyses were conducted for all included studies, which assessed vitamin C concentrations (means
and standard deviations in μmol/L for blood tests and mg/day for FFQs), and mean MMSE scores.
2.7. Z Statistical Analysis-Correlation Between Blood Vitamin C and MMSE Score
Using IBM SPSS (version 23, Chicago, IL, USA) t-tests were conducted, comparing the baseline
blood vitamin C concentrations and baseline MMSE scores between cognitively intact and impaired
participants. Due to the ordinal nature of MMSE scores and ratio scales for blood test concentrations,
a Spearman’s correlation coefficient analysis (r values) was conducted. R-squared values, assessing
goodness of fit and test of normality were conducted to establish the correlation between mean vitamin
C concentrations and MMSE scores.
Only studies which measured blood vitamin C concentrations and cognition through the MMSE
were compared. Comparable mean vitamin C blood concentrations and MMSE scores were extracted
as separate data points from each of the studies and plotted graphically. A number of studies
assessing cognitively impaired individuals also used healthy controls. The mean MMSE and vitamin
C concentrations from these controls was added to the mean scores of other cognitively intact samples
for comparison.
FFQ-based vitamin C levels were also converted to predicted blood concentrations, where every
1.97 mg of consumed vitamin C equates to 1 μmol/L of ascorbate plasma. A constant plateau
in ascorbic acid concentration (60–80 μmol/L) is reached at 150 mg of consumed vitamin C [34].
Given the non-linear link between vitamin C consumption and absorption, the converted FFQ blood
concentrations were added to the scatterplot for comparison, but were not included in the analysis.
Additionally, ascorbate CSF concentrations were not included in the analysis due to a non-linear
relationship with plasma vitamin C.
Additionally, qualitative analyses were conducted on the studies that utilized a range of other
cognitive assessments and direct plasma vitamin C measures. These studies were reported qualitatively
due to a large diversity in cognitive assessments and statistical reporting of results (odds ratios,
confidence intervals, etc.). The overall trend of results and quality of these trials was taken into account
for the qualitative analysis.
3. Results
The search captured exactly 500 articles, of which 50 studies were included in the systematic review
(Figure 1). Of these, 14 studies involved cognitively impaired participants, e.g., dementia including
Alzheimer’s disease and 36 studies were conducted on cognitively intact participants. The cognitively
impaired subgroup included 3 RCTS [37–39], 4 prospective [26,40,41], 4 cross-sectional [42–45] and
4 case-control [46–49] studies (Table 1). The cognitively intact subgroup included 2 RCTS [50,51],
21 prospective [52–72], 13 cross-sectional [73–85], and no case-control studies (Table 2). Table 3
summarises the trials that were excluded from the review, and the reason for their exclusion.
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Figure 1. Flow chart of steps in systematic review.
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Paper Study Design N Age (years) Quality
Assessment
Cognitive Measure Vitamin C Measure Outcome
Lindemann, 2000 [78] Cross 195 ≥65 3
MMSE, WAIS-R Digits Forward,
Fuld Object Memory Evaluation,
Clock drawing, Two Color Trail
Making Tests
Serum ascorbate Lower vit C not associated with cognition. There was a trend.Low vit C linked with a history of depression
Perrig, 1997 [79] Cross 442 ≥65 3
Computerised cognitive test




Free recall, recognition, and vocabulary (not priming or
working memory) correlated with ascorbic acid
concentrations (semantic memory p = 0.034, vocabulary test p
≤ 0.021)
Schmidt, 1998 [80] Cross 1769 50–75 2 Mattis Dementia Rating Scale Plasma (chromatograph) No association between cognitive scores and plasmaconcentrations (odds ratio = 1, p = 0.87)
Sato, 2006 [81] Cross 544 ≥65 2.5 Digit symbol substitution task(DSST), MMSE Ascorbate plasma, Block’s FFQ
Highest fifth of plasma ascorbate associated with better
DSST, marginally with MMSE
Whalley, 2003 [82] Cross 176 77 2.5 MMSE, Raven’sProgressive Matrices Ascorbate plasma, FFQ (MONICA)
No difference between those taking vitamin C supplements
and controls, after controlling for childhood IQ, education,
socioeconomic status and cardiovascular health
Perkins, 1998 [83] Cross 4809 >60 2 Delayed word recall, Delayedstory recall Serum ascorbate
After adjusting for socioeconomic factors and other trace
elements, vitamin C concentrations were not associated with
poor memory performance
Ortega, 1997 [84] Cross 260 65–90 1.5 MMSE, Pfeiffer’s mentalstatus questionnaire Food frequency for 7 days
Higher cognition correlated with great vitamin C intake
across 7 days
Requejo, 2003 [85] Cross 168 65–90 0.5 MMSE Food record Those with a greater intake of vitamin C were more likely todisplay adequate cognitive ability
Key: MCI = Mild cognitive impairment, AD = Alzheimer’s, VaD = vascular dementia RCT = Randomized control trial, Pros = prospective, Cross = cross-sectional, CC = case-control,
Vit = vitamin, FFQ = food frequency questionnaire, CSF = cerebrospinal fluid, MMSE = Mini mental state examination, 3MS = Modified Mini Mental State Examination.
Table 3. List of studies with reasons for exclusion.
Study Study Design Reason for Exclusion
Kennedy (2011) [86] RCT Mood/fatigue primary measures, vitamin C status not assessed
Smith (1999) [87] RCT Self-reported cognitive failures (subjective cognitive assessment)
Kumar (2008) [88] RCT Vitamin C status not assessed
Yaffe (2004) [89] RCT Cognition not assessed at baseline, vitamin C status not assessed
Kang (2009) [90] RCT Cognition not assessed at baseline, only 3.5 years after intervention
Chui (2008) [91] RCT Vitamin C status not assessed, no placebo/blinding
Day (1988) [92] RCT Vitamin C status not assessed, assessed only confusion
Paraskevas (1997) [93]/Quinn (2004) [27]/Woo (1989) [94]/Polidori (2002) [95]/Foy (1998) [96] CS No cognitive tests administered
Talley [97] Pre-test post-test Simple orientation/consciousness assessment
Legend: RCT = Randomised control trial, CS = case-control.
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In the cognitively impaired samples, eight out of 14 studies used blood tests to measure vitamin
C [26,39,42–44,46–48], two used CSF [37,38] and four used FFQs alone [40,41,45,49]. A series of
cognitive tests were conducted in these studies. Eleven studies [26,37–39,42–44,47–49] used the
MMSE and six [37,40–42,45,49] used alternate forms of cognitive assessment. In the cognitively
intact samples, 11 out of 36 used blood tests to measure vitamin C status [50–53,76,78–83],
and 25 studies conducted FFQs [54–75,77,84,85]. A series of cognitive tests were conducted
in these studies. Fifteen studies [50,51,54–58,73,74,77,78,81,82,84,85] used the MMSE and
31 studies [50,52–56,58–67,69–76,78–84,98] used other forms of cognitive assessment.
Mean MMSE scores and measured or derived blood vitamin C concentrations are plotted in
Figure 2 and presented in Tables 4 and 5. In the cognitively impaired group, these means were extracted
from seven studies (sample sizes ranged from 12–88 participants, with a total of 391 participants).
Independent samples t-tests revealed that mean vitamin C concentrations in the cognitively intact
subgroup were significantly higher than in the cognitively impaired (t (15) = 4.5, p < 0.01) and mean
MMSE scores were also significantly higher in this subgroup (t (10.3) = 5.7, p < 0.01).
Ref 39.AD
Ref 39. AD
Ref 26. Mild AD




Ref 49. Moderate AD
Ref 49. hospitalised
AD





































Mean MMSE (cognition) score









Figure 2. Scatterplot of baseline mean MMSE scores against blood vitamin C concentrations. Blue circles
represent cognitively impaired groups of participants, and green triangles and crosses represent
cognitively intact groups (triangles: direct plasma vit C measure, cross: converted from FFQ).
No correlation analyses were conducted on the cognitively intact data points. The blue line represents
the correlation slope amongst the studies of cognitively impaired groups of participants (rs (11) = 0.009,
p = 0.98). Key: Ref = study reference, * Not included in the analysis, AD = Alzheimer’s disease,
CSF = Cerebral Spinal Fluid, FFQ = Food Frequency Questionnaire; MCI = mild cognitive impairment,
mg/day = milligram per day, VaD = Vascular dementia, Con = concentration, MMSE = Mini Mental
State Examination.
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Table 4. Cognitively impaired participants (Mean blood vitamin C/MMSE scores).
Paper Study Design N Mean Vitamin C Level in μmol/L (SD) Mean MMSE Score (SD)
Burns (1989) [39] RCT 81
Intervention baseline-33.5 (28)
Placebo baseline-31.8 (31)




Bowman (2009) [26] Pros 32 41 (30) 19 (5)










Glaso (2004) [47] CC 20 AD-44 (25) 16.9










Legend: SD, standard deviation; RCT = randomised controlled trial, Pros = prospective, CS = cross-sectional,
CC = case-control, # not a baseline value therefore not included in analysis, blue circles representing cognitively
impaired blood values.
Table 5. Cognitively intact participants (Mean blood vitamin C/MMSE scores).
Paper Study Design N Vitamin C Level in μmol/L (SD) MMSE Score (SD)
Engelhart (2002) [56] * Pros 5395 61.7 (27) 28
Jama (1996) [77] * CS 5182 57.5 28
Ortega (1997) [84] CS 260 62.7 (33.5) 27.4 (4.8)





Glaso (2004) [47] CC 18 Control group-80 (28) 27.2
Polidori (2004) [43] CS 55 Control group-52.4 (16.4) 28.7 (1)
Rinaldi (2003) [42] CS 53 Control group-52.4 (16.5) 28.1 (1.4)










Sato (2006) [81] # CC 544
Median = 74.9 (interquartile range = 57.8–90.7)
Median = 78.9 (interquartile range = 64.1–99.2)
<27
>27







Legend: RCT = randomised controlled trial, Pros = prospective, CS = cross-sectional, CC = case-control, * converted
FFQ to blood vitamin C (μmol/L) represented by crosses on Figure 2 (not included in analysis), green circles
representing cognitively intact blood values (Figure 2), # Not included in analysis.
In the cognitively impaired subgroup, there was a wide distribution of both MMSE scores (mean
score range = 1.9–26.9) and vitamin C concentrations (19–44 μmol/L) (Figure 2). Mean vitamin C
concentration (Mean score ± standard deviation (SD) = 29.91 ± 8 μmol/L) corresponded with a
borderline vitamin C depletion (<28 μmol/L) [33]. Mean MMSE scores (Mean score = 14.63 ± 7.8)
corresponded to a severe cognitive impairment (scores >17) [99].
In the cognitively intact subgroup, mean vitamin C and MMSE scores were extracted from
5 studies (sample sizes ranged 18–260 participants, with a total of 496 participants). In this group, mean
vitamin C concentrations (Mean score ± SD = 54.9 ± 16) μmol/L) were widely spread (33.7–80 μmol/L)
but mean MMSE scores (Mean score = 28.1 ± 0.7) were not (27.2–28.9). The lack of variance in MMSE
scores precluded correlational analysis in this subgroup.
In the cognitively impaired subgroup the scatterplot (Figure 2/Table 4) and a Pearson r2 value of
0.0016 revealed low variance and a spread in means around the fitted regression line. The Spearman’s
correlation also revealed no significant correlation between MMSE scores and vitamin C concentrations
(rs (11) = 0.009, p = 0.98).
A number of studies [44,50,78,81] (Table 5) did not report numerical mean vitamin C
concentrations or MMSE scores (0–30) but instead placed the means into categories (e.g., MMSE
score of over/under 27, Vitamin C concentrations into deficient/adequate ranges). The results from
these studies followed our observed trend where participants whose vitamin C concentrations were
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categorized into adequate ranges produced higher mean MMSE scores and those who were categorized
into scoring under 27 on the MMSE had lower mean vitamin C concentrations.
Additional studies using cognitively intact groups of participants (Table 2) assessed cognition
using a number of different cognitive measures and plasma vitamin C. Examples of these cognitive
measures included the digit span backwards/forwards, the East Boston memory test, Wechsler memory
test, clock drawing, delayed word recall, etc. (Table 2). A majority of these studies [50,52,78,79,81]
revealed an association between vitamin C blood concentrations and cognitive performance on various
cognitive tasks. Some of the cognitive domains included short-term memory, information processing,
abstract thinking and working memory. A number of studies [80,82,83] did fail to demonstrate a link
between vitamin C and cognition. However, the quality assessment revealed lower ratings for these
studies than for those demonstrating a link. Additionally, one study [42] using cognitively impaired
groups of participants (Table 1) assessed cognition with alternative assessments to the MMSE and
demonstrated superior performance in those with higher vitamin C concentrations.
The predicted blood vitamin C concentrations generated from FFQs in the cognitively intact
participants when plotted (Figure 2), were relatively similar to the blood concentrations generated by
studies primarily using blood tests. These converted values were not used in correlation analyses.
4. Discussion
This review evaluated 50 studies exploring the link between vitamin C and cognitive function.
Extrapolated mean vitamin C concentrations and MMSE scores from a number of these studies
indicated that the cognitively intact groups of participants had higher mean vitamin C concentrations
and MMSE scores than the cognitively impaired groups. However, there was no significant correlation
between mean vitamin C concentrations and mean MMSE scores in the cognitively impaired studies
(n = 7, n = 391 participants). In contrast, correlation analysis between blood vitamin C concentrations
and MMSE scores in the cognitively intact studies was not feasible due to the low variance in
MMSE scores, demonstrating the unsuitability of the MMSE in the cognitively healthy participants.
Quantitative assessment of those studies in the cognitively intact groups revealed a potential
association between plasma vitamin C concentrations and cognition. Our findings are consistent
with a number of studies [42,48,95] that showed a significantly lower vitamin C blood concentrations
between cognitively impaired compared to healthy individuals.
This may be explained by a reduction in dietary intake amongst the elderly in general [100], and
those living alone or in aged care/hospital facilities [101] who are often unable to prepare their own
meals, may have chewing problems, and may make poor food choices such as not including fruits and
vegetables in their diet.
Subjects with AD may be nutrient deficient, particularly in the later phase of the disease. However,
case-control studies have also demonstrated lower plasma vitamin C concentrations in the early AD
stages in well-nourished subjects [48].
A more recent, second hypothesis for the depleted blood vitamin C concentrations in the
cognitively impaired is the increased oxidation of vitamin C in response to elevated free radical
production in the brain. Vitamin C has been reported to be the first barrier to free radicals produced in
biological fluids [102]. In the cognitively impaired, studies have demonstrated an increased sensitivity
to free radicals in the cerebral cortex [103]. The mechanisms of free radical production hypothesized
for AD include: activated microglia surrounding senile plaques [104], neuronal mitochondrial
dysfunction [105], intraneuronal amyloid accumulation [106] and presence of redox active metals [107].
Thirdly, disturbances in iron metabolism found in the vicinity of the senile plaques [108], could catalyse
the production of free radicals. Noradrenergic and serotoninergic deficiencies have also been reported
in AD [109], requiring the utilisation of vitamin C to restore these deficiencies.
The lack of linearity in vitamin C concentrations and MMSE scores in the cognitively impaired
group could be explained by the non-linear relationship between plasma vitamin C and ascorbate
CSF absorption. Due to a homeostatic mechanism [26], the amount of ascorbate CSF and vitamin C
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reaching the brain could show little variability at varying plasma concentrations, even with deficient
plasma concentrations (<28 μmol/L). This could result in similar cognitive scores at varying plasma
vitamin C concentrations.
4.1. Limitations
The results from the current review do need to be interpreted cautiously due to a number
of limitations:
While blood samples are a more reliable measure of vitamin C status than FFQ-based Vitamin
C determination, a number of further methodical issues may exist. Many factors can contribute to
the instability of ascorbic acid in biological samples due to the oxidation of vitamin C in plasma
is accelerated by heat, light, and elevated pH (acidity). These issues arise as a result of a lack of
full appreciation of the redox chemistry and biology of ascorbic acid [110]. A number of handling
techniques should be incorporated in order to ensure quality measures.
A majority of studies included in this review failed to thoroughly explain blood sample handling
and biochemical analysis. Ideal handling conditions of samples intended for ascorbate analysis include
immediate coverage from light, immediate plasma isolation, rapid acidification, and freezing below
−20 ◦C to avoid misinterpretations compounded by the use of poorly preserved samples [110]. In order
for plasma to be transported, it needs to be covered from light and transported on dry ice (−70 ◦C)
before thawing and analysis.
Underestimation of vitamin C concentrations could occur if samples were not handled properly.
Frequent freeze-thaw cycles or exposure to any metals (such as iron in the haemolysis of red blood cells)
could both lead to rapid degradation of vitamin C in the sample [111]. It has been shown that there is
a significant loss of ascorbate plasma in EDTA tubes [112], with lithium heparin tubes being ideal.
Several limitations can arise from the use of FFQs in determining nutrient level [32].
Plasma vitamin C concentrations are dependent on recent dietary intake, due to the vitamin’s water
soluble properties and excretion, therefore blood plasma measures would be most reflective of foods
consumed recently (1–2 weeks). Incorporating food questionnaires relating to most recent food
consumption, would be most indicative of blood concentrations. Given the overreliance on FFQs in
the reviewed studies, especially in those incorporating prospective designs, instead of blood samples
interpretation of findings is limited. A direct comparison between FFQ and blood samples could
validate the effective of the questionnaire. A recent meta-analysis demonstrated that FFQ and food
diaries have a moderate relationship with plasma vitamin C, with multiple factors affecting this
relationship [32].
While converted FFQ-based vitamin C levels were of a similar range to blood concentrations,
this conversion needs to be interpreted with caution. The conversion ratio of 1.95 mg to 1 μmol/L in
plasma was based on a study that used 8 healthy participants [34]. However, this ratio may not be
applicable for all individuals as individual factors could affect vitamin C absorption and distribution
(i.e., oxidative stress, infection, etc.).
Plasma vitamin C differs according to polymorphisms of sodium dependent active transporters
(SVCT2 and SVCT1) despite equivalent vitamin C intake indicating that SVCT1 and 2 genotype
may determine the strength of the association between vitamin C intake and circulating vitamin C
concentrations [113]. Some people may require greater than the recommended daily allowance to
maintain optimal vitamin C concentrations. These differences could render food diary information
even less accurate as perceived intake may not be equivalent to absorption [111].
In addition, dietary assessment has reliability and validity issues in relation to even mild cognitive
deficits, which are frequent in older populations [114]. These include recall errors but even when food
types and amounts are recalled correctly, differences in storage and cooking can decrease the vitamin
C level in the food [115]. It is close to impossible to determine the concentrations retained in foods
following manipulations such as cooking [116]. Furthermore, high levels of vitamin C gained from
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dietary sources will often be accompanied by higher levels of a number of other beneficial compounds
(vitamins, phytochemicals) also found from the same sources [111].
Moreover, the reviewed randomised controlled studies have failed to assess the effects of a vitamin
C intervention on its own, by using multivitamins. A large portion of the included studies have made
efforts to statistically control for potential confounders. Although our review did demonstrate lower
plasma vitamin C concentrations in the cognitively impaired, other studies using impaired samples
have shown depletions in a number of other vitamin and minerals including: vitamin B12 [117],
vitamin E [118], vitamin D [119], vitamin K [120], folate [117], and elevated homocysteine [117].
Additionally, it is important to note that when antioxidant function is involved, vitamins can work
synergistically with other vitamins, e.g., vitamin C recycles α-tocopherol radical (vitamin E) [111]. The
consumption and supplementation of these vitamins should be considered as potential confounders
and should be monitored, especially in cognitive impaired participants.
Moreover, it can be speculated that a consistently high Vitamin C status acts in a preventive
manner, while vitamin C supplementation per se is not a treatment for clinical AD [48]. Thus, infrequent
supplement users may not achieve the same benefits as individuals with consistent intake of adequate
vitamin C. Controlling for vitamin C supplementation use, or taking it into account, is crucial.
Intake at the time of measurement may not reflect lifetime dietary habits and given data that
suggest that amyloid plaque burden begins to form well before middle age [121], intakes during
younger adulthood may be equally as important as supplements taken by older adults, perhaps
contributing to a biological buffer against disease pathogenesis. Measuring and controlling for a
history of consumption and supplementation is crucial, especially in longer prospective studies where
the development of neurodegeneration is being investigated.
In addition to the limitations on vitamin C levels, there were limitations regarding the type of
cognitive measures. A number of long term prospective studies incorporated cognitive tests suitable
for screening and assessing the incidence of Alzheimer’s, such as the MMSE. Given the simplicity
of such tests, and the scales used to measure performance, it becomes difficult to establish cognitive
changes unless the cognitive decline is extremely severe. These MMSE scales have been effective
in measuring cognition in those clinically diagnosed with a neurodegenerative condition [48,96],
and were useful in the cognitively impaired subgroup in this review.
The sensitivity of the MMSE to detect differences in cognitively intact samples has been
questioned [122,123]. This can lead to a lack of variance in MMSE scores. In our review, the mean
MMSE score ranged 27.2–28.9 in this group (<24 = mild cognitive impairment). In this review, a number
of studies conducted on the cognitively intact group did use a range of other, more suitable cognitive
tests, including the digit span forwards/backwards, delayed word recall, letter digit substitution
test, etc., with mixed results. A number of these studies [55,67,70,74,83] failed to demonstrate a link
between vitamin C status and cognition whereas a number of studies [50,61,76,79,81] demonstrated the
effects of vitamin C on a number of cognitive domains such as free recall, short-term memory, abstract
thinking, visuospatial performance and recognition. However, comparison of different cognitive tests
was beyond the scope of this review.
A further limitation to be considered is the often self-selection of healthier, more cognitively-able
population in population studies. As a consequence of high baseline performance in cognitively intact
participants, ceiling effects with narrow ranges in results can occur [124]. This effectively minimizes
several confounding factors, but narrows the chance of detecting cognitive effects.
In cognitively intact samples, cognitive tests sensitive to age-associated cognitive decline should
be employed to maximize the observation of any potential effects. Programs such as The Cambridge
Neuropsychological Test Automated Battery [125] and The National Institute of Health (NIH)
Toolbox [126] are available that tap into a wide range of cognitive domains sensitive to change from
mid adulthood such as fluid intelligence would be ideal for establishing its association with nutrition
or intervention [127]. In the present review, one study [79] using cognitively intact participants
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incorporated a computerized test battery assessing a number of cognitive domains. This study
demonstrated a significant link between vitamin C status and free recall, recognition and vocabulary.
4.2. Future Directions
Future studies should incorporate a number of recommendations. Firstly, the most reliable
and practical measure of vitamin C is the measurement of biological blood samples. Moreover,
the incorporation of FFQs would allow a measure of possible confounding variables (vitamin B12,
vitamin E, etc.). Age-sensitive cognitive tests assessing response time and accuracy should be
administered [127], particularly in the case of cognitively intact individuals. A number of potential
confounding factors such as supplementation, and the long term intake of other vitamins and minerals
associated with cognition need to be take into account.
5. Conclusions
In summary, studies included in this systematic review demonstrated higher mean vitamin C
concentrations in the cognitively intact groups of participants compared to the impaired groups.
No correlation was found between vitamin C concentrations and MMSE scores in the cognitively
impaired groups of participants. Analysis of the studies that used a variety of cognitive assessments
was beyond the scope of this review, however, qualitative assessment in the cognitively intact groups
revealed a potential association between plasma vitamin C concentrations and cognition. Due to a
number of limitations, further research, assessing plasma vitamin C concentrations, taking confounding
factors such as vitamin B12 and vitamin E into account, and the use of more sensitive cognitive
assessment methodology for cognitively intact participants are needed to provide more insights into
the relationship between vitamin C and cognition.
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Abstract: A cohort of 50-year-olds from Canterbury, New Zealand (N = 404), representative of
midlife adults, undertook comprehensive health and dietary assessments. Fasting plasma vitamin C
concentrations (N = 369) and dietary vitamin C intake (N = 250) were determined. The mean plasma
vitamin C concentration was 44.2 μmol/L (95% CI 42.4, 46.0); 62% of the cohort had inadequate
plasma vitamin C concentrations (i.e., <50 μmol/L), 13% of the cohort had hypovitaminosis C (i.e.,
<23 μmol/L), and 2.4% had plasma vitamin C concentrations indicating deficiency (i.e., <11 μmol/L).
Men had a lower mean plasma vitamin C concentration than women, and a higher percentage of
vitamin C inadequacy and deficiency. A higher prevalence of hypovitaminosis C and deficiency was
observed in those of lower socio-economic status and in current smokers. Adults with higher vitamin
C levels exhibited lower weight, BMI and waist circumference, and better measures of metabolic
health, including HbA1c, insulin and triglycerides, all risk factors for type 2 diabetes. Lower levels of
mild cognitive impairment were observed in those with the highest plasma vitamin C concentrations.
Plasma vitamin C showed a stronger correlation with markers of metabolic health and cognitive
impairment than dietary vitamin C.
Keywords: ascorbate; cognition; HbA1c; insulin; glucose; hypovitaminosis C
1. Introduction
The role of vitamin C in health and disease has been actively studied since its discovery over
80 years ago [1]. Vitamin C has a number of well-recognized biological functions, all of which
depend upon its ability to act as an electron donor [2]. One of the most significant of these is its
cofactor activity for a variety of enzymes with critical functions throughout the body. These include
the copper-containing monoxygenases dopamine hydroxylase and peptidyl-glycine α-amidating
monooxygenase [3] and the Fe (II) and 2-oxoglutarate-dependent family of dioxygenases [4]. The latter
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is a large and varied family, with a continually expanding membership that includes the collagen
prolyl hydroxylases responsible for stabilization of the tertiary structure of collagen, the prolyl and
asparaginyl hydroxylases which regulate hypoxia-inducible factors (HIF) activity, and DNA and
histone demethylases involved in the epigenetic regulation of gene expression. Vitamin C also functions
as a highly effective water-soluble antioxidant, protecting in vivo biomolecules from oxidation [5], and
there is good evidence to suggest it is involved in the regeneration of vitamin E in vivo [6,7].
Because humans are unable to synthesize their own vitamin C, it must be obtained from the
diet, principally through fruit and vegetable consumption. Inadequate dietary intake results in the
potentially fatal deficiency disease, scurvy. As little as 10 mg/day vitamin C is sufficient to prevent
overt scurvy [8] and, although scurvy is considered to be relatively rare in Western populations,
vitamin C deficiency is the fourth most prevalent nutrient deficiency reported in the United States [9,10].
Hypovitaminosis C (defined as a plasma concentration ≤23 μmol/L) affects a significant proportion
of the population, with estimates as large as 15–20% in the United States [9]. Similar data for the
New Zealand population are lacking, although dietary vitamin C intake has been used to estimate the
prevalence of inadequate intake, defined as not meeting the estimated average requirement (EAR) [11].
The classical symptoms of scurvy, such as joint pain, lassitude, bleeding and ulceration are
thought to be due to the loss in activity of the vitamin C-cofactor enzymes, particularly the collagen
hydroxylases. It is becoming increasingly acknowledged, however, that vitamin C is required
at concentrations above those needed for the prevention of scurvy for the maintenance of good
health [12,13]. For example, individuals with hypovitaminosis C are known to present with fatigue,
depression and deficiencies in wound healing [14,15], suggesting a requirement for vitamin C status
to be above 23 μmol/L in plasma to support these functions. There is also epidemiological evidence
to support a role for vitamin C in the prevention of some chronic disease, with intakes >100 mg/day
recommended [12]; these intakes will provide adequate plasma levels (i.e., >50 μmol/L) [14,16].
Although the Australasian Recommended Dietary Intake (RDI) for vitamin C is only 45 mg/day, the
New Zealand Ministry of Health, in accord with other international bodies, has a suggested dietary
target of ~200 mg/day vitamin C for the reduction of chronic disease risk [17]. As the many cofactor
functions of vitamin C become more widely understood, epidemiological studies in areas in which its
biological activity can be justified are required.
The CHALICE (Canterbury Health, Ageing and Lifecourse) study is a unique New Zealand
study comprising a comprehensive database of determinants of health. It has prospectively recruited
~400 fifty-year-olds at random from the electoral roll within the Canterbury region. Participants have
undergone extensive health, dietary and social assessments [18]. Here we report on the plasma vitamin
C status and dietary vitamin C intake of the participants, and examine the relationships between these
measures and a range of health indicators.
2. Materials and Methods
2.1. Study Population
Participants were from a random sample drawn from the New Zealand electoral roll, recruited
to take part in a prospective longitudinal study of health and wellbeing (2010–2013), called the
Canterbury Health, Ageing and Lifecourse (CHALICE) study (detailed in [18]). Participants had to be
aged 49–51 years, intend to reside within the greater Christchurch area for at least 6 of the next 12 months,
live in the community (i.e., not in a prison or a rest home) and be able to complete the assessment (e.g.,
speak English proficiently). Māori, the indigenous people of New Zealand, were over-sampled so that
they represented 15% of the CHALICE study sample. Enrolment statistics estimate that, in 2012, 94.9%
of the target population were registered to vote in the Christchurch City Council area [19]. Relative to
the rest of New Zealand, the Canterbury area has a slightly higher proportion of people aged ≥40 years
and a higher proportion of people living in the least economically deprived national quintile [20].
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Ethical approval was obtained from the Upper South A Regional Ethics Committee (URA/10/03/021)
and all participants provided written informed consent.
Data were collected during a 4–6 h interview, via self-completed questionnaires and lifestyle
diaries, and from blood and urine tests. The full cohort was 404 participants, and the present analysis
is based on the 369 participants for whom fasting plasma vitamin C measurements were obtained and
a sample of 250 for whom dietary vitamin C intake was determined.
2.2. Blood Sample Collection
Fasting blood samples were collected into EDTA anticoagulant tubes and sent to Canterbury
Health Laboratories, an International Accreditation New Zealand (IANZ) laboratory, for analysis of
biomarkers. Additional fasting samples were centrifuged at 4000 rpm for 10 min at 4 ◦C to separate
plasma, and the plasma stored at −80 ◦C for vitamin C analysis.
2.3. Sample Preparation for Vitamin C Analysis
Stored EDTA-plasma was rapidly thawed and a 500 μL aliquot was treated with an equal volume
of ice-cold 0.54 M HPLC-grade perchloric acid solution (containing 100 μmol/L of the metal chelator
DTPA) to precipitate protein and stabilize the vitamin C. Samples were mixed, incubated on ice for
a few minutes, then centrifuged. A 100 μL aliquot of the deproteinated supernatant was treated
with 10 μL of the reducing agent TCEP (100 mg/mL stock) for 2 h at 4 ◦C to recover any oxidized
vitamin C [21]. Samples were further diluted with an equal volume of ice-cold 77 mM perchloric
acid/DTPA solution for HPLC analysis.
2.4. Vitamin C HPLC Analysis
The total vitamin C content (ascorbic acid plus dehydroascorbic acid) of the samples was
determined by HPLC with electrochemical detection as described previously [22]. Samples (20 μL)
were separated on a Synergi 4 μ Hydro-RP 80A column 150 mm × 4.6 mm (Phenomenex NZ Ltd,
Auckland, New Zealand) using a Dionex Ultimate 3000 HPLC unit (with autosampler chilled to 4 ◦C
and column temperature set at 30 ◦C) and an ESA coulochem II detector (+200 mV electrode potential
and 20 μA sensitivity). The mobile phase comprised 80 mM sodium acetate buffer, pH 4.8, containing
DTPA (0.54 mmol/L) and freshly added ion pair reagent n-octylamine (1 μmol/L), delivered at a flow
rate of 1.2 mL/min. A standard curve of sodium-L-ascorbate, standardized spectrophotometrically at
245 nm (ε = 9860), was freshly prepared for each HPLC run in 77 mmol/L HPLC-grade perchloric acid
containing DTPA (100 μmol/L). Plasma vitamin C content is expressed as μmol/L.
Fasting plasma vitamin C concentrations were classified as follows; deficient <11 μmol/L,
marginal 11–23 μmol/L, inadequate 23–50 μmol/L or adequate >50 μmol/L [13,15].
2.5. Metabolic and Heart Health Assessments
Metabolic health was assessed by body measurements and fasting blood tests. Participants’
height, weight and waist circumference were taken by the study interviewer, and body mass index
(BMI) calculated (kg/m2). Fasting blood tests comprised triglycerides, high-density lipoprotein (HDL),
glucose, HbA1c and insulin (Canterbury Health Laboratories).
Heart health was assessed by blood pressure and participants had their NZ cardiovascular risk
score calculated. Blood pressure measurements were taken while seated. Five year cardiovascular risk
(%) was derived according to the New Zealand adaptation of the Framingham risk score; the following
variables are included in the calculation: age, gender, systolic blood pressure, diabetic status, smoking
history, and total cholesterol to HDL ratio [23].
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2.6. Dietary Intake Assessment
Participants were asked to complete the Four Day Estimated Food Diary (4DEFD) in the week after
their interview; on one weekend day and three weekdays. The 4DEFD included detailed instructions on
how to record portion sizes, using common household measures. The completed 4DEFD were checked
by a trained nutritionist and additional information obtained from participants where necessary before
the data were entered into the nutrient analysis program Kai-culator (version 1.08d, Department of
Human Nutrition, University of Otago, Dunedin, New Zealand). Dietary analysis was performed on
250 of the CHALICE participants, who had dietary data entered and cleaned at the time of analysis, for
whom the mean daily intake of vitamin C was calculated. Data entry was undertaken by experienced
nutritionists and all diaries were further checked for accuracy by one person who also made any
necessary changes, to ensure consistency of data entry.
2.7. Wellbeing, Depression and Cognition
2.7.1. Mental Wellbeing
The Warwick–Edinburgh Mental Wellbeing Scale (WEMWBS) was used to assess general
wellbeing. The 14 item questionnaire aims to measure positive mental health by assessing both
aspects of well-being: eudaimonic and hedonic [24].
2.7.2. Depression
During the assessment, trained interviewers used the Mini-International Neuropsychiatric
Interview (MINI) for diagnosis of current and past depressive episodes using DSM IV criteria [25].
2.7.3. Cognition
Participants completed the Montreal Cognitive Assessment (MoCA) version 7.1 (original
version) [26], a short screening test for mild cognitive impairment. It assesses the cognitive domains
of attention and concentration, executive functions, memory, language, visuoconstructional skills,
conceptual thinking, calculations, and orientation. A score of 26 or more indicates normal functioning,
while a score less than 26 might indicate mild cognitive impairment. MoCA scores were excluded
from the analysis if English was the second language or if a previous event (e.g., carbon monoxide
poisoning) had affected cognitive ability.
2.8. Socio-Economic Status
The Economic Living Standard Index Short Form (ELSISF) was used to assess standard of
living [27]. Developed in New Zealand, the ELSISF assesses a person’s consumption and personal
possessions, calculating a total score by combining information from all items of the survey. The ELSISF
scores range from 0–31, with those who score 0–16 described as being in hardship, scores of 17–24
as comfortable and scores of 25 or above as socio-economically good or very good. The ELSISF has
excellent internal consistency (coefficient alpha of 0.88).
2.9. Statistical Analyses
Statistical analyses were performed using R 3.3.1 software (R Foundation for Statistical Computing,
Vienna, Austria). Univariate tests on continuous variables were t-tests with Satterthwhaite’s adjustment
for unequal variances while Wald odds ratios and Fisher exact p-values were calculated for categorical
variables. Sample characteristics were compared with census proportions using the chi squared
goodness of fit test. All health measures were examined independently for association with vitamin
C (plasma vitamin C concentration or dietary vitamin C intake) using linear or logistic regression
models. The models fitted the dietary measure, gender (dichotomous), Māori ethnicity (dichotomous)
and current smoking (dichotomous). Models were fitted on males and females separately and the whole
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cohort combined. Modeling assumptions were verified with no material departures observed. For each
outcome, the p values were adjusted for multiple comparisons using the Benjamini and Yekutieli method.
The nominal p value for statistical significance is the usual 0.05 or 5% type II error rate. All p < 0.1 are
shown in the tables with p > 0.1 shown as NS (not significant). The odds of currently smoking for those
in the lowest socio-economic strata was 3.8 times that of the highest strata (95% CI 1.7–9.0), p = 0.002.
Similarly the odds of current smoking were 3.4 times higher in the least educated strata than the most
educated (95% CI 1.75, 6.54), p = 0.0006. To prevent over fitting, socio-economic status and education
were not fitted, however smoking acts as a reasonable proxy for population modeling.
3. Results
3.1. Characteristics of the Study Population
Of the full CHALICE cohort (N = 404), 46.8% (189) were male, with 83.7% (338) self-identifying as
New Zealand European and 14.9% (60) as Māori (Table 1). The majority of the participants were in the
highest ELSISF category. There were 60 current smokers in the cohort.





Female 215 53.2 50.9
NSMale 189 46.8 49.1
Ethnicity Māori 60 14.9 4.5 <0.0001NZ European 338 83.7 74.2
Socio-Economic
Status
Low (ELSISF score 0–16) 30 7.4 8.2
NSMedium (ELSISF score 17–24) 122 30.2 29.4
High (ELSISF score 25–31) 252 62.4 62.5
Education
No Qualification 53 13.1 23.9
<0.0001
Secondary School Qualification 110 27.2 35.2
Post-secondary 168 41.6 25.6
University Degree 73 18.1 15.3
Current Smoker 60 14.9 16.6 NS
N = 404; p (χ2n−1) > 0.1 shown as not significant, NS.
Table 1 compares the CHALICE participants to the New Zealand Census 2006 data for similar age
and region. The CHALICE participants had higher rates of Māori ethnicity and higher qualifications
than the Canterbury average (Table 1), whereas socio-economic status and smoking were within
stochastic limits. This suggests the sample is reasonably representative of Canterbury 50-year-olds and
hence the national cohort allowing for regional bias.
The CHALICE cohort also had typical levels of health for a community sample (Table 2).
Anthropometric measures were close to those of the New Zealand population. Average metabolic and
cardiac markers for the cohort were generally within the healthy range. However, the high prevalence
of chronic conditions in the New Zealand population was also readily apparent.
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Table 2. Health of CHALICE participants and normal ranges for the New Zealand population.
Female Male
Body Measurements Mean Min Max NZ Female Mean Mean Min Max NZ Male Mean
Weight kg 78.6 49.1 149.9 74.8 (73.5–76.1) 88.4 50.8 143.8 88.0 (86.9–89.1)
BMI kg/m2 29.1 17.4 63.4 28.1 (27.6–28.6) 28.1 19.2 48.6 28.6 (28.2–28.9)
Waist cm 92.0 63.0 144.0 86.6 (85.5–87.6) 98.3 72.5 148.0 98.4 (97.4–99.3)
Metabolism Mean Min Max Healthy Range Mean Min Max Healthy Range
Triglycerides mmol/L 1.3 0.4 11.7 <1.7 1.6 0.4 11.7 <1.7
HDL mmol/L 1.4 0.8 2.7 1.0–2.2 1.2 0.7 1.9 0.9–2.0
Glucose mmol/L 5.1 3.2 10.8 <6.1 5.4 3.7 17.9 <6.1
HbA1c mmol/L 38.2 27.0 74.0 <40 39.9 28.0 102.0 <40
Insulin pmol/L 60.9 10.0 277.0 10–80 61.2 4.0 480.0 10–80
Heart Health Mean Min Max Healthy Range Mean Min Max Healthy Range
BP (systolic) mmHg 131.1 104.0 183.7 120 134.2 97.7 185.7 120
BP (diastolic) mmHg 82.5 60.3 106.0 80 85.0 61.0 128.3 80
CVD risk score % 2.5–5 <2.5 20–25 <2.5 5–10 2.5–5 20–25 <2.5
Mental Health Mean Min Max Mean Min Max
Wellbeing 53.0 16 70 52.7 30 70
Cognition 27.1 19 30 26.6 16 30
Current Depression n (%) 17 (7.9) 12 (6.3)
BMI: body mass index, HDL: high-density lipoprotein, BP: blood pressure, CVD: Cardiovascular disease. Body
measurements compared with New Zealand mean (95% confidence interval) for 45–55 age range [28]. Metabolic
and heart health compared with normal healthy range [23,29,30]. Wellbeing measured by Warwick–Edinburgh
scale, cognition by MoCA. Current depression is those currently clinically depressed excluding those diagnosed
bipolar (N = 203 female, 179 male). One female has no waist measurement, three females no fasting metabolic
measures, one male no fasting metabolic measures, one male glucose assay failed and two males HbA1c assay
failed, otherwise data are for 215 females and 189 males.
3.2. Vitamin C Status of the Study Population
Fasting plasma vitamin C measurements were available for 369 of the CHALICE participants.
The mean plasma vitamin C concentration was 44.2 μmol/L (95% CI 42.4, 46.0); 62% of the participants
were below the adequate level (i.e., 50 μmol/L), and 93% of the participants were below the optimal
saturating level (i.e., 70 μmol/L; Figure 1). Ten percent of the cohort had marginal vitamin C
concentrations (i.e., 11–23 μmol/L), and vitamin C deficiency, defined as a plasma concentration
of <11 μmol/L, was apparent in 2.4% of the cohort (Table 3).
Plasma vitamin C status was substantially lower in men than in women (p = 0.005), and it also
varied by socio-economic status (p = 0.003). For example, 8% of those in the lowest socio-economic
category were vitamin C deficient compared to 2.4% of the entire cohort (n = 369). Smoking status
was also associated with plasma vitamin C status with current smokers having lower vitamin C levels
(p < 0.001; Table 3).
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Figure 1. Density plot of plasma vitamin C. Proportion of sample at given vitamin C level; n = 369.
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Table 3. Categories of vitamin C status.
Plasma Vitamin C Deficient Marginal Inadequate Adequate p
Mean 95% CI n % n % n % n %
Total 44.2 (42.4, 46.0) 9 2.4 39 10.6 183 49.6 138 37.4
Gender
Female 47.4 (44.9, 49.9) 2 1.0 20 10.3 85 43.6 88 45.1 0.005
Male 40.6 (38.2, 43.0) 7 4.0 19 10.9 98 56.3 50 28.7
Ethnicity Non Māori 44.5 (42.6, 46.4) 7 2.2 31 9.8 159 50.3 119 37.7 NS




Low 36.8 (28.3, 45.3) 2 8.0 7 28.0 9 36.0 7 28.0 0.003
Medium 43.7 (40.3, 47.1) 4 3.5 14 12.3 53 46.5 43 37.7
High 45.3 (43.2, 47.4) 3 1.3 18 7.8 121 52.6 88 38.3
Education
None 38.7 (33.6, 43.9) 3 6.1 6 12.2 26 53.1 14 28.6 NS
Secondary School 45.9 (42.1, 49.7) 1 1.0 13 12.6 49 47.6 40 38.8
Post-secondary 43.1 (40.6, 45.7) 5 3.3 16 10.6 75 49.7 55 36.4
University Degree 48.1 (44.4, 51.9) 0 0.0 4 6.1 33 50.0 29 43.9
Tobacco
Not Current Smoker 45.9 (44.1, 47.8) 6 1.9 26 8.2 157 49.7 127 40.2 <0.001
Current Smoker 34.1 (29.2, 38.9) 3 5.7 13 24.5 26 49.1 11 20.8
Plasma vitamin C classified as deficient <11 μmol/L, marginal 11–23 μmol/L, inadequate 23–50 μmol/L or adequate
>50 μmol/L; n = 369.
Study participants with and without vitamin C measurements do not differ significantly by
gender, ethnicity, education, socio-economic status, smoking status, waist, weight or BMI (all p > 0.13),
hence are treated as missing at random.
3.3. Associations of Vitamin C Status with Markers of Metabolic and Mental Health
The results of the statistical modeling with plasma vitamin C are summarized in Table 4. Higher
plasma vitamin C status was associated with lower weight, BMI and waist circumference in the
CHALICE cohort, even after adjustment for gender, ethnicity and current smoking. Of the other
markers of metabolic health, plasma vitamin C was negatively associated with blood triglycerides,
HbA1c and insulin, and positively associated with HDL levels. However, after multiple adjustment
only triglycerides, HbA1c and insulin levels remained significant. No correlation was found between
plasma vitamin C and the two indicators of heart health; blood pressure and cardiovascular risk score.
Table 4. Significant plasma vitamin C effects for body measures, metabolic health and mental health.
Vitamin C <23 μmol/L
(n = 47)
Vitamin C >23 μmol/L
(n = 321) p p Adjusted
Mean 95% CI Mean 95% CI
Body measurements
Weight 90.3 (83.3, 97.4) 81.7 (79.8, 83.6) 0.024 0.004
BMI 31.4 (28.7, 34.0) 28.1 (27.5, 28.7) 0.021 <0.001
Waist 103.3 (97.6, 108.9) 93.3 (91.8, 94.8) 0.001 <0.001
Metabolism
Triglycerides 1.8 (1.4, 2.3) 1.4 (1.3, 1.5) 0.061 0.029
HDL 1.3 (1.2, 1.3) 1.4 (1.3, 1.4) 0.033 NS
Glucose 5.6 (5.2, 6.0) 5.2 (5.0, 5.3) 0.072 0.073
HbA1c 42.2 (39.6, 44.8) 38.5 (37.7, 39.3) 0.009 0.015
Insulin 91.0 (68.4, 113.6) 56.3 (51.9, 60.8) 0.004 0.000
Heart health
BP (systolic) 132.2 (128.0, 136.4) 132.5 (130.8, 134.2) NS NS
BP (diastolic) 83.6 (81.0, 86.3) 83.5 (82.4, 84.6) NS NS
CVD risk score 5–10% (<2.5%, 20–25%) 2.5–5% (3.5–5%, 5–10%) 0.057 NS
Mental Health
Wellbeing 50.9 (48.4, 53.4) 53.0 (52.0, 53.9) NS NS
n % n %
MCI 17 40.5 66 21.5 0.012 0.02
Current Depression 6 12.5 20 6.2 NS NS
MCI: Mild Cognitive Impairment indicated by MoCA score <26 for those without excluding conditions.
Current depression is for those without Bipolar Disorder. P values less than 0.1 shown otherwise NS: Not Significant.
p values adjusted for gender, ethnicity and current smoking.
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Mild cognitive impairment was assessed by the MoCA test. Higher plasma vitamin C status was
correlated with lower mild cognitive impairment, which was maintained after adjustment for gender,
ethnicity and current smoking (Table 4). A 1 μmol/L increase in plasma vitamin C was associated with
3% reduced odds of mild cognitive impairment (OR = 0.97, 95% CI = (0.96, 0.99), p = 0.004). Indeed,
the odds of mild cognitive impairment were twice as high for those below 23 μmol/L plasma vitamin
C (OR = 2.1, 95% CI = (1.2, 3.7), p = 0.01). Plasma vitamin C status was not associated with wellbeing
or depression.
3.4. Dietary Vitamin C Intake
Dietary intake analysis was performed on 250 of the CHALICE participants. The average dietary
vitamin C intake was 110 mg/day, with 12% falling below the New Zealand recommended dietary
intake (RDI, Table 5). There was little effect of gender, ethnicity or socio-economic status on dietary
intake. However, those with the lowest educational qualifications tended to have lower dietary vitamin
C intake, although this was not quite significant. Current smokers also had a lower dietary intake
of vitamin C (p < 0.001). Dietary vitamin C intake correlated somewhat less than expected with
plasma levels of vitamin C, although the correlation was statistically significant (Pearson’s correlation
coefficient r = 0.27, p = 0.00002).
Table 5. Categories of dietary vitamin C intake.
Dietary Vitamin C Below RDI RDI-Average Above Average p
Mean 95% CI n % n % n %
Total 109.8 (101.5, 118.1) 30 12 126 50.4 94 37.6
Gender
Female 107.4 (96.6, 118.2) 13 9.7 73 54.5 48 35.8
NSMale 112.6 (99.7, 125.6) 17 14.7 53 45.7 46 39.7
Ethnicity Non Māori 112.0 (102.7, 121.2) 22 10.3 111 51.9 81 37.9 NSMāori 97.2 (79.6, 114.7) 8 22.2 15 41.7 13 36.1
Socio-Economic
Status
Low 78.8 (54.4, 103.1) 4 26.7 8 53.3 3 20.0
NSMedium 105.0 (90.7, 119.2) 12 15.2 36 45.6 31 39.2
High 115.3 (104.4, 126.1) 14 9.0 82 52.6 60 38.5
Education
None 83.5 (64.2, 102.7) 8 28.6 13 46.4 7 25.0
0.1
Secondary School 117.1 (98.4, 135.7) 6 10.0 32 53.3 22 36.7
Post-secondary 108.6 (97.1, 120.1) 11 9.9 59 53.2 41 36.9
University Degree 118.4 (97.6, 139.2) 5 9.8 22 43.1 24 47.1
Tobacco
Not Current Smoker 114.1 (105.3, 122.8) 20 9.0 112 50.7 89 40.3
<0.001Current Smoker 77.5 (54.6, 100.5) 10 34.5 14 48.3 5 17.2
The cut-off values for the vitamin C categories are as follows: New Zealand recommended dietary intake is
45 mg/day, the average New Zealand intake is 109 mg/day for men and 106 mg/day for women [11]; n = 250.
3.5. Associations of Dietary Vitamin C Intake with Markers of Metabolic and Mental Health
There was evidence that higher dietary intake of vitamin C was associated with lower waist
circumference and insulin levels, after adjustment for gender, ethnicity and current smoking (Table 6).
Glucose and HbA1c levels were inversely associated with dietary vitamin C intake in the initial
models, however they did not remain so after correction for multiple comparisons. Higher dietary
vitamin C intake was also associated with lower blood pressure, although there was no effect on
cardiovascular risk score. There was little association between dietary vitamin C intake and mental
health measures, although dietary intake was inversely associated with mild cognitive impairment in
the unadjusted model.
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Table 6. Significant dietary vitamin C effects based on average intake for body measures, metabolic
health and heart health.
Intake < Average (n = 147) Intake > Average (n = 103) p p Adjusted
Mean 95% CI Mean 95% CI
Body measurements
Weight 82.2 (79.2, 85.3) 79.8 (76.4, 83.3) NS NS
BMI 28.5 (27.4, 29.6) 27.2 (26.2, 28.1) 0.08 0.063
Waist 94.6 (92.2, 97.0) 91.2 (88.5, 93.8) 0.06 0.047
Metabolism
Triglycerides 1.4 (1.3, 1.5) 1.3 (1.1, 1.6) NS NS
HDL 1.4 (1.3, 1.4) 1.4 (1.3, 1.4) NS NS
Glucose 5.3 (5.1, 5.5) 5.0 (4.9, 5.2) 0.03 0.078
HbA1c 39.6 (38.3, 41.0) 37.8 (36.9, 38.7) 0.03 NS
Insulin 64.6 (55.5, 73.6) 52.3 (44.3, 60.3) 0.05 0.041
Heart health
BP (systolic) 135.0 (132.5, 137.5) 130.6 (127.4, 133.8) 0.03 0.016
BP (diastolic) 85.2 (83.6, 86.7) 82.3 (80.4, 84.1) 0.02 0.007
CVD risk score 2.8 (2.6, 3.0) 2.6 (2.2, 2.9) NS NS
Mental Health
Wellbeing 52.5 (51.1, 53.8) 52.9 (51.3, 54.4) NS NS
n % n %
MCI 36 24.5 14 13.6 0.04 NS
Current Depression 13 8.8 4 3.9 NS NS
MCI Mild Cognitive Impairment indicated by MoCA score <26 for those without excluding conditions. Current
depression is for those without Bipolar Disorder. p values less than 0.1 shown otherwise NS: Not Significant.
p values adjusted for gender, ethnicity and current smoking. Average is New Zealand average of 109 mg/day for
men, 106 mg/day for women [11].
4. Discussion
These findings were drawn from the first phase of the CHALICE study, a longitudinal
observational study of randomly selected 50-year-olds from the Canterbury region, New Zealand
in 2010–2013. The comprehensive range of instruments used in the CHALICE study gives a broad
picture of the cohort’s health and the agreement between the study data and national demographics
provides confidence that the study is representative of the health of 50-year-old New Zealanders in 2010.
The cohort has typical levels of metabolic and cardiac markers, with indications of overweight/obesity
and hypertension in some individuals. Our study provides new evidence that mid-life adults with
higher vitamin C levels exhibited better measures of metabolic health and lower levels of mild
cognitive impairment.
In New Zealand, dietary vitamin C intake has been estimated by several comprehensive national
dietary surveys, including the 2008/2009 New Zealand Adult Nutrition Survey in which the mean
usual adult daily intake was 108 mg based on 24 h dietary recall data [11]. This is close to the average
dietary intake of 110 mg/day found in the current study. However, measuring vitamin C concentrations
in the body has a number of advantages over dietary intake. It does not rely on participant’s recall of
their diet, and takes in all sources of the vitamin, including supplements, and the potential impact of
vitamin C losses due to food processing and preparation. More particularly, it accounts for confounders
of vitamin C status such as smoking, alcohol consumption, prescription medications and health
conditions which may affect turnover of the vitamin [31]. The CHALICE study is the first representative
study of plasma vitamin C status within the New Zealand population. Only smaller studies in specific,
non-representative groups have measured plasma vitamin C concentrations within the New Zealand
population [32,33].
In our study, we found that 2.4% of 50-year-olds were deficient in vitamin C (i.e., <11 μmol/L),
putting them at higher risk of developing scurvy and other health effects that may be associated with
very low vitamin C status. Men were at greater risk of being deficient than women, and having lower
socio-economic status significantly increased risk. Smoking also increased the risk of deficiency, most
likely due to increased oxidative stress causing faster turnover of the vitamin [31]. In addition, in our
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cohort, smokers had a lower dietary intake of vitamin C. Numerous studies have previously shown
gender, socio-economic status and smoking to be important predictors of vitamin C status [9,33–37].
A recent study suggests the effect of gender on vitamin C status may be due to the differing fat free
mass between men and women, meaning vitamin C is distributed throughout a higher volume in men,
leading to lower vitamin C concentrations in the plasma [36].
Data from large international cohorts show similar levels of vitamin C deficiency and
hypovitaminosis C to the CHALICE cohort [37,38], although the United States and lower
socio-economic groups in the United Kingdom stand out as having higher rates of deficiency [9,34].
In the current study, hypovitaminosis C (i.e., <23 μmol/L) was apparent in 13% of participants, and
this increased to 36% for those in the lowest socio-economic category. Symptoms such as decreased
mood and energy levels may be observed with hypovitaminosis C, and are possibly related to the role
of vitamin C as a cofactor in carnitine and catecholamine neurotransmitter synthesis [3,14]. A high
proportion (63%) of our participants had inadequate plasma vitamin C concentrations (i.e., <50μmol/L).
Indeed, very few of our participants, only 7%, had saturating plasma vitamin C status (i.e., >70 μmol/L),
implying that current Ministry of Health guidelines recommending consumption of at least five servings
of vegetables and fruit per day are ineffective [39]. Since the vitamin C content of fruit and vegetables is
quite variable, we suggest that it is important to highlight the consumption of high vitamin C-content
fruit and/or vegetables to provide plasma saturation in this age group.
High vitamin C concentrations in the blood were associated with significantly lower weight,
waist circumference and BMI, and the effect of plasma vitamin C status was significant enough to
survive the correction for multiple comparisons. The association of low vitamin C with obesity in
this study replicates results in the literature [35,40–44], and it is apparent that individuals with higher
weight require higher intakes of vitamin C to reach adequate vitamin C status [45,46]. We also show
that higher plasma vitamin C status is associated with lower circulating levels of blood triglycerides,
insulin and HbA1c, associations which survive correction for gender, ethnicity and current smoking.
These findings are in agreement with a number of smaller intervention studies that have found inverse
relationships of vitamin C with various markers of metabolic health [47–49], although others have
failed to observe an effect of intervention [50]. Dakhale and coworkers show a small decrease in HbA1c
and fasting blood glucose in individuals with type 2 diabetes after vitamin C supplementation of
1 g/day for 12 weeks [51]. Observational studies also provide evidence that low vitamin C status is
associated with increased risk of metabolic syndrome [52–54].
A role for vitamin C in the prevention or management of diabetes and/or metabolic syndrome
has been suggested [47,51,53,54]. Obesity is a major risk factor for diabetes, and it may be that
vitamin C has a role in moderating the inflammatory effect of adipose tissue. Vitamin C is thought
to have anti-inflammatory activity, decreasing levels of inflammatory markers such as C-reactive
protein and pro-inflammatory cytokines, although the exact mechanism(s) responsible for this are
unknown [55,56]. Disorders of energy balance and metabolism are common worldwide. For example,
in New Zealand, around 241,000 individuals have been diagnosed with diabetes, and significant
numbers have undiagnosed diabetes, or pre-diabetes [57]. Further, among people aged over 15 years,
65% of individuals meet the criteria for overweight and obesity [58]. Diet and lifestyle factors are
associated with these disorders and represent key modifiable determinants. Interestingly, in the
CHALICE cohort there were no consistent significant effects identified between plasma vitamin C
status and blood pressure or cardiovascular disease risk, although higher dietary vitamin C intake was
associated with decreased blood pressure, an effect that has been observed previously [59].
In this study, we also demonstrate lower levels of mild cognitive impairment in those with high
vitamin C status, even after adjustment for gender, ethnicity and smoking. Current smoking was a
good proxy for socio-economic status and educational achievement in the model; thus, the relationship
with vitamin C status survived correction for these important predictors of cognitive impairment.
The odds of mild cognitive impairment were twice as high for those below 23 μmol/L plasma vitamin
C concentration. Vitamin C is present at very high concentrations in the brain [60], and animal
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models have shown that the brain is the last organ to be depleted of the vitamin during prolonged
deficiency [61], suggesting an important requirement for vitamin C in the central nervous system.
A recent animal study has shown that moderate vitamin C deficiency may play a role in accelerating
amyloid plaque accumulation in Alzheimer’s disease, the most common form of dementia [62].
However, epidemiological studies have been inconclusive in regards to whether vitamin C status
may affect cognitive decline [63,64] and Alzheimer’s disease specifically [65,66]. Lu and co-workers
investigated the relationship between dietary nutrients and mild cognitive impairment in 2892 elderly
Chinese participants using the MoCA test, and found that vitamin C intake exhibited a significant
protective effect [64]. Our study has the advantage over many in that plasma vitamin C concentrations
have been measured; we were not reliant on dietary intake, which may be susceptible to problems
with recall ability and the other confounders mentioned above.
In later life, dementia and disorders of cognition are highly prevalent. Even in the CHALICE
sample of 50-year-olds, 15% of the sample scored below the recommended cut point on the MoCA.
There is considerable interest in the effect of diet on maintaining cognitive function and delaying
neuro-degenerative disease in old age. A 2015 study with 37 older healthy adults demonstrated
reduced rates of cognitive decline following consumption of orange juice [67]. This was attributed to
the high flavanone content of the orange juice, since flavonoids have been associated with reduced
rates of cognitive decline [68,69]. However, it is possible that the vitamin C content of the orange
juice may have contributed to the observed effect. In support of this premise, studies have shown
that supplementation of older adults with the antioxidant vitamins C and E was able to preserve
cognitive performance [70–72]. Another study, however, found no impact of antioxidant vitamin
supplementation on cognition, despite improvements in markers of oxidative stress [73], demonstrating
mixed results in the literature. Intervention studies often look for relatively short-term impacts on
cognition instruments in response to different nutrient intakes. In contrast, the CHALICE study
measured the association of plasma vitamin C status and dietary intake, more likely to be markers of
longer-term lifestyle patterns, with a cognitive instrument (MoCA) as an assessment of current mild
cognitive impairment.
There are several limitations to our study, notably the observational design, in which associations
do not imply causation. Many factors impact on the health status of individuals and groups, including
diet, exercise, temperament, behaviors, socio-economic status and genetics. These factors typically
interact and correlate with each other, as they do in the CHALICE cohort, with the result that predictors
of health outcomes are related (e.g., low blood pressure is associated with low BMI). We have addressed
multiple testing issues with the use of corrected p values, and multi-collinearity does not affect
individual models as each model only has one independent predictor, with the dichotomous covariates
having limited capacity to induce collinearity. While we have focused on the associations of vitamin C
with health outcomes, these associations could include the effects of unmeasured nutrients associated
with vitamin C intake. Dietary vitamin C and plasma vitamin C status did not always correlate with
the same health indicators. However, as detailed above, this is likely due to fasting plasma vitamin C
concentration being a more accurate indicator of body status.
5. Conclusions
The CHALICE cohort of 404 individuals aged 50 years had an average vitamin C intake of
~110 mg/day, which should provide adequate plasma concentrations [14]. Despite this, a significant
proportion of the participants had inadequate plasma vitamin C status. This indicates the likely effects
of confounding factors, such as chronic disease, on plasma vitamin C status, and suggests that dietary
interventions targeting increased consumption of fruit and vegetables, and increased vitamin C intake
in particular, are required for this age group. Metabolic health markers were significantly better
in participants with higher plasma vitamin C concentrations, even after correction for confounders.
The association of high vitamin C concentrations with the reduction in risk of impaired cognition is
intriguing and merits further investigation.
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Abstract: Vitamin C (ascorbate) is an essential micronutrient in humans, being required for a number
of important biological functions via acting as an enzymatic cofactor and reducing agent. There is
some evidence to suggest that people with type 2 diabetes mellitus (T2DM) have lower plasma
vitamin C concentrations compared to those with normal glucose tolerance (NGT). The aim of this
study was to investigate plasma vitamin C concentrations across the glycaemic spectrum and to
explore correlations with indices of metabolic health. This is a cross-sectional observational pilot
study in adults across the glycaemic spectrum from NGT to T2DM. Demographic and anthropometric
data along with information on physical activity were collected and participants were asked to
complete a four-day weighed food diary. Venous blood samples were collected and glycaemic indices,
plasma vitamin C concentrations, hormone tests, lipid profiles, and high-sensitivity C-reactive protein
(hs-CRP) were analysed. A total of 89 participants completed the study, including individuals with
NGT (n = 35), prediabetes (n = 25), and T2DM managed by diet alone or on a regimen of Metformin
only (n = 29). Plasma vitamin C concentrations were significantly lower in individuals with T2DM
compared to those with NGT (41.2 μmol/L versus 57.4 μmol/L, p < 0.05) and a higher proportion of
vitamin C deficiency (i.e. <11.0 μmol/L) was observed in both the prediabetes and T2DM groups.
The results showed fasting glucose (p = 0.001), BMI (p = 0.001), smoking history (p = 0.003), and
dietary vitamin C intake (p = 0.032) to be significant independent predictors of plasma vitamin C
concentrations. In conclusion, these results suggest that adults with a history of smoking, prediabetes
or T2DM, and/or obesity, have greater vitamin C requirements. Future research is required to
investigate whether eating more vitamin C rich foods and/or taking vitamin C supplements may
reduce the risk of progression to, and/or complications associated with, T2DM.
Keywords: vitamin C; glycaemic control; metabolic health; prediabetes; type 2 diabetes mellitus
1. Introduction
Type 2 diabetes mellitus (T2DM) is a complex disorder influenced by both genetic and
environmental factors. It is characterized by chronic hyperglycemia, altered insulin secretion, and
insulin resistance [1]. As in many Western countries, T2DM is associated with increased morbidity and
mortality due to microvascular (e.g. retinopathy, nephropathy, and neuropathy) and macrovascular
Nutrients 2017, 9, 997; doi:10.3390/nu9090997 www.mdpi.com/journal/nutrients172
Nutrients 2017, 9, 997
complications (e.g. myocardial infarction, peripheral vascular disease, and stroke) [1]. Diabetes is
one of the largest global health emergencies with 415 million people between the ages of 20 and 70
worldwide estimated as having diabetes in 2015 and the prevalence is increasing [2]. T2DM accounts
for at least 90% of all cases of diabetes [2]. In 2016, approximately 5% of New Zealanders were living
with diabetes compared to an estimated 6.5% of people in the UK [3,4].
Research suggests that chronic low grade inflammation and oxidative stress plays a pivotal
role in the development of insulin resistance and T2DM, as well as the related complications [5].
Vitamin C is an essential micronutrient with potent antioxidant properties [6]. Vitamin C can
protect important biomolecules from oxidation through participating in oxidation-reduction reactions
whereby it is readily oxidized to dehydroascorbic acid, which in turn is rapidly reduced back to
ascorbate [7]. Vitamin C is naturally present in fruit and vegetables, is often added as a preservative
to foods/beverages, and is also used as a dietary supplement [6]. As a result of being water-soluble,
it has a relatively short half-life in the body due to rapid renal clearance and a regular and adequate
intake is required to prevent deficiency.
Previous research suggests that people with T2DM have lower plasma vitamin C concentrations
than those with normal glucose control [8–10]. There are several proposed mechanisms including:
(1) increased ascorbate excretion in those with microalbuminuria, (2) blood glucose may compete with
vitamin C for uptake into cells due to its structural similarity to the oxidised form (dehydroascorbic
acid), and (3) increased oxidative stress may deplete antioxidant stores [8]. Recent research has
indicated that the glucose-dependent inhibition of dehydroascorbic acid uptake into erythrocytes may
contribute to enhanced erythrocyte fragility and could potentially contribute to complications such as
diabetic microvascular angiopathy [11].
As dietary vitamin C contributes to plasma vitamin C concentrations, potential differences in the
intake between those with normal glucose control and T2DM must also be considered. A prospective
study of 48,850 men revealed that while the baseline consumption of fruit and vegetables was similar,
men who developed T2DM increased their consumption of fruit and vegetables by 1.6 serves/week
compared to an increase of 0.7 serves/week in those who remained diabetes free [12]. Therefore, it
seems that people with T2DM are altering their diet in an attempt to manage their blood sugar. Indeed,
clinical advice to those newly-diagnosed with T2DM focuses on improving the diet. However, the
dietary changes appear to be small and, furthermore, those with T2DM appear to have a similar intake
of fruit and vegetables to those without T2DM [12].
The lower plasma vitamin C concentrations reported in people with T2DM has led to a growing
interest in the role that vitamin C may afford against the development of T2DM and associated
complications. A prospective survey of the Dutch and Finnish cohorts within the Seven Countries
Study revealed an inverse association between dietary vitamin C intake and glucose intolerance,
suggesting that antioxidants such as vitamin C may play a protective role against the development
of impaired glucose tolerance and T2DM [13]. Further, the European Prospective Investigation of
Cancer (EPIC)-Norfolk Study of some 21,000 individuals ascertained 735 cases of T2DM after a 12 year
follow-up, and demonstrated a strong inverse association between plasma vitamin C concentration
and T2DM risk [14].
However, studies investigating plasma vitamin C and glycaemic control have often failed to
account for factors such as smoking status and dietary vitamin C intake, which are known to impact
plasma vitamin C concentrations. When dietary intake is taken into account there are conflicting results,
with one study showing a low plasma vitamin C concentration in people with diabetes consuming a
similar amount of dietary vitamin C to those without diabetes [15], compared to another study that
reported no differences in serum vitamin C concentrations in people grouped by T2DM status after
adjustment for dietary vitamin C intake [16]. Therefore, the objective of this study was to determine
the association between plasma vitamin C status and glycaemic control accounting for vitamin C
intake in adults.
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2. Materials and Methods
2.1. Study Participants
This study was approved by the New Zealand Central Health and Disability Ethics Committee
(consent no. 14/CEN/34). Written informed consent was obtained from all participants. Individuals
aged ≥ 18 years meeting the inclusion criteria detailed below were recruited from General
Practice, Prediabetes and Diabetes Services, Retinal Screening Services, Pharmacies, and from local
advertisements. Fasting glucose cut-off values for normal glucose tolerance (NGT), prediabetes, and
T2DM were based on the American Diabetes Association (ADA) criteria [1]. Those taking Metformin
were also included in the T2DM group. A total of 101 individuals underwent a screening questionnaire
to ascertain the eligibility for the study. Ninety participants were enrolled and 89 participants
completed the study. One participant was excluded due to incomplete sample collection.
2.2. Study Design
This was a cross-sectional observational pilot study that was part of a wider study on the gut
microbiota and glycaemic control. At their study appointment, participants completed demographic
and physical activity questionnaires. Anthropometric data were collected including the body mass
index (BMI), waist and hip circumference, and bioelectrical impedance. The completed four-day
weighed food diary was reviewed and additional information was added if necessary. A venous blood
sample was also collected after an overnight fast and the blood pressure was measured.
2.2.1. Inclusion Criteria
Individuals aged ≥18 years with: NGT (fasting glucose ≤5.5 mmol/L) (n = 35),
prediabetes (fasting glucose ≥5.6 mmol/L) (n = 25), T2DM taking no diabetes medication
(fasting glucose ≥7.0 mmol/L) or on a regimen of Metformin only (n = 29).
2.2.2. Exclusion Criteria
Individuals unable to give informed consent, those who had taken antibiotics in the last month,
those with a medical history of significant gastrointestinal disease e.g. inflammatory bowel disease,
those who had undergone a previous bowel resection, and individuals taking diabetes medication
other than Metformin.
2.3. Demographic Information
Participants recorded their date of birth, sex, ethnicity, qualification, and smoking status. They also
recorded information on current medication and supplement use.
2.4. Anthropometric Measures
Weight (kg). Participants were asked to remove their footwear and heavy outer clothing such
as jackets and were weighed to the nearest 0.1 kg on calibrated Tanita scales (Model BWB-800A,
Tanita Corporation, Tokyo, Japan).
Height (m). Measured once to the nearest mm using calibrated height measures.
BMI (kg/m2). Widely accepted as an appropriate population-level indicator of excess body fat [17].
BMI is calculated by weight in kilograms divided by height in metres squared.
Waist circumference and the waist-to-hip ratio are alternative anthropometric measures that also
indicate whether excess body fat is centrally or peripherally located.
Waist circumference (cm). The World Health Organisation (WHO) STEPwise Approach to
Surveillance (STEPS) protocol for measuring the waist circumference was used. The measurement
was made at the approximate midpoint between the lower margin of the last palpable rib and the top
of the iliac crest [18]. The tightness of the tape was controlled by using a Gulick II Measuring tape
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(Model 67020, Country Technology Inc, Gays Mills, Wisconsin, WI, USA). Two to three measures were
recorded and if the difference between the measurements exceeded 1.5 cm, a third measure was taken.
The measures for each participant were averaged.
Hip circumference (cm). Measured to the nearest mm around the widest portion of the buttocks
with the tape parallel to the floor using a Gulick II Measuring tape, as described above.
Waist-to-hip ratio. Calculated by dividing the waist circumference by the hip measurement.
Fat mass (%). Measured using the BIA 450 Bioimpedance Analyser (Biodynamics Corporation,
Seattle, Washington, DC, USA). Patient assessments were conducted using a connection between the
individual’s wrist and ankle and the analyser using standard ECG sensor pad electrodes (CONMED
Corporation, Utica, New York, NY, USA).
Blood Pressure. Measured using an automated blood pressure monitor (Bp TRU, BTM-300,
Omron Healthcare Co., Ltd, Muko, Kyoto, Japan). The measurement was repeated if the results were
outside the normal range. If there was an obvious outlier, this result was removed and the other results
were averaged.
2.5. Blood Parameters
Venous blood samples were collected after a 12–hour fast.
Glycated haemoglobin (HbA1c). Determined in EDTA blood by standard methods (Bio-rad
Variant HPLC, Bio-Rad, Hercules, California, CA, USA) at an International Accreditation New Zealand
(IANZ) laboratory.
Glucose. Fasting glucose was measured in blood collected in fluoride oxalate venoject tubes
by standard methods (Glucose Hexokinase Enzymatic Assay, Abbott c series analyser, Abbott Park,
Illinois, USA) at an IANZ laboratory.
Lipid parameters. Total cholesterol (TC), HDL-cholesterol (HDL), LDL-cholesterol (LDL), and
triglycerides (TG) were determined in lithium heparin blood by standard methods (Abbott c series
analyser, Abbott Park, Illinois, IL, USA) at an IANZ laboratory.
High-sensitivity C-reactive protein (hs-CRP). The inflammatory marker hs-CRP was measured
using end-point nephelometry at an IANZ laboratory.
Plasma vitamin C and hormones. EDTA blood was collected and centrifuged for 15 min at 1500 g
at 4 ◦C. The plasma was stored −80 ◦C prior to analysis.
2.5.1. Plasma Vitamin C
Stored plasma was rapidly thawed, and acidified with perchloric acid and a metal chelator (DTPA)
to precipitate the protein and stabilise the ascorbate [19]. Following centrifugation, the supernatant was
treated with a reducing agent (TCEP) to recover any ascorbate that had become oxidised during the
processing and storage of the samples [20]. The vitamin C concentration of the processed samples was
determined using high performance liquid chromatography (HPLC) with electrochemical detection in
the Department of Pathology, University of Otago Christchurch, as described previously [19].
2.5.2. Plasma Ghrelin, Leptin, and Adiponectin
Plasma hormones were determined by the Christchurch Heart Institute, Department of Medicine,
University of Otago, Christchurch.
Plasma ghrelin was measured by an in-house radioimmunoassay (RIA) following extraction from
plasma using Sep Pak C18 cartridges, as described previously [21]. The assay recognises the total
circulating ghrelin (i.e. both octanoyl and non-octanoyl forms). The cross reactivities of other peptides
in the assay, including vasointestinal peptide, prolactin, galanin, growth hormone releasing hormone,
neuropeptide Y, brain natriuretic peptide, atrial natriuretic peptide, endothelin-1, and angiotensin II
were all less than 0.03%. The RIA had a mean detection limit of 10.8 ± 0.8 pmol/L and mean ED50 of
136.2 ± 10.0 pmol/L over 23 consecutive assays.
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Plasma leptin and adiponectin were measured using commercial enzyme-linked immunosorbent
assays (ELISA) from BioVendor (Brno, Czech Republic), Research and Diagnostic products
(RD191001100 Human Leptin ELISA and RD191023100 Human Adiponectin ELISA) according to the
manufacturer’s instructions.
2.5.3. Plasma Insulin
Plasma insulin was measured using the Roche Cobas e411 method in an IANZ laboratory.
After storage at −80 ◦C, thawed plasma was pre-treated using 25% polyethylene glycol to precipitate
any unwanted antibodies.
2.6. Dietary Intake of Vitamin C, Macronutrients, and Fibre
Participants completed a four day (non-consecutive) weighed food diary (including one weekend
day) prior to their study visit. Participants received training using the Salter digital scales and on how
to record the data, either at home or in the clinic, prior to the diary being completed. Once completed,
the diary was also reviewed at their second study visit to add any missing information if necessary. The
food diaries were entered into the nutrient analysis programme Kai-culator (version 1.08d, Department
of Human Nutrition, University of Otago, Dunedin, New Zealand). Kai-culator uses the 2014 version
of the New Zealand food composition database “NZ FOODfiles”. The methodology for entering the
diaries was developed by a dietitian and data entry was undertaken by an experienced dietitian and
an experienced nutritionist who cross-checked each other’s data and were overseen by an experienced
nutritionist and dietitian. A further 16% of the diaries were checked again for accuracy. The Acceptable
Macronutrient Distribution Ranges (AMDR) are the recommendations for the balance of protein, fat,
and carbohydrate in the diet with respect to the relative contribution to dietary energy [22]. Total daily
vitamin C, energy, and fibre were calculated, along with the percent energy values for fat, carbohydrate,
and protein. Participants were asked to record the name of dietary supplements taken within the last
month, the amount per dose, the frequency, when they started taking the supplement, and when their
last dose was.
2.7. Physical Activity
Participants completed the self-administered short form version of the International Physical
Activity Questionnaire (IPAQ). The questionnaire asks about physical activity over the previous
seven days.
2.8. Statistical Analyses
Standard descriptive statistics including means, standard deviations, frequencies, and percentages
as appropriate were used to summarise the demographic, anthropometric, and laboratory results
across participants grouped by fasting glucose and T2DM treatment. Four of the laboratory measures
(hs-CRP, Ghrelin, Leptin, and Adiponectin) showed a strong positive skew and were therefore
loge transformed prior to analyses. These variables are described using geometric means and 95%
confidence intervals. Associations between the clinical characteristics of the cohorts grouped by fasting
glucose (including those treated with Metformin) were tested using one way analysis of variance
(ANOVA) and chi-squared tests as appropriate. Where significant associations were identified, these
were further explored with pair-wise comparisons amongst the fasting glucose groups. The univariate
associations between plasma vitamin C and demographic, anthropometric, and laboratory measures
were tested using Pearson’s Correlations coefficients and one way ANOVA. Significant predictors
identified from these univariate analyses were then combined in a multiple regression analysis to
identify significant independent associations with plasma vitamin C. The two-tailed p-value < 0.05
was taken to indicate statistical significance. All statistical analyses were undertaken using SPSS
(version 24.0, IBM Corp., Armonk, New York, NY, USA).
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3. Results
3.1. Participant Characteristics
The NGT group was slightly younger than the prediabetes and T2DM groups and there were more
females in the NGT group and less in the T2DM group. The majority of participants were European
and there were a mix of qualifications, as would be expected given the age of the participants (Table 1).
There were no significant differences in physical activity between the study groups although those in
the NGT and prediabetes groups had reported slightly higher levels of activity than those with T2DM.
Table 1. General characteristics of participants classified as having normal glucose tolerance (NGT)
(n = 35), prediabetes (n = 25), and T2DM (n = 29).
Characteristics NGT Prediabetes T2DM Total
Age * (years) 55 ± 13 a 63 ± 9 b 61 ± 11 b 59 ± 11
Sex *
Female % (n) 74 (26) a 52 (13) ab 35 (10) b 55% (49)
Male % (n) 26 (9) 48 (12) 66 (19) 45% (40)
Ethnicity
European % (n) 86 (30) 88 (22) 97 (28) 90% (80)
Maori % (n) 9 (3) 4 (1) 3 (1) 6% (5)
Pacific Island % (n) 0 (0) 4 (1) 0 (0) 1% (1)
Asian % (n) 3 (1) 4 (1) 0 (0) 2% (2)
Other % (n) 3 (1) 0 (0) 0 (0) 1% (1)
Qualification
No Qualification % (n) 96 (3) 20 (5) 25 (7) 17% (15)
Secondary School % (n) 20 (7) 24 (6) 32 (9) 25% (22)
Post-Secondary Certificate, Diploma or Trade Diploma % (n) 43 (15) 20 (5) 25 (7) 31% (27)
University % (n) 27 (10) 36 (9) 18 (5) 27% (24)
Physical Activity (MET min/week) 1723 ± 1687 2496 ± 3671 1320 ± 1490 1772 ± 2327
Anthropometry
Weight * (kg) 76 ± 18 a 89 ± 19 b 96 ± 20 b 86 ± 21
BMI * (kg/m2) 28 ± 6 a 30 ± 7 ab 33 ± 6 b 30 ± 7
Fat Mass (%) 32 ± 8 33 ± 8 35 ± 7 33 ± 8
Waist Circumference * (cm) 89 ± 16 a 99 ± 14 b 110 ± 15 c 99 ± 17
Waist-to-Hip Ratio * 0.9 ± 0.1 a 0.9 ± 0.1 b 1.0 ± 0.1 b 0.9 ± 0.1
Blood Pressure Diastolic (mmHg) 78 ± 9 83 ± 8 79 ± 9 80 ± 9
Blood Pressure Systolic * (mmHg) 125 ± 14 a 132 ± 14 ab 135 ± 15 b 130 ± 15
Smoking Status
Current Smoker % (n) 7 (2) 5 (1) 3 (1) 5% (4)
Ex-smoker % (n) 28 (8) 439 (9) 38 (11) 35% (28)
Non-smoker % (n) 66 (19) 52 (11) 59 (17) 60% (47)
Values represented as mean ± SD unless stated otherwise. *All p values from ANOVA tests. Groups sharing a
common subscript letter denotes the study groups that do not differ significantly from each other at the 0.05 level
based on characteristics from Post Hoc analysis. Note: There was missing data from one participant for qualification
(1 × T2DM), 12 participants for physical activity (7 × NGT and 5 × prediabetes), five participants for waist-to-hip
ratio (2 × NGT and 3 × prediabetes), nine participants for blood pressure measures (4 × NGT and 5 × prediabetes),
and 10 participants did not provide smoking status data (6 × NGT, 4 × prediabetes).
The mean BMI for the NGT and prediabetes groups reflects the international BMI cut-off points
for overweight (25.00–29.99 kg/m2) and the T2DM group were obese (≥30.00 kg/m2). The waist
circumference and waist-to-hip ratio increased across the groups from NGT to T2DM along with fat
mass (%), as would be expected given that obesity is a risk factor for T2DM.
3.2. Metabolic and Inflammatory Plasma Biomarkers
Glycaemic measures (fasting glucose and HbA1c), used as the basis for defining prediabetes and
T2DM, increased from NGT to T2DM as expected and differed significantly between the study groups
(p < 0.05, Table 2). Although fasting glucose was used as the basis for classifying participants in the
analysis, the mean HbA1c of 35 mmol/mol for the NGT group and 40 mmol/mol for the prediabetes
group were consistent with the New Zealand guidelines for the classification of diabetes based on
HbA1c [23]. The mean HbA1c of 47 mmol/mol for the T2DM group is lower than the current threshold
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for the diagnosis of diabetes in New Zealand (50 mmol/mol) using this measure because some of the
individuals in this category were treated with the biguanide oral hypoglycaemic drug, Metformin.
Fasting and postprandial glucose were likely reduced in these treated individuals. The mean HbA1c
for all participants was 41 mmol/mol (Table 2). While hs-CRP was inversely associated with glycaemic
control, this was not significant.
Table 2. Laboratory measures of participants classified as having normal glucose tolerance (NGT)
(n = 35), prediabetes (n = 25), and T2DM (n = 29).
Laboratory Measures NGT Prediabetes T2DM Total
Fasting Glucose * (mmol/L) 5.0 ± 0.4 a 6.2 ± 0.4 b 7.2 ± 1.3 c 6.0 ± 1.2
HbA1c * (mmol/mol) 35 ± 4 a 40 ± 5 b 47 ± 9 c 41 ± 8
hs-CRP (mg/L) Mean (95% CI) 1.2 (0.9–1.6) 1.6 (1.0–2.3) 2.1 (1.4–2.8) 1.6 (1.31.9)
Total Cholesterol * (mmol/L) 5.3 ± 0.9 a 5.9 ± 1.2 a 4.3 ± 1.1 b 5.0 ± 1.1
Cholesterol HDL * (mmol/L) 1.5 ± 0.4 a 1.3 ± 0.3 b 1.1 ± 0.2 b 1.3 ± 0.3
Cholesterol LDL * (Calc) (mmol/L) 3.4 ± 0.8 a 3.3 ± 1.0 a 2.5 ± 1.0 b 3.1 ± 1.0
Triglycerides * (mmol/L) 1.1 ± 0.4 a 1.3 ± 0.7 ab 1.4 ± 0.6 b 1.3 ± 0.6
Cholesterol (total/HDL) (ratio) 3.8 ± 0.8 4.2 ± 0.8 3.9 ± 1.1 4.0 ± 0.9
Fasting Insulin * (pmol/L) 53 ± 37 a 89 ± 53 b 95 ± 48 b 77 ± 49
Ghrelin * (pmol/L) Mean (95% CI) 171 (142–207) a 111 (88–140) b 112 (91–139) b 132 (117–150)
Leptin (ng/mL) Mean (95% CI) 27 (20–38) 33 (20–54) 33 (23–47) 31 (25–38)
Adiponectin * (μg/mL) Mean (95% CI) 11 (9–13) a 9 (7–11) a 7 (6–8) b 9 (8–10)
Plasma vitamin C * (μmol/L) 57 ± 14 a 48 ± 16 b 41 ± 18 b 49 ± 17
Values represented as mean ± SD unless stated otherwise. *All p values from ANOVA tests. Groups sharing a
common subscript letter denotes the study groups that do not differ significantly from each other at the 0.05
level based on characteristics from Post Hoc analysis. Log conversion was carried out for Ghrelin, Leptin,
Adiponectin, and hs-CRP. Note: There was missing data from three participants for plasma vitamin C (2 × NGT
and 1 × prediabetes).
The average fasting insulin concentrations were consistent with the glycaemic measures and
were significantly higher in the T2DM group compared to the NGT group. The increasing BMI
across the groups was associated with the increase in leptin concentrations, and the reduction in
ghrelin concentrations.
Total, HDL, and LDL cholesterol decreased from the NGT to the T2DM group, which may reflect
the use of lipid lowering medications which are routinely used in individuals with T2DM.
There was a slight increase in TG across the groups, with the average for each group remaining
below the recommended cut-off in New Zealand (<1.7 mmol/L). There were no significant differences
in the total cholesterol/HDL ratio between groups, and each group was below the recommended
cut-off in New Zealand of 4.5.
3.3. Dietary Intake of Vitamin C, Macronutrients, and Fibre
There were no significant differences in macronutrient intake and dietary vitamin C intake across
the groups (Table 3). The AMDR range for protein is 15–25% of total energy, total fat 20−35% of total
energy, and carbohydrate 45–65% of total energy [22]. All study groups had slightly higher average
total fat intakes and slightly lower CHO intakes than recommended, but the average protein intake for
all groups fell within the recommended range.
The adequate intake (AI) for dietary fibre in New Zealand and Australia is set at the median for
dietary fibre intake recorded in the 1995 National Nutrition Survey of Australia (ABS 1998) and the
1997 National Nutrition Survey of New Zealand (MOH 1999) [22]. The AI is 25 g for women and 30 g
for men. Although fibre intake is not reported by sex in Table 1, the average daily fibre intake for each
group of 24 g, 25 g, and 27 g for the NGT, prediabetes, and T2DM groups, respectively, was similar
to recommendations.
Six participants reported taking a high dose vitamin C supplement (≥500 mg vitamin C). The
plasma vitamin C concentration of five of these participants ranged from 36–59 μmol/L, which
reflects inadequate to adequate plasma vitamin C concentrations and suggests that they didn’t take
the supplement close to their study appointment. The other participant had a plasma vitamin C
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concentration of 74 μmol/L, which is a saturating concentration, but they also had an average dietary
vitamin C intake of 194 mg/day and so this high plasma concentration could be explained by their
dietary intake as 200 mg/day will saturate plasma [19].
Table 3. Dietary intake of participants classified as having normal glucose tolerance (NGT) (n = 35),
prediabetes (n = 25), and T2DM (n = 29).
Total Daily Dietary intake NGT Prediabetes T2DM Total
Energy (KJ) 8192 ± 2336 8430 ± 2260 8033 ± 2416 8204 ± 2321
Fibre (g) 24 ± 9 25 ± 8 27 ± 9 25 ± 9
Protein (% of Energy) 17 ± 3 18 ± 4 17 ± 3 17 ± 3
Fat (% of Energy) 37 ± 6 39 ± 8 36 ± 7 37 ± 7
Carbohydrate (% of Energy) 44 ± 6 40 ± 8 44 ± 8 43 ± 7
Dietary Vitamin C Intake (mg) 103 ± 76 94 ± 58 101 ± 61 100 ± 66
Values represented as mean ± SD unless stated otherwise. Note: There was missing data from one participant for
dietary information (1 × prediabetes). There were no significant differences between the study groups for any of
the dietary intake measures.
3.4. Plasma Vitamin C Status and Dietary Vitamin C Intakes
A significant decrease in the mean plasma vitamin C concentration was observed between the
NGT (57.4 μmol/L) and the prediabetes group (48.2 μmol/L) (p = 0.035) and the T2DM (41.2 μmol/L)
group (p < 0.001) (Table 2). Furthermore, there was a much higher proportion of individuals with
prediabetes and T2DM with deficient (4% and 3% respectively), marginal (14% in T2DM group), and
inadequate (58% in prediabetes and 52% in T2DM group) plasma vitamin C concentrations, compared


























Figure 1. Plasma vitamin C status of individuals within study groups. Percentage of individuals from
each study group [normal glucose tolerance (NGT), prediabetes, and type 2 diabetes mellitus (T2DM),
including those taking no diabetes medication (fasting glucose ≥ 7.0 mmol/L or on a regimen of
Metformin only (T2DM)], classified as having saturating (>70 μmol/L), adequate (51.0–69.9 μmol/L),
inadequate (24.0–50.9 μmol/L), marginal (11.0–23.9 μmol/L), and deficient (<11.0 μmol/L) plasma
vitamin C concentrations [24].
Although plasma vitamin C decreased from NGT to T2DM, there were no significant differences
in dietary vitamin C concentrations between study groups determined from the four day weighed
food diaries (Table 3). The majority of participants met the New Zealand recommended dietary intake
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(RDI) of 45 mg/day (Figure 2). Furthermore, there were no participants in the T2DM group that had
intakes below the New Zealand estimated average requirement (EAR) (30 mg/day). At the group level,
it appears that most participants had an adequate fruit and vegetable intake to meet the recommended
vitamin C intakes. However, few participants were reaching the New Zealand Ministry of Health’s
suggested dietary targets (SDT) to reduce chronic disease risk, i.e. 220 mg/day for men and 190 mg/d


























Figure 2. Individuals meeting New Zealand dietary intake recommendations for vitamin C. Percentage
of individuals from each study group [normal glucose tolerance (NGT), prediabetes, and type 2 diabetes
mellitus (T2DM), including those taking no diabetes medication (fasting glucose ≥7.0 mmol/L or on a
regimen of Metformin only (T2DM)], meeting the estimated average requirement (EAR) (30 mg/day),
recommended dietary intake (RDI) (45 mg/day), and suggested dietary target (SDT) to reduce chronic
disease risk (220 mg/day for men and 190 mg/day for women) for dietary vitamin C intake using the
nutrient reference values for Australia and New Zealand [22].
3.5. Plasma Vitamin C Correlations
There were no significant associations between age, gender, ethnicity, education level, and
plasma vitamin C concentrations. There was a significant association between smoking history
and plasma vitamin C concentration (p = 0.035), with current (mean 30.9 μmol/L) and ex-smokers
(mean 47.3 μmol/L) having lower concentrations than non-smokers (mean 52.6 μmol/L). There was a
significant linear association between vitamin C intake and plasma vitamin C concentration (r = 0.353,
p = 0.001).
The three anthropometric measures (BMI, fat mass, and waist-to-hip ratio) were all significantly
negatively associated with plasma vitamin C (p < 0.05) when conducting univariate analyses. When
these three variables were included in a multiple regression, only BMI was independently negatively
associated with plasma vitamin C (p < 0.001). Laboratory measurements (HbA1c, fasting glucose, TG,
total chol/HDL chol, insulin, and hs-CRP) were negatively associated with plasma vitamin C (p < 0.05)
and HDL chol and ghrelin were positively associated with plasma vitamin C (p < 0.05) in the univariate
anlaysis (Table 4). When these variables were included in a multiple regression, only hs-CRP and
fasting glucose were independently negatively associated with plasma vitamin C (p < 0.05).
A final multiple regression showed fasting glucose (p = 0.001), BMI (p = 0.001) and smoking
history (p = 0.003) to be significant independent predictors of plasma vitamin C. Fasting glucose and
BMI were negatively associated with plasma vitamin C, and current and ex-smokers had reduced
plasma vitamin C concentrations compared to non-smokers. There was a strong positive association
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between hs-CRP concentrations and BMI (r = 0.618, p < 0.001). Accordingly, hs-CRP does not feature
as an independent predictor of plasma vitamin C. Including dietary vitamin C intake in the above
model (Table 5) showed that this was a significant independent predictor (p = 0.032) of plasma vitamin
C concentrations, and BMI, fasting glucose, and smoking history remained as significant independent
predictors (R2 = 0.43).
Table 4. Pearson correlations of plasma vitamin C, glycaemic indices, hormones, lipids, high sensitivity
C-reactive protein, and anthropometric measures.
Measure Pearson Correlation
Fasting Glucose (mmol/L) −0.411 ***
HbA1c (mmol/mol) −0.334 ***
Total Cholesterol (mmol/L) 0.093
Triglycerides (mmol/L) −0.322 **
Cholesterol (HDL) 0.295 **
Cholesterol (total/HDL) −0.214 *
Cholesterol (LDL) calculated 0.086
Insulin (pmol/L) −0.353 **
hs-CRP (mg/L) −0.333 **
Ghrelin (pmol/L) 0.295 **
Leptin (ng/mL) −0.183
Adiponectin (ng/mL) 0.202
BMI (kg/m2) −0.446 ***
Waist-to-Hip Ratio −0.274 *
Fat Mass (%) −0.295 **
*** correlations significant at 0.001 level (2-tailed); ** correlations significant at the 0.01 level (2-tailed); * correlations
significant at the 0.05 level (2-tailed).
Table 5. Multiple regression analysis showing significant associations with plasma vitamin
C concentrations.
Measure B Lower 95% CI Upper 95% CI p Value
BMI −0.9 −1.4 −0.4 0.001
Current Smoker −21.9 −35.8 −7.9 0.003
Ex-Smoker −4.9 −11.2 1.5 0.128
Fasting Glucose −4.4 −7.1 −1.8 0.001
Dietary vitamin C 0.05 0.01 0.10 0.032
B: coefficient from the multiple linear regression model.
4. Discussion
4.1. Predictors of Plasma Vitamin C
This study showed fasting glucose, BMI, smoking history, and dietary vitamin C intake to be
significant independent predictors of plasma vitamin C concentrations. The inverse association
between fasting glucose and plasma vitamin C concentration shown in this study is in agreement
with earlier studies [8–10]. In addition, the mean plasma vitamin C concentration was significantly
lower in the prediabetes group (compared to the NGT group, suggesting that a reduction in plasma
vitamin C concentration occurs in parallel with the decline in glucose tolerance during the progression
to T2DM. It has been proposed that the uptake of dehydroascorbic acid, the oxidized form of vitamin
C, by the glucose transporters (GLUTs), could be competitively inhibited by elevated blood glucose
levels [25]. This could contribute to complications such as diabetic microvascular angiopathy due to
erythrocyte fragility, as erythrocytes lack the sodium-dependent vitamin C transporters (SVCTs) and
are dependent on the GLUTs for the uptake of vitamin C [11]. Our study also found plasma vitamin C
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concentration to be inversely related to BMI, which concurs with previous research [26]. Individuals
with a higher weight are prone to vitamin C inadequacy and are known to require higher intakes of
vitamin C in order to reach adequate plasma concentrations [27,28].
Oxidative stress is defined as a significant imbalance between the production of reactive oxygen
species (ROS) and antioxidant defenses, and leads to alterations in signalling pathways and to potential
tissue damage [29]. ROS activate nuclear factor κB (NFκB), a pro-inflammatory transcription factor,
triggering a signalling cascade that leads to the continued synthesis of oxidative species and low-grade
chronic inflammation [29]. High-sensitivity CRP, produced by the liver, reflects the presence of
inflammation in the body. The concentration of hs-CRP increased with the deterioration of glycaemic
control and increase in BMI. This result is consistent with the evidence suggesting that obesity can lead
to chronic activation of the innate immune system and low-grade systemic inflammation and oxidative
stress, which have been implicated in the development of insulin resistance and T2DM [5,30,31].
Hyperglycaemia, increased plasma concentrations of free fatty acids (FFAs), and hyperinsulinaemia
have all been linked to an increased production of ROS [29,31]. Our data showed an inverse relationship
between hs-CRP and plasma vitamin C. It is therefore hypothesized that lower plasma vitamin C
in those with higher BMI, prediabetes, and T2DM reflects the depletion of the vitamin due to its
antioxidant and anti-inflammatory activities.
Consistent with the role of vitamin C as an antioxidant, our data showed a significant
inverse relationship between plasma vitamin C concentration and smoking status, with ex- and
current-smokers having lower plasma vitamin C concentrations than non-smokers, which is consistent
with previous research [32,33]. It has long been recognised that smokers and passive smokers have
a lower vitamin C status than non-smokers partly due to poor dietary habits, but also due to the
oxidizing properties of tobacco smoke, resulting in an increased turnover of vitamin C [34].
As expected, dietary vitamin C was found to be a predictor for plasma vitamin C concentration.
However, when the dietary intake of the vitamin was corrected for by covariate analysis fasting
glucose, BMI and smoking status remained as significant independent predictors of plasma vitamin
C concentration. That is, the associations observed were not solely explained by differences in
dietary intake. This result is at odds with one study that reported no differences in serum vitamin C
concentrations in people grouped by diabetes status after adjustment for dietary vitamin C intake [16].
4.2. Metabolic Hormones
The average fasting insulin concentrations were consistent with the glycaemic measures and
were significantly higher in the T2DM group compared to the NGT group. A higher fasting insulin
concentration indicates insulin resistance, a well-known contributor to impaired glucose tolerance
and T2DM. Leptin and ghrelin are two hormones that have a major influence on energy balance [35].
Leptin is a mediator of long-term regulation of energy balance, suppressing food intake and thereby
inducing weight loss. Ghrelin, on the other hand, is a fast-acting hormone, seemingly playing a role
in meal initiation. In obese patients, the circulating concentration of leptin is increased, whereas
surprisingly, ghrelin is decreased [35]. It is now established that obese patients are leptin-resistant [35].
Indeed, in this study, the increasing BMI across the groups was associated with an increase in leptin
concentrations and a reduction in ghrelin concentrations. There was an inverse relationship between
insulin and leptin and plasma vitamin C, and a positive relationship between ghrelin and plasma
vitamin C; however, these hormones were also associated with fasting glucose and were thus not
included as independent predictors of plasma vitamin C.
4.3. Clinical Significance
As hyperglycemia is associated with increased oxidative stress, a role for antioxidants such
as vitamin C in the prevention of T2DM and/or the reduction of complications is a reasonable
proposition. Indeed, a recent meta-analysis of 15 randomized control trials (RCTs) investigating vitamin
C supplementation and insulin resistance and biomarkers of glycaemic control (fasting glucose, HbA1c)
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found that doses of ≥200 mg/day vitamin C significantly reduced glucose concentrations in patients
with T2DM, particularly if the intervention was for more than 30 days and in older individuals [36].
Furthermore, a recent 12 month RCT found that treating those with T2DM with both Metformin
and vitamin C was more effective at reducing HbA1c and risk factors for diabetes-related long-term
complications than treating with Metformin alone [37].
Although T2DM is not traditionally considered a risk factor for vitamin C deficiency, our research
indicates that those with prediabetes or T2DM are more likely to have inadequate or deficient plasma
vitamin C concentrations. This did not appear to be due to a lower dietary vitamin C intake, so dietary
advice needs to emphasise the importance of consuming high vitamin C foods, aiming for an intake
of at least 200 mg/day [22]. This is particularly relevant in light of the associated T2DM risk factors
of higher BMI and smoking status, both of which impact vitamin C status. Further research into the
possibility of a higher RDI for vitamin C for those with prediabetes and T2DM is warranted, in line
with what has been recommended in some countries for smokers [38].
4.4. Study Strengths and Limitations
Our study used robust methodology for dietary intake, plasma vitamin C, and statistical analysis,
and accounted for other factors that are known to impact plasma vitamin C concentration such as
smoking status, dietary vitamin C intake, and supplement use. The participants with T2DM were
clinically well defined and were either not treated with diabetes medication or treated with a single oral
hypoglycaemic agent only (Metformin). Those taking Metformin were included in the overall analysis.
When the Metformin treated cases were excluded, the correlation between fasting glucose and plasma
vitamin C concentrations was similar in direction and magnitude (n = 64, r = −0.477, p < 0.001) to the
entire cohort (n = 86, r = −0.411, p = 0.001). Further, the current norm is for Metformin treatment to
be initiated at diagnosis, rather than after the failure of diet and lifestyle changes to optimize glucose
control. As such, it will become increasingly difficult to recruit treatment-naïve individuals with T2DM
to studies.
T2DM has been shown to increase the urinary excretion of vitamin C, leading to reduced plasma
vitamin C concentrations in a rodent model [39]. Whether this also occurs in humans is unknown. In
addition, the duration of T2DM was not reported. Indeed, many individuals have undiagnosed T2DM
for a significant period of time prior to formal diagnosis, making it very difficult to interpret data on
the duration of the disease. There are always limitations around the self-reporting of dietary data and
supplement use, and the study cohort was relatively small with 89 participants. Our study had only
one measure of plasma vitamin C per participant and so future research should ideally incorporate
repeated samples to account for any temporal fluctuations. There was a limitation around the lack of
detail with regards to vitamin C supplement use; however, only six participants reported taking high
dose vitamin C supplements and the use was sporadic.
5. Conclusions
Our cross-sectional observational study has identified a moderate inverse relationship between
plasma vitamin C and both fasting glucose and BMI in adult subjects across the glycaemic spectrum.
The relationship can be explained by the depletion of vitamin C due to oxidative stress and
inflammation resulting from dysglycaemia, overweight/obesity, and smoking, rather than lower
dietary intakes. Further research is required to determine whether those with an increased dietary
intake through fruit and vegetables and/or vitamin C supplementation have a decreased risk of
progression to T2DM and/or complications associated with the metabolic syndrome and T2DM.
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Abstract: Vitamin C (vitC) is essential for normal pregnancy and fetal development and poor vitC
status has been related to complications of pregnancy. We have previously shown lower vitC status
in diabetic women throughout pregnancy compared to that of non-diabetic controls. Here, we
evaluate the relationship between vitC status late in diabetic pregnancy in relation to fetal outcome,
complications of pregnancy, diabetic characteristics, and glycemic control based on data of 47 women
from the same cohort. We found a significant relationship between the maternal vitC level > or ≤ the
50% percentile of 26.6 μmol/L, respectively, and the umbilical cord blood vitC level (mean (SD)):
101.0 μmol/L (16.6) versus 78.5 μmol/L (27.8), p = 0.02; n = 12/16), while no relation to birth weight
or Apgar score was observed. Diabetic women with complications of pregnancy had significantly
lower vitC levels compared to the women without complications (mean (SD): 24.2 μmol/L (10.6) vs.
34.6 μmol/L (14.4), p = 0.01; n = 19 and 28, respectively) and the subgroup of women (about 28%)
characterized by hypovitaminosis C (<23 μmol/L) had an increased relative risk of complications of
pregnancy that was 2.4 fold higher than the one found in the group of women with a vitC status above
this level (p = 0.02, 95% confidence interval 1.2–4.4). No correlation between diabetic characteristics
of the pregnant women and vitC status was observed, while a negative association of maternal vitC
with HbA1c at delivery was found at regression analysis (r = −0.39, p < 0.01, n = 46). In conclusion,
our results may suggest that hypovitaminosis C in diabetic women is associated with increased risk
of complications of pregnancy.
Keywords: type 1 diabetes; pregnancy; vitamin C; pregnancy outcome; pregnancy complications;
cross-sectional study
1. Introduction
The importance of an adequate supply of micronutrients for normal pregnancy and fetal
development is well established, particularly in the last trimester due to the increasing needs during
the growth spurt of the fetus [1,2]. As early as 1938, Teel and co-workers described the fetus as acting
as a parasite on the mother’s vitamin C pool based on the observed gradient between maternal plasma
and umbilical cord vitamin C (vitC) concentration at term, and the fact that the fetus apparently was
preferentially supplied with vitC at the expense of the mother [3–5]. Subsequently, several studies
have reported that pregnancy in healthy women is associated with a significant decrease in maternal
vitC status during pregnancy [4,6–8], perhaps partly due to increased blood volume in pregnancy.
Nutrients 2017, 9, 186; doi:10.3390/nu9030186 www.mdpi.com/journal/nutrients187
Nutrients 2017, 9, 186
In experimental studies in guinea pigs, which like humans depend on an adequate supply of
vitC through their diet, the offspring of vitC deficient guinea pigs have shown abnormalities of fetal
bone development, with atrophy of the osteoblasts and retarded osteoid formation [9]. Macroscopic
fetal, uterine, and placental hemorrhages as well as poor attachment of the placenta to the uterus
were also evident in vitC deficient animals [9]. Other experimental studies have shown an association
of infertility, increased incidence of premature- and stillbirths, and increased frequency of abortion
with vitC deficiency [10,11]. Intrauterine growth retardation was related to insufficient vitC status in
guinea pigs [10]. More recently, experimental reports from animal studies demonstrated that CNS
development in particular requires high amounts of vitC and may be impaired by an inadequate
maternal supply [12–15].
In humans, abortion and premature rupture of the fetal membrane are related to low levels of
vitC in plasma, leucocytes, and amniotic fluid [16–24]. Abnormalities of cardiotocography (CTG) and
discolored/green amniotic fluid was also associated with low vitC status at the time of delivery [25].
Furthermore, vitC deficiency may play a leading role in placental abruption [26]. Human studies
suggest that poor vitC status leads to fetal oxidative stress and impaired placental implantation due
to oxidative stress is thought to increase risk of preeclampsia and miscarriages [27]. Epidemiological
studies have also supported an association between vitC deficiency and preeclampsia [28,29]. However
recently, human intervention studies using vitC in the prevention of preeclampsia have produced
conflicting results [30–32]. Another study found no effect of vitamin C on prevention of spontaneous
preterm birth [33]. A recent review concluded that a general recommendation of vitC supplementation
to pregnant women was not warranted, but subpopulations such as women with vitC deficiency,
smokers or diabetics were not discussed [34].
Thus in diabetic animals, experimental data support the amelioration of these risks by vitC
supplementation [35–38]. In one human study, borderline gestational diabetes mellitus had an
increased risk of adverse health outcomes compared with women no diabetes [39]. Another human
controlled intervention study in type 1 diabetes mellitus (T1DM) pregnancy found a lower risk
of premature birth in women receiving vitC and E supplementation and suggested regarding
preeclampsia that vitC supplementation may be beneficial in women with a low antioxidant status at
baseline; no effect on preeclampsia was observed in the T1DM cohort as a whole [40]. Another study
also failed to prevent preeclampsia with vitC and E supplementation in women with T1DM and even
a high risk pro-angiogenic haptoglobin genotype [41].
In T1DM, vitC levels are significantly lower than in non-diabetic subjects [42,43]. This seems to be
the case in the diabetic pregnancy, too, as we recently reported in a prospective study [8]. We found that
the level of vitC was lower throughout pregnancy compared to the control group, and hypovitaminosis
C (vitC < 23 μmol/L [44]) was found in 51% of the diabetic women at some stage during pregnancy.
Here, we report our evaluation of vitC status in the same cohort of pregnant T1DM women with regard
to labor data and the outcome of pregnancies.
2. Materials and Methods
All T1DM women from June 1992 to August 1994 attending the Department of Obstetrics, Aarhus
University Hospital (Aarhus, Denmark), were screened for participation in the prospective study on
vitC during pregnancy and compared to controls as described previously [8]. The inclusion criteria
were pregestational T1DM, age >18 years, no other systemic disease than diabetes, and singleton
pregnancy. Blood samples for vitC were taken when the diabetic women attended the maternity ward
and were taken in a non-fasting state to avoid hypoglycemic episodes. At delivery, an umbilical blood
sample for vitC was taken from the newborn. In total, 76 women with T1DM consented to participate
in the prospective study [8]. Of these, 47 women had vitC measurements taken in late pregnancy
within four weeks of delivery and were included in the present cross-sectional evaluation of vitC status
in relation to labor data and outcome of pregnancy. If more than one sample in the 4-week interval
before labor were obtained, the mean concentration of the samples was used in the analysis.
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Blood samples for plasma vitC measurements were stabilized in sodium EDTA-anticoagulated
vacutainer tubes containing dithiothreitol. Tubes were centrifuged and plasma was removed and
deproteinized by the addition of 6% perchloric acid. The samples were kept at minus 80 degrees
Celsius until analysis and assayed by HPLC using 3,4-dihydroxybenzylamine hydrobromide as internal
standard [45]. A plot of the ratio of vitC to internal standard versus the concentration of 6 aqueous
standards resulted in a linear curve to at least 86 μmol/L (y = 0.16x − 0.028, R2 = 0.99). The within-day
and between-day coefficient of variation was 2.6% and 3.9%, respectively, of a mean concentration
of 19 μmol/L. Limit of detection and limit of quantification were 0.525 μmol/L and 1.75 μmol/L,
respectively. The analytical recoveries were 111%, 104%, 102%, and 101% at vitC concentrations of 5.75,
28.75, 43.125, and 57.5 μmol/L, respectively.
We carried out predefined plasma vitC subgroup analyses according to the 50% percentile of
maternal vitC level and these subgroups were used for evaluating other quantitative and qualitative
data on pregnancy, labor, and neonates. This 50% percentile was chosen as we a priori had calculated,
that we thereby had sufficient data to minimize a type2 error (power > 80%) on expected SDs in relation
to third trimester measurements of pregnancy and in relation to labor and fetus related features as we
earlier have reported in T1DM pregnancy [8].
Twenty-eight blood samples from the umbilical cords were also obtained as a surrogate measure
of the level of vitC of the fetus. However umbilical cord blood was in the same level as found in the
heel blood of 200 newborns [25].
The following data were recorded: Age, duration of diabetes, presence of diabetic
microangiopathy, glycemic control, diurnal blood pressure, albumin excretion rate, creatinine,
creatinine clearance, pregnancy and labor data, and the neonate’s Apgar score at one minute, birth
weight, and presence of malformations. The study was part of an evaluation of morbidity in diabetic
pregnancy with respect to nephropathy and retinopathy approved by the local Ethics Committee
(jr.nr.1992/2523, 1998/4147, and 2026-99). It was performed in concordance with the Helsinki II
declaration and all women had given their informed consent. The collection of samples for vitC was
approved by the local Ethics Committee (jr.nr. 1992/2328). Hypovitaminosis C was defined as a
plasma vitC <23 μmol/L [44].
Preeclampsia was defined as systolic/diastolic blood pressure >140/90 mmHg when
normo-hypertensive before week 20 and, simultaneously, albuminuria >300 mg in previously
normo-albuminuric women. Pregnancy-induced hypertension was defined as hypertension without
signs of preeclampsia. Preterm delivery was defined as delivery following <37 weeks of gestation.
Statistics was performed with IBM SPSS Statistics 20. Difference between two means was tested
with Student’s t-test if data followed Gaussian distribution; otherwise, Mann-Whitney’s test was used.
Proportional data were analyzed by χ2 test or Fisher’s Exact test. Values are given as mean ± SD
if not otherwise stated. Median (25%–75% interval) indicates variable of non-Gaussian distribution
and values were subjected to non-parametric testing. A two-sided p < 0.05 was chosen as level
of significance.
3. Results
Clinical data from the pregnant diabetic women are shown in Table 1 and are also presented
in subgroups according to the median value (25%–75%) of maternal plasma vitC taken within four
weeks of delivery. All comparisons of baseline data and diabetic characteristics in relation to the
50% percentile of vitC (26.6 (22.0–37.2) μmol/L) were non-significant (Table 1). The range (0%–100%)
of plasma vitC in the cohort was 3.1–61.0 μmol/L.
Results regarding pregnancy and fetal related features are presented in Table 2. No relationship
between maternal vitC level and birth weight or Apgar score was observed. Nor was the way of
delivery (acute cesarean section, elective cesarean and induced delivery; 7/19/21) associated with vitC
status. Moreover, no difference was observed in the level of HbA1c in relation of the median maternal
vitC of 26.6 μmol/L, but a negative association of maternal vitC with HbA1c at delivery was found at
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regression analysis (r = −0.39, p = 0.006, n = 46). The vitC levels of the umbilical cord blood correlated
positively with the obtained Apgar score of the newborn (r = 0.45, p = 0.011), also when corrected for
maternal vitC, HbA1c and diabetes duration (r = 0.52, p = 0.025).
Table 1. Clinical data and characteristics of the diabetic status by maternal vitamin C (vitC) within the




≤26.6 μmol/L p Value
Characteristics of
the Whole Cohort
Vit C (μmol/L), n = 23/24/47 37.1 (28.2–61.0) 1 22.1 (3.1–28.2) 30.1 (13.6)
Age (yr), n = 23/24/47 28.8 (3.7) 2 27.7 (3.5) 0.314 27 (26–31)
Maternal weight at delivery (kg) n = 12/11/23 78.5 (72.3–87.5) 74.0 (68.0–86.0) 0.32 78 (70–86)
Maternal height (cm), n = 11/11/22 166.2 (6.2) 164.4 (8.3) 0.569 165.3 (7.2)
Diabetes duration (year), n = 23/24/47 15.0 (8.9) 13.2 (9.0) 0.486 14.1 (8.9)
Parity, n = 23/24/47 1.8 (0.8) 1.8 (0.7) 0.876 2 (1.2)
Systolic blood pressure at entry (mmHg), n = 15/14/29 120.1 (10.3) 120.5 (9.9) 0.641 120.0 (9.9)
Diastolic blood pressure at entry (mmHg) n = 15/14/29 72.1 (6.6) 70.9 (6.7) 0.673 71.2 (6.9)
Retinopathy Non/Simplex/Proliferative, n = N/S/P 12/8/3 12/9/3 0.881 24/17/6
BMI (kg/m2) at delivery, n = 11/10/21 29.2 (3.8) 27.6 (4.4) 0.607 28.6 (4.3)
Normo-/Micro-/Macro-albuminuria n = N/Mi/Ma 18/4/1 20/4/0 0.581 38/8/1
HbA1c (%) at entry, n = 22/23/45 7.7 (1.6) 7.9 (1.2) 0.0697 7.7 (1.4)
Creatinine clearance at entry (ml/min) n = 15/15/30 123.3 (22.1) 116.2 (32.3) 0.869 122.1 (27.1)
Smoking, n = Yes/no/unknown 6/16/1 10/14/0 0.538 16/30/1
1 VitC levels in each subgroup is reported given as median (range); 2 Other data are listed as mean (SD), median
(25%–75%) or n-values.
Table 2. Labor and fetus related features in relation to above or below the median level of maternal




≤26.6 μmol/L p Value
VitC in umbilical cord (μmol/L), n = 12/16 101.0 (16.6) 1 78.5 (27.8) 0.02
Umbilical cord/maternal vitC ratio, n = 12/16 2.6 (2.1–2.9) 4.1 (2.8–5.1) 0.007
Apgar score at one minute, n = 19/23 10 (9–10) 9 (9–10) 0.56
Birth weight (g), n = 23/24 3867 (649) 3533 (771) 0.12
Gestations age at labor (weeks), n = 23/24 37.4 (1.1) 37.2 (1.5) 0.64
Normal delivery (n) 0 0
Induced delivery and elective section/acute
section, (n/n) 20/3 20/4 1.0
HbA1c at delivery (%), n = 23/23 6.7 (1.1) 7.2 (1.0) 0.14
1 Data are listed as mean (SD), median (25%–75%) or n-values.
Hypovitaminosis C was found in 13 out of 47 diabetic women (28%) and was associated with a
risk of complications of 69%, while the risk of complications was 29% in case of higher levels of vitC
(Table 3). The relative risk of having complications of pregnancy was 2.4 times in case of maternal
hypovitaminosis C compared to higher levels of maternal vitC (p = 0.02). In accordance, the diabetic
women with complications of pregnancy had a significantly lower vitC status in late pregnancy
compared to those without complications (mean (SD) 24.2 μmol/L (95% CI: 19.4–30) vs. 34.6 μmol/L
(95% CI: 29.6–40); p = 0.011, n = 19 and 28, respectively). The type and distribution of complications
are given in Table 4.






All Women Fisher‘s Exact Test
Yes (n) 9 10 19
No (n) 4 24 28
Total (n) 13 34 47 p = 0.02
1 Plasma concentration <23 μmol/L.
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Table 4. The type and distribution of complications in T1DM women (n = 47). Recorded complications were
prematurity, gestational hypertension, asphyxia, malformation, still birth, placental abruption, preeclampsia.
Complication Frequency VitC μmol/L Mean (SD)
Women with/without complications 19/47 vs. 28/47 24.2 (10.6)/34.6 (14.4)
Fetal malformation 4/47 1 18.1 (9.0)
Asphyxia/abnormal CTG 2 9/47 22.9 (12.8)
Preeclampsia 5/47 25.0 (10.6)
Prematurity 5/47 20.9 (6.0)
Placental abruption 2/47 18.6 (0.9)
Still birth 2/47 30.9 (0.4)
Pregnancy-induced hypertension 2/47 30.0 (7.1)
1 The fetal malformations consisted of two neonates with cardiac malformations with transposition and atrium
septum defect and two others were related to skeletal abnormalities; 2 CTG: Cardiotocography. Abnormal CTG
was diagnosed in nine women at delivery and of these, seven ended in acute cesarean section and two in induced
delivery. Women may have more than one complication.
4. Discussion
The present cross-sectional study of T1DM pregnancy found an inverse relationship between vitC
status and risks of complications in pregnancy. Thus, poor vitC status within four weeks of delivery
was a positive predictor (69%) for complications of pregnancy, while a maternal vitC >23 μmol/L was
a negative predictor (71%) for complications of pregnancy, respectively. In support of the observed
relationship between maternal vitC status in late pregnancy and complications, we found a low
maternal plasma vitC in case of complications of pregnancy (power of test > 80%).
The mean level of vitC was 24.2 μmol/L in the group with complications in pregnancy, thus in
this normally distributed group nearly the half of the women had a level of vitC characterized as
hypovitaminosis C. Much of the literature showing associations between vitC status and complications
in pregnancy was conducted in pregnant experimental animals with or without induced diabetes and
related to severe vitC deficiency (<11 μmol/L). This level increases the risk of developing outright
scurvy, the ultimately mortal manifestation of prolonged severe vitC deficiency. However, only about
4% of the present cohort (2 patients out of 47) had severe vitC deficiency within four weeks of delivery
and no clinical symptoms of scurvy were recorded in the case records of the pregnant women in
this study. Therefore, it appears that the complications in diabetic pregnancy are already present at
suboptimal vitC levels. In agreement, previous human studies identified a range of complications
of pregnancy in non-diabetic women, the risks of which were inversely correlated with plasma vitC;
this was, indeed, found over a wide concentration range above the level critical for development of
scorbutic manifestations [16–27]. Thus, although higher levels of vitC are not associated with scurvy,
lack of scurvy does not preclude the presence of several other negative health effects of a suboptimal
vitC status, and the optimal vitC intake in humans is still a matter of considerable debate [46].
In humans, a randomized placebo-controlled intervention study with vitamin C and E in T1DM
pregnancies showed no overall effect of supplementation (1000 mg vitamin C and 400 IU vitamin E
(α-tocopherol) daily until delivery) on the incidence of preeclampsia [40]. However, subgroup analysis
did reveal a significant positive effect of supplementation vs placebo on preeclampsia among patients
who were vitC deficient at baseline (<10 μmol/L). Thus, the authors suggested that the significant
benefit of supplementation on preeclampsia may be limited to women with severe vitC deficiency [40].
VitC and E supplementation also resulted in fewer preterm deliveries compared to placebo in the cohort
as a whole, but the potential correlation to vitC status at entry was not explored [40]. Another study has
also reported lack of effects of supplementation with vitC on the incidence of preeclampsia in high-risk
T1DM women [41]. The absence of effect of vitC supplementation on preeclampsia in humans with
or without diabetes may arise from the variation in the degree of plasma saturation and subsequent
differential outcomes of supplementation as discussed elsewhere [47].
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Another interesting result of the present study is the difference in vitC level in umbilical cord
blood of newborns reflects some of the difference in the mothers’ vitC level. Combined with the
observation that the ratio of umbilical cord/maternal vitC favors babies born by mothers with vitC
level below the median, our data collectively support the notion that the fetus is preferentially supplied
with vitC at the expense of the mother [5,48]. However, as the vitC level in these babies is significantly
lower than that of those born by mothers with vitC level above the median, it also suggests that such
a preferential supply cannot fully compensate for poor maternal vitC status. The maternal as well
the umbilical vitC measurements were conducted with sufficient data to minimize a type 2 error on
conclusions (power of t test > 80%). Thus in this study—in spite of the fetus acting as a “parasite” as
described by Teel et al. [3]—the newborns of mothers with low maternal vitC seem not to be able to
obtain the same level of vitC in the umbilical cord as newborns of mothers with a higher vitC level,
although their ratio is larger. This is in line with experimental data from guinea pigs showing that the
preferential fetal transport may be overridden by increased needs of the mother during situations of
deficiency, thereby potentially influencing the health of the offspring [13,49]. In accordance, the vitC
levels of the umbilical cord blood correlated positively with the obtained Apgar score of the newborn.
Finally, no correlation between diabetic characteristics of the pregnant women and vitC status was
observed, although glycemic control measured as HbA1c showed an inverse correlation with maternal
vitC level. VitC is thought to be actively transported by SVCT transporters in the placenta [50]; however,
it also shares the same transporters as glucose via the GLUT-mediated transport of dehydroascorbic
acid (DHA; the oxidized form of vitC) [51]. Thus, it may be speculated that the degree of glycemic
control and, consequently, the level of oxidative stress and ascorbate oxidation rate may affect the
bioavailability of vitC in T1DM pregnant women through competitive inhibition of DHA transport as
proposed by Mann and Newton already in 1975 [52] and supported by the NHANES study 2003–2006
data [53]; here an inverse relationship between vitC and HbA1c was reported in 7697 non-diabetic
participants. Moreover, Tu et al. have recently proposed that impaired red cell recycling of DHA may
be a key link in diabetes [54].
Limitations of the present study include the small number of participants and that the registration
of complications of pregnancy was done retrospectively on the case report forms, which in some
cases may be imprecise. The included T1DM patients with diabetic complications, i.e., retino- and
nephropathy, could potentially influence the outcome of pregnancy. However, we did not find any
relationship of these variables with vitC probably due to the small number of participants. Finally, the
samples for vitC were taken in a non-fasting state to avoid hypoglycemic episodes, which may have
increased the SD of the vitC measurements and, thus, the risk of type 2 error.
5. Conclusions
In conclusion, the results from this small study of a pregnant T1DM cohort suggest that
hypovitaminosis C in late pregnancy may be associated with an increased risk of developing
complications in pregnancy and may also, to some extent, limit the obtainable level of vitC of the fetus
as measured by umbilical values in the newborn. Further investigations are needed to disclose the
possible clinical significance of vitC in the diabetic pregnancy and to confirm in larger studies that a
benefit of vitC supplementation exists in pregnancies characterized by hypovitaminosis C.
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Abstract: Acute kidney injury causes significant morbidity and mortality in the community and clinic.
Various pathologies, including renal and cardiovascular disease, traumatic injury/rhabdomyolysis,
sepsis, and nephrotoxicity, that cause acute kidney injury (AKI), induce general or regional decreases
in renal blood flow. The ensuing renal hypoxia and ischemia promotes the formation of reactive
oxygen species (ROS) such as superoxide radical anions, peroxides, and hydroxyl radicals, that
can oxidatively damage biomolecules and membranes, and affect organelle function and induce
renal tubule cell injury, inflammation, and vascular dysfunction. Acute kidney injury is associated
with increased oxidative damage, and various endogenous and synthetic antioxidants that mitigate
source and derived oxidants are beneficial in cell-based and animal studies. However, the benefit of
synthetic antioxidant supplementation in human acute kidney injury and renal disease remains to be
realized. The endogenous low-molecular weight, non-proteinaceous antioxidant, ascorbate (vitamin
C), is a promising therapeutic in human renal injury in critical illness and nephrotoxicity. Ascorbate
may exert significant protection by reducing reactive oxygen species and renal oxidative damage
via its antioxidant activity, and/or by its non-antioxidant functions in maintaining hydroxylase and
monooxygenase enzymes, and endothelium and vascular function. Ascorbate supplementation may
be particularly important in renal injury patients with low vitamin C status.
Keywords: antioxidant; renal injury; oxidant; hypoxia; ischemia; vitamin C; endothelium
1. Introduction
Acute kidney injury (AKI, also known as acute renal failure) is an increasing healthcare
challenge [1]. It is defined as a sudden reduction in renal function or glomerular filtration rate
(GFR), leading to azotemia and/or insufficient urine production caused by reduced renal blood flow,
and kidney damage, inflammation, or obstruction. Clinical presentation of AKI can be wide-ranging,
and risk factors include peripheral artery disease, hypertension and diabetes. It is an important cause
of morbidity and mortality, and a common complication of traumatic physical injury, sepsis, severe
burns, and complex surgery. The socioeconomic importance of AKI is rising, as it is recognized to
increase the risk of chronic or end-stage kidney disease, or adverse complications in non-renal tissues
such as heart and lung [2].
The majority of AKI causes are associated with ischemia and acute hypoxia from general or
regional decreases in renal blood flow. Ischemia severely limits cellular oxygen and nutrient uptake,
resulting in acute tubular necrosis and inflammation that can exacerbate renal injury and cause
functional changes in the kidney [3]. Ischemia and reperfusion are well-known activators of tissue
damage via reactive oxygen species (ROS) [4]. Although ROS perform physiological functions, supra-
or unregulated ROS accumulation can cause biomolecule oxidative damage, and perturbations in
membrane, macromolecule, and organelle functionality. Detoxification or decomposition processes
facilitated by endogenous antioxidants normally counterbalance oxidant production. However,
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pathophysiological conditions can enhance ROS production and overwhelm the availability and/or
decrease endogenous antioxidant activity and promote vascular dysfunction, inflammation, and renal
tubule cell cytotoxicity typically observed in the pathogenesis of acute kidney injury (AKI) [5].
Although the exact mechanism whereby ROS are generated in AKI is not defined, decreased ROS
generation and oxidative damage are potential therapeutic end points. Antioxidants have the potential
to intervene early in the pathogenesis of kidney injury by directly eliminating ROS or the oxidant
source. Studies in renal cells, kidney tubules, and animal models of AKI, have identified reno-protective
agents with antioxidant activities that mitigate renal oxidative damage (see reviews [5–8]). This review
will focus on oxidative stress in AKI and the therapeutic potential of antioxidants, including the
nutrient vitamin C, in experimental and human acute renal injury.
2. Oxidative Damage in Acute Renal Injury and Disease
There is considerable evidence that oxidative damage to tubular cells and renal tissue is linked
to AKI. Animal studies demonstrate increased oxidative damage and decreased tissue antioxidant
status after renal ischemia and/or nephrotoxicity [9,10]. Studies in critically ill or sepsis patients with
kidney injury and varying degrees of renal insufficiency, show increased circulating biomarkers of
protein and lipid oxidation that correlate with markers of pro-inflammatory, pro-oxidative mediators,
and cytokines [11]. Moreover, uremia is associated with increased circulating carbonyl and indole
compounds, with the potential to increase systemic oxidative stress [12]. Further, oxidative stress
and reactive oxygen species (ROS) are thought to be driving factors in other chronic diseases such as
cardiovascular disease and diabetes, that predispose to AKI or are present as co-morbidities in the
same subjects [5].
Chronic reduction in renal blood flow from pre-existing medical conditions such as liver and
renal disease, atherosclerosis, hypertension, diabetes, or from severe illness (traumatic injury, heart
failure, sepsis, rhabdomyolysis), or localized acute blood flow insufficiency due to renal ischemia
or nephrotoxicity, are responsible for the majority of AKI cases, and primarily manifest as acute
obstruction that prevents urine flow [13,14]. The importance of ROS in the pathogenesis of AKI
has been intensely examined because hypoxia and ischemia, that link to renal injury, can induce
ROS [4] (Figure 1). The kidney is highly sensitive to hypoxia and ischemia may be unavoidable in
some clinical settings such as renal transplantation. Further, inflammation and oxidative damage
are closely linked in ischemia/reperfusion (I/R) injury and AKI [14], as ROS can promote immune
responses and vice versa. Experimental models of AKI show that endothelium activation that promotes
leukocyte recruitment and microvascular congestion, as well as altered nitric oxide (NO•) biosynthesis,
mitochondrial dysfunction, and redox active iron, contribute to heightened ROS generation and
oxidative damage.
2.1. Sources of ROS in Various Causes of AKI
Various patho/physiological ROS, including the free radicals superoxide anion (O2•−) and
hydroxyl radical (OH•), and the non-radical oxidants hydrogen peroxide (H2O2), hypochlorous acid
(HOCl), and peroxynitrite (ONOO−), may be relevant oxidants in AKI [5,15,16]. O2•− is a significant
precursor of ROS such as H2O2, HOCl and OH•, and can react with other radicals including NO• to
form reactive nitrogen species (RNS) such as peroxynitrite. Cellular O2•− is produced by dysfunctional
mitochondria in hypoxia, ischemia, and toxicity [3], and enzymically by plasma membrane and
phagocyte NADPH oxidase (NOX). Limiting substrate or cofactors in injury or pathological conditions
can uncouple nitric oxide synthase (NOS) to also generate O2•− [15]. ROS, including those derived
from O2•−, can induce lipid and protein oxidation observed in renal injury.
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Figure 1. Increased reactive oxygen species (ROS) levels in acute kidney injury (AKI) induce renal
oxidative damage and injury. Hypoxia and ischemia perturb microcirculation, cellular enzymes, and
mitochondrial function, supporting production of intracellular ROS such as O2•− and H2O2, resulting
in mitochondrial damage, depletion of ATP, and activation of cell death pathways. Reperfusion after
ischemia also increases ROS. Ischemic injury activates endothelial cells up-regulating pro-inflammatory
cytokines and recruiting phagocytes that contribute ROS via NOX and MPO. Inflammation induces
ROS and iNOS, promoting peroxynitrite formation. Trauma and toxins generate oxidative stress by
depleting endogenous antioxidants and increasing redox-active metal ions. Vascular dysfunction
promoted by ischemia, inflammation, or toxicity, affects eNOS function, inducing ROS generation.
ROS perturb kinase/phosphatase activities and transcription factor signaling pathways important in
cell homeostasis. Oxidative modification of membranes and proteins disrupts cell ion and nutrient
transport, energy metabolism, and organelle function, ultimately affecting kidney viability.
A causal role for ROS in ischemia-induced AKI was suggested in early studies in animal models
showing significantly increased lipid peroxidation in kidney tissue after renal ischemia, which
correlates with injury and tubular dysfunction [9]. Exploring this correlation further, several agents
that inhibited ROS formation in vitro, including small molecular weight and enzymatic antioxidants
and metal chelators, were effective in alleviating ischemic AKI [9,17]. Lipid peroxidation and DNA
damage in ischemia are associated with the formation of 3-nitrotyrosine, a biomarker for ROS/RNS,
suggesting that NO•, O2•−, and/or peroxynitrite, contribute to renal oxidative damage [18,19].
ROS may also be a causative factor in sepsis-mediated AKI. The extensive immune response
induces severe renal vasoconstriction, kidney endothelial cell injury, and localized tissue hypoxia that
supports ROS formation. Inflammatory cytokines and ischemia also activate vascular endothelium,
recruiting immune cells that produce O2•− via NOX, and HOCl from H2O2, and phagocyte
myeloperoxidase (MPO) [16]. Inflammation-induced xanthine oxidase (XO) may also produce O2•− [3].
Decreased plasma antioxidants (vitamins C and E, and thiols), and increased lipid peroxidation, are
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also found together with alterations in redox regulatory genes, such as mitochondrial superoxide
dismutase (SOD), NOX, endothelial nitric oxide synthase (eNOS), heme oxygenase-1 (HO-1), and
tumour necrosis factor (TNF) [16]. Mitochondrial dysfunction and bio-energetic failure is also evident
in sepsis and mitochondrial complex I activity that correlates with reduced glutathione (GSH) and
ATP levels, and is inversely associated with shock severity in non-surviving patients [20]. Further,
inducible NOS (iNOS) is up-regulated in various organs, and shock severity is associated with NO•
levels [20]. Enhanced vascular NO• production can outcompete SOD for O2•−, thereby promoting
peroxynitrite and other ROS/RNS formation, and this may impact on vascular tone [21].
Rhabdomyolysis (RM) is a major cause of AKI in traumatic injury and severe burns.
Extensive muscle myolysis releases large quantities of heme-containing myoglobin (Mb) resulting
in myoglobinuria, severe renal vasoconstriction, and vascular dysfunction from obstruction by
Mb-protein casts or uric acid crystals in kidney tubules [8]. Studies in animal models show that
myoglobinuric damage is associated with lipid peroxidation and GSH depletion [10]. Redox active
iron released from Mb may induce OH• generation through degradation of low molecular weight
peroxides. However, autoxidation of Mb, that is pH dependent and favored in acidosis, or oxidation
of Mb by endogenous peroxides, can also generate protein-based radicals and ferric/ferryl heme, to
promote radical-mediated reactions such as lipid peroxidation [22,23]. Potent vasoactive signaling
molecules, e.g., isoprostanes, are found in animal models of RM, suggestive of lipid peroxidation in
situ [24,25].
Nephrotoxicity accounts for a large cohort of AKI, as renal detoxification and/or filtration of
various drugs exposes the kidney to a high toxin risk. AKI induced by common pharmaceuticals
and radio-contrast dyes is a significant clinical problem [26]. Renal accumulation of drugs and/or
metabolites can cause direct toxic effects on tubular cells, as well as microvascular inflammation and
ischemia promoting ROS. Further, drug biotransformation in the kidney is performed by ROS-inducing
renal enzymes, such as cytochrome P450 [10]. Antibiotics (gentamycin) and cancer therapies (cisplatin
and cyclosporine A) induce kidney tissue lipid peroxidation and renal dysfunction via increased ROS
formation, and iron release from renal cortical mitochondria in vitro and in vivo [10]. Drug-induced
oxidative stress may also involve depletion of antioxidants, particularly the enzymic cofactor GSH,
permitting unregulated ROS/RNS accumulation and renal cell injury [10,27].
2.2. Is Oxidative Stress Causally Related to Renal Dysfunction?
Outcomes from the influential study PICARD (Project to Improve Care in Acute Renal Disease),
demonstrated that acute renal failure in critically ill patients was associated with significantly
more oxidative stress than that observed in subjects without AKI, healthy controls, or end-stage
kidney disease [11]. Thus, plasma protein thiols, employed as a surrogate measure of antioxidant
capacity, were significantly decreased, and advanced protein oxidation products were significantly
increased, in subjects with clinical AKI. Also, impaired renal function associated with increased plasma
pro-inflammatory cytokines (IL-6, IL-8 and TNF-α), and further, cytokines and thiols were inversely
related, suggesting that inflammation promotes oxidative stress in AKI. Oxidative stress may also
be important in developing chronic kidney disease, as lipid peroxidation products associate with
advancing disease, as does endothelial dysfunction and loss of plasma SOD, glutathione peroxidase
(GPx) activity, and selenium [28].
While pre-clinical and human studies of AKI and renal insufficiency consistently associate
oxidative stress/damage and renal dysfunction, there is limited direct demonstration of the role
of ROS, so it is difficult to assign the latter a definitive casual role. Some recent studies have tried to
address this using non-invasive in vivo imaging techniques, or more specific indicators, to track ROS
formation in AKI. For example, a stable, electron paramagnetic resonance (EPR) spin probe injected
into rats showed only partial recovery of kidney reducing (antioxidant) activity after renal I/R, despite
improvements in renal function and tissue phospholipid oxidation, suggesting that ongoing oxidative
stress depletes antioxidant reserves in renal ischemia [29].
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Loss of ATP, and alterations in mitochondrial structure, are early events in AKI that contribute
to bio-energetic dysfunction [3,10]. A recent study of endogenous and exogenous multi-photon
imaging in vivo, assessed kidney mitochondrial redox state, structure, and function in rodents during
ischemic and nephrotoxic AKI [30]. Alterations in mitochondrial NADH and proton motive force,
as well as increased mitochondrial O2•− levels in proximal tubules and fragmented mitochondria
were observed, suggesting that this organelle is a major source of ROS, and that mitochondrial
dysfunction is an important early event in renal ischemia [30]. In comparison, abnormalities in renal
epithelial lysosomes and brush border cells after gentamycin treatment, preceded heterogeneous and
sporadic alterations in mitochondrial morphology, NADH, and proton motive force, suggesting that
mitochondrial dysfunction is a relatively late event in nephrotoxic AKI [30]. This study not only
provided direct visualization of ROS alongside cell damage, but also highlighted the variation in
pathophysiology and roles of ROS and mitochondrial dysfunction in different causes of AKI.
Unlike pre-clinical studies, direct measurement of ROS in renal injury/disease patients is
practically limited to non-invasive biomarkers. Specific and stable markers of in vivo free radical
mediated-lipid oxidation, such as isoprostanes, have been utilized to show substantial lipid
peroxidation in patients with RM [31], and with progression of chronic kidney disease [32]. Increased
plasma F2-isoprostanes are also found in renal failure in sepsis [33], and with postoperative AKI [34].
In the latter study, hemoprotein-induced oxidative damage was suggested to play a role in the
pathogenesis of AKI. Isofurans contain a substituted tetrahydrofuran ring and are also derived
from free radical-mediated lipid oxidation, but are favoured with high oxygen tension as can occur
in mitochondrial dysfunction [35]. Plasma isofuran levels similarly increase in sepsis [33], and
cardiopulmonary bypass [34] patients with AKI, and in chronic kidney disease [35].
3. Mitigation of Renal Oxidative Stress and Therapeutic Benefit
Whilst ROS perform important roles in cell signaling and physiological processes [36], they are
clearly linked with acute and chronic renal injury. Antioxidants participate in ROS detoxification and
decomposition processes to maintain redox balance in vivo, and to protect against adverse oxidation.
The major endogenous antioxidants mitigate source ROS, such as O2•− and H2O2, and their reaction
with other radicals [37], and can also directly interact with pertinent non-radical oxidants derived from
O2•−, such as HOCl and peroxynitrite [38]. Notable antioxidants include the vitamins C (ascorbate)
and E (tocopherol family), GSH, antioxidant proteins such as SOD, catalase and GPx, and proteins
that sequester metals (ferritin, metallothionein) or degrade heme (HO-1) (Nath, 2014). Exogenous
and synthetic compounds may act as direct antioxidants, or may activate adaptive systems such as
the nuclear factor E2-related factor (Nrf2) signaling pathway that regulates endogenous antioxidant
enzymes and cytoprotective genes [39]. Antioxidants that quench ROS or boost the endogenous
antioxidant pool, may be therapeutic in AKI.
3.1. Inhibition of ROS Source
A wide range of free radical scavengers, metal chelators (that inhibit redox cycling of bound
metals), and inhibitors of ROS enzyme sources, decrease lipid peroxidation, DNA damage, and/or
protein oxidation/nitration, and this is closely associated with improved renal function and
inflammation in animal models of AKI, and related renal cell studies. These outcomes have
prompted attempts to remove potential ROS sources with inhibitors, genetic knockout techniques, or
antioxidants, to not only assign a mechanistic role for ROS in AKI, but also identify ROS as a target for
therapeutic advantage.
3.1.1. Pro-Oxidant Metals
The role of pro-oxidant metal ions and metal-containing heme has been intensely studied in AKI,
as potent ROS such as OH• and oxidised lipids, that are vasoactive, can be formed by redox active
metals in the presence of O2•−/peroxide, and because the latter are increased in injury. Several studies
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affirm that metal chelators, such as desferrioxamine, are protective against oxidative damage, and
renal dysfunction in animal models of nephrotoxic and injurious AKI [40–42]. These studies also show
renal protection and reduced lipid oxidation afforded by so-called OH• scavengers, and more specific
antioxidants such as SOD, GSH, and vitamin E [10].
One source of released iron is heme-containing proteins in mitochondria or endoplasmic reticulum
or Mb, the latter being released in large amounts in RM-induced AKI [10]. Other hemoproteins may
also contribute to oxidative stress. For example, cytochrome P450 inhibitors modulate kidney iron
levels and improve renal function and injury in both RM-mediated AKI and cisplatin nephrotoxicity in
rats, suggesting that redox cycling of this enzyme is important to renal injury [43,44]. Down-regulation
of cytochrome P450 2E1, using a specific transcription inhibitor, also modulates lipid peroxidation, and
associates with normalising antioxidant enzymes and iron levels, and is reno-protective in RM-induced
AKI in rats [45].
Maintaining Mb heme-iron in a chemically reduced (Fe2+) state also appears to ameliorate AKI
and renal dysfunction, and may explain the positive effects of endogenous antioxidant replacement,
and also some of the action of desferrioxamine that can reduce Mb heme [23]. Further, inhibition of
Mb heme redox cycling by alkalinisation [24], or inhibition of endogenous lipid peroxidation with
acetaminophen, prevents isoprostane formation and renal injury associated with RM [25]. Notably,
acetaminophen was effective in reducing oxidant injury and renal dysfunction when administered
either pre- or post-treatment. Whether acetaminophen removes seed lipid peroxides, or also acts on
renal inflammation, is not known. In any case, removing pro-oxidant forms of iron by antioxidant
therapy or chelation appears to be efficacious, particularly in injurious AKI.
3.1.2. Superoxide Radical Anion and Derived ROS Sources (NOX, Mitochondrial ROS)
The available evidence indicates that SOD and other antioxidant enzymes are decreased in
pre-clinical models of AKI [46], and genetic impairment of SOD increases sensitivity to AKI in
ischemia [47] and chronic hypoxia [48]. Generation of O2•−, oxidative damage, and reduced SOD and
catalase activity, persist following transient renal ischemia in rodents, and associate with functional
defects that promote kidney disease. Long-term treatment with a SOD mimetic (MnTMPyp) [49] or
the NOX inhibitor apocyanin (which can also act as an antioxidant radical scavenger [50], alleviated
oxidation parameters and reduced the functional defects in this injury model [3]. Notably, NOX
gene levels did not appear to be altered, however, other pro-oxidant genes were increased, including
MPO and dual oxidase I (shares homology with NOX), whereas extracellular GPx3 was chronically
decreased [3]. In comparison, NOX2/4 mRNA and protein are elevated in a pre-clinical model
of nephrotoxicity [51], and both total NOX activity and NOX4 protein are increased in contrast
dye-induced (CI-)AKI in hypercholesterolemic rats [52]. Also, polymorphisms affecting activity in
NOX p22phox subunit gene associate with oxidation biomarkers and adverse outcomes in acute renal
failure patients [53].
Blockage of ROS production from O2•− sources such as XO, NOX, and mitochondria, alleviates
animal model AKI. Allopurinol, a XO inhibitor, modulates oxidative damage and improves renal
function in renal ischemia [54] and RM-induced AKI [55]. Allopurinol also reduces vascular oxidative
stress and improves endothelium function in chronic kidney disease [56,57]. Apocynin, a prototypical
inhibitor of NOX, is protective against renal dysfunction and lipid peroxidation [3], and loss of SOD
after I/R in rats with a similar efficacy to allopurinol [58], although whether protection is due to
direct inhibition of NOX or the inhibitor antioxidant activity, per se, is not clear. Treatment with
a combination of apocynanin and allopurinol failed to show any further efficacy than individual drug
administration [58], suggesting that a common target, i.e., ROS, was adequately quenched by either
inhibitor. In another recent study in rats, apocynin normalized kidney MPO and GPx protein, reduced
lipid peroxidation, and improved kidney function after renal ischemia [59].
Mitochondrial structural damage is an early, distinctive marker in AKI, and is linked to increased
production of ROS and activation of cell death pathways, and an inflammatory response that
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potentiates ROS formation [3]. Whether mitochondrial ROS are causative or formed subsequently in
AKI is not known, however, there is ongoing interest in the development of therapeutic antioxidants
specifically targeted to this organelle, and several show efficacy in preclinical AKI, and are the focus of
clinical trials, especially for I/R injury [60]. For example, the ubiquinone analogue MitoQ effectively
protects against kidney dysfunction and oxidative damage in renal I/R [61], nephrotoxic AKI [51],
and cold storage ex vivo indices of oxidative stress and kidney damage [60]. Also, mitochondrial
targeted peptides thought to protect cardiolipin from cytochrome C peroxidation, show efficacy against
oxidative stress, tubular cell damage, and dysfunction in renal I/R injury [60].
3.1.3. NO• Derived ROS/RNS
Peroxynitrite causes oxidation and/or nitration of lipid and protein, amino acids and DNA,
depletion of thiols and antioxidants, and oxidation of heme proteins. Nitration of tyrosine residues is
often used as a biological marker of peroxynitrite generation, and 3-nitrotyrosine is found in ischemic,
nephrotoxic and injurious AKI. However, it should be noted that several peroxidases, including MPO,
provide an alternative mechanism of protein tyrosine nitration via NO• oxidase activity [62]. Thus, in
addition to SOD, MPO may be considered a modulator of NO• signaling during inflammation [62],
and this may be relevant in sepsis where the inflammation response may contribute substantial MPO.
Thus, considering that iNOS and MPO are up-regulated in infection/inflammation, the observation of
3-nitrotyrosine in vivo in various causes of AKI, is probably restricted to a nonspecific indication of
ROS/RNS.
An imbalance in NO• and O2•− production during hypoxia and I/R injury may contribute to
renal cell damage [18,19]. However, use of agents to globally inhibit NO• production, including that
from constitutive eNOS, is not reno-protective in I/R injury [63]. Interestingly, iNOS is constitutively
expressed in the kidney [64], emphasizing a role for NO• in normal renal function [15]. However,
sustained NO• release from iNOS may also be pathogenic, as mice deficient in iNOS are resistant to
renal I/R injury [65]. Moreover, specific inhibition of iNOS reduces oxidative and nitrosative damage,
and renal dysfunction in animal models of renal ischemia [18,66], sepsis [67,68], and nephrotoxic
AKI [27].
3.2. Antioxidant Interventions; Supplementation and Up-Regulation
Several strategies for modulation of AKI using antioxidant compounds have been tested in human
and animal studies [6–8]. These include increasing bioavailability by intervention with nutrient-derived
and/or synthetic antioxidants, identifying new reno-protectants with antioxidant activity, and targeting
of antioxidants to specific ROS cellular domains (e.g., mitochondria). Also, anti-inflammatory agents
may potentially reduce ROS via stabilising endothelium function and NO• bioactivity, as well as
up-regulating gene responses linked to antioxidation and cytoprotection.
3.2.1. Small Molecular Weight Endogenous/Nutrient or Synthetic Antioxidants
Several small molecular weight compounds with antioxidant and ROS scavenging
actions improve renal function and decrease tubular damage. For example, edaravone
(3-methyl-1-phenyl-2-pyrazolin-5-one; norphenazone, MCI-186) shows efficacy in ischemia and is
an approved treatment for stroke in Japan [69]. It has been widely reported to inhibit oxidative damage
and lipid peroxidation in ischemia, however, it also shows anti-inflammatory properties that may
be unrelated to its antioxidant activity [69]. Edaravone attenuates ROS radical generation in kidney
tubular cells in vitro, and lipid peroxidation measured as aldehyde-modified proteins in vivo, and
ameliorates renal dysfunction in I/R [70] and nephrotoxicity [71] in rats. Edaravone also improves
survival rates in warm and cold I/R injury in rats [72] and dogs [73], and in the latter, significantly
improved renal function and reduced renal tubular cell damage, lipid, and DNA oxidation [73],
suggesting that it may prevent preservation injury in transplantation. Despite these positive effects,
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there are reports of edaravone treatment causally associated with AKI in ischemic stroke, however,
this has not been validated by a recent survey [74].
N-acetylcysteine (NAc) is a synthetic derivative of cysteine and precursor of GSH, and exhibits
ROS scavenging activity via its sulfhydryl group. It is protective in ischemic, nephrotoxic, and
RM-induced AKI in animal models [8], and improves kidney function, renal GSH and systemic
oxidative stress, and reduces renal inflammation. However, it has no effect on urinary isoprostanes,
suggesting cellular activity in addition, or unrelated, to a primary antioxidation mechanism. NAc
has been tested in several clinical studies of CI-AKI [75]. However, on balance, NAc shows no
overall benefit in preventing or treating CI-AKI in humans, and meta-analysis of these trials highlight
heterogeneity, under-reporting of negative/no benefit, and confounding serum creatinine levels as
possible contributors to the neutral effect. In addition, inadequate animal models for CI-AKI may have
hampered translation. Similar to CI-AKI, pre-, intra-, or post-operative use of NAc in clinical trials to
preserve renal function in cardiac or abdominal aortic surgery has largely failed to show benefit [7].
Endogenous or dietary antioxidants are protective against oxidation and/or inflammation
and kidney damage in AKI. For example, vitamin E and selenium (that can enhance activity of
GSH-dependent antioxidant enzymes) attenuate nephrotoxicity [7]. Interestingly, Se supplementation
inhibited renal oxidative damage and inflammation, yet was not reno-protective in an animal model
of RM-mediated AKI [76]. Vitamin C also attenuates oxidative damage, inflammation and renal
injury in several animal models, including CI-AKI [75], and other nephrotoxic AKI [7], ischemia- [5,6]
and RM-induced renal injury [8,77] (and see Table 1 for results of recent vitamin C intervention
studies on oxidative damage and/or antioxidant status and kidney function in animals). Loss of GSH
or GSH reductase activity worsens renal function in RM [10] and renal ischemia [78]. Conversely,
supplementation of GSH decreases renal cell/tubule oxidative injury [78,79] and improves renal
function in AKI [80]. NAc, that can increase intracellular GSH, and the GPx mimetic ebselen, both show
efficacy in AKI in animal models [3,5]. Ebselen may also be protective by scavenging peroxynitrite [5]
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Renal I/R in rats 50, 100 ↓ tissue lipid oxidation, O2
•−,
MPO ↑ tissue GSH, nitrate/nitrite
↓ serum urea, microproteinuria,
urate improved creatinine
clearance, anuria
activation of NO/soluble guanylyl
cyclase pathway inhibitors reverse
benefit
[82]
Aortic I/R in rats 50, 100 ↓ tissue lipid oxidation, iNOS,MPO, IL-6 not determined
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Endogenous antioxidants act in coordinated networks to mitigate oxidative damage, and this may
help explain why they are efficacious in AKI. The low-molecular weight antioxidants, α-tocopherol
and ascorbate, inhibit propagation reactions, and are effective terminating antioxidants. However,
they also act as co-antioxidants to spare other antioxidants and transfer radicals away from susceptible
moieties [90]. GSH performs multiple ROS detoxification roles, including ROS scavenging, preventing
protein thiol oxidation, as a co-factor for the GPx enzyme family that reduces peroxides and detoxifies
xenobiotics via glutathione S-transferase conjugation. GSH is regenerated from its oxidation product,
GSSG, by glutathione reductase and cofactor NADPH. Further, mutual maintenance of ascorbate and
GSH may occur in vivo, as ascorbate can maintain intracellular GSH, GSH can overcome scurvy, and
vitamin C is recycled via GSH and/or GSH or NADH-dependent enzymes [91].
In addition to endogenous antioxidants, several dietary plant polyphenols and flavonoids
including curcumin, quercetin, resveratrol, and red wine polyphenols, appear to be efficacious
in RM- [7,9] and ischemic AKI [6] in animal models. While several of these phytochemicals
display antioxidant activity in vitro, they are well known to activate the Nrf2 signaling cascade [39]
that up-regulates several antioxidant genes, including enzymes that interconnect H2O2 and thiol
modification (e.g., GSH biosynthesis and GSH-dependent enzymes, thioredoxin, peroxiredoxin, and
GPx). Nrf2 also activates transcription of HO-1, and ferritin that can mitigate AKI and renal injury [5,7].
Synthetic phenols with antioxidant activity may also act via Nrf2 to up-regulate reno-protective HO-1
(see below and [77,92]).
3.2.2. Antioxidant Enzymes
Enhancement of antioxidant enzyme activity appears to be protective in several animal models of
AKI. Early studies of ischemia showed that SOD or catalase administration attenuates ROS in proximal
tubule injury after hypoxia in vitro [93], and that SOD diminishes oxygen radicals in vivo after renal
ischemia in rabbits [94]. Also, SOD improved renal function and reduced kidney tissue injury and
cortical mitochondrial lipid peroxidation in rats [9]. Further studies confirmed that SOD reduced
ROS and was cytoprotective to renal cells in vitro and in vivo (reviewed in [3,10]). Pharmacologic
agents with SOD mimetic activity (Tempol, MnTMPyP) attenuate sepsis- [95,96] and ischemia-induced
AKI [97,98]. Further, MnTMPyP attenuates chronic increases in ROS and oxidative damage, and
a reduction in SOD associated with kidney fibrosis after ischemic AKI [49]. In animal sepsis, MnTMPyP
blocked O2•− and peroxynitrite formation, and reversed functional kidney deficits when added 6 h
post-septic insult, suggesting that antioxidant intervention is beneficial, and that halting ROS formation
can ameliorate microvascular failure and renal injury [96].
Over-expression of MnSOD, but not catalase, attenuates cisplatin-induced renal epithelial cell
injury in vitro [99], further suggesting that O2•− is important in AKI. Also, hyperglycemia that
contributes to diabetic nephropathy, induces O2•− within mitochondria and inactivates complex III,
and these changes can be alleviated by MnSOD over-expression [100]. MnSOD efficiently converts
O2•− to H2O2, allowing ROS to exit the organelle. However, renal MnSOD inactivation (up to 50%)
associated with increased mitochondrial O2•−, has been demonstrated in mouse sepsis, and this can
be attenuated with the mitochondria-targeted antioxidant Mito-TEMPO [101]. Further, Mito-TEMPO
mitigated renal mitochondrial and circulation dysfunction, together with doubling the survival
rate, and was effective when administered post-septic insult. Whether other low-molecular weight
cyclic nitroxide SOD mimetics, that also show anti-inflammatory activity independent of radical
quenching [102], can provide reno-protection, requires further investigation. Similarly, the SOD
mimetic, Mito-CP, also targets mitochondria and protects against tubular cell dysfunction, injury,
apoptosis, and inflammation in mice administered cisplatin, accompanied by reduced NOX2/4 mRNA
and protein, lipid oxidation, protein nitration, and pro-inflammation markers (MPO, ICAM-1) [51].
Thus, targeting the initial toxic insult that induces mitochondrial ROS with antioxidants may prevent
further ROS formation facilitated by inflammatory cell infiltration and NOX [51].
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3.2.3. HO-1 and Heme Metabolism
Heme oxygenase, normally found in the reticulo-endothelial system, can be rapidly induced
in various tissues as a stress (including oxidative) protein, including the kidney. It is considered
an antioxidant as it metabolizes heme from various proteins, including Mb, allowing clearance and
sequestration of redox-active iron (by ferritin), and its re-utilization. In addition, heme metabolism
by HO-1 produces biliverdin that can be converted to the plasma antioxidant bilirubin and CO;
the latter participates in cell signaling and is cytoprotective in the vasculature [103]. Both HO-1
and ferritin are induced as an adaptive response to myoglobinuria in rats injected with glycerol to
induce RM, and treatment with a competitive HO-1 inhibitor worsens renal function, while HO-1
induction by hemoglobin is protective [104]. However, it is well known that exposure of cells to heme
renders them sensitive to ROS, such as H2O2 [105]. This suggests a fine balance between adaptive
and maladaptive responses to heme, where small pre-treatment doses may be protective, similar to
ischemic pre-conditioning (see below), and reliant on cell signaling processes involving antioxidant,
anti-inflammatory, and vascular cytoprotective pathways.
Pharmacologic and genetic manipulation of HO-1 in animal studies suggests HO-1 is protective
in other causes of AKI, including nephrotoxicity, ischemia, and sepsis [7,103]. For example, inhibition
of HO-1 hinders recovery of renal function in rats after renal ischemia [106]. Transgenic deficiency
in HO-1 renders mice more susceptible to renal failure and injury after cisplatin treatment and,
hemin addition to renal proximal tubule cells in vitro induces HO-1 and a pronounced cytoprotective
effect [107]. Furthermore, HO-1 is protective in AKI following renal transplantation, and its products
inhibit tubulo-glomerular feedback and thrombotic microangiopathy in sepsis [103]. Moreover, loss
of proximal tubule ferritin worsens AKI [108], and HO-1 knockout mice display increased lipid and
protein oxidation, and iron deposition in kidneys [109]. HO-1 also confers protective effects in specific
organelles, such as mitochondria, and appears to be induced in specific renal sites aligned with the
AKI insult, and targeting of HO-1 to the proximal tubule is protective in nephrotoxicity [110].
3.2.4. Maintenance of Endothelial Function
Biomarkers of endothelium dysfunction are associated with increased risk of AKI in critically
ill patients, suggesting that endothelial cell activation predisposes to developing kidney injury [111].
Ischemia can drive endothelium activation by inducing chemo/cytokines that recruit immune cells and
allow their transmigration, and maintaining endothelium function may be important in limiting I/R
injury in AKI. For example, ICAM-1 induces leukocyte adhesion to endothelial cells, and up-regulation
of inflammatory mediators causing endothelium dysfunction and administration of an ICAM-1
antibody, genetic knockout of ICAM-1, or prevention of neutrophil infiltration in mice attenuates renal
ischemia-induced AKI [112]. Various anti-inflammatory agents that hinder phagocyte infiltration,
NF-Kb, and fibrosis mediators, are also effective in preserving renal function in various AKI [6,8].
I/R can induce direct endothelial cell damage via ROS and/or mitochondrial dysfunction, thereby
interfering with NO• homeostasis and vascular function. Several positive modulators of NO• via
eNOS, and selective inhibition of iNOS and/or peroxynitrite formation via SOD mimetics, reverse
renal dysfunction and oxidative injury in various AKI models [5,6,8].
Pre-conditioning by imposing a stress prior to subsequent injury may be effective in renal ischemic
injury. As ROS are important signaling molecules, short bursts of ischemia can promote signaling
cascades that protect renal cells from more prolonged I/R injury. Thus, transcription activators such as
Nrf2 and hypoxia-inducible factors (HIF) up-regulate stress-response and cytoprotective genes, e.g.,
HO-1, and these may be integral to the protective effects observed in remote and pharmacological
pre-conditioning strategies [3]. For example, pre-conditional induction of HIF protects against ischemic
AKI in rodents [113]. Some antioxidants (ascorbate, SOD) can block protection afforded by ischemic
pre-conditioning in the heart [114], further indicating that ROS are important signaling molecules
in vivo. A role for up-regulation of renal NO• production and improved vascular function via enhanced
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NO• bioavailability has also been suggested, as pre-conditioning benefits are reduced in NOS-inhibited
or eNOS deficient mice [115].
4. Vitamin C and Renal Protection
There is substantial interest in vitamin C (ascorbate) as a therapeutic antioxidant in renal
dysfunction, and vitamin C supplementation has been shown to be protective against ischemic,
injurious and toxicity-induced oxidative stress, and kidney dysfunction/AKI in animal models, and
human studies of critical illness (see Figure 2, overview of proposed mechanisms of vitamin C
reno-protection). Ascorbate is an essential nutrient obtained from the diet, and is a highly effective
non-protein reducing agent capable of donating electrons in various enzymatic and non-enzymatic
reactions [116]. In this capacity, it can undergo two consecutive one-electron oxidations to yield
first ascorbyl radical, and then dehydroascorbic acid (DHA), and both of these forms are recycled to
ascorbate by thiols/GSH and/or GSH, or NAD(P)H-dependent enzymes, effectively enhancing the
potential protective action of ascorbate.
Figure 2. Key activities of vitamin C and proposed benefit mechanisms in acute renal injury. BH4 =
tetrahydrobiopterin; RNS = reactive nitrogen species; CI-AKI = chemical induced acute kidney injury
Ascorbate acts as an enzyme cofactor in several hydroxylase reactions by maintaining active-site
metals in a reduced (active) state. In this regard, it is essential for functional collagen synthesis, and
vitamin C deficiency adversely affects wound healing and blood vessel wall integrity, and causes
scurvy. It is also a cofactor for cytoplasmic prolyl hydroxylases that control activation of HIF and
up-regulation of pro-survival glycolytic and angiogenic genes [117]. In addition to these activities,
vitamin C is proposed to have an important physiological role as an effective in vivo antioxidant. The
basis of this is related to its low reduction potential, that allows direct interaction with a wide range of
physiological ROS/RNS [118], and a large body of in vitro evidence demonstrates the effectiveness of
ascorbate in inhibiting biomolecule oxidation [116].
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Ascorbate is an efficient ROS/RNS scavenger in both tissue and plasma, and these non-enzymatic,
antioxidant bioactivities have prompted therapeutic investigations of ascorbate in AKI and renal
injury. Thus, ascorbate protects against ROS damage to protein, lipid, DNA, and carbohydrate in
aqueous milieu both extra- and intra-cellularly, and in several ROS-induced pathologies [116,117].
It scavenges radicals (O2•−, (hydro)peroxyl, nitroxide) and non-radical (HOCl, peroxynitrite) oxidants,
and reduces levels of α-tocopheroxyl radical in lipids and membranes, allowing recycling of vitamin E,
and inhibition of lipid peroxidation [90], and can spare GSH and protein thiols. It is also safe, with
high pharmaco-economic benefit, is fast acting on systemic antioxidant status, and large quantities can
be administered acutely with minimal adverse effects via various modes [117,119].
Intestinal uptake and renal re-absorption is important in ascorbate bioavailability, as humans,
unlike most mammals, cannot synthesize the vitamin de novo. Circulation levels of ascorbate
are tightly controlled in the micromolar range, whereas intracellular levels are much higher [120].
Ascorbate is distributed by vitamin C membrane transporters (SVCT) in nucleated cells, whereas
DHA, the 2e-oxidation product of ascorbate, is transported by Na+-independent glucose transporters
(GLUT), and is rapidly reduced intracellularly. Interestingly, activation of the HIF transcription
factor during ischemia also increases expression of the GLUT-1 transporter [117], and this may be
a mechanism to bolster ascorbate, as well as glucose, for energy metabolism. Ascorbate oxidation can
substantially increase DHA levels allowing vitamin C accumulation in various cell types, and this
may be important to its antioxidant function [120]. Thus, large amounts of ascorbate can be made
available during an inflammation response, e.g., phagocytic cells undergoing respiratory burst, to
balance ROS production. However, genetic polymorphisms in human vitamin C transport genes affect
plasma ascorbate levels, and hence disease risk and individuals with low dietary intake may be more
susceptible to the effects of genetic variation [121].
Whether ascorbate performs antioxidant roles in vivo is largely unproven. Its clinical use is
restricted to prevention of scurvy and promoting intestinal non-heme iron absorption, though it is
currently being investigated as a pro-drug in cancer [117]. Epidemiological studies consistently show
that low plasma ascorbate levels are associated with increased chronic disease risk, though vitamin
C supplementation is yet to show definitive benefits [122]. Low plasma vitamin C is a risk factor for
mortality and adverse cardiovascular events in hemodialysis patients [123], and AKI co-morbidities,
such as diabetes, are associated with vitamin C deficiency [124]. The renal system is important in
vitamin C re-absorption [125], and impairment may affect plasma ascorbate levels. Patients with
renal dysfunction, such as septic, critically ill, and elderly, demonstrate low ascorbate levels [119], and
bolstering vitamin C intake may prevent ROS-mediated renal damage in AKI.
4.1. Evidence for Vitamin C Efficacy in Animal Models of AKI and Proposed Actions
4.1.1. Vitamin C and Nephrotoxicity
Animal studies consistently show efficacy of vitamin C supplementation in nephrotoxic AKI by
reducing ROS and inflammation damage [7]. This positive benefit on renal function is predominantly
attributed to its antioxidant function and ability to reduce ROS arising from the initial toxic insult
and/or secondary wave ROS induced by inflammation (Table 1). Vitamin C also appears to maintain
GSH [126]. A large analysis of pre-clinical studies of aminoglycoside antibiotic-induced nephrotoxic
AKI showed that both natural and synthetic compounds, including vitamin C with attributed
antioxidant activity, are reno-protective [127]. Vitamin C also protects against NSAID-induced AKI in
rats by improving kidney function and renal lesions, serum oxidative stress, and tissue inflammation,
comparatively to vitamin E administration [89]. It is also protective against nickel-induced toxicity in
mice, by improving renal function, inflammation and renal tubular degeneration, and necrosis [128].
This finding supports earlier evidence of decreased nickel-induced oxidative stress in other organ
systems with ascorbate [129]. Interestingly, vitamin C supplementation reduces nickel accumulation in
the kidney [128], suggesting benefit independent of ROS scavenging.
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Ascorbate also improves RM-induced renal injury in animal models (Table 1). Thus, rats
administered a bolus of vitamin C intraperitoneally immediately after RM induction, showed
significant reductions in kidney tissue lipid peroxidation, increased antioxidant enzymes, and reduced
tissue iron content and tubular necrosis [85]. Yet, no significant improvements to renal function were
observed. This may be partially explained by the low dose of vitamin C chosen. However, studies in our
lab have similarly demonstrated a lack of amelioration of AKI with antioxidant (synthetic polyphenol,
vitamin E, selenium) supplementation in animal models of RM, despite ameliorating oxidative stress
and decreasing biomarkers of inflammation, together suggesting that oxidative stress may not be
causally related to renal dysfunction [76,130]. We recently compared treatment with vitamin C or
the synthetic polyphenol tert-butyl-bisphenol (3,3′,5,5′-tetratert-butyl-biphenyl-4,4′-diol) in a murine
model of RM-induced AKI [77]. Tert-butyl-bisphenol shows antioxidant activity similar to ascorbate,
and inhibits Mb-induced renal cell dysfunction in vitro [131]. Both ascorbate and tert-butyl-bisphenol
comparatively decreased plasma and kidney oxidative markers, inflammation and tissue kinase
activity (Table 1) when administered alone or in combination [77]. However, only vitamin C showed
potential clinical benefit and reduced proteinuria, plasma urate and renal tubule casts. This data
suggests that antioxidants with enhanced water solubility, such as ascorbate, may prevent intratubule
obstruction and tubular epithelial cell damage by Mb casts or urate crystals. Alternatively, ascorbate
may exhibit protective activities adjunct to its ROS scavenging/antioxidant activity [77]. Vitamin C
can positively affect endothelium function and exert anti-inflammatory actions, and anti-inflammation
and vasoprotective therapies attenuate RM-induced AKI [8].
In addition to the above, ascorbate displays a multifunctional antioxidant role in animal models of
cell-free hemoglobin exchange to prevent heme protein-mediated oxidative stress in vivo [132]. Thus,
EPR spectroscopic studies show that ascorbate scavenges globin-centered radicals and reduces plasma
methemoglobin (metHb, Fe3+) and ferryl hemoglobin (Fe4+-oxo), to remove the potential for ROS
formation from peroxide/redox active heme-peroxidase reactions. Erythrocytes promote reduction of
metHb by rapid recycling of ascorbate from ascorbyl radical. These antioxidant actions of ascorbate in
plasma and whole blood may be relevant in reducing kidney damage when large amounts of heme
proteins are released into extracellular spaces, such as in trauma and RM-induced AKI [132].
4.1.2. Vitamin C and I/R-Induced AKI
Vitamin C supplementation is also associated with improvements in I/R-induced AKI, again, largely
associated with ROS scavenging and improved antioxidant status. Thus, vitamin C administration
improved plasma levels of antioxidant enzymes in a model of canine renal allograft [133,134], and
reduced renal lipid oxidation and reversed loss of GSH in rat renal I/R [81]. The latter study
demonstrated cytoprotective and antioxidant efficacy within a short period of I/R, and with one bolus
dose of vitamin C pre-ischemia, suggesting that it may be beneficial and practical in defined elective
procedures, such as renal transplantation. A renal ischemic injury study in mice also showed improved
kidney function and decreased tubule cell injury with vitamin C pretreatment that was associated
with decreased renal lipid oxidation and improved SOD and GSH levels [84]. In this study, vitamin C
also significantly improved kidney NO• levels and in vivo arterial resistance and vascular reactivity of
excised renal arteries, indicating that ascorbate protects vascular function by direct ROS scavenging,
and/or via up-regulation of SOD, to prevent renal injury.
Ascorbate is an electron donor for peptide alpha-amidating monooxygenases responsible for
steroid and peptide hormone stability and activity. It is involved in progesterone biosynthesis [135],
and progesterone shows similar antioxidant and anti-inflammatory activities to ascorbate in several
diseases, including I/R-induced AKI. For example, progesterone mitigates oxidative stress and
inflammation, and up-regulates antioxidant enzymes, and improves renal function in an animal
model of renal I/R [87]. Interestingly, antagonism of progesterone receptors in male rats exposed
to renal I/R abolished the antioxidant and anti-inflammation effects of vitamin C, suggesting the
involvement of steroid receptors in ascorbate-mediated reno-protection [87].
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Acute I/R injury to renal tissue from remote organ damage/surgery can be alleviated by vitamin C.
Thus, renal ischemia injury in rats induced by abdominal aortic surgery that increased plasma and
tissue lipid oxidation and acute inflammation, was attenuated with vitamin C, similarly, or more
effectively, than a synthetic prostaglandin (PGI2) analogue (Iloprost) [88]. PGI2 inhibits platelet
activation and is an effective vasodilator, and Iloprost is used clinically for pulmonary hypertension
and ischemia. Thus, vitamin C’s ability to inhibit lipid peroxidation and reduce inflammation, may
prevent platelet aggregation and leukocyte adhesion [88]. Indeed, an earlier study showed that vitamin
C decreases venous blood platelet activating factor (PAF) and PAF-like lipids during reperfusion after
renal I/R in rabbits and rats [136]. PAF is a potent phospholipid activator of vascular and immune
responses, and is up-regulated in pathological conditions, and some lipid oxidation products have
PAF-like activity. The decrease in PAF activity was associated with decreased inflammation (specifically
MPO activity) and DNA oxidation, and amelioration of kidney dysfunction and tubulointerstitial
damage, suggesting that ascorbate can intervene in the oxidative-inflammatory response in I/R.
In another study, vitamin C reduced lipid oxidation, inflammation and kidney injury, and partially
improved renal oxygen delivery and consumption [83]. Despite these positive effects, vitamin C had
no effect on kidney hemodynamics and urine output, reminiscent of other studies where antioxidants
improve renal oxidative stress, damage or inflammation but do not improve kidney function [77].
4.1.3. Positive Effects of Vitamin C on Endothelial Function and Vascular Tone in Renal Injury
Ascorbate is vaso-protective of endothelium function, and this may be important in renal injury.
Several mechanisms have been proposed, including enhancing NO• bioavailability by up-regulating
eNOS, and/or increasing its activity independently of, or via, maintaining tetrahydrobiopterin
(BH4) [137]. Ascorbate may also maintain vessel integrity via scavenging ROS/antioxidant activity,
preventing injury and/or inflammation, or via its other known physiological role as a co-factor of
hydroxylase enzymes important in vascular structure/function [120]. Some animal AKI studies have
compared the effect of L-arginine (NO donor) and vitamin C supplementation on biomarkers of
lipid, DNA and protein oxidation, and kidney function, and have demonstrated superior protection
afforded by vitamin C [86,138]. These improvements in renal function and oxidative stress markers
in I/R-induced AKI in rats, may involve NO/soluble guanylyl cyclase (cGC), as inhibitors of this
pathway (L-NAME and methylene blue) reduced the reno-protective effects of vitamin C [82]. Further,
ascorbate increased tissue GSH and nitrate/nitrite levels, suggesting a preservation of NO• levels.
Chemical NO• donors similarly reduce renal I/R in animal studies [6].
In addition to ischemia, vitamin C shows benefit in animal models of sepsis by improving
edema, vascular tone, blood flow and pressure, platelet adhesion, coagulation, and survival [139].
The proposed mechanisms include decreased ROS/RNS, NOX, iNOS, and improved pro-inflammatory
markers and GSH [119]. Vitamin C may be therapeutic in sepsis via NO• maintenance, as alleviation
of septic symptoms and improved capillary blood flow observed with ascorbate injection or BH4
superfusion is not evident in eNOS knockout mice [139]. Ascorbate can also stimulate eNOS activity
in experimental sepsis via modulation of phosphorylation status, whereas other antioxidants such
as NAc and trolox do not exhibit this activity [140]. Additionally, ascorbate may prevent endothelial
barrier dysfunction in sepsis by modulating NOX derived ROS and peroxynitrite generation, thereby
protecting the distribution of the endothelial tight junction protein occludin [140].
It is noteworthy that most mammals synthesise vitamin C de novo, and therefore, the
overwhelming majority of vitamin C intervention studies that show benefit in animal AKI are
performed on species (rats and mice) that are not deficient. This may suggest that endogenous
levels of vitamin C are compromised in severe ischemic, nephrotoxic and/or injurious AKI, and
that renal reabsorption is important in maintaining systemic vitamin C. Alternatively, vitamin C
biosynthesis, that depends on adequate nutrient supply and liver function, may also be perturbed in
these injury models.
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4.2. Antioxidant Therapy in Human Renal Injury
AKI causes a high incidence of morbidity and mortality. Preventing AKI largely involves attempts
to mitigate the inducing drug/injury/illness and renal replacement therapy (dialysis) to remove fluid
overload and uremia, balance electrolytes, and correct metabolic acidosis. Addressing imbalances in
nutrient-derived antioxidants, such as vitamin C, particularly after traumatic injury and in critically ill
and elderly patients that show depletion of plasma antioxidants, may prevent renal injury [119,140].
Despite data showing positive benefit of antioxidants in animal models of AKI and renal injury,
translation of antioxidant therapy to human studies has been of limited success. Thus, Nac has
undergone several trials, but has proved largely inconclusive in alleviating CI- and other AKI [75] or
chronic kidney disease [5]. It does however show some benefit in end stage renal disease and kidney
transplantation. Vitamin E shows contrasting effects, either reducing chronic kidney disease risk,
or displaying no benefit [5]. A clinical trial of the Nrf2 pathway enhancer bardoxolone methyl on end
stage renal disease among type 2 diabetes patients and chronic kidney disease, was halted because of
increased mortality (cardiovascular events) in the treatment arm [141].
4.2.1. Reno-Protection in CI-AKI
In comparison to other antioxidants, vitamin C does appear to mitigate microvascular dysfunction
and renal failure in I/R and sepsis. For example, vitamin C shows promising reno-protection
in AKI [5,75]. Several controlled human studies have been now been performed with vitamin C
supplementation prior, during, or post contrast dye procedures, usually coronary angiography or
percutaneous coronary intervention. Although some studies included patients with existing renal
dysfunction, recent meta-analyses show overall benefit of vitamin C in preventing CI-AKI compared
to placebo or normal saline hydration [142,143]. An exact mechanism of reno-protection by ascorbate
cannot be delineated from these analyses due to lack of available biochemical data. However, it is
suggested that antioxidant ROS scavenging and vascular protection may predominate, largely based
on animal studies of nephrotoxic AKI, and a human study showing that vitamin C exerted a positive
change in total antioxidant status immediately after drug administration, and at follow-up [144].
Although a further recent study failed to show benefit of a standard dose of intravenous vitamin C
in preventing CI-AKI in patients with chronic renal insufficiency, a post hoc analysis of the data did
support a reduced rate of CI-AKI in patients with mildly impaired renal function [145].
4.2.2. Benefit in Critical Illness and Sepsis
As well as providing benefit in cardiac surgery patients, vitamin C appears to benefit critically ill
subjects with reduced new organ failure, ventilation, and/or time in ICU. In these studies, vitamin
C was typically administered in combination with other micronutrients, vitamins E/B1, and/or
selenium, so that its precise role was obscured [119,139]. However, in severe burn patients, a very high
parenteral dose of vitamin C significantly reduced fluid requirements and improved urinary output,
suggesting that early administration of vitamin C alone may improve morbidity in burn-induced
shock [119]. Also, a recent phase I study of the safety of pharmacological doses of parenteral vitamin
C, demonstrated significantly reduced multiple organ failure and pro-inflammation biomarkers in
severe sepsis [146]. Low plasma vitamin C is common in patients with traumatic and critical illness,
including sepsis and after cardiac surgery, and high intravenous dosages may be required to restore
adequacy [119]. In a recent observational study of sepsis, early use of a combination of intravenous
vitamin C, hydrocortisone, and thiamine, significantly reduced AKI, mortality, and progressive organ
failure in septic patients [147]. In this study, vitamin C and hydrocortisone were proposed to act
synergistically to preserve endothelium integrity and improve clinical outcomes.
Previous human studies relevant to renal injury support vitamin C producing beneficial
effects on endothelium function. For example, a high intra-arterial dose of vitamin C improves
endothelial-dependent vasodilatation after I/R injury and endotoxemia [148,149]. Also, vitamin C
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improves endothelium function and serum lipid oxidation in renal allograft transplant patients [150].
High-dose vitamin C supplementation in severe sepsis and shock may also positively benefit
endogenous vasopressor synthesis via hydroxylase and monooxygenase enzymes that require
ascorbate as a co-factor [151]. Vasopressors such as norepinephrine and vasopressin are important in
regulating blood pressure and renal water retention in critically ill patients. An observational trial of
vitamin C/hydrocortisone/thiamine supplementation in sepsis reported significant reduction in the
use of vasopressors in patients receiving vitamin C [147].
Thus, in accordance with pre-clinical studies, vitamin C appears to be protective in pathologies
relevant to human AKI via preserving endothelium and vascular function. Whether this benefit is
attributed to direct ROS scavenging, or involves non-antioxidant functions, remains to be defined,
but is important as ascorbate is a co-factor of various hydroxylase enzymes involved in vascular
wall integrity and cell signaling processes. Regarding the latter, ascorbate controls HIF-1 activity by
stabilizing its regulator prolyl hydroxylase, via maintaining the active site iron in a reduced (active)
state. HIF-1 is a pro-survival transcription factor activated by limited oxygen, metabolic disturbance
and oxidative stress, and may be important in preventing AKI via ischemic pre-conditioning [113].
However, over-activation of HIF-1 may be maladaptive in some pathologies [152] as intermittent
hypoxia can mediate chronic ischemia-induced NOX expression to generate persistently elevated
oxidative stress. Further, iNOS and some pro-inflammatory cytokines are activated by HIF-1 and NO•
can induce HIF-1 under non-limiting oxygen conditions (normoxia) such as inflammation [139,152].
Whether over-activation of HIF-1 contributes to renal injury in sepsis is largely unknown, however,
ascorbate inhibits iNOS expression and activity in microvascular endothelial cells in vitro and in
animal models of sepsis [140]. Thus, part of the mechanism whereby ascorbate shows efficacy in sepsis
may also be via suppression of HIF-1-dependent genes.
Overall, whilst ROS and oxidative stress are closely linked to AKI, and this maybe a mechanism
whereby ascorbate, as an antioxidant, intervenes, non-antioxidant bioactivities of vitamin C in immune
and vascular function may contribute to its therapeutic action in renal injury and disease. Further
studies are warranted to determine optimal dose and route of administration, as well as timing, e.g., in
ischemic pre-conditioning, and to establish whether ascorbate supplementation is beneficial in cohorts
with low vitamin C status, and if so, the precise mechanism of action.
5. Conclusions and Limitations
Despite advances in knowledge and treatment, AKI patients continue to have high mortality
and morbidity, especially those with chronic medical conditions. Pre-clinical studies show that
antioxidants alleviate renal injury and improve kidney function via reducing oxidative damage and/or
inflammation, though several therapeutic antioxidants have largely failed to show benefit in human
AKI. Vitamin C does appear to be efficacious in AKI in pathologies with endothelium dysfunction, or
where low vitamin C predominates. The reno-protective effects of ascorbate may derive from its known
antioxidant activity in scavenging source and derived ROS, including non-radical oxidants, and/or
maintaining GSH for peroxidase activity, or BH4 for eNOS function. Ascorbate may also preserve
vascular structure and microcirculatory flow independent of antioxidant function, via maintenance of
Fe2+ and Cu+-containing hydroxylase and monooxygenase enzymes. The latter are essential in collagen
and vasopressin synthesis central to vascular structure and functionality, and also modulate redox
activated signaling pathways, such as HIF-1, down-regulating genes involved in pro-inflammation.
Vitamin C shows promise as a reno-protectant in kidney injury, however, whether this is via its
physiological role as an enzyme co-factor, or its recognized biochemical activity as an antioxidant, or
both, remains to be fully defined.
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Abstract: Vitamin C may reduce inflammation and is inversely associated with mortality in the
general population. We investigated the association of plasma vitamin C with all-cause mortality in
renal transplant recipients (RTR); and whether this association would be mediated by inflammatory
biomarkers. Vitamin C, high sensitive C-reactive protein (hs-CRP), soluble intercellular cell adhesion
molecule 1 (sICAM-1), and soluble vascular cell adhesion molecule 1 (sVCAM-1) were measured in a
cohort of 598 RTR. Cox regression analyses were used to analyze the association between vitamin C
depletion (≤28 μmol/L; 22% of RTR) and mortality. Mediation analyses were performed according to
Preacher and Hayes’s procedure. At a median follow-up of 7.0 (6.2–7.5) years, 131 (21%) patients died.
Vitamin C depletion was univariately associated with almost two-fold higher risk of mortality (Hazard
ratio (HR) 1.95; 95% confidence interval (95%CI) 1.35–2.81, p < 0.001). This association remained
independent of potential confounders (HR 1.74; 95%CI 1.18–2.57, p = 0.005). Hs-CRP, sICAM-1,
sVCAM-1 and a composite score of inflammatory biomarkers mediated 16%, 17%, 15%, and 32%
of the association, respectively. Vitamin C depletion is frequent and independently associated with
almost two-fold higher risk of mortality in RTR. It may be hypothesized that the beneficial effect of
vitamin C at least partly occurs through decreasing inflammation.
Keywords: renal transplant; vitamin C; mortality; inflammation; hs-CRP
1. Introduction
Renal transplantation is currently considered the “gold standard” treatment for end-stage renal
disease (ESRD) patients, since it offers superior survival, quality of life and cost-effectiveness compared
to chronic dialysis treatment [1–8]. Nevertheless, survival of renal transplant recipients (RTR) is
significantly lower than of age-matched controls in the general population [9].
It is worth noting that after renal transplantation a long-term ongoing inflammatory status
persists [10–12]. It was recently reported that higher inflammatory status is associated with an
increased risk of mortality in RTR [13]. In keeping with this finding, high sensitive C-reactive protein
(hs-CRP), an established marker of inflammation, has been associated with increased risk of mortality in
RTR [14,15]. It has been reported that vitamin C (ascorbic acid) is negatively correlated with C-reactive
protein [16]. Both oral and high-dose intravenous vitamin C therapy reduced CRP levels and other
pro-inflammatory cytokines [17–19]. Furthermore, vitamin C has been shown to be inversely associated
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with risk of all-cause mortality in the general population [20–24]. However, to date the role and
long-term effects of vitamin C status on inflammatory biomarkers and adverse outcomes such as
all-cause mortality in stable RTR remains unexplored, yet the results are of significant interest.
In this study, we aimed to investigate prospectively whether plasma vitamin C concentration and,
specifically, its depletion (≤28 μmol/L) [25–31] is associated with risk of all-cause mortality in RTR.
In addition, we aimed to evaluate whether a putative association between vitamin C concentration
and risk of all-cause mortality in RTR would be mediated by inflammatory parameters such as hs-CRP,
soluble intercellular cell adhesion molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1
(sVCAM-1).
2. Materials and Methods
2.1. Study Design
In this prospective cohort study, all adult RTR who survived with a functioning allograft beyond
the first year after transplantation, and without known or apparent systemic illnesses (i.e., malignancies,
opportunistic infections) were invited to participate during their next visit to the outpatient clinic.
From a total of 847 eligible RTR, 606 (72%) patients signed informed consent. The group that did not
sign informed consent was comparable with the group that signed informed consent with respect to
age, sex, body mass index (BMI), serum creatinine, creatinine clearance, and proteinuria. Baseline
data was collected between August 2001 and July 2003 at a median 5.9 (interquartile range (IQR):
2.6–11.4) years after renal transplantation. For the statistical analyses we excluded patients missing
plasma vitamin C measurements (n = 8), resulting in 598 RTR eligible for analyses. Use of vitamin C
supplements or multivitamin supplements containing vitamin C were documented in all RTR. The
Institutional Review Board approved the study protocol (METc 2001/039). The clinical and research
activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in
the ‘Declaration of Istanbul on Organ Trafficking and Transplant Tourism’.
The primary endpoint of this study was RTR mortality of all cause in nature. The continuous
surveillance system of the outpatient program ensures up-to-date information on patient status.
We contacted general practitioners or referring nephrologists in case the status of a patient was
unknown. There was no loss due to follow-up.
2.2. Renal Transplant Characteristics
Relevant transplant characteristics including both donor and recipient age and gender, as well
as transplant information were extracted from the Groningen Renal Transplant Database, which
contains information about all renal transplantations that have been performed at the University
Medical Centre Groningen since 1986. Smoking status was obtained using a self-report questionnaire.
Smoking behavior was classified as never, former or current smoker. Cardiovascular disease history
was considered positive if participants had a myocardial infarction, transient ischemic attack or
cerebrovascular accident. Data on cumulative dose of steroids, incidence of acute rejection episodes and
use of mechanistic target of rapamycin (m-TOR) inhibitors were retrieved from individual patient files.
Cumulative dose of prednisolone was calculated as the sum of maintenance dose of prednisolone until
inclusion and the dose of prednisolone or methylprednisolone required for treatment of acute rejection
(a conversion factor of 1.25 was used to convert methylprednisolone dose to dose of prednisolone).
2.3. Measurements
Body mass index was calculated as weight in kilograms, divided by height in meters squared.
Waist circumference was measured on bare skin midway between the iliac crest and the 10th rib.
Blood pressure was measured as the average of three automated (Omron M4, Omron Europe B.V.,
Hoofddorp, The Netherlands) measurements with 1-min intervals after a 6-min rest in supine position.
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Blood was drawn in the morning after an 8 to 12 h overnight fasting period, which included
no medication intake. In order to measure plasma vitamin C concentration, blood was directly after
phlebotomy transferred to the laboratory on ice, deproteinized and stored in the dark at –20 ◦C until
analysis. For quantitative measurement ascorbic acid is enzymatically transformed to dehydroascorbic
acid, which in turn is derivatized to 3-(1,2-dihydroxyethyl)furo-[3,4-b]quinoxaline-1-one. Then,
reversed phase liquid chromatography with fluorescence detection is applied (excitation 355 nm,
emission 425 nm). Serum high sensitive C-reactive protein was assessed as described before [32].
Plasma sICAM-1 and sVCAM-1 concentrations were measured by enzyme-linked immunosorbent
assay kits (Diaclone Research, Besançon, France). Serum creatinine concentrations were determined
using the Jaffé method (MEGA AU510, Merck Diagnostica, Darmstadt, Germany). Total cholesterol
was determined using the cholesterol oxidase-phenol aminophenazone method (MEGA AU510,
Merck Diagnostica, Darmstadt, Germany), and serum triglycerides were determined with the
glycerol-3-phosphate oxidase-phenol aminophenazone method (MEGA AU510, Merck Diagnostica,
Darmstadt, Germany). High density lipoprotein (HDL)-cholesterol was determined with the cholesterol
oxidase-phenol aminophenazone method on a Technikon RA-1000 (Bayer Diagnostics, Mijdrecht,
The Netherlands), and low density lipoprotein (LDL)-cholesterol was calculated using the Friedewald
formula [33]. Plasma glucose was determined by the glucose-oxidase method (YSI 2300 Stat plus,
Yellow Springs, OH, USA). Glycated hemoglobin (HbA1c) was determined by high performance liquid
chromatography (VARIANTTM HbA1c Program with Bio-Rad CARIANT Hb Testing System, Bio-Rad,
Hercules, CA, USA).
According to a strict protocol all RTR were asked to collect a 24-hour urine sample during the
day before their visit to the outpatient clinic. Urine was collected under oil and chlorohexidine was
added as an antiseptic agent. Proteinuria was defined as urinary protein excretion >0.5 g/24 h. Renal
function was assessed by estimated Glomerular Filtration Rate (eGFR) applying the Chronic Kidney
Disease Epidemiology Collaboration equation [34].
2.4. Statistical Analysis
Data were analyzed using IBM SPSS software version 23.0 (SPSS Inc., Chicago, IL, USA),
STATA 12.0 (StataCorp LP, College Station, TX, USA) and R version 3.2.3. In all analyses, a 2-sided
p < 0.05 was considered significant. Hazard ratio (HR) are reported with 95% confidence interval (CI).
Continuous variables were summarized using mean (standard deviation (SD)) for normally distributed
data, whereas skewed distributed variables are given as median (IQR); percentages were used to
summarize categorical variables. Linear regression analyses were performed to evaluate the association
of plasma vitamin C concentration with recipient-related and transplantation-related characteristics.
Natural log transformation was used for analyses of variables with a skewed distribution.
A log-rank test was run to determine if there were differences in the survival distribution
between plasma vitamin C status (depleted and non-depleted; ≤ or >28 μmol/L, respectively)
of RTR. To analyze whether plasma vitamin C concentration is independently associated with
mortality, we performed Cox-proportional hazards regression analyses. For these analyses plasma
vitamin C concentration was used as categorical variable according to depleted or not depleted
concentration [25,26,28–30]; and as continuous variable (2 base of log-transformed values to achieve
a normal distribution), in order to obtain the best fitting model. First, we performed univariate Cox
regression analyses. Hereafter, we adjusted for age and sex (Model 2); for eGFR, proteinuria, primary
renal diseases and time since transplantation (Model 3). To avoid inclusion of too many variables
for the number of events, further models were performed with additive adjustments to model 3.
We performed additional adjustments for smoking status and alcohol use (Model 4); for diabetes
mellitus (Model 5); and for systolic blood pressure, BMI, serum HDL cholesterol and triglycerides
concentration (Model 6); and for use of calcineurin inhibitors, use of antimetabolites, use of m-TOR
inhibitors, use of induction therapy, and cumulative dose of prednisolone (model 7).
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As secondary analyses, we also performed classic mediation analyses according to Preacher
and Hayes [35,36], which are based on logistic regression; to establish whether hs-CRP sICAM-1 and
sVCAM-1 concentrations, separately and combined (sum of individual Z scores of hs-CRP + sICAM-1 +
sVCAM-1), mediated the association between plasma vitamin C concentration and all-cause mortality.
These analyses allow for testing significance and magnitude of mediation.
3. Results
3.1. Baseline Characteristics
A total of 598 stable RTR were included (mean age 51 ± 12 years, 54% male, 96% caucasian) at
5.9 (2.6–11.4) years after transplantation. Among them 133 (22%) RTR were vitamin C depleted.
None of the patients used vitamin C supplements or multivitamin supplements containing
vitamin C. Median (IQR) plasma vitamin C, hs-CRP, sICAM-1 and sVCAM-1 concentration were
44 (31–55) μmol/L, 2.0 (0.7–4.8) mg/L, 602 (514–720) ng/L, and 965 (772–1196) ng/L, respectively.
Mean eGFR was 47 ± 15 mL/min/1.73 m2, 166 (28%) participants had proteinuria. Additional baseline
characteristics are shown in Table 1.





Std. β p Value
No. of patients 598 - -
Vitamin C, μmol/L 44 (31–55) - -
Demographics
Age, years 51 ± 12 −0.05 * 0.23 *
Sex (male), n (%) 328 (54) −0.18 * <0.001 *
Ethnicity (caucasian), n (%) 577 (96) −0.02 0.60
Body Composition
Body surface area, m2 1.87 ± 0.19 −0.04 0.22
Body mass index, kg/m2 26.0 ± 4.3 −0.08 0.06
Primary Renal Diseases −0.02 0.61
Primary glomerulonephritis, n (%) 169 (28) - -
Glomerulonephritis due to vascular or autoimmune disease, n (%) 36 (6) - -
Tubulointerstitial nephritis and pyelonephritis, n (%) 92 (15) - -
Polycystic kidney disease, n (%) 106 (18) - -
Dysplasia and hypoplasia, n (%) 21 (4) - -
Renovascular disease, n (%) 32 (5) - -
Diabetic nephropathy, n (%) 22 (4) - -
Hereditary diseases and other, n (%) 117 (20) - -
Tobacco Use −0.08 0.06
Never smoker, n (%) 214 (35) - -
Ex-smoker, n (%) 251 (42) - -
Current smoker, n (%) 131 (21) - -
Blood Pressure
Systolic blood pressure, mmHg 153 ± 22 −0.11 0.004
Diastolic blood pressure, mmHg 89 ± 9 −0.11 0.01
Use of ACE-inhibitor or aII-antagonist, n (%) 201 (33) 0.07 0.11
Use of beta-blocker, n (%) 368 (61) −0.07 0.11
Prior History of CV Disease
History of MI, n (%) 48 (8) −0.01 0.75
History of TIA/CVA, n (%) 32 (5) −0.04 0.36
224





Std. β p Value
Transplantation
Time since transplantation, years 5.9 (2.6–11.4) 0.20 <0.001
Dialysis vintage, months −0.14 0.001
141 (24) - -
1–5 years 363 (61) - -
>5 years 94 (16) - -
Deceased donor, n (%) 515 (86) 0.02 0.61
Immunosuppressive Therapy
Prednisolone, mg/day 10.0 (7.5–10.0) −0.11 0.008
Use of calcineurin inhibitors −0.09 0.02
Cyclosporine, n (%) 386 (65) - -
Tacrolimus, n (%) 84 (14) - -
None, n (%) 128 (21) - -
Use of antimetabolites −0.06 0.19
Azathioprine, n (%) 194 (32) - -
Mycophenolic acid, n (%) 247 (41) - -
None, (%) 157 (26) - -
Use of m-TOR inhibitors, n (%) 10 (2) −0.10 0.02
Induction therapy −0.20 <0.001
Anti-thymocyte globulin, n (%) 70 (12) - -
Muromonab-CD3 , n (%) 26 (4) - -
Anti-CD25 monoclonal antibodies, n (%) 10 (2) - -
None, n (%) 492 (82) - -
Acute rejection treatment −0.13 0.03
High doses of steroids, n (%) 186 (31) - -
Other rejection therapy, n (%) 82 (14) - -
Cumulative dose of prednisolone, grams 21.3 (11.3–37.9) 0.21 <0.001
Ischemia Times
Cold ischemia time, hours 22 (15–27) 0.01 0.75
Total warm ischemia, minutes 35 (30–45) 0.02 0.72
Renal Allograft Function
eGFR, mL/min/1.73 m2 47 ± 15 0.11 0.009
Urinary protein excretion, g/24 h 0.2 (0.0–0.5) −0.06 0.22
Proteinuria (>0.5 g/24 h), n (%) 166 (27) −0.11 0.006
Inflammation
hs-CRP, mg/L 2.0 (0.7–4.8) −0.19 <0.001
sICAM-1, ng/L 602 (514–720) −0.17 <0.001
sVCAM-1, ng/L 965 (772–1196) −0.16 <0.001
Lipids
Total colesterol, mmol/L 5.6 ± 1.0 0.05 0.24
HDL colesterol, mmol/L 1.0 ± 0.3 0.11 0.004
LDL cholesterol, mmol/L 3.5 ± 0.9 0.07 0.09
Triglycerides, mmol/L 1.9 (1.4–2.6) −0.13 0.001
Use of statins, n (%) 295 (49) 0.06 0.13
Oxidative Stress
Gamma glutamate, U/L 24 (18–39) −0.10 0.02
Alkaline phophatase, U/L 72 (57–94) −0.21 <0.001
Uric acid, mmol/L 0.4 (0.3–0.5) −0.08 0.05
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Std. β p Value
Glucose Homeostasis
Insulin, μU/mL 11 (7–16) −0.08 0.04
Glucose, mmol/L 4.5 (4.1–5.0) −0.07 0.06
HbA1c, % 6.5 ± 1.0 −0.12 0.002
Diabetes, n (%) 105 (17) −0.11 0.008
Hematology
Leukocyte count, x 109/L 8.5 ± 2.4 −0.03 0.42
Hemoglobin, mmol/L 8.5 ± 0.9 0.01 0.77
Platelets count, x 109/L 231 ± 69 −0.02 0.56
* Unadjusted. Abbreviations: ACE, angiotensin converting enzyme; CV, cardiovascular; CVA, cardiovascular
accident; eGFR, estimated Glomerular Filtration Rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein;
hs-CRP, high-sensitive C reactive protein; LDL; low-density lipoprotein; m-TOR, mechanistic target of rapamycin;
MI, myocardial infarction; sICAM-1, soluble intercellular cell adhesion molecule 1; sVCAM-1, soluble vascular
cell adhesion molecule 1; TIA, transient ischemic attack; RTR, renal transplant recipients. Baseline characteristics
normally distributed are summarized using means (SD), whereas skewed distributed variables are given as medians
(IQR); percentages were used to summarize categorical variables. Multivariate linear regression analyses were
performed to obtain a p value of potential associations of baseline characteristics of renal transplant recipients with
plasma vitamin C concentration.
3.2. Association of Plasma Vitamin C Concentration with Clinical Variables
Age- and sex-adjusted plasma vitamin C concentration was associated with hs-CRP
(std. β = −0.19; p < 0.001), sICAM-1 (std. β = −0.17; p < 0.001) and sVCAM-1 (std. β = −0.16;
p < 0.001) concentrations. Moreover, alkaline phosphatase (std. β = −0.21; p < 0.001) and gamma
glutamate (std. β = −0.10; p = 0.02) were associated with plasma vitamin C concentration. Furthermore,
vitamin C was significantly associated with HbA1c (std. β = −0.12; p = 0.002), diabetes (std. β = −0.11;
p = 0.008), and insulin concentration (std. β = −0.08; p = 0.04). Likewise, eGFR (std. β = 0.11; p = 0.009),
systolic blood pressure (std. β = −0.11; p = 0.004) and diastolic blood pressure (std. β = −0.11;
p = 0.01) were associated to vitamin C concentration. Dialysis vintage (std. β = −0.14; p = 0.001) and
immunosuppressive therapy including use of calcineurin inhibitors (std. β = −0.09; p = 0.02), use of
m-TOR inhibitors (std. β = −0.10; p = 0.02), induction therapy (std. β = −0.20; p < 0.001), acute rejection
treatment (std. β = −0.13; p = 0.03), and cumulative dose of prednisolone (std. β = −0.21; p ≤ 0.001),
were associated to plasma vitamin C concentration (Table 1).
3.3. Prospective Analyses
During a median follow-up of 7.0 (6.2–7.5) years, 131 (21%) patients died. 32% of plasma vitamin C
depleted patients died, whereas among non-depleted patients 18% died. The survival distributions
between depleted and non-depleted RTR were significantly different (log-rank test p < 0.001).
A Kaplan-Meier curve for all-cause mortality according to plasma vitamin C status is shown in Figure 1.
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Figure 1. Kaplan-Meier curve for all-cause mortality according to plasma vitamin C status (depleted
versus non-depleted) among renal transplant recipients. Vitamin C depleted: ≤28 μmol/L; Vitamin C
non-depleted: >28 μmol/L.
Results of univariate and multivariate Cox-proportional hazard regression analyses are shown
in Table 2. Prospective analyses of the association between vitamin C concentration with all-cause
mortality showed that plasma vitamin C depleted RTR had an almost double risk of mortality (HR 1.95;
95% CI 1.35–2.81, p < 0.001). This association was independent of further adjustment for potential
confounders, with e.g., an HR of 1.88; 95% CI 1.28–2.76, p = 0.001 after adjustment for age, sex,
eGFR, proteinuria, primary renal disease, time since transplantation and dialysis vintage. Further
adjustment for other potential confounders (i.e., smoking and alcohol status, diabetes mellitus, systolic
blood pressure, BMI, HDL cholesterol and triglycerides concentration, use of calcineurin inhibitors,
use of antimetabolites, use of m-TOR inhibitors, use of induction therapy, and cumulative dose of
prednisolone) did not materially alter the association.
Table 2. Prospective analysis of plasma vitamin C on all-cause mortality in RTR.







HR 95% CI p Reference HR 95% CI p
Model 1 1.95 1.35–2.81 <0.001 1.00 0.71 0.59–0.87 0.001
Model 2 1.92 1.33–2.77 0.001 1.00 0.74 0.61–0.90 0.002
Model 3 1.88 1.28–2.76 0.001 1.00 0.76 0.62–0.94 0.011
Model 4 1.91 1.30–2.82 0.001 1.00 0.76 0.62–0.94 0.012
Model 5 1.80 1.22–2.65 0.003 1.00 0.79 0.64–0.98 0.030
Model 6 1.70 1.15–2.52 0.008 1.00 0.79 0.63–0.98 0.030
Model 7 1.74 1.18–2.57 0.005 1.00 0.78 0.63–0.97 0.024
Abbreviations: RTR, renal transplant recipients; HR, hazard ratio; CI, confidence interval. Model 1: Univariate.
Model 2: Age and sex adjusted. Model 3: Model 2 + adjustment for estimated Glomerular Filtration Rate, proteinuria,
primary renal disease, time since transplantation, and dialysis vintage. Model 4: Model 3 + adjustment for smoking
and alcohol use. Model 5: Model 3 + adjustment for diabetes mellitus. Model 6: Model 3 + adjustment for systolic
blood pressure, body mass index, high density lipoprotein cholesterol, and triglycerides concentration. Model 7:
Model 3 + adjustment for use of calcineurin inhibitors, use of antimetabolites, use of m-TOR inhibitors, use of
induction therapy, and cumulative dose of prednisolone.
Vitamin C as a continuous variable was univariately associated with all-cause mortality (HR 0.71;
95% CI 0.59–0.87, p = 0.001), with the point estimate of the HR below 1.00 indicating that risk decreases
with increasing vitamin C concentrations. In multivariable analysis, after adjustment for potential
confounders the association remained, with a HR of 0.76; 95% CI 0.62–0.94, p = 0.011 (Table 2; Figure 2).
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Figure 2. Association of plasma vitamin C with risk of all-cause mortality. The line in the graph
represents the hazard ratio. The grey area represents the 95% confidence interval of the hazard ratio.
3.4. Mediation Analyses
In mediation analyses according to the procedures of Preacher and Hayes [35,36], hs-CRP, sICAM-1
and sVCAM-1 concentration were significant mediators (p value for indirect effect <0.05) in the
association of vitamin C concentration with mortality. The magnitude of the mediating effects of
hs-CRP, sICAM-1 and sVCAM-1 accounted 16, 17 and 15%, respectively. Furthermore, combined
inflammatory biomarkers mediated 32% on the association of plasma vitamin C concentration with
risk of all-cause mortality in RTR (Table 3; Figure A1).
Table 3. Mediating effects of hs-CRP, sICAM-1, sVCAM-1 separately and combined on the association










Indirect effect (ab path) −0.016 (−0.036; −0.004)
16% ***Total effect (ab + c’ path) −0.103 (−0.189; −0.010)
sICAM-1
Indirect effect (ab path) −0.018 (−0.043; −0.003)
17% ***Total effect (ab + c’ path) −0.103 (−0.194; −0.016)
sVCAM-1
Indirect effect (ab path) −0.015 (−0.040; −0.003)
15% ***Total effect (ab + c’ path) −0.103 (−0.200; −0.015)
Combined inflammation
Indirect effect (ab path) −0.033 (−0.065; −0.012)
32% ***Total effect (ab + c’ path) −0.103 (−0.191; −0.013)
Abbreviations: hs-CRP, high sensitive C-reactive protein; sICAM-1, soluble intercellular cell adhesion molecule 1;
sVCAM-1, soluble vascular cell adhesion molecule 1; RTR, renal transplant recipients; CI, confidence interval.
* The coefficients of the indirect ab path and the total ab + c’ path are standardized for the standard deviations of the
potential mediators, plasma vitamin C concentration and outcomes. ** All coefficients are adjusted for age, sex,
estimated Glomerular Filtration Rate, time since transplantation, primary renal disease, and proteinuria. *** The size
of the significant mediated effect is calculated as the standardized indirect effect divided by the standardized total
effect multiplied by 100. † 95% confidence intervals for the indirect and total effects were bias-corrected confidence
intervals after running 2000 bootstrap samples.
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4. Discussion
This study showed, first, that vitamin C depletion was common in a stable outpatient population
of RTR, and that plasma vitamin C concentration was independently and inversely associated with risk
of all-cause mortality in RTR. Particularly, plasma vitamin C depletion was detrimental, as depicted by
an almost two fold higher risk of mortality within patients that had plasma vitamin C concentration
equal or lower than 28 μmol/L [25–31]. Importantly, adjustment for several potential confounders did
not alter the association. Of note, the association between vitamin C and mortality has been previously
reported in the general population [20–24]; however, to our knowledge, this is the first study that
examines the association of plasma vitamin C concentration with all-cause mortality in RTR and,
specifically, the effect of plasma vitamin C depletion on patient survival after renal transplantation.
Further, we found that combined inflammatory biomarkers mediated the robust proportion
of about one third of the association of plasma vitamin C concentration with all-cause mortality.
Notwithstanding that the underlying mechanisms leading to significantly lower survival of RTR
compared to age-matched controls in the general population [9] are not completely understood, it is
noteworthy that a long-term ongoing inflammatory status remains after renal transplantation [10–12].
Indeed, Abedini et al. [15], reported that in a cohort of 2102 RTR, over a follow-up period
of 5–6 years, hs-CRP was independently associated with all-cause mortality in RTR. Likewise,
Winkelmayer et al. [14] found that, at a median follow-up of 7.8 years after renal transplantation
in a cohort of 438 RTR, CRP levels of more than 5 mg/L were associated with an 83% greater mortality
risk compared with lower levels of this inflammatory marker. These observations are in agreement
with our findings and support the influence of low-grade ongoing inflammation on patient survival
after renal transplantation. On the basis of these findings and currently available literature [10–15]
one might propose that inflammation plays a major role in the underlying mechanisms leading to
decreased survival after renal transplantation. Finally, taking into account that we found that vitamin C
concentration was inversely associated with inflammatory biomarkers, which is in agreement with
previous reports [16–19], we hypothesize that the beneficial effect of adequate vitamin C status on
survival of RTR is at least partly mediated by diminishing inflammatory status.
On the basis of current findings it is expected that reduction of inflammation through vitamin C
supplementation, could be an approach to encourage protection against tissue injury and improve
current survival rates of RTR. A recent randomized controlled trial evaluated the effect of oral vitamin C
supplementation (200 mg/day during 3 months) on inflammatory status among 100 maintenance
hemodialysis patients [37]. Compared with patients that did not receive supplementation, a significant
decrease of hs-CRP levels was found among the vitamin C supplemented group. Moreover, the hs-CRP
levels returned to their original state after the supplementation was withdraw. In turn, Atallah et al.
reported the effect of intravenous vitamin C supplementation (300 mg each dialysis session) on
inflammatory parameters in hemodialysis patients. This study showed that CRP levels between
baseline and 6 months were significantly decreased in the supplemented, but not in the control
group [38]. Nevertheless, to our knowledge no randomized controlled trial has been reported
evaluating the effect of vitamin C supplementation strategies on inflammatory biomarkers or
prospective outcomes in RTR.
The strength of this study lays in its prospective design; and that it comprises a large cohort of
stable RTR which were closely monitored by regular check-up in the outpatient clinic, which gives
complete information on patient status. A limitation is that we did not have repeated measurements of
vitamin C levels. However, it should be realized that if intra-individual variability of vitamin C is taken
into account, the predictive properties become stronger. The higher the intra-individual day-to-day
variation of vitamin C would be, the greater one would expect the benefit of repeated measurement
for prediction of outcomes [39,40]. Moreover, as with any observational study, reversed causation
or unmeasured confounding may occur, despite the substantial number of potentially confounding
factors for which we adjusted. As we have no data on nutrition, we cannot exclude the possibility
that the association exists as a consequence of vitamin C being a marker of poor nutrition. Finally,
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since this is a single center study; the predictive value of vitamin C on mortality in RTR requires to be
confirmed within a multicenter study.
5. Conclusions
In conclusion, plasma vitamin C depletion is common in stable RTR, and is independently and
inversely associated with all-cause mortality after renal transplantation. Since hs-CRP, sICAM-1 and
sVCAM-1 were found to be important mediators in the association between vitamin C and all-cause
mortality, we hypothesize that the beneficial effect of vitamin C would occur through decreasing
inflammatory status. On the basis of the current findings, further research is needed to evaluate
whether vitamin C supplementation could be a therapeutic strategy in order to increase survival after
renal transplantation. The present study should encourage the design of multicenter, randomized,
double-blind, placebo-controlled trial, aimed to test the efficacy of this novel therapeutic strategy.
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Figure A1. Mediation analysis of combined score between hs-CRP, sICAM-1 and sVCAM-1 on the
association of plasma vitamin C concentration with all-cause mortality. a, b and c are the standardized
regression coefficients between variables. The indirect effect (through a potential mediator) is calculated
as a × b. Total effect (c) is a × b + c’. Magnitude of mediation is calculated as indirect effect divided by
total effect.
230
Nutrients 2017, 9, 568
References
1. Schippers, H.; Kalff, M.W. Cost Comparison Haemodialysis and Renal Transplantation. HLA 1976, 7, 86–90.
[CrossRef]
2. Laupacis, A.; Keown, P.; Pus, N.; Krueger, H.; Ferguson, B.; Wong, C.; Muirhead, N. A Study of the Quality
of Life and Cost-Utility of Renal Transplantation. Kidney Int. 1996, 50, 235–242. [CrossRef] [PubMed]
3. Jofre, R.; Lopez-Gomez, J.M.; Moreno, F.; Sanz-Guajardo, D.; Valderrabano, F. Changes in Quality of Life
After Renal Transplantation. Am. J. Kidney Dis. 1998, 32, 93–100. [CrossRef] [PubMed]
4. Wolfe, R.A.; Ashby, V.B.; Milford, E.L.; Ojo, A.O.; Ettenger, R.E.; Agodoa, L.Y.C.; Held, P.J.; Port, F.K.
Comparison of Mortality in all Patients on Dialysis, Patients on Dialysis Awaiting Transplantation,
and Recipients of a First Cadaveric Transplant. N. Engl. J. Med. 1999, 341, 1725–1730. [CrossRef] [PubMed]
5. Fujisawa, M.; Ichikawa, Y.; Yoshiya, K.; Isotani, S.; Higuchi, A.; Nagano, S.; Arakawa, S.; Hamami, G.;
Matsumoto, O.; Kamidono, S. Assessment of Health-Related Quality of Life in Renal Transplant and
Hemodialysis Patients using the SF-36 Health Survey. Urology 2000, 56, 201–206. [CrossRef]
6. Oniscu, G.C.; Brown, H.; Forsythe, J.L. Impact of Cadaveric Renal Transplantation on Survival in Patients
Listed for Transplantation. J. Am. Soc. Nephrol. 2005, 16, 1859–1865. [CrossRef] [PubMed]
7. Chkhotua, A.; Pantsulaia, T.; Managadze, L. The Quality of Life Analysis in Renal Transplant Recipients and
Dialysis Patients. Georgian Med. News 2011, 11, 10–17. [PubMed]
8. Tonelli, M.; Wiebe, N.; Knoll, G.; Bello, A.; Browne, S.; Jadhav, D.; Klarenbach, S.; Gill, J. Systematic Review:
Kidney Transplantation Compared with Dialysis in Clinically Relevant Outcomes. Am. J. Transpl. 2011, 11,
2093–2109. [CrossRef] [PubMed]
9. Oterdoom, L.H.; de Vries, A.P.; van Ree, R.M.; Gansevoort, R.T.; van Son, W.J.; van der Heide, J.J.H.;
Navis, G.; de Jong, P.E.; Gans, R.O.; Bakker, S.J. N-Terminal Pro-B-Type Natriuretic Peptide and Mortality in
Renal Transplant Recipients Versus the General Population. Transplantation 2009, 87, 1562–1570. [CrossRef]
[PubMed]
10. Kocak, H.; Ceken, K.; Yavuz, A.; Yucel, S.; Gurkan, A.; Erdogan, O.; Ersoy, F.; Yakupoglu, G.;
Demirbas, A.; Tuncer, M. Effect of Renal Transplantation on Endothelial Function in Haemodialysis Patients.
Nephrol. Dial. Transpl. 2006, 21, 203–207. [CrossRef] [PubMed]
11. Turkmen, K.; Tonbul, H.Z.; Toker, A.; Gaipov, A.; Erdur, F.M.; Cicekler, H.; Anil, M.; Ozbek, O.; Selcuk, N.Y.;
Yeksan, M. The Relationship between Oxidative Stress, Inflammation, and Atherosclerosis in Renal
Transplant and End-Stage Renal Disease Patients. Ren. Fail. 2012, 34, 1229–1237. [CrossRef] [PubMed]
12. Ocak, N.; Dirican, M.; Ersoy, A.; Sarandol, E. Adiponectin, Leptin, Nitric Oxide, and C-Reactive Protein
Levels in Kidney Transplant Recipients: Comparison with the Hemodialysis and Chronic Renal Failure.
Ren. Fail. 2016, 38, 1639–1646. [CrossRef] [PubMed]
13. Cañas, L.; Iglesias, E.; Pastor, M.C.; Barallat, J.; Juega, J.; Bancu, I.; Lauzurica, R. Inflammation and Oxidation:
Do they Improve After Kidney Transplantation? Relationship with Mortality After Transplantation.
Int. Urol. Nephrol. 2017, 49, 533–540. [CrossRef] [PubMed]
14. Winkelmayer, W.C.; Lorenz, M.; Kramar, R.; Födinger, M.; Hörl, W.H.; Sunder-Plassmann, G. C-Reactive
Protein and Body Mass Index Independently Predict Mortality in Kidney Transplant Recipients.
Am. J. Transplant. 2004, 4, 1148–1154. [CrossRef] [PubMed]
15. Abedini, S.; Holme, I.; Marz, W.; Weihrauch, G.; Fellstrom, B.; Jardine, A.; Cole, E.; Maes, B.; Neumayer, H.H.;
Gronhagen-Riska, C.; et al. Inflammation in Renal Transplantation. Clin. J. Am. Soc. Nephrol. 2009, 4,
1246–1254. [CrossRef] [PubMed]
16. Langlois, M.; Duprez, D.; Delanghe, J.; De Buyzere, M.; Clement, D.L. Serum Vitamin C Concentration is
Low in Peripheral Arterial Disease and is Associated with Inflammation and Severity of Atherosclerosis.
Circulation 2001, 103, 1863–1868. [CrossRef] [PubMed]
17. Korantzopoulos, P.; Kolettis, T.M.; Kountouris, E.; Dimitroula, V.; Karanikis, P.; Pappa, E.; Siogas, K.;
Goudevenos, J.A. Oral Vitamin C Administration Reduces Early Recurrence Rates After Electrical
Cardioversion of Persistent Atrial Fibrillation and Attenuates Associated Inflammation. Int. J. Cardiol.
2005, 102, 321–326. [CrossRef] [PubMed]
18. Mikirova, N.; Casciari, J.; Rogers, A.; Taylor, P. Effect of High-Dose Intravenous Vitamin C on Inflammation
in Cancer Patients. J. Transl. Med. 2012, 10, 189. [CrossRef] [PubMed]
231
Nutrients 2017, 9, 568
19. Mikirova, N.; Casciari, J.; Riordan, N.; Hunninghake, R. Clinical Experience with Intravenous Administration
of Ascorbic Acid: Achievable Levels in Blood for Different States of Inflammation and Disease in Cancer
Patients. J. Transl. Med. 2013, 11, 191. [CrossRef] [PubMed]
20. Enstrom, J.E.; Kanim, L.E.; Klein, M.A. Vitamin C Intake and Mortality among a Sample of the United States
Population. Epidemiology 1992, 3, 194–202. [CrossRef] [PubMed]
21. Pandey, D.K.; Shekelle, R.; Selwyn, B.J.; Tangney, C.; Stamler, J. Dietary Vitamin C and B-Carotene and Risk
of Death in Middle-Aged Men the Western Electric Study. Am. J. Epidemiol. 1995, 142, 1269–1278. [CrossRef]
[PubMed]
22. Sahyoun, N.R.; Jacques, P.F.; Russell, R.M. Carotenoids, Vitamins C and E, and Mortality in an Eiderly
Population. Am. J. Epidemiol. 1996, 144, 501–511. [CrossRef] [PubMed]
23. Loria, C.M.; Klag, M.J.; Caulfield, L.E.; Whelton, P.K. Vitamin C Status and Mortality in US Adults. Am. J.
Clin. Nutr. 2000, 72, 139–145. [PubMed]
24. Khaw, K.; Bingham, S.; Welch, A.; Luben, R.; Wareham, N.; Oakes, S.; Day, N. Relation between Plasma
Ascorbic Acid and Mortality in Men and Women in EPIC-Norfolk Prospective Study: A Prospective
Population Study. Lancet 2001, 357, 657–663. [CrossRef]
25. Irwin, M.I.; Hutchins, B.K. A Conspectus of Research on Vitamin C Requirements of Man. J. Nutr. 1976, 106,
821–879. [PubMed]
26. Jacob, R.A.; Skala, J.H.; Omaye, S.T. Biochemical Indices of Human Vitamin C Status. Am. J. Clin. Nutr. 1987,
46, 818–826. [PubMed]
27. Sauberlich, H.E.; Kretsch, M.J.; Taylor, P.C.; Johnson, H.L.; Skala, J.H. Ascorbic Acid and Erythorbic Acid
Metabolism in Nonpregnant Women. Am. J. Clin. Nutr. 1989, 50, 1039–1049. [PubMed]
28. Blanchard, J.; Conrad, K.A.; Watson, R.R.; Garry, P.J.; Crawley, J.D. Comparison of Plasma, Mononuclear
and Polymorphonuclear Leucocyte Vitamin C Levels in Young and Elderly Women during Depletion and
Supplementation. Eur. J. Clin. Nutr. 1989, 43, 97–106. [PubMed]
29. Jacob, R.A. Assessment of Human Vitamin C status12. J. Nutr. 1990, 120, 1480–1485. [PubMed]
30. Johnston, C.S.; Thompson, L.L. Vitamin C Status of an Outpatient Population. J. Am. Coll. Nutr. 1998, 17,
366–370. [CrossRef] [PubMed]
31. Johnston, C.S.; Solomon, R.E.; Corte, C. Vitamin C Depletion is Associated with Alterations in Blood
Histamine and Plasma Free Carnitine in Adults. J. Am. Coll. Nutr. 1996, 15, 586–591. [CrossRef] [PubMed]
32. De Leeuw, K.; Sanders, J.S.; Stegeman, C.; Smit, A.; Kallenberg, C.G.; Bijl, M. Accelerated Atherosclerosis in
Patients with Wegener’s Granulomatosis. Ann. Rheum. Dis. 2005, 64, 753–759. [CrossRef] [PubMed]
33. Montoye, H.J.; Kemper, H.C.; Saris, W.H.; Washburn, R.A. Measuring Physical Activity and Energy Expenditure;
Human Kinetics: Champaign, IL, USA, 1996.
34. Levey, A.S.; Stevens, L.A.; Schmid, C.H.; Zhang, Y.L.; Castro, A.F.; Feldman, H.I.; Kusek, J.W.; Eggers, P.;
Van Lente, F.; Greene, T. A New Equation to Estimate Glomerular Filtration Rate. Ann. Intern. Med. 2009,
150, 604–612. [CrossRef] [PubMed]
35. Preacher, K.J.; Hayes, A.F. SPSS and SAS Procedures for Estimating Indirect Effects in Simple Mediation
Models. Behav. Res. Methods 2004, 36, 717–731. [CrossRef]
36. Hayes, A.F. Beyond Baron and Kenny: Statistical Mediation Analysis in the New Millennium.
Commun. Monogr. 2009, 76, 408–420. [CrossRef]
37. Zhang, K.; Li, Y.; Cheng, X.; Liu, L.; Bai, W.; Guo, W.; Wu, L.; Zuo, L. Cross-over study of influence of oral
vitamin C supplementation on inflammatory status in maintenance hemodialysis patients. BMC Nephrol.
2013, 14, 252. [CrossRef] [PubMed]
38. Attallah, N.; Osman-Malik, Y.; Frinak, S.; Besarab, A. Effect of intravenous ascorbic acid in hemodialysis
patients with EPO-hyporesponsive anemia and hyperferritinemia. Am. J. Kidney Dis. 2006, 47, 644–654.
[CrossRef] [PubMed]
232
Nutrients 2017, 9, 568
39. Koenig, W.; Sund, M.; Frohlich, M.; Lowel, H.; Hutchinson, W.L.; Pepys, M.B. Refinement of the Association
of Serum C-Reactive Protein Concentration and Coronary Heart Disease Risk by Correction for within-Subject
Variation Over Time: The MONICA Augsburg Studies, 1984 and 1987. Am. J. Epidemiol. 2003, 158, 357–364.
[CrossRef] [PubMed]
40. Danesh, J.; Wheeler, J.G.; Hirschfield, G.M.; Eda, S.; Eiriksdottir, G.; Rumley, A.; Lowe, G.D.; Pepys, M.B.;
Gudnason, V. C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of
Coronary Heart Disease. N. Engl. J. Med. 2004, 350, 1387–1397. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




The Roles of Vitamin C in Skin Health
Juliet M. Pullar, Anitra C. Carr and Margreet C. M. Vissers *
Department of Pathology, University of Otago, Christchurch, P.O. Box 4345, Christchurch 8140, New Zealand;
juliet.pullar@otago.ac.nz (J.M.P.); anitra.carr@otago.ac.nz (A.C.C.)
* Correspondence: margreet.vissers@otago.ac.nz; Tel.: +64-3364-1524
Received: 10 July 2017; Accepted: 9 August 2017; Published: 12 August 2017
Abstract: The primary function of the skin is to act as a barrier against insults from the environment,
and its unique structure reflects this. The skin is composed of two layers: the epidermal outer layer is
highly cellular and provides the barrier function, and the inner dermal layer ensures strength and
elasticity and gives nutritional support to the epidermis. Normal skin contains high concentrations of
vitamin C, which supports important and well-known functions, stimulating collagen synthesis and
assisting in antioxidant protection against UV-induced photodamage. This knowledge is often used
as a rationale for the addition of vitamin C to topical applications, but the efficacy of such treatment,
as opposed to optimising dietary vitamin C intake, is poorly understood. This review discusses
the potential roles for vitamin C in skin health and summarises the in vitro and in vivo research to
date. We compare the efficacy of nutritional intake of vitamin C versus topical application, identify
the areas where lack of evidence limits our understanding of the potential benefits of vitamin C on
skin health, and suggest which skin properties are most likely to benefit from improved nutritional
vitamin C intake.
Keywords: ascorbate; dermis; epidermis; skin barrier function; vitamin C status; skin aging; wound
healing; collagen; UV protection
1. Introduction
The skin is a multi-functional organ, the largest in the body, and its appearance generally reflects
the health and efficacy of its underlying structures. It has many functions, but its fundamental role
is to provide a protective interface between the external environment and an individual’s tissues,
providing shielding from mechanical and chemical threats, pathogens, ultraviolet radiation and even
dehydration (functions reviewed in [1]). Being in constant contact with the external environment,
the skin is subject to more insults than most of our other organs, and is where the first visible signs of
aging occur.
The skin is composed of two main layers with quite different underlying structures—the
outermost epidermis and the deeper dermis (Figure 1). The epidermis fulfils most of the barrier
functions of the skin and is predominantly made up of cells, mostly keratinocytes [2]. The keratinocytes
are arranged in layers throughout the epidermis; as these cells divide and proliferate away from
the basal layer, which is closest to the dermis, they begin to differentiate. This process is called
keratinization, and involves the production of specialized structural proteins, secretion of lipids, and
the formation of a cellular envelope of cross-linked proteins. During differentiation, virtually all of
the subcellular organelles disappear, including the nucleus [3,4]. The cytoplasm is also removed,
although there is evidence that some enzymes remain [4]. Thus, the uppermost layer of the epidermis
that interacts with the outside environment is composed of flattened metabolically ‘dead’ cells (the
terminally differentiated keratinocytes). These cells are sealed together with lipid-rich domains,
forming a water-impermeable barrier. This layer is known as the stratum corneum (Figure 1) and fulfils
the primary barrier function of the epidermis, although the lower epidermal layers also contribute [5].
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Figure 1. Micrograph of human breast skin sample, showing the full depth of the dermis (pink
staining) in comparison to the thin layer of epidermis (purple staining). The scale bar indicates
200 μm. A zoomed-in image is shown within the box. The stratum corneum, the outermost layer of
the epidermis, is indicated by the arrows, with its characteristic basket-weave structure. The collagen
bundles in the dermis are very clear, as are the scattered purple-stained fibroblasts that generate
this structure.
In contrast, the dermal skin layer provides strength and elasticity, and includes the vascular,
lymphatic and neuronal systems. It is relatively acellular and is primarily made up of complex
extracellular matrix proteins [6], being particularly rich in collagen fibres, which make up ~75% of
the dermis dry weight (Figure 1). The major cell type present in the dermis is fibroblasts, which are
heavily involved in the synthesis of many of the extracellular matrix components. Blood vessels that
supply nutrients to both skin layers are also present in the dermis [1,2]. Between the two main layers
is the dermal–epidermal junction, a specialised basement membrane structure that fixes the epidermis
to the dermis below.
2. Role of Nutrition in Skin Health
It is accepted that nutritional status with respect to both macronutrients and micronutrients is
important for skin health and appearance [7]. Evidence of this is provided by the many vitamin
deficiency diseases that result in significant disorders of the skin [8]. Dermatological signs of B vitamin
deficiency, for example, include a patchy red rash, seborrhoeic dermatitis and fungal skin and nail
infections [9,10]. The vitamin C deficiency disease scurvy is characterised by skin fragility, bleeding
gums and corkscrew hairs as well as impaired wound healing [11–18].
Nutritional status is vital for maintaining normal functioning of the skin during collagen synthesis
and keratinocyte differentiation [7]. Additionally, many of the components of our antioxidant defences
such as vitamins C and E and selenium are obtained from the diet, and these are likely to be important
for protection against UV-induced damage [19–23].
Nutrition Issues Specific to the Skin
The epidermis is a challenged environment for nutrient delivery, as it lacks the blood vessels
that normally deliver nutrients to cells. Delivery of nutrients is dependent on diffusion from the
vascularized dermis [24], and this may be particularly limited for the outermost layers of the epidermis
(Figure 2). Delivery is further compounded by the chemical nature of these outer epidermal layers in
which there is little movement of extracellular fluid between cells due to the complex lipid/protein
crosslink structure forming the skin barrier. All of this makes it likely that dietary nutrients are not
easily able to reach the cells in the outermost layers of the epidermis, and these cells receive little
nutrient support.
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Figure 2. Delivery of nutrients to the skin. The location of the vitamin C transport proteins SVCT1
and SVCT2 are indicated. Red arrows depict nutrient flow from the blood vessels in the dermis to the
epidermal layer. Nutrients delivered by topical application would need to penetrate the barrier formed
by the stratum corneum.
The skin can be targeted for nutrient delivery through topical application (Figure 2). However,
in this case the delivery vehicle is influential, as the stratum corneum functions as an effective
aqueous barrier and prevents the passage of many substances [1]. Although some uncharged and
lipid-soluble molecules can pass through the surface layer, it is unlikely that nutrients delivered via
topical application would easily penetrate into the lower layers of the dermis [22]. The dermal layer
functions are therefore best supported by nutrients delivered through the bloodstream.
3. Vitamin C Content of Skin
Normal skin contains high concentrations of vitamin C, with levels comparable to other body
tissues and well above plasma concentrations, suggesting active accumulation from the circulation.
Most of the vitamin C in the skin appears to be in intracellular compartments, with concentrations
likely to be in the millimolar range [25–27]. It is transported into cells from the blood vessels present in
the dermal layer. Skin vitamin C levels have not often been reported and there is considerable variation
in the published levels, with a 10-fold range across a number of independent studies (Table 1). Levels
are similar to that found in numerous other body organs. The variation in reported levels most likely
reflects the difficulty in handling skin tissue, which is very resilient to degradation and solubilisation,
but may also be due to the location of the skin sample and the age of the donor.
Table 1. Vitamin C content of human skin and a comparison with other tissues.
Tissue Vitamin C Content (mg/100 g Wet Weight) References
Adrenal glands 30–40 [28]





Heart muscle 5–15 [28,29,31]
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Several reports have indicated that vitamin C levels are lower in aged or photodamaged
skin [25–27]. Whether this association reflects cause or effect is unknown, but it has also been
reported that excessive exposure to oxidant stress via pollutants or UV irradiation is associated
with depleted vitamin C levels in the epidermal layer [33,34]. Indeed, more vitamin C is found in
the epidermal layer than in the dermis, with differences of 2–5-fold between the two layers being
consistently reported (Table 1 and [25,26]). Levels of vitamin C in skin are similar to the levels of other
water soluble antioxidants such as glutathione [25–27,35]. There is a suggestion that vitamin C in the
stratum corneum layer of the epidermis exists in a concentration gradient [36]. The lowest vitamin C
concentration was present at the outer surface of the epidermis of the SKH-1 hairless mouse, a model
of human skin, with a sharp increase in concentration in the deeper layers of the stratum corneum,
possibly reflecting depletion in the outer cells due to chronic exposure to the environment [36].
3.1. The Bioavailability and Uptake of Vitamin C into the Skin
3.1.1. The Sodium-Dependent Vitamin C Transporters
Vitamin C uptake from the plasma and transport across the skin layers is mediated by specific
sodium-dependent vitamin C transporters (SVCTs) that are present throughout the body and are also
responsible for transport into other tissues. Interestingly, cells in the epidermis express both types
of vitamin C transporter, SVCT1 and SVCT2 (Figure 2) [37]. This contrasts with most other tissues,
which express SVCT2 only [37–39]. SVCT1 expression in the body is largely confined to the epithelial
cells in the small intestine and the kidney and is associated with active inter-cellular transport of the
vitamin [40,41]. The specific localisation of SVCT1 in the epidermis is of interest due to the lack of
vasculature in this tissue, and suggests that the combined expression of both transporters 1 and 2
ensures effective uptake and intracellular accumulation of the vitamin. Together with the high levels
of vitamin C measured in the epidermal layer, the dual expression of the SVCTs suggests a high
dependency on vitamin C in this tissue.
Both transporters are hydrophobic membrane proteins that co-transport sodium, driving the
uptake of vitamin C into cells. Replacement of sodium with other positively charged ions completely
abolishes transport [42]. SVCT1 and SVCT2 have quite different uptake kinetics reflecting their
different physiological functions. SVCT1 transports vitamin C with a low affinity but with a high
capacity (Km of 65–237 μmol/L) mediating uptake of vitamin C from the diet and re-uptake in the
tubule cells in the kidney [41]. SVCT2, which is present in almost every cell in the body, is thought
to be a high-affinity, low capacity transporter, with a Km of ~20 μM meaning it can function at low
concentrations of vitamin C [41]. As well as transporter affinity, vitamin C transport is regulated by
the availability of the SVCT proteins on the plasma membrane.
3.1.2. Bioavailability and Uptake
Most tissues of the body respond to plasma availability of vitamin C and concentrations vary
accordingly, with lower tissue levels being reported when plasma levels are below saturation [43–47].
The kinetics of uptake varies between tissues, with vitamin C levels in some organs (e.g., the brain)
reaching a plateau at lower plasma vitamin C status, whereas other tissue levels (e.g., skeletal muscle)
continue to increase in close association with increasing plasma supply [32,44,45,48].
Very little is known about vitamin C accumulation in the skin and there are no studies that have
investigated the relationship between skin vitamin C content and nutrient intake or plasma supply.
Two human studies have shown an increase in skin vitamin C content following supplementation with
vitamin C, but neither contained adequate measures of plasma vitamin C levels in the participants
before or after supplementation [27,49]. In one other study, vitamin C content was measured in
buccal keratinocytes, as these cells are proposed to be a good model for skin keratinocytes [50].
The keratinocyte vitamin C concentration doubled upon supplementation of the participants with
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3 g/day vitamin C for six weeks, a dosage that is significantly higher than the recommended daily
intake and would achieve plasma saturation and likely also tissue saturation [44].
Thus it appears likely that, as with many other tissues, skin vitamin C levels respond to increases
in plasma supply [27,50]. A paper by Nusgens and co-workers suggests that skin levels do not increase
further once plasma saturation is reached [51]. Dietary supplementation is therefore only expected to
be effective in elevating skin vitamin C in individuals who have below-saturation plasma levels prior
to intervention.
3.1.3. Topical Application of Vitamin C
When plasma levels are low, some vitamin C can be delivered to the epidermal layer by topical
application, although the efficacy of this is dependent on the formulation of the cream or serum
used on the skin [51–55]. Vitamin C, as a water-soluble and charged molecule, is repelled by the
physical barrier of the terminally differentiated epidermal cells. It is only when pH levels are below
4 and vitamin C is present as ascorbic acid that some penetration occurs [56], but whether this results
in increased levels in the metabolically compromised stratum corneum is unknown. A great deal
of effort has been put into the development of ascorbic acid derivatives for the purpose of topical
application. Such derivatives need to ensure stabilization of the molecule from oxidation and also
overcome the significant challenge of skin penetration. In addition, they must be converted to ascorbic
acid in vivo in order to be effective. Whether there is a single solution to all these challenges is
unclear [57]. The addition of a phosphate group confers greater stability and these derivatives may be
converted to ascorbic acid in vivo, albeit at a slow rate [58], but they are poorly absorbed through the
skin [56,59,60]. Ascorbyl glucoside also exhibits superior stability and can penetrate, but the rate of
its in vivo conversion is not known [57,61–63]. Derivatives containing lipid-soluble moieties such as
palmitate are designed to assist with delivery, and although increased uptake has been demonstrated
in animals [64], they do not necessarily show improved stability and there is some doubt as to whether
these derivatives are efficiently converted in vivo [57]. Recent studies suggest that encapsulation into
a lipospheric form may assist with transport into the lower layers of the epidermis and could result
in increased uptake [65–67]. However, the most pertinent issue for the efficacy of topical application
is likely to be the plasma status of the individual: if plasma levels are saturated, then it appears that
topical application does not increase skin vitamin C content [51].
3.1.4. Vitamin C Deficiency
One of the most compelling arguments for a vital role for vitamin C in skin health is the association
between vitamin C deficiency and the loss of a number of important skin functions. In particular,
poor wound healing (associated with collagen formation), thickening of the stratum corneum and
subcutaneous bleeding (due to fragility and loss of connective tissue morphology) are extreme and
rapid in onset in vitamin-C-deficient individuals [11,15–18]. It is thought that similar processes occur
when body stores are below optimal, although to a lesser extent [46,68].
4. Potential Functions of Vitamin C in the Skin
The high concentration of vitamin C in the skin indicates that it has a number of important
biological functions that are relevant to skin health. Based on what we know about vitamin C function,
attention has been focused on collagen formation and antioxidant protection; however, evidence is
emerging for other activities.
4.1. The Promotion of Collagen Formation
Vitamin C acts as a co-factor for the proline and lysine hydroxylases that stabilise the collagen
molecule tertiary structure, and it also promotes collagen gene expression [69–77]. In the skin, collagen
formation is carried out mostly by the fibroblasts in the dermis, resulting in the generation of the
basement membrane and dermal collagen matrix (Figure 3) [75,78]. The dependence of the collagen
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hydroxylase enzymes on vitamin C has been demonstrated in a number of studies with fibroblast
cells in vitro [69,73,79], with both decreased total synthesis and decreased crosslinking when vitamin
C is absent [80–82]. The activity of the hydroxylases is much more difficult to measure in vivo,
as the amount of collagen synthesised may vary only a little [51,52]. Rather, animal studies with
the vitamin-C-deficient GULO mouse indicate that the stability of the synthesised collagen varies
with vitamin C availability, reflecting the stabilising function of the collagen crosslinks formed by the
hydroxylases [76]. In addition to stabilising the collagen molecule by hydroxylation, vitamin C also
stimulates collagen mRNA production by fibroblasts [78,83].
Figure 3. Structure of the dermis. Higher magnification of H&E-stained dermis, showing the irregular
nature of the bundled collagen fibres (pink stained) and sparse presence of the fibroblasts (blue nuclear
staining). Vitamin C present in the fibroblasts supports the synthesis of the collagen fibres.
4.2. The Ability to Scavenge Free Radicals and Dispose of Toxic Oxidants
Vitamin C is a potent antioxidant that can neutralise and remove oxidants, such as those found in
environmental pollutants and after exposure to ultraviolet radiation. This activity appears to be of
particular importance in the epidermis, where vitamin C is concentrated in the skin. However, vitamin
C is only one player in the antioxidant arsenal that includes enzymatic defences (catalase, glutathione
peroxidase and superoxide dismutase) as well as other non-enzymatic defences (vitamin E, glutathione,
uric acid and other putative antioxidants such as carotenoids) [19,21,33,34,84–88]. Most intervention
studies carried out to determine the capacity of antioxidants to prevent oxidative damage to skin have
used a cocktail of these compounds [21,88–90]. Vitamin C is particularly effective at reducing oxidative
damage to the skin when it is used in conjunction with vitamin E [21,54,89,91,92]. This is in accord with
its known function as a regenerator of oxidised vitamin E, thereby effectively recycling this important
lipid-soluble radical scavenger and limiting oxidative damage to cell membrane structures [92,93]
(Figure 4).
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Figure 4. The central role for vitamin C and other antioxidants pertinent to the skin. The interdependence
of vitamins E and C, and glutathione, in the scavenging of free radicals and regeneration of the reduced
antioxidants, is shown. Vitamin E is in the lipid fraction of the cell, whereas vitamin C and glutathione
are water-soluble and present in the cytosol.
4.3. Inhibition of Melanogenesis
Vitamin C derivatives, including the magnesium phosophate ascorbyl derivative, have been
shown to decrease melanin synthesis both in cultured melanocytes and in vivo [94,95]. This activity has
been proposed to be due to its ability to interfere with the action of tyrosinase, the rate-limiting enzyme
in melanogenesis. Tyrosinase catalyses the hydroxylation of tyrosine to dihydroxyphenylalanine
(DOPA), and the oxidation of DOPA to its corresponding ortho-quinone. The inhibition in melanin
production by vitamin C is thought to be due to the vitamin’s ability to reduce the ortho-quinones
generated by tyrosinase [94], although other mechanisms are also possible [96]. Agents that decrease
melanogenesis are used to treat skin hyperpigmentation in conditions such as melisma or age spots.
4.4. Interaction with Cell Signalling Pathways
In vitro studies clearly show that vitamin C can play a role in the differentiation of keratinocytes
(Table 2). For example, vitamin C enhanced the differentiation of rat epidermal keratinocytes cells
in an organotypic culture model [97], with markedly improved ultrastructural organisation of the
stratum corneum, accompanied by enhanced barrier function. Vitamin C also increased numbers
of keratohyalin granules and levels of the late differentiation marker filaggrin, which appeared
to be due to altered gene expression [97]. Others have also shown that vitamin C promotes
synthesis and organization of barrier lipids and increased cornified envelope formation during
differentiation [98–102]. The mechanism(s) by which vitamin C modulates keratinocyte differentiation
is not yet elucidated; however, it has been hypothesized to be under the control of protein kinase C
and AP-1 [99].
In addition to vitamin C’s ability to promote collagen synthesis [73,79], there is evidence to
suggest that vitamin C increases proliferation and migration of dermal fibroblasts [78,82,102], functions
vital for effective wound healing, although the underlying mechanisms driving this activity are not
yet known [78]. Through the stimulation of regulatory hydroxylases, vitamin C also regulates the
stabilization and activation of the hypoxia-inducible factor (HIF)-1, a metabolic sensor that controls
the expression of hundreds of genes involved with cell survival and tissue remodelling, including
collagenases [103–105]. Vitamin C has been shown to both stimulate [69] and inhibit elastin synthesis
in cultured fibroblasts [81]. Glycosaminoglycan synthesis as part of extracellular matrix formation is
also increased by vitamin C treatment [106], and it may also influence gene expression of antioxidant
enzymes, including those involved in DNA repair [78]. As such, vitamin C has been shown to increase
the repair of oxidatively damaged bases. [78]. The modulation of gene expression may be important
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for its ability to protect during UV exposure via its inhibition of pro-inflammatory cytokine secretion
and apoptosis [107–109].
4.5. Modulation of Epigenetic Pathways
In addition to the gene regulatory activities listed above, vitamin C has a role in epigenetic
regulation of gene expression by functioning as a co-factor for the ten-eleven translocation (TET)
family of enzymes, which catalyse the removal of methylated cytosine through its hydroxylation to
5-hydroxymethylcytosine (5 hmC) [110–112]. As well as being a DNA demethylation intermediate, it
appears that 5 hmC is an epigenetic mark in its own right, with transcriptional regulatory activity [113].
Aberrant epigenetic alterations are thought to have a role in cancer progression, and there is data to
suggest that a loss of 5 hmC occurs during the early development and progression of melanoma [114].
Interestingly, vitamin C treatment has been shown to increase 5 hmC content in melanoma cell lines,
also causing a consequent alteration in the transcriptome and a decrease in malignant phenotype [115].
Because TETs have a specific requirement for vitamin C to maintain enzyme activity [116], this provides
a further mechanism by which the vitamin may affect gene expression and cell function. For example,
Lin and co-workers showed that vitamin C protected against UV-induced apoptosis of an epidermal cell
line via a TET-dependent mechanism, which involved increases in p21 and p16 gene expression [117].
Table 2. Summary of key in vitro studies investigating potential effects of vitamin C on the skin.
Study Description Measured Parameters Outcome and Comment Reference
Effects on collagen and elastin synthesis
Vit. C effects on collagen and
elastin synthesis in human skin
fibroblasts and vascular smooth
muscle cells.
Monitored vit. C time of exposure
and dose on collagen synthesis
and gene expression, and elastin
synthesis and gene regulation.
Vit. C exposure increased collagen,
decreased elastin. Stabilization of
collagen mRNA, lesser stability of
elastin mRNA, and repression of
elastin gene transcription.
[81]
Effect of vit. C on collagen
synthesis and SVCT2 expression
in human skin fibroblasts. Vit. C
added to culture medium for
5 days.
Vit. C uptake measured into cells,
collagen I and IV measured with
RT-PCR and ELISA, and RT-PCR
for SVCT2.
Vit. C increased collagen I and IV,
and increased SVCT2 expression. [73]
Effect of vit. C on elastin
generation by fibroblasts from
normal human skin,
stretch-marked skin, keloids and
dermal fat.
Immunohistochemistry and
western blotting for detection of
elastin and precursors.
50 and 200 μM vit. C increased
elastin production, 800 μM
inhibited. No measures of vit. C
uptake into cells.
[69]
Effects on morphology, differentiation and gene expression
Vit. C addition to cultures of rat
keratinocytes (REK).




increased keratohyalin granules and
organization of intercellular lipid




Effect of vit. C on human





CE formation and keratinocyte
differentiation induced by vit. C,
suggesting a role in formation of
stratum corneum and barrier
formation in vivo.
[99]
Effect of vit. C supplementation
on gene expression in human
skin fibroblasts.
Total RNA nano assay, for genetic
profiling, with and without vit. C
in culture medium.
Increased gene expression for DNA
replication and repair and cell cycle
progression. Increased mitogenic
stimulation and cell motility in the
context of wound healing. Faster
repair of damaged DNA bases.
[78]
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Table 2. Cont.
Study Description Measured Parameters Outcome and Comment Reference
Effect of vit. C on dermal




membrane protein deposition and
mRNA expression.
Vit. C improved keratinocyte and
basement membrane organisation.















Protective effects against UV irradiation
Effect of vit. C on UVA irradiation
of primary cultures of human
keratinocytes.
Vit. C added in low
concentrations, monitored MDA,
TBA, GSH, cell viability, IL-1,
IL-6 generation.
Vit. C improved resistance to UVA,
decreased MDA and TBA levels,
increased GSH levels, decreased
IL-1 and IL-6 levels.
[109]
Effect of vit. C uptake into human
keratinocyte (HaCaT) cell line on
outcome to UV irradiation.
Accumulation of vit. C in
keratinocytes, antioxidant
capacity by DHDCF and apoptosis
induction by UV irradiation.
Keratinocytes accumulated mM
levels of vit. C, increasing
antioxidant status and protecting
against apoptosis.
[108]
Effect of UVB on vit. C uptake
into human keratinocyte cell line
(HaCaT) and effects on
inflammatory gene expression.
Cellular vit. C measured by
HPLC, mRNA expression for
chemokines, western blotting for
SVCT localisation.





Protective effects against ozone exposure
Effect of antioxidant mixtures of
vit. C, vit. E and ferulic acid on
exposure of cultured normal
human keratinocytes to ozone.




Vit. C-containing mixtures inhibited
toxicity. The presence of vit. E
provided additional protection
against HNE and protein carbonyls.
[118]
Protection of cultured skin cells
against ozone exposure with vit.




Cell death, HNE levels, expression
of transcription factors Nrf-2 and
NfkappaB
Extensive protection against cell
damage with mixtures containing
vit. C. Increased expression of
antioxidant proteins. Additional
effect of vit. E + C. No effect with
Vit. E alone.
[119]
5. Challenges to the Maintenance of Skin Health and Potential Protection by Vitamin C
During the course of a normal lifetime, the skin is exposed to a number of challenges that can
affect structure, function and appearance, including:
• Deterioration due to normal aging, contributing to loss of elasticity and wrinkle formation.
• Exposure to the elements, leading to discolouration, dryness and accelerated wrinkling.
• Chemical insults including exposure to oxidising beauty and cleansing products (hair dyes, soaps,
detergents, bleaches).
• Direct injury, as in wounding and burning.
Vitamin C may provide significant protection against these changes and regeneration of healthy
skin following insult and injury is a goal for most of us. The following sections, and the summary in
Tables 3 and 4, review the available evidence of a role for vitamin C in the maintenance of healthy skin
and the prevention of damage.
5.1. Skin Aging
Like the rest of the human body, the skin is subject to changes caused by the process of natural
aging. All skin layers show age-related changes in structure and functional capacity [6,120] and,
as occurs in other body systems, this may result in increased susceptibility to a variety of disorders
and diseases, such as the development of dermatoses and skin cancer [6,22,121,122]. As well as this,
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changes in the appearance of skin are often the first visible signs of aging and this can have implications
for our emotional and mental wellbeing.
Aging of skin can be thought of as two distinct processes—natural or ‘intrinsic’ aging, caused
simply by the passage of time, and environmental aging [121,123,124]. Lifestyle factors such as
smoking and exposure to environmental pollutants increase the rate of environmental aging, and
can have a marked impact on the function and appearance of skin [22,121–124]. Exposure to chronic
ultraviolet radiation from sunlight is also a major environmental factor that prematurely damages our
skin (effects are detailed in the photoaging section below) [125]. The changes due to environmental
aging are usually superimposed on those that occur naturally, often making it difficult to distinguish
between the two [22].
Intrinsic aging is a slow process and, in the absence of environmental aging, changes are not
usually apparent until advanced age, when smooth skin with fine wrinkles, pale skin tone, reduced
elasticity, and occasional exaggerated expression lines are evident [6,22,24]. There is a reduction in the
thickness of the dermal layer [22], along with fewer fibroblasts and mast cells, less collagen production
and reduced vascularisation [24]. Specifically, during intrinsic aging there is gradual degradation of
the extracellular matrix components, particularly elastin and collagen [124,126]. The loss of elastin
results in the reduction in elasticity and capacity for recoil that is observed in aging skin.
Dry skin is very common in older adults [127], largely due to a loss of glycosaminoglycans and
accompanied reduction in the ability to maintain moisture levels [126,128]. The dermal-epidermal
junction may also become flattened, losing surface area and leading to increased skin fragility [22],
and potentially causing reduced nutrient transfer between the two layers. In general, the dermis
suffers from greater age-related changes than the epidermis [1]. However, the aged epidermis shows a
reduced barrier function and also reduced repair following insult [6]. Antioxidant capacity, immune
function and melanin production may also be impaired in aged skin [22].
Intrinsic aging is largely unavoidable and may be largely dependent on our genetic background
and other factors [129,130]. Some mitigation of these effects may be achieved by:
• Limiting exposure to environmental risk factors such as smoking, poor nutrition and chronic
exposure to sunlight, which cause premature skin aging.
• Using treatments to potentially reverse skin damage, including topical or systemic treatments
that help regenerate the elastic fibre system and collagen [126].
5.1.1. The Role of Vitamin C in the Prevention of Skin Aging
The ability of vitamin C to limit natural aging is difficult to distinguish from its ability to prevent
the additional insults due to excessive sun exposure, smoking or environmental stress and there is very
limited information available concerning a relationship between vitamin C levels and general skin
deterioration. The most compelling argument for a role of vitamin C in protecting skin function comes
from observations that deficiency causes obvious skin problems—early signs of scurvy, for example,
include skin fragility, corkscrew hairs and poor wound healing [11–17].
Because vitamin C deficiency results in impaired function, it is assumed that increasing intake
will be beneficial. However, there are no studies that have measured vitamin C levels or intake and
associated aging changes [130]. Vitamin C is almost never measured in the skin and this information is
needed before we can improve our understanding of what level of intake might be beneficial for skin
health and protection against aging-related changes.
5.1.2. Nutritional Studies Linking Vitamin C with Skin Health
Although there is no information specific to vitamin C and aging in the skin, many studies have
attempted to determine the role of nutrition more generally [85,131–133]. A recent systematic review of
studies involving nutrition and appearance identified 27 studies that were either dietary intervention
studies or reported dietary intakes [134]. The analysis indicated that, in the most reliable studies,
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intervention with a nutrient supplement (15 studies) or general foods (one study) was associated
with improved measures of skin elasticity, facial wrinkling, roughness and colour [134]. Many of the
nutrient interventions that showed a benefit included a high intake of fruit and vegetables, which
contribute significant levels of vitamin C to the diet.
A double-blind nutrition intervention study has evaluated the effects of dietary supplementation
with a fermented papaya extract, thought to have antioxidant activity [135], and an antioxidant
cocktail containing 10 mg trans resveratrol, 60 μg selenium, 10 mg vitamin E and 50 mg vitamin C
in a population of healthy individuals aged between 40 and 65, all with visible signs of skin aging.
Following a 90-day supplementation period, skin surface, brown spots, evenness, moisture, elasticity
(face), lipid peroxidation markers, superoxide dismutase activity, nitric oxide (NO) concentration, and
the expression levels of key genes were measured. Notably, the intervention resulted in a measureable
improvement in skin physical parameters, with a generally enhanced response from the fermented
papaya extract compared with the antioxidant cocktail. Gene expression, measured by RNA extraction
and RT-PCR, indicated that the papaya extract increased expression of aquaporin-3, and decreased
expression of cyclophilin A and CD147. Aquaporin 3 regulates water transport across the lipid
bilayer in keratinocytes and fibroblasts and therefore improves skin health [136]; cyclophilin A and
the transmembrane glycoprotein CD147 negatively impact on skin DNA repair mechanisms and
affect the inflammatory response, therefore negatively impacting skin health. This is an interesting
study and suggests that antioxidant supplementation, including vitamin C, could benefit skin health
generally. The antioxidant cocktail did not affect gene expression, and this may reflect the low
concentrations of each component in the supplement, which is unlikely to influence levels in a healthy
population. Although there were no direct measures to determine whether antioxidant status was
actually improved in the participants, antioxidant activity was improved in the skin following intake of
the papaya extract, as evidenced by decreased markers of lipid peroxidation and increased superoxide
dismutase activity.
5.2. UV Radiation and Photoaging
There is mounting evidence to suggest that the most significant environmental challenge to the
skin is chronic exposure to ultraviolet radiation from the sun or from tanning beds [22,90,123,137].
UV radiation damages skin through the production of reactive oxygen species, which can damage the
extracellular matrix components and affect both the structure and function of cells. While the skin
contains endogenous antioxidant defences, vitamins E and C and antioxidant enzymes to quench these
oxidants and repair the resultant damage, these antioxidants will be consumed by repeated exposure
and the skin’s defences can thereby be overwhelmed [25,138–141].
Acute exposure of skin to UV radiation can cause sunburn, resulting in a large inflammatory
response causing characteristic redness, swelling and heat. In addition, altered pigmentation,
immune suppression and damage to the dermal extracellular matrix can occur [24,25,56,142,143].
By comparison, chronic long-term exposure to UV radiation causes premature aging of the skin,
with dramatic and significant disruption to skin structure, and leads to the development of skin
cancer [6,24]. Termed photoaging, the most obvious features are wrinkles, hyperpigmentation and
marked changes in skin elasticity that cause skin sagging, with the skin also becoming sallow and
rougher with age [123,144]. Photoaged skin is most likely to be found on the face, chest and upper
surface of the arms.
Both the epidermal and dermal layers of skin are susceptible to chronic UV exposure; however,
the most profound changes occur in the extracellular matrix of the dermis [24]. Changes include
a significant loss of collagen fibrils within the dermis, but also specific loss of collagen anchoring
fibrils at the dermal–epidermal junction [126]. Dermal glycosaminoglycan content is increased in what
appear to be disorganised aggregates [126]. Elastic fibres throughout the dermis are also susceptible to
UV radiation, with accumulation of disorganised elastic fibre proteins evident in severely photoaged
skin. Indeed, this accumulation, termed ‘solar elastosis’, is considered to be a defining characteristic
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of severely photoaged skin [6,22,24,126]. There is also evidence of epidermal atrophy or ‘wasting
away’ during photoaging, and of a reduction in the barrier function [6]. In addition, the epidermis
can become hyperpigmented from chronic UV exposure; these lesions are known as age spots or
liver spots.
Preventing exposure to UV radiation is the best means of protecting the skin from the detrimental
effects of photoaging. However, avoidance is not always possible, so sunscreen is commonly used
to block or reduce the amount of UV reaching the skin. However, sunscreens expose the skin to
chemicals that may cause other problems such as disruption of the skin barrier function or induction
of inflammation [56].
Vitamin-C-Mediated Protection against Photoaging and UV Damage
Changes to the skin due to UV exposure have much in common with the rather slower process of
‘natural’ aging, with one major difference being a more acute onset. It is established that vitamin C
limits the damage induced by UV exposure [27,54,89,145,146]. This type of injury is directly mediated
by a radical-generating process, and protection is primarily related to its antioxidant activity. This
has been demonstrated with cells in vitro and in vivo, using both topical and dietary intake of
vitamin C [54,139,147,148]. It appears that UV light depletes vitamin C content in the epidermis,
which also indicates that it is targeted by the oxidants induced by such exposure [138,149]. Vitamin
C prevents lipid peroxidation in cultured keratinocytes following UV exposure and also protects the
keratinocyte from apoptosis and increases cell survival [21,99,107].
Sunburn is measured as the minimal erythemal dose (MED) in response to acute UV exposure.
A number of studies have shown that supplementation with vitamin C increases the resistance
of the skin to UV exposure. However, vitamin C in isolation is only minimally effective, and
most studies showing a benefit use a multi-component intervention [21,50,86,90,107,150–152]. In
particular, a synergy exists between vitamin C and vitamin E, with the combination being particularly
effective [50]. These results indicate the need for complete oxidant scavenging and recycling as
indicated in Figure 4, in order to provide effective protection from UV irradiation. This combination
also decreases the inflammation induced by excessive UV exposure.
Topical application of vitamin C, in combination with vitamin E and other compounds, has also
been shown to reduce injury due to UV irradiation [50,54,65,89,150,152,153]. However, the efficacy of
topical vitamin C and other nutrients may depend on the pre-existing status of the skin. One study
suggests that when health status is already optimal there is no absorption of vitamin C following
topical application. Hence, “beauty from the inside”, via nutrition, may be more effective than topical
application [132].
Vitamin-C-mediated prevention of radiation injury from acute UV exposure is relatively easily
demonstrated, and these studies are highlighted above. However, reversal of photoaging due to
prior, chronic sun damage is much more problematic. Although there are a number of studies
that claim a significant benefit from an antioxidant supplement or topical cream, interpretation of
the data is confounded by the complex formulation of the interventions, with most studies using
a cocktail of compounds and with the formulation of topical creams providing a moisturising effect in
itself [23,61,88,154].
5.3. Dry Skin
Dry skin is a common condition typically experienced by most people at some stage in their lives.
It can occur in response to a particular skin care regime, illness, medications, or due to environmental
changes in temperature, air flow and humidity. The prevalence of dry skin also increases with age [127];
this was originally believed to be due to decreased water content or sebum production in the skin as
we get older. However, it is now considered likely to be due to alterations in the keratinisation process
and lipid content of the stratum corneum [127].
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The pathogenesis of dry skin is becoming clearer and three contributing deficiencies have
been identified.
• A deficiency in the skin barrier lipids, the ceramides, has been identified. These lipids are the main
intercellular lipids in the stratum corneum, accounting for 40 to 50 percent of total lipids [155].
• A reduction in substances known as the natural moisturising factor (NMF) [156,157] is also
thought to be involved in dry skin. These substances are found in the stratum corneum within
the corneocytes, where they bind water, allowing the corneocyte to remain hydrated despite the
drying effects of the environment.
• More recently, a deficiency of the skin’s own moisture network in the epidermis, mediated by the
newly discovered aquaporin water channels, has been suggested to play a role [131].
Treatment of dry skin involves maintenance of the lipid barrier and the natural moisturising factor
components of the stratum corneum, generally through topical application (91), although nutritional
support of the dermis may also be useful [135,156].
Potential for Vitamin C to Prevent Dry Skin Conditions
Cell culture studies have shown that the addition of vitamin C enhances the production of barrier
lipids and induces differentiation of keratinocytes, and from these observations it has been proposed
that vitamin C may be instrumental in the formation of the stratum corneum and may thereby influence
the ability of the skin to protect itself from water loss [99,157]. Some studies have indicated that topical
application of vitamin C may result in decreased roughness, although this may depend more on
the formulation of the cream than on the vitamin C content [52,55]. Because most studies in this
area involve topical application, the complex and variable effects (pH and additional compounds) of
topical formulations make it difficult to come to any firm conclusion as to whether vitamin C affects
skin dryness.
5.4. Wrinkles
Wrinkles are formed during chronological aging and the process is markedly accelerated by
external factors such as exposure to UV radiation or smoking. The formation of wrinkles is thought
to be due to changes in the lower, dermal layer of the skin [22] but little is known about the specific
molecular mechanisms responsible. It is thought that loss of collagen, deterioration of collagen and
elastic fibres and changes to the dermal–epidermal junction may contribute [22,120,158–160]. One
hypothesis is that UV light induces cytokine production, which triggers fibroblast elastase expression
causing degradation of elastic fibres, loss of elasticity and consequent wrinkle formation.
The Effect of Vitamin C on Wrinkle Formation and Reversal
The appearance of wrinkles, or fine lines in the skin, has a major impact on appearance and
is therefore often a focus of intervention studies. Most have used topical applications, generally
containing a mixture of vitamin C and other antioxidants or natural compounds, with varied
efficacy [51,52,161]. Generally the demonstration of wrinkle decrease in these studies is less than
convincing, and the technology to measure these changes is limited. More recently, improved and
impartial imaging technologies such as ultrasound have been used to determine the thickness of the
various skin layers [135,149]. Once again, the efficacy of topical vitamin C creams on wrinkled skin
may depend on the vitamin C status of the person involved. An indication that improved vitamin
C status could protect against wrinkle formation through improved collagen synthesis comes from
the measured differences in wound healing and collagen synthesis in smokers, abstinent smokers
and non-smokers with associated variances in plasma vitamin C status [162]. Smokers had depleted
vitamin C levels compared with non-smokers; these levels could be improved by smoking cessation,
with an associated improvement in wound healing and collagen formation [162].
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5.5. Wound Healing
Wound healing is a complex process with three main consecutive and overlapping stages;
inflammation, new tissue formation and remodelling [163]. Following vasoconstriction and fibrin clot
formation to stem bleeding, inflammatory cells are recruited to the wound site. The first of these cells
is the neutrophil, which clears the wound of any damaged tissue and infectious material and signals
the recruitment of tissue macrophages [164]. Macrophages continue clearing damaged material and
bacteria, including spent neutrophils. Crucially, they are thought to be involved in orchestrating the
healing process, signalling fibroblasts to remodel tissue at the wound site and providing vital signals
for re-epithelialisation and dermal repair [163,164].
Re-epithelisation restores the skin’s barrier function, and occurs by a combination of migration
and proliferation of the epidermal keratinocytes that reside close to the damaged area. Epidermal stem
cells may also be involved in re-epithelisation [163]. In addition to the epidermal layer, the underlying
dermis must also be restored. Fibroblasts from a number of sources also proliferate and move into
the wound area [165], where they synthesise extracellular matrix components. These cells remove the
fibrin clot from the wound area, replacing it with a more stable collagen matrix. They are also involved
in wound contraction, and the reordering of collagen fibres. Proliferation of blood vessels is initiated
by growth factor production by macrophages, keratinocytes and fibroblasts.
Typically, the final result of the healing process is the formation of a scar. This is an area of
fibrous tissue generally made up of collagen arranged in unidirectional layers, rather than the normal
basket-weave pattern. As such, the strength of skin at the repair site is never as great as the uninjured
skin [163]. Variations in scar formation can occur, resulting in keloids—raised and fibrous scars—or
weak thin scar tissue. At this stage no intervention has been able to prevent the formation of scar tissue
although the extent of scarring may be ameliorated [166]. It is thought that nutritional support for
regeneration of the skin layers is important for development of strong healthy skin [167].
Vitamin C and the Benefits for Wound Healing
Of all effects of vitamin C on skin health, its beneficial effect on wound healing is the most
dramatic and reproducible. This is directly related to its co-factor activity for the synthesis of collagen,
with impaired wound healing an early indicator of hypovitaminosis C [68,168]. Vitamin C turnover at
wound sites, due to both local inflammation and the demands of increased collagen production, means
that supplementation is useful, and both topical application and increased nutrient intake have been
shown to be beneficial [166,169,170]. Supplementation with both vitamin C and vitamin E improved
the rate of wound healing in children with extensive burns [171], and plasma vitamin C levels in
smokers, abstaining smokers and non-smokers were positively associated with the rate of wound
healing [162]. However, it would appear that the extent of the benefits of supplemented vitamin C
intake is, once again, dependent upon the status of the individual at baseline, with any benefit being
less apparent if nutritional intake is already adequate [167,168]. However, the complexity and poor
selection of study population has often made it difficult to come to firm conclusions about the efficacy
of nutritional interventions, as summarised in a meta-analysis of the effects of varied treatments on
ulcer healing [172]. In a recent study, topical application of vitamin C in a silicone gel resulted in
a significant reduction in permanent scar formation in an Asian population [166].
5.6. Skin Inflammatory Conditions
Inflammation in the skin underlies a number of debilitating conditions such as atopic dermatitis,
psoriasis and acne, with symptoms including pain, dryness and itching. The pathology underlying
these conditions is complex and involves activation of auto-immune or allergic inflammation with
associated generation of cytokines and cellular dysfunction, and consequent breakdown of the
skin epidermal lipid barrier [173,174]. Treatments are therefore targeted at both the underlying
inflammation and the repair and maintenance of the epidermal structures. Nutrition plays an
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integral part in both these aspects and numerous studies have investigated the impact of dietary
manipulation for alleviation of acute and chronic skin pathologies, although firm conclusions
as to efficacy remain elusive [175–177]. Treatments involving supplementation with essential
omega-fatty acids, lipid-soluble vitamins E and A are often employed in an attempt to assist the
generation of the lipid barriers and to retain moisture in the skin [177]. Vitamin C is often used in
anti-inflammatory formulations or as a component of nutrition studies but its individual efficacy has
not been investigated [175–177].
Vitamin C and Skin Inflammation
Vitamin C status has been reported to be compromised in individuals with skin inflammation,
with lower levels measured compared with unaffected individuals [178,179]. This may reflect increased
turnover of the redox-labile vitamin C, as is seen in many inflammatory conditions [180–182], and
decreased vitamin C status could be expected to impact on the numerous essential functions for which
it is essential as detailed in the sections above. Recent studies have begun to provide more detailed
information as to specific functional implications for suboptimal vitamin C status in inflamed skin
lesions. One notable study [179] has reported significantly compromised vitamin C status in patients
with atopic dermatitis, with plasma levels ranging between 6 and 31 μmol/L (optimal healthy levels
> 60 μM), and an inverse relationship between plasma vitamin C and total ceramide levels in the
epidermis of the affected individuals. As indicated in the sections above, ceramide is the main lipid of
the stratum corneum and its synthesis involves an essential hydroxylation step catalysed by ceramide
synthase, an enzyme with a co-factor requirement for vitamin C [100]. Hence the potential impact of
vitamin C extends far beyond its capacity as an inflammatory antioxidant in a pathological setting.
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Table 4. Summary of key and recent in vivo studies providing evidence of vitamin C effects in the skin.




pregnant female rats. Addition of
1.25 mg/mL vitamin C to drinking
water for duration of gestation.
Monitored collagen and elastin
content of uterosacral ligaments
by histology staining and
subjective assessment.
Increased collagen production in vit.-
C-supplemented rats, decreased elastin
loss. Implied prevention of pelvic organ
prolapse and stress urinary incontinence.
[183]
Wound healing in guinea pigs
following supplementation with
moderate and high-dose vit. C.
Dorsal wound healing rate and
strength of repair monitored.
Increased vit. C associated with faster
wound recovery and strength of skin
integrity. Small sample size limited stats.
[184]
Topical application
Topical application of vit. C and
vit. E-containing cream to nude
mice, followed by UV irradiation.
Measured melanocyte
differentiation post-irradiation.
Change of skin colour—tanning,
inflammation.
UVR-induced proliferation and
melanogenesis of melanocytes were
reduced by vit. C and E. Melanocyte
population and confluence reduced
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Increased cell viability and basement
membrane development in vitro, better




90-day oral supplementation with
a fermented papaya preparation
or an antioxidant cocktail (10 mg
trans-resveratrol, 60 μg selenium,
10 mg vitamin E, 50 mg vitamin C)
in 60 healthy non-smoker males
and females aged 40–65 years, all
with clinical signs of skin aging.




dismutase levels, nitric oxide
(NO) generation, and the
expression levels of key genes
(outer forearm sample).
Improved skin elasticity, moisture and
antioxidant capacity with both
fermented papaya and antioxidant
cocktail. Increased effect of papaya
extract and on gene expression. No
baseline measures in study population.
Antioxidant components of the
fermented papaya unknown and direct
link with vit. C not available.
[135]
Intervention with 47 men aged
30–45 given oral supplement of 54
mg or 22 mg of vit. C, 28 mg
tomato extract, 27 mg grape seed
extract, 210 mg of marine complex,
4 mg zinc gluconate for 180 days.
Subjective assessment of
appearance and objective
measures of collagen and elastin
(histology and measurement in
biopsy material).
Improvement in erythema, hydration,
radiance, and overall appearance.
Decreased intensity of general skin spots,
UV spots, and brown spots, improved
skin texture and appearance of pores.
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Table 4. Cont.
Study Description Measured Parameters Outcome and Comment References
Supplementation of 33 healthy
men and women (aged 22–50),
with placebo, 100 mg vit. C or 180
mg vit. C daily for four weeks.
EPR measurement of TEMPO
scavenging in skin on arm.
Raman resonance spectroscopy
for skin carotenoids.
Improved oxygen radical scavenging
with vit. C supplementation, dose
dependency indicated and rapid
response (obvious within two weeks).
[38]
Three month supplementation of
12 males and six females (21–77 y)
with 2 g vit. C and 1000 IU
D-alpha-tocopherol.
Measured blood vitamin levels
before and after, skin resilience
to UVB, detection of DNA
crosslinks in skin biopsy.
Serum vit. C and vit. E doubled during
intervention (implies sub-saturation at
baseline). Minimal erythema dose




capacity in human skin before and
after UV irradiation; effect of
supplementation with 500 mg vit.
C per day.
Measurement of erythema and
antioxidant levels following
UVB irradiation.
Vit. C and E levels increased, but levels
not realistic (plasma vit. C 21 μM before
and 26 μM after 500 mg daily). Skin
MDA and glutathione content lowered,
no effect on MED.
[27]
Topical application
Topical application of vit. C cream
in advance of application of hair
dye product p-phenylenediamine.
Visual assessment of allergic
reaction following patch
application on volunteer skin
(on back).
Decreased or ablation of dermatitis and
allergic response due to local antioxidant
action of vit. C in cream.
[170]
Clinical study applying vit. C in
liposomes to human skin
(abdomen), then exposure to UV
irradiation.
Measured penetration through
skin layers, delivery of vit. C,
loss of Trolox, TNFalpha and
Il-1beta.
Increased vit. C levels in epidermis and
dermis with liposomes. Protection
against UV increased over liposomes
alone.
[67]
Microneedle skin patches to
deliver vit. C into the skin
assessed on areas of slight wrinkle
formation (around eyes).
Global Photodamage Score by
visual inspection. Skin replica
analysis and skin assessment by
visiometer.
Slightly improved photodamage score
and lessening of wrinkles after 12 weeks
of treatment with vit. C-loaded patches.
[186]
Vit. C-based solution containing
Rosa moschata oil rich in vitamins
A, C, E, essential fatty acids
/placebo moisturizer cream
applied to facial skin of 60 healthy
female subjects for 40–60 days.
Ultrasound monitoring
thickness of the epidermis and
dermis, and low (LEP), medium




(LEP), and structure of collagen,
elastin and microfibrils (MEP
and LEP).
Data suggest epidermis but not the
dermis increased in thickness. Increase
in MEP and HEP (collagen and elastin
synthesis) and decreased LEP
(inflammation and collagen
degeneration). No vit. C status
measurements in skin of individuals.
[149]
In vivo study with 30 healthy
adults. Protective effect of SPF30
sunscreen with and without
anti-oxidants (vit. E, grape seed
extract, ubiquinone and vit. C)
against Infra-Red A irradiation on
previously unexposed skin
(buttock).
Skin biopsy analysis; mRNA
and RT-PCR for matrix
metalloprotein-1 (MMP-1)
expression 24 h post irradiation.
Sunscreen plus antioxidants protected
skin against MMP-1 increase, sunscreen
alone did not. No indication of levels of
antioxidants, or whether they were able
to penetrate into skin layers.
Multi-component antioxidant mix.
[153]
In vivo study of 15 healthy adults.
Protective effect of vitamin C
mixtures (vit. C, vit. E, ferulic acid
OR vitamin C, phoretin, ferulic
acid) on ozone exposure on
forearms.
Skin biopsy analysis; 4-HNE




III collagen. After 5 days of 0.8
ppm ozone for 3h/d.
Vitamin C mixture reduced ozone
induced elevation in lipid peroxidation
products, NF-kB p65, cyclooxygenase-2
expression and completely prevented
MMP-9 induction by ozone. No
indication of levels of antioxidants, or




Test of topical silicone gel with vit.
C on scar formation in a
population of 80 Asian people.
Gel applied for six months after
operation.
Scar formation monitored by
modified Vancouver Scar Scale
(VSS) as well as erythema and
melanin indices by
spectrophotometer.
Vit. C decreased scar elevation and
erythema, decreased melanin index.




The role of vitamin C in skin health has been under discussion since its discovery in the 1930s as
the remedy for scurvy. The co-factor role for collagen hydroxylases was the first vitamin C function
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that was closely tied to the symptoms of scurvy and the realisation of the importance of this function
for the maintenance of skin health throughout the human lifespan led to the hypothesised skin health
benefit of vitamin C. In addition, the antioxidant activity of vitamin C made it an excellent candidate
as a protective factor against UV irradiation. These two hypotheses have driven most of the research
into the role of vitamin C and skin health to date.
The following information is available as a result of research into the role of vitamin C in skin
health, and Tables 2 and 4 list a sample of key studies:
• Skin fibroblasts have an absolute dependence on vitamin C for the synthesis of collagen, and for
the regulation of the collagen/elastin balance in the dermis. There is ample in vitro data with
cultured cells demonstrating this dependency. In addition, vitamin C supplementation of animals
has shown improved collagen synthesis in vivo.
• Skin keratinocytes have the capacity to accumulate high concentrations of vitamin C, and this
in association with vitamin E affords protection against UV irradiation. This information is
available from in vitro studies with cultured cells, with supportive information from animal and
human studies.
• Analysis of keratinocytes in culture has shown that vitamin C influences gene expression of
antioxidant enzymes, the organisation and accumulation of phospholipids, and promotes the
formation of the stratum corneum and the differentiation of the epithelium in general.
• Delivery of vitamin C into the skin via topical application remains challenging. Although some
human studies have suggested a beneficial effect with respect to UV irradiation protection, most
effective formulations contain both vitamins C and E, plus a delivery vehicle.
• Good skin health is positively associated with fruit and vegetable intake in a number of
well-executed intervention studies. The active component in the fruit and vegetables responsible
for the observed benefit is unidentified, and the effect is likely to be multi-factorial, although
vitamin C status is closely aligned with fruit and vegetable intake.
• Signs of aging in human skin can be ameliorated through the provision of vitamin C. A number
of studies support this, although measurement of skin changes is difficult. Some studies include
objective measures of collagen deposition and wrinkle depth.
• The provision of vitamin C to the skin greatly assists wound healing and minimises raised scar
formation. This has been demonstrated in numerous clinical studies in humans and animals.
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Abstract: Ascorbic acid (AA) possesses multiple beneficial functions, such as regulating collagen
biosynthesis and redox balance in the skin. AA derivatives have been developed to overcome this
compound’s high fragility and to assist with AA supplementation to the skin. However, how AA
derivatives are transferred into cells and converted to AA in the skin remains unclear. In the present
study, we showed that AA treatment failed to increase the cellular AA level in the presence of
AA transporter inhibitors, indicating an AA transporter-dependent action. In contrast, torisodium
ascorbyl 6-palmitate 2-phosphate (APPS) treatment significantly enhanced the cellular AA level in
skin cells despite the presence of inhibitors. In ex vivo experiments, APPS treatment also increased
the AA content in a human epidermis model. Interestingly, APPS was readily metabolized and
converted to AA in keratinocyte lysates via an intrinsic mechanism. Furthermore, APPS markedly
repressed the intracellular superoxide generation and promoted viability associated with an enhanced
AA level in Sod1-deficient skin cells. These findings indicate that APPS effectively restores the AA
level and normalizes the redox balance in skin cells in an AA transporter-independent manner.
Topical treatment of APPS is a beneficial strategy for supplying AA and improving the physiology of
damaged skin.
Keywords: ascorbic acid; ascorbic acid transporter; ascorbic acid derivative; skin
1. Introduction
Ascorbic acid (AA) is a major soluble vitamin distributed in the tissues of all organisms, including
animals and plants. In humans, organs such as the skin contain millimolar-order levels of AA, while
plasma contains relatively low levels of AA (40–60 μM) [1,2]. Environmental factors such as lifestyle
and nutrients consumed in the diet regulate the physiological kinetics of AA for maintaining organ
homeostasis in the body. For example, smoking and an insufficient intake of vegetables and fruits
adversely affect the AA status in the human body [3].
Accumulating evidence has shown that the chemical characteristics of AA as an electron donor
play an important role in redox regulation in the human body [2,4–6]. AA also regulates many oxidase
and hydroxylase activities as a cofactor to maintain cellular metabolism [4,7]. In particular, AA is
an essential cofactor for post-translational modifications by lysyl oxidase and prolyl hydroxylase in
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collagen formation and further enhances the transcript levels of type I and III collagen genes [5,8].
AA also interferes with pigment production by interacting with copper ions at the tyrosinase activity
site and reducing dopaquinone [9]. In this context, AA supplementation has been largely used to
maintain the skin function and prevent skin aging in cosmetic and supplement fields worldwide.
As AA is highly fragile and not very liposoluble, allowing it to penetrate the skin and
sustain its physiological function over a long period of time is difficult. To increase the
stability and liposolubility of AA, various AA derivatives have been developed for dermatological
application [10,11]. A phosphate group- and long hydrophobic chain-conjugated derivative,
torisodium ascorbyl 6-palmitate 2-phosphate (APPS), was also developed to increase liposolubility [12].
In clinical applications, Inui and Itami have reported that topical treatment with APPS lotion for four
weeks attenuated perifollicular pigmentation in female subjects [13].
AA is incorporated into cells through two types of transporters: sodium-dependent vitamin C
transporters (SVCT1 and SVCT2) and hexose transporters (GLUT1, GULT3, and GLUT4) [14]. AA and
oxidized AA, known as dehydroascorbic acid (DHAA), are separately transported into the cytoplasm
by SVCTs and GULTs, respectively. However, precisely how the AA derivative is transported to skin
cells and converted to AA remains unclear.
In the present study, we measured the cellular intake and transporter utilization of AA or APPS
to estimate the intake efficiency of AA in skin cells. We also investigated the conversion mechanism
of APPS to AA in cells. Furthermore, we investigated the redox regulation by APPS treatment in
skin cells associated with oxidative damage. We then discussed the potential utility of APPS in AA
supplementation and proposed an ideal protocol for applying AA derivatives to skin.
2. Materials and Methods
2.1. Materials
APPS (Figure 1) was provided by Showa Denko K.K. (Tokyo, Japan).
Figure 1. The structures of ascorbic acid (AA), A6Pal, APS, and APPS. L-ascorbyl 6-palmitate (A6Pal)
is additionally conjugated with a long hydrophobic chain. Sodium ascorbyl 2-phosphate (APS) is
additionally conjugated with a phosphate group. Torisodium ascorbyl 6-palmitate 2-phosphate (APPS)
is additionally conjugated with a phosphate group and a long hydrophobic chain.
2.2. Measurement of AA Content in Skin Cells
Human fibroblasts (TIG118) were purchased from Health Science Research Resources Bank
(Tokyo, Japan). TIG118 cells were maintained in DMEM (Nacalai Tesque, Kyoto, Japan) supplemented
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with 10% FBS (Life Technologies Corporation, Carlsbad, CA, USA), 100 units/mL of penicillin
(Sigma-Aldrich, St. Louis, MO, USA), and 0.1 mg/mL of streptomycin (Sigma-Aldrich) at 37 ◦C in a
humidified incubator with 5% CO2. Cells were pre-incubated with or without phorbol 12-myristate
13-acetate (PMA) and glucose for 1 h to inhibit ascorbate transporters [15,16]. After pre-incubation,
cells were washed three times with PBS and cultured for 1 h in culture medium with or without
10 μM AA and 10 μM APPS. Isolated cells were sonicated with 5.4% metaphosphoric acid (Wako,
Osaka, Japan) to suppress oxidation. The homogenate was centrifuged at 10,000× g for 15 min
at 4 ◦C, and the supernatant was then used for the assay. The AA level was measured using the
Vitamin C quantitative determination Kit (SHIMA Laboratories, Tokyo, Japan) in accordance with the
manufacturer’s instructions (Figure 2).
2.3. A Kinetic Analysis of APPS Metabolism in Vitro
Human keratinocytes (NHEKs) were purchased from KURABO Industries (Osaka, Japan). NHEKs
were cultured in HuMedia KG-2 (KURABO Industries) in accordance with the manufacturer’s
instructions. Cultured keratinocytes were collected and homogenized with HEPES buffer
(1 × 106 cells/mL). To the homogenate was added 300 μM APPS (final concentration), and the
solution was incubated at 37 ◦C. At each sampling point, the homogenate was centrifuged at
10,000× g for 15 min at 4 ◦C, and the supernatant was collected. Samples were filtered through
a 0.22-μm membrane and measured for APPS and its metabolites (Figure 1) by high-performance
liquid chromatography (HPLC) using a Shimadzu Prominence 20A system (Shimadzu Corporation,
Kyoto, Japan). The separation conditions of AA, APS, A6Pal, and APPS were as follows, respectively:
(1) for AA, Shodex Asahipak NH2P-50 4E column (Showa Denko K.K., Tokyo, Japan); detection
wavelength, 254 nm; mobile phase, 60 mM H3PO4/acetonitrile (20/80); flow rate, 0.8 mL/min; (2) for
APS, Shodex Asahipak NH2P-50 4E column; detection wavelength, 245 nm; mobile phase, 45 mM
Na2SO4, 50 mM H3PO4/acetonitrile (80/20); flow rate, 1 mL/min; (3) for A6Pal and APPS, Shodex
Silica C18P 4E column (Showa Denko K.K., Tokyo, Japan); detection wavelength, 265 nm; mobile phase,
30 mM K2HPO4 (pH 7.0)/tetrahydrofuran (35/65); flow rate, 0.7 mL/min. The levels of APPS and its
metabolites were determined on the basis of the peak area of the standard AA curve (Figure 3A).
Figure 2. APPS upregulates the cellular AA level in an AA transporter-independent manner.
(A) Intracellular ascorbic acid (AA) contents in human cells treated with 10 μM AA or 10 μM APPS
for 1 h. These data represent the mean ± SE; * p < 0.05; (B) Intracellular AA contents in human
cells. Human cells were pre-incubated with or without 10 μM PMA and 10 μM glucose for 1 h. After
pre-incubation, cells were washed and cultured for 1h in culture medium with or without 10 μM AA
and 10 μM APPS. These data represent the mean ± SEM; * p < 0.05 vs. no treatment control, ** p < 0.01
vs. no treatment control.
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Figure 3. APPS is converted to AA by endogenous convertases. (A) A kinetics analysis of APPS
metabolites including AA, A6Pal, and APS in keratinocyte lysates; (B) A human epidermal skin model
(LabCyte EPI-MODEL) was used in ex vivo experiments; (C) AA contents in epidermis and conditioned
medium in an ex vivo human epidermal skin model treated with APPS at various doses. These data
represent the mean ± SEM; * p < 0.05 vs. no AA treatment, ** p < 0.01 vs. no AA treatment.
2.4. Treatment with APPS in a Human Epidermal Skin Model
A human epidermal skin model (LabCyte EPI-MODEL; J-TEC, Aichi, Japan) was cultured in
accordance with the manufacturer’s instructions (Figure 3B). The skin model was treated with APPS
solution and cultured at 37 ◦C for 24 h. After incubation, skin tissues and conditioned medium were
collected. Skin tissues (10 mm diameter) were homogenized with 50% ethanol (three tissues/1.5 mL)
using a Biomasher (Nippi, Ibaraki, Japan). The skin homogenate was centrifuged at 15,000× g for
30 s at 4 ◦C. To the supernatant and conditioned medium was added 66% metaphosphoric acid
(10 μL/200 μL supernatant), and this solution was then incubated first at 4 ◦C for 30 min and then
with 22 mg/mL dithioerythritol (10 μL/200 μL supernatant; MP Biomedicals, LLC, Illkirch, France)
at 4 ◦C for 30 min. The supernatant was centrifuged and filtered for a later analysis. The levels of
APPS and its metabolites were measured with HPLC equipped with a Shodex Asahipak NH2P-50
4E column. The separation conditions were as follows: detection wavelength, 245 nm; mobile phase,
60 mM H3PO4/acetonitrile (20/80) (Figure 3C).
2.5. Measurement of AA Content in Sod1-decifient Cells
Sod1+/+ and Sod1−/− dermal fibroblasts were cultured in accordance with a previous
description [17]. Cells were cultured for 6 h in culture medium with or without 10 μM AA and
10 μM APPS. The AA level was measured using the Vitamin C quantitative determination Kit (SHIMA
Laboratories, Tokyo, Japan) as described above (Figure 4A).
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2.6. Intracellular Reactive Oxygen Species
Sod1+/+ and Sod1−/− dermal fibroblasts were cultured with 10 μM AA or 10 μM APPS for
24 h in 1% O2, followed by incubation under 20% O2 condition for 16 h to induce oxidative stress.
After treatment, the fibroblasts were stained with 10 μM dihydroethidium (DHE) fluorescent probe
(Life Technologies Corporation, Carlsbad, CA, USA) and 10 μM Hoechst 33342 (Merck Millipore,
Darmstadt, Germany) for 20 min under 20% O2. The intracellular superoxide (O2−) generation was
calculated as the DHE-positive area per nuclei number using fluorescent microscopy with the Leica
Qwin V3 image software program (Leica Microsystems, Buffalo Grove, IL, USA).
2.7. Cell Viability and Proliferation Assay
Sod1+/+ and Sod1−/− skin cells were cultured, and the number of cells was directly counted as
described previously [17]. The collected medium was centrifuged at 400× g for 5 min at 4 ◦C, and
the supernatant was used for the subsequent assays. The lactate dehydrogenase (LDH) level was
measured using the LDH cytotoxicity assay kit (Cayman Chemical Company, Ann Arbor, MI, USA) in
accordance with the manufacturer’s instructions.
2.8. Statistical Analyses
The statistical analyses were performed using Student’s t-test for comparisons between two groups
and Tukey’s test for comparisons among three groups. Differences between the data were considered
significant when the p values were less than 0.05. All data are expressed as the mean ± standard error
of the mean (SEM).
3. Results
3.1. APPS Positively Increases the Intracellular AA Contents in an AA Transporter-Independent Manner
AA has been largely used in cosmetics to maintain the skin function because of its beneficial
effects, such as antioxidation and regulation of collagen biosynthesis. However, its high fragility as
well as low liposolubility limit its penetration into the skin and physiological action. A number of AA
derivatives have been developed to overcome these disadvantages [10,11]. One such derivative, APPS,
was generated through the conjugation of a phosphate group and a long hydrophobic chain (Figure 1).
In order to evaluate the permeability of AA, we treated human skin cells with AA or APPS and
biochemically measured the cellular AA contents (Figure 2A). APPS treatment for 1 h significantly
increased the cellular AA levels by 4.1-fold compared to the control skin, whereas AA treatment
increased them only by 2.3-fold (Figure 2A). AA is usually transported into cells through AA
transporters, such as SVCTs and GLUTs [18,19]. To investigate the transporter utilization of APPS and
AA, we pre-treated human skin cells with PMA and glucose as AA transport inhibitors. As shown
in Figure 2B, PMA and glucose markedly inhibited the uptake of AA with only AA addition alone.
In contrast, APPS treatment sustained high levels of cellular AA in fibroblasts in the presence of both
PMA and glucose (Figure 2B). These results demonstrated that APPS supplementation effectively and
stably enhanced the intracellular AA contents in an AA transporter-independent manner.
3.2. Topical APPS is Effectively Converted to AA in Skin Cells
Next, to investigate the conversion mechanism of APPS to AA in skin cells, we incubated APPS
in homogenates of human keratinocytes and monitored the dynamics of APPS and other metabolites,
including AA, L-ascorbyl 6-palmitate (A6Pal), and sodium ascorbyl 2-phosphate (APS) (Figure 1).
As expected, the APPS contents were rapidly reduced at 2 h after incubation (Figure 3A). In contrast, the
contents of A6Pal, a metabolite with phosphate group cleavage, were increased at 2 h after incubation
and gradually decreased until 8 h (Figure 3A). Concomitantly, the AA contents were gradually increased
in a time-dependent manner (Figure 3A). Interestingly, the APS contents were not altered in the
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homogenates (Figure 3A). Indeed, potent phosphatase and esterase activities have been detected in
human as well as rodent skin tissue [20–23]. Taken together, these present and previous findings suggest
that endogenous phosphatases first cleave the phosphate group of APPS followed by intrinsic esterases
to release the palmitate group of A6Pal, resulting in the production of AA in the conversion process.
To estimate the permeability of APPS, we applied APPS to our human epidermis models, which
consist of a stratum corneum layer on keratinocyte culture (Figure 3B). Skin tissues without APPS
treatment possessed AA contents below detection limit. When we treated the model with APPS for
24 h, the AA contents in the tissue was significantly increased in a dose-dependent manner (Figure 3C),
suggesting that APPS was converted to AA in the tissue. Furthermore, the AA contents in the
conditioned medium at the bottom of the dish were also significantly increased in cases of high-dose
treatment (Figure 3C). These results indicated that APPS is effectively converted to AA and transferred
into skin cells.
3.3. APPS Attenuates Cellular Oxidative Damage in Skin
SOD1, a major antioxidant enzyme in cytoplasm, plays an important role in maintaining the
cellular redox balance. SOD1 loss significantly exhibited low viability associated with enhanced
intracellular reactive oxygen species and cellular damage [24–32]. Interestingly, we failed to detect
trace levels of cellular AA in Sod1−/− cells, indicating impairment of the AA-glutathione cycle and
redox balance (Figure 4A). APPS and AA treatment enhanced the cellular AA level in both Sod1−/−
and Sod1+/+ skin cells (Figure 4A). Pre-treatment with APPS and AA completely suppressed the
O2− generation in Sod1−/− cells, resulting in production at the same level as in the Sod1+/+ cells
(Figure 4B). APPS treatment also improved the viability and promoted proliferation associated with
the suppression of cellular damage (Figure 4C). These findings showed that APPS ameliorates cellular
damage by increasing the cellular AA level in damaged skin cells.
Figure 4. APPS elevates the cellular AA levels and attenuates cellular damage in skin cells.
(A) Intracellular AA contents in Sod1+/+ and Sod1−/− cells treated with 10 μM AA or 10 μM APPS for
6 h; (B) For the measurement of intracellular reactive oxygen species, cultured Sod1+/+ and Sod1−/−
cells treated with 10 μM AA or 10 μM APPS for 24 h were stained with dihydroethidium. The scale bar
represents 100 μm; (C) The viability and proliferation of Sod1+/+ and Sod1−/− cells with or without
10 μM APPS treatment for 96 h were analyzed. The lactate dehydrogenase activity in the conditioned
medium used to culture the Sod1+/+ and Sod1−/− skin cells for 96 h was measured. These data
represent the mean ± SEM; * p < 0.05, ** p < 0.01.
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4. Discussion
4.1. APPS is Effectively Converted to AA by Cellular Convertases, Resulting in AA Transport into the
Cytoplasm of Skin Cells in an AA Transporter-Independent Manner
Since skin innately includes relatively high levels of AA (approximately 50-fold that of
plasma) [1,2], the skin AA level generally depends on and is maintained by AA transport activity rather
than concentration-directed diffusion. In the present study, we showed that APPS treatment effectively
supplied AA to the cytoplasm in skin cells compared to AA treatment in vitro (Figure 2A). APPS, but
not AA, significantly increased the intracellular AA level even though both SVCTs and GLUTs were
inhibited (Figure 2B). This preferential capacity of APPS is due to an AA transporter-independent
action. As shown in Figure 3A, the addition of APPS to cell lysate rapidly increased the content of
A6Pal, but not APS, and then gradually increased the AA content. We also found that APPS efficiently
penetrated and converted AA in epidermal cells, leading to passed through AA in the conditioned
medium in a three-dimensional epidermis model (Figure 3C). Since skin cells possess high phosphatase
and esterase activity [20–23], endogenous cellular convertases can cleave the phosphate and palmitate
groups of APPS.
Glatz et al. reported that fatty acids, including palmitate, can directly traverse the plasma
membrane and that albumin proteins located at the outer cell surface may play an additional role in
the delivery of fatty acids into the cytoplasm in cells [33,34]. These multiple transport mechanisms of
fatty acid may help facilitate the permeability of skin cells to APPS, leading to its conversion to AA by
endogenous cellular enzymes, such as phosphatases and esterases.
4.2. APPS Improves the AA Level and Skin Function by Regulating Redox Balance
In the present study, in vitro experiments showed that the supply of AA by APPS treatment
effectively increased the cellular AA level and suppressed the O2− generation associated with
improved viability in Sod1−/− cells, resulting in physiological redox level (Figure 4A,B). We also
showed that treatment with APPS significantly promoted the proliferation and migration of Sod1−/−
skin cells associated with the suppression of LDH activity (Figure 4C). Du et al. reported that APPS
treatment improved viability of PC12 cells treated with hydrogen peroxide [12], suggesting that APPS
treatment protect cells from various types of oxidative damage. AA highly reacts with oxygen and O2−,
resulting in oxidized AA forms such as mono-DHAA and DHAA [35,36]. Mono-DHAA and DHAA
serve as AA radicals to capture electrons and can also be recycled back into AA by direct reduction in
the AA-glutathione cycle [37]. Under highly oxidative conditions, mono-DHAA and DHAA are further
degraded via hydrolysis or oxidation to 2,3-diketogulonic acid with no AA potency [38]. These results
suggest that AA supplementation by APPS may increase AA recycling via these systems, resulting in
improvement in the redox balance in damaged skin, such as under conditions of Sod1 deficiency.
Long chain fatty acids, including palmitate, are required for the lipid synthesis in skin to
maintain tissue homeostasis [39]. Kim et al. reported that ultraviolet (UV) irradiation and aging stress
caused a reduction in the contents of palmitate, eicosatrienoic acid, and other fatty acid in skin [40].
Treatment with eicosatrienoic acid downregulated the expression of MMP1 in human keratinocytes
irradiated by UV [40]. Palmitoleic acid, metabolites from palmitate, also inhibited the gene expression
of Mmp9 and RANKL-induced NF-κB activation in murine macrophages [41]. These results suggest
that fatty acid supplementation to the skin may act as a regulator of skin homeostasis. In this context,
palmitate cleaved from APPS in the skin might also protect skin cells from exogenous insults, such as
pro-oxidants and UV.
4.3. Topical Application of APPS for Damaged Skin
The SVCT function is obligatorily dependent on a favorable inward gradient for Na+, which in turn
is sustained by the continuous extrusion of Na+ by ATP-dependent Na+/K+-ATPase [42,43]. Indeed,
the replacement of Na+ with K+, Li+, or choline almost completely abolishes the AA uptake [42,44].
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Furthermore, SVCT2 is modulated by Ca2+ and Mg2+ ions, which switch the transporter from an
inactive to an active form [45]. We previously reported that Sod1 deficiency induced age-related skin
atrophy and a reduction in the AA contents in skin [25]. We also provided evidence that Sod1−/− skin
cells showed aberrantly increased intracellular Ca2+ levels (data not shown) and loss of mitochondrial
membrane potential associated with ATP depletion [46], indicating alteration of intracellular Ca2+ and
ATP utilization in skin. We previously demonstrated that the topical treatment of APPS completely
cured atrophy and oxidative damage in Sod1−/− skins [17,27]. Taken together, these findings also
implied that APPS thus appears to be useful for the supply of AA to the skin and also for the mitigation
of oxidative damage via penetration mechanisms independent from AA transporters. Topical treatment
of APPS is a beneficial strategy for supplying AA and improving the physiology of damaged skin.
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Abstract: Establishing intake recommendations for vitamin C remains a challenge, as no suitable
functional parameter has yet been agreed upon. In this report, we review the emerging evidence on
neutrophil motility as a possible marker of vitamin C requirements and put the results in perspective
with other approaches. A recent in vitro study showed that adequate levels of vitamin C were needed
for this function to work optimally when measured as chemotaxis and chemokinesis. In a human
study, neutrophil motility was optimal at intakes ≥250 mg/day. Interestingly, a Cochrane review
showed a significant reduction in the duration of episodes of common cold with regular vitamin C
intakes in a similar range. Additionally, it was shown that at a plasma level of 75 μmol/L, which
is reached with vitamin C intakes ≥200 mg/day, incidences of cardiovascular disease were lowest.
This evidence would suggest that daily intakes of 200 mg vitamin C might be advisable for the general
adult population, which can be achieved by means of a diverse diet. However, additional studies are
warranted to investigate the usefulness of neutrophil motility as a marker of vitamin C requirements.
Keywords: vitamin C; ascorbic acid; dietary reference value; immune function; neutrophil motility
1. Introduction
Vitamin C is an essential micronutrient. As humans cannot produce it, the daily amount needed to
ensure an adequate intake is defined in dietary reference values established in many countries around
the globe. The guiding principle for the definition of dietary reference values for vitamin C, as for
other essential micronutrients, has changed in the past few decades from only preventing deficiency
syndromes to maintaining or even improving human health and ultimately reducing the risk of
non-communicable diseases [1]. Scurvy—the clinical manifestation of vitamin C deficiency—develops
when intake is below 10 mg/day for a prolonged period [2]. While it takes very little vitamin C to
prevent an overt deficiency, the challenge is to define the daily intake required to maintain adequate
health given the many metabolic processes that vitamin C is involved in.
The role of vitamin C in the human immune defense in particular is a widely researched field.
However, the heterogeneity of study designs and the variability or even inconsistency of outcomes
make it difficult to use these data as the basis for daily reference values. In the past, they were
consequently deemed insufficient to reliably estimate the vitamin C requirement for apparently
healthy individuals. The fact that vitamin C is actively accumulated in the leukocytes resulting in
an up to 20 times higher concentration in neutrophils than in the plasma underscores its important
role in immune defense. Agencies such as the Institute of Medicine (IOM) in North America used
the near-maximal neutrophil concentration with minimal urinary loss to derive vitamin C reference
values [1]. In that approach, the vitamin C intake required to near saturate the vitamin C concentration
in neutrophils was employed to define the daily reference values.
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Recently, additional evidence has emerged on the functional capacity of neutrophils relative to
vitamin C concentration in vitro [3] and intakes in humans [4]. It is the aim of this contribution to
review the potential of neutrophil motility as a possible marker for defining intake requirements for
vitamin C in light of these recent findings. We will also discuss the current levels of vitamin C intakes
and how to achieve appropriate intakes.
2. Physiologic Functions of Vitamin C in Human Health
Vitamin C can be in the form of L-ascorbic acid and the oxidized form L-dehydroascorbic acid, and
both are essential for a range of vital functions (Figure 1). Humans, as well as some other species such
as monkeys, guinea pigs, some fish species, and birds, have lost L-gulonolactone oxidase, the enzyme
catalyzing the last step in the synthesis of vitamin C, which makes them dependent on ample amounts
of vitamin C from the diet [5,6].
Figure 1. Summary of the functions of vitamin C and established health claims by European Food
Safety Authority (EFSA), Article 13.1 and 14.
Thanks to its reducing power, vitamin C mainly functions either as an antioxidant [7] or as
a cofactor in enzymatic reactions [5]. As an antioxidant, it scavenges free radicals such as reactive
oxygen species and reactive nitrogen species, turning them into less reactive molecules [8]. Through this
mechanism, vitamin C protects proteins, lipids, and nucleic acids, and thus the body in general, from
oxidative damage. Due to its antioxidant function, it contributes, for instance, to the protection of
skin from UV irradiation [9,10] and is able to recycle other antioxidants such as vitamin E [11–13].
By doing so, it helps prevent low density lipoprotein (LDL) oxidation and protects cell lipids from
peroxidation [12], thus it is essential for the proper function of the endothelium. In addition, vitamin C
increases the bioavailability of non-hem iron by reducing it to the ferrous form, the only form which
can be absorbed in the intestine [14,15]. It also increases iron solubility in the stomach and duodenum
and reduces the likelihood of iron being affected by inhibitors of iron absorption [16].
As an essential cofactor of iron- and copper-dependent enzymes, vitamin C is involved as
an electron donor in a range of catalytic redox-reactions [5]: It helps catalyze the synthesis of
L-carnitine from L-lysine, which plays an important role in energy production via ß-oxidation in
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mitochondria [17–19]. However, in this reaction, its essentiality is discussed controversially, as it may
be replaced by glutathione [20]. The synthesis of the catecholamine noradrenaline, a hormone and
neurotransmitter, from dopamine by the enzyme dopamine β-monooxygenase also requires vitamin
C [21]. Furthermore, the alpha-amidating monooxygenase needs it to increase the stability and activity
of peptide hormones such as oxytocin and vasopressin [22]. Vitamin C also plays a role in the synthesis
of hypoxia-inducible factor-1 alpha [23], and it is involved in tyrosine metabolism [24].
The vitamin C-dependent enzymes proline-hydroxylases and the lysine hydroxylase are essential
for the synthesis of the proteoglycan collagen, which is the main molecule in connective tissues found
for example in bone, periodontium, cartilage, skin, ligaments, tendons, and blood vessels [25,26].
Impaired collagen formation due to low vitamin C intake for several weeks leads to the typical
symptoms of scurvy such as bleeding gums with the loss of teeth, malformation of bones, and weak
blood vessels. This ultimately results in vasomotor instability and open wounds. For the formation
and remodeling of bones, not only minerals are needed but also the organic matrix which contains up
to 90% collagen produced in osteoblasts. Vitamin C deficiency will lead to bone loss or reduction in
bone formation [27–29]. In addition, for wound healing, adequate amounts of vitamin C are needed
because it is essential for fibroblast maturation, for the formation of cross-links between collagen fibers,
and for angiogenesis [30,31], and thus it also has positive effects on pressure ulcers and burns [32].
Furthermore, vitamin C is a cofactor for the rate-limiting enzyme in bile acid synthesis, which may
also enhance the expression of LDL receptors on hepatocytes, thus reducing LDL blood levels [33,34].
A recent review showed significant reductions in blood lipids after vitamin C supplementation in
sub-populations with dyslipidemia or low vitamin C status at baseline [35]. This is in line with its
positive impact towards a healthy cardiovascular system, reducing the prevalence of coronary heart
disease [34] and stroke [36]. Its antioxidant effects reduce oxidative stress and enhance endothelial
function through its effects on nitric oxide preservation and generation. Nitric oxide is a signaling
molecule that activates endothelial and smooth muscle cells, which increases vasodilation, thus
reducing blood pressure and preventing cardiovascular disease (CVD) [37]. Recent meta-analyses
support this [38,39], showing that vitamin C improves endothelial function. Antihypertensive effects of
vitamin C, particularly by reducing systolic blood pressure, have been shown in short-term trials [40].
Based on this evidence, it was concluded that vitamin C may be a useful nutritional intervention for
the secondary prevention of CVD [2].
Furthermore, vitamin C plays an essential role in immune function, which is impaired by insufficient
supply and re-established through supplementation [41,42]. It exerts its effect via the promotion of T-cell
maturation by modulating the epigenetic regulation of gene expression as a cofactor of dioxygenases [43].
For the circulating immune cells, the importance of vitamin C is highlighted by the preferential uptake
via active transport by the sodium-dependent vitamin C transporter located in their cell membranes,
resulting in vitamin C concentrations from 20 to 60 times higher than in the surrounding plasma [44,45].
It is assumed that the high vitamin C concentration protects neutrophils from the reactive oxygen
species (ROS) they generate to kill pathogens such as bacteria and viruses. Subsequently, extracellularly
accumulated L-dehydroascorbic acid is rapidly transported back by glucose transporters and recycled
to L-ascorbic acid [5]. Furthermore, it could be shown that vitamin C improves the immune function by
influencing chemotaxis (CT) and chemokinesis (CK) of neutrophil leukocytes [46]. The enhancement in
leukocyte motility by ascorbic acid goes along with its ability to assemble microtubule organelles [47].
These findings are supported by the observation that the vitamin C level is affected in people with
infections, chronic diseases [48], and higher oxidative stress, as they lead to higher metabolic losses:
e.g., during common cold [49] and in smokers, a 40% higher turnover is seen [50]. The multiple
functions of vitamin C are also reflected by EFSA health claims (Figure 1).
3. Approaches Used to Define Vitamin C Requirements
Currently, the recommended intakes for adults tend to vary for the genders, but they also depend
on the agency issuing them (Table 1). Moreover, most have additional allowances for periods of
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elevated needs, typically pregnancy and lactation [1,51–58]. In some recommendations, smokers are
also advised to increase their intakes because their vitamin C status is lower than in non-smokers most
likely due to the oxidative potential of the inhaled smoke [1,56,59]. Even though some differences
exist in the data used to evaluate dietary requirements and the rationale applied in interpreting them,
dietary reference values no longer simply aim at preventing overt deficiencies. They are meant to
define intakes associated with optimal health for the majority of individuals—typically 95% to 97.5%
of a specific age and gender group.
Table 1. Examples for a wide range of recommended daily intakes for vitamin C in adults (≥19 years)
in different countries and regions.
Country Men (mg) Women (mg)
Germany, Austria, and Switzerland [56,59] 110 95
United States [1] 90 75
United Kingdom [52] 40 40
Australia and New Zealand [54] 45 45
Japan [58] 100 100
Philippines [55] 75 70
Singapore [57] 105 85
South Africa [51] 90 90
FAO/WHO [53] 45 45
FAO: Food and Agriculture Organization of the United Nations; WHO: World Health Organization
The first physiological marker used to define intake recommendations was the symptoms of
scurvy. These could be prevented with daily intakes of around 10 mg, which led, with the inclusion
of a safety margin of 30 to 50 mg, to the first set of recommendations for vitamin C of 60 mg per
day [60,61]. However, even 20 years ago, this approach was challenged with the argument that a lack
of overt deficiency did not necessarily indicate the adequacy of intake [61]. It was therefore suggested
that recommended intakes should be at a level that assures optimal functioning of all processes
requiring vitamin C, but still sufficiently below those known to provoke adverse effects [60,61].
As a consequence, bodies such as IoM and EFSA defined new levels of adequate intakes [1,56,62].
Moreover, they discussed potential biological markers of physiological functions, such as health
outcomes associated with vitamin C intake. However, it was concluded that these were insufficiently
established, and consequently the recommendations were still based on indicators of vitamin C status.
EFSA determined the Average Requirement (AR) for healthy adults based on the vitamin C
intake that balanced losses as metabolic and urinary losses and the quantity of vitamin C required
for the replacement of these losses to metabolic losses and maintained fasting plasma ascorbate
concentrations at about 50 μmol/L. This led them to propose daily vitamin C intakes such as
the Population Reference Intake (PRI) of 110 mg and 95 mg for healthy adult men and women,
respectively [62]. The German-speaking countries adapted their joint reference values to the EFSA
recommendations [57]. IoM chose a slightly different approach by using the near-maximal neutrophil
concentration with minimal urinary excretion of ascorbate to provide antioxidant protection, which
led them to define a Recommended Daily Allowances (RDA) of 90 mg for adult men and 75 mg for
adult women [1]. However, both IoM and EFSA highlighted the need to establish an accurate, specific,
and easily measurable functional marker for vitamin C (e.g., IoM [1]).
Given the range of functions vitamin C has in the human body, there are many putative functional
markers. However, their lack of specificity was one of the main reasons why they were deemed
unsuitable as a basis to define vitamin C intake recommendations [63]: Assessing hepatic enzyme
systems by measuring cholesterol concentration and detoxification has been proposed [64], but it
is influenced by a range of factors and is therefore not specific enough to define vitamin C status.
The same applies to measuring DNA oxidation as an indicator of DNA damage [63]. Collagen turnover
measured as hydroxyproline excretion was another potential candidate [65]. Unfortunately, the high
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inter- and intra-individual variation in the response to varying vitamin C intakes reduces its usefulness
as a biomarker to define intake recommendations [66]. Given the inverse relationship between vitamin
C and blood pressure, this has been discussed as a putative physiological biomarker, but again, it is not
sufficiently specific for vitamin C status [67–69]. Furthermore, the urinary excretion of vitamin C has
been proposed as a sign of adequate intake. However, this is not a functional marker and reflects only
one aspect of vitamin C plasma homeostasis. It could be shown that the bioavailability is complete
for 200 mg vitamin C as a single dose [45]. These examples show that a putative marker needs to be
reasonably specific to vitamin C status, sensitive to changes in intake within the relevant range, and
reliably measurable.
4. New Insights Support Reassessment of Current Vitamin C RDAs
Recently published data might be able to shed some light on the question of suitable indicators
and consequently enable us to define more appropriate recommendations for daily intakes. The effect
of vitamin C on motility in neutrophils seems to be a promising candidate for such a marker [70].
In the following paragraphs, we review the suitability for the use of this marker and how it fits with
the well-established knowledge.
Neutrophils are the most abundant type of leukocytes (40% to 75%) and play an important role in
the innate immune system [71]. The cells are highly motile and are able to migrate from the blood into
the affected tissues in a process initiated and orchestrated by chemoattractants such as pathogen-derived
products or host-derived factors [72]. Chemotaxis (CT) and chemokinesis (CK) describe this movement:
while the former is directional, the later consists of random movement [70]. Neutrophils contain high
concentrations of vitamin C compared to plasma levels [45], and it is thought that they function best
if adequate amounts of vitamin C are available [47]. It has, for example, been shown that inadequate
intakes could impair CT in guinea pig leukocytes [73]. The underlying mechanism is thought to be the
ability of vitamin C to promote the assembly of microtubule organelles [47].
Similar effects could be shown in a recent in vitro study investigating the impact of vitamin C
on CT and CK in cell cultures [3]. It showed that extracellular vitamin C significantly increased CT
in vitamin C-preloaded peripheral blood leukocytes, which predominantly consist of neutrophils [3].
Furthermore, vitamin C at physiological concentrations also affected CK, indicating that vitamin
C enhances directional and random migration at concentrations comparable to those observed in
plasma [3]. This could be seen as a further indication that neutrophil function could be a suitable
functional marker to define vitamin C intake. Nevertheless, previous clinical studies investigating the
role of vitamin C on neutrophil chemotaxis showed inconsistent effects, and they did not allow for
the estimation of the vitamin C requirement for apparently healthy individuals reliably [1]. Therefore,
further well designed human studies are warranted.
The findings of the in vitro studies are corroborated by a human study investigating the
effect of vitamin C supplementation on the function of neutrophils [4]: Healthy young men with
suboptimal plasma vitamin C status (<50 μmol/L) were supplemented with vitamin C rich kiwi
fruits (~260 mg/day vitamin C) for four weeks. This is in line with the postulation that such studies
should use the baseline vitamin status below a defined threshold as inclusion criteria [74]. Despite the
relatively small sample size of 12 participants, the plasma and neutrophil vitamin C content as well as
chemotaxis of neutrophils and superoxide generation increased significantly [4].
These results suggest that supplementation of vitamin C from kiwi fruits is associated with the
improvement of important neutrophil functions and consequently enhanced immunity. Given the
study design, it cannot be excluded that other components of the kiwi fruits contributed to this effect.
This needs to be confirmed with an intervention using vitamin C supplements at different doses and a
placebo group including more subjects to prove which is the right dose. However, based on the results
from the in vitro study, it is very likely that vitamin C was the active compound. While neutrophil
saturation was already reached at intakes of 100 mg/day [45], it seems that for optimal maturation and
functioning of these cells, intakes of ≥200 mg/day result in additional benefits [3,4]. This is supported
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by the results from a study showing that intakes of ~110 mg (~60 mg from the diet plus ~53 mg vitamin
C from one-half kiwifruit) resulted in saturated neutrophil levels, but not saturated plasma levels. [75].
When they increased the dose of kiwi fruit to two per day with a total vitamin C intake of around
210 mg, plasma vitamin C levels, as well as urinary excretion, further increased [76]. This is thought
to be sufficient to achieve a plasma level of ≥70 μmol/L, which should be reached to ensure optimal
immune function by the neutrophil leucocytes. Moreover, this is also within the range where the
human sodium-dependent vitamin C transporter 2, which is responsible for the uptake of vitamin C
into target tissues, is at maximum velocity [77]. In addition, this level of intake enables optimal vitamin
C supply in all stages of the neutrophil development and therefore ensures maximal functions of these
short-lived immune cells. Importantly, intakes ≥200 mg/day were not associated with any adverse
outcomes [45] and are well within the range of <2000 mg/day, which are considered safe by IoM [1].
EFSA considers that supplemental daily doses of vitamin C up to about 1 g are not associated with
adverse gastrointestinal effects, and an increased risk of kidney stones was not found in individuals
with habitual intakes of 1.5 g/day [78].
For healthy young women, the intakes required for plasma and plasma saturation were slightly
lower (100 to 200 mg/day) [79]. However, the authors of this subsequent pharmacokinetics study
still concluded that vitamin C intakes of 200 mg from foods are probably required, as bioavailability
might be lower from whole fruits and vegetables compared to supplements [79]. Further studies in
women are needed to assess the optimal dose of the vitamin for neutrophil function. Moreover, the
requirements might also increase with age and possibly body weight as well, given the increased
level of inflammation and consequently oxidative stress accompanying both [80,81]. To adapt the
recommendation to different groups requires further evaluations.
5. The Improvement of Neutrophil Function by Vitamin C in a Broader Human Health Perspective
5.1. Common Cold
Given its importance for the immune system, improved vitamin C status can be expected to
translate into clinical endpoints when faced with infections. This was assessed in a recent Cochrane
review investigating the effect of vitamin C intake on the common cold in adults and children [82].
In this meta-analysis, no significant effect of supplementation with between 200 mg and 2000 mg
of vitamin C daily on the incidence of common cold was found. However, as is often the case in
nutritional randomized controlled trials, the placebo group did not have zero intake of vitamin C, as the
participants’ diets provide potentially significant amounts of the nutrient in question [83]. Therefore,
it is crucial to enroll subjects with hypovitaminosis (plasma vitamin C <50 μmol/L) for such trials [74]
to be able to work with an approximation of an actual placebo group. Moreover, in a few studies, the
‘placebo’ groups also received 50 to 70 mg/day vitamin C for ethical reasons [82]. The fact that in
a subgroup analysis of persons with ‘acute physical activity’ and consequently, higher requirements,
vitamin C supplementation reduced the number of incidents by half (Risk Ratio 0.48, 95% Confidence
Interval 0.35 to 0.64) supports this interpretation. Interestingly, this was not the case in those with
long-term physical stress.
Despite these limitations, it was found that vitamin C supplementation of ≥200 mg significantly
reduced the duration of common cold symptoms: In children, the effect was reduced by ~14% and
in adults, it was reduced by nearly 8% [82]. Interestingly, it was found that in children, it increased
to 18% if only studies supplementing ≥1000 mg were included. This might indicate that during
an acute infection, higher intakes could be beneficial—even though this effect was not seen in adults.
Neutrophils are under increased oxidative stress during an infection, and it has been shown that
vitamin C concentrations greatly increase when they are activated (see the review by Padayatty and
Levine [5]). Moreover, supplementation led to a modest but significant reduction in the days that the
participants missed from work or school due to the common cold.
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On average, episodes of common colds last around 10 days [84] and children tend to have 3 to 5
per year, while for adults it is 1 to 2. Consequently, it can be estimated that an adequate supply with
vitamin C can reduce the days spent being ill by 4 to 6 and 1 to 2 for children and adults, respectively
(see Figure 2). In addition, the meta-analysis reported a reduction in the severity of the common cold
thanks to supplementation with vitamin C, even though the interpretation of this is difficult due to the
wide range of the definitions of ‘severity‘ used in the various studies [82].
The findings of studies starting vitamin C supplementation only after the onset of symptoms of
common cold were equivocal [82]. This is not surprising, considering that neutrophils are crucial in
recognizing an infection and initiating an immune response to fight it. They should therefore already
be functioning well before a cold is caught. Given their short half-life, only regular intake at adequate
levels can ensure that sufficient mature neutrophils are produced. Marginal vitamin C levels, on the
other hand, reduce the CT and CK of the neutrophils, which leads to a slowed immune response.
Figure 2. Duration of the common cold. Effect of regular, prophylactic supplementation of vitamin C
(≥200 mg/day) on the duration of the common cold, assuming a 10-day illness in adults * (17 trials, 8%;
p = 0.0002) and in children ** (total 14 trials, 14% for ≥200 mg/day and 10 trials, 18% for 1 to 2 g/day;
p < 0.0001), adapted from Hemila and Chalker, 2013 [82].
5.2. Non-Communicable Diseases
Vitamin C is thought to play an important role in the prevention of non-communicable diseases
such as CVD and cancer [48,85]. One difficulty is that randomized controlled trials are not necessarily
suitable for detecting such a relationship between a nutrient and a disease [83]. One review found that
none of the available studies used low plasma vitamin C concentrations as inclusion criteria, and that
the participants of a large majority of these trials (34 out of 35) were unlikely to show a benefit given
their baseline plasma concentrations [74].
The link between inadequate vitamin C intake and non-communicable disease is best documented
for CVD (for a detailed review of the evidence, see Frei et al., 2012 [85] and Moser et al., 2016 [86]).
Given that atherosclerosis is an inflammatory disease [87], it seems likely that vitamin C plays an
important role in protecting against it: Vitamin C depletion is thought to increase the susceptibility
of LDL cholesterol to oxidation, a risk factor for CVD [88]. However, it is now equally recognized
that reactive oxygen species formed by the inflammatory response in an existing atherosclerotic lesion
may in turn reduce vitamin C antioxidant levels [87]. A recent review of epidemiologic studies
supports the finding that endothelial function and lipid profiles, especially in subjects with low
plasma levels, are improved by vitamin C. This is in line with large prospective studies that have
shown an inverse relationship between plasma vitamin C status and the risk of CVD [88–92]. Also,
Langlois and colleagues [93] showed a relationship between vitamin C concentration and the severity
of atherosclerosis and inflammation in peripheral artery disease patients. Moreover, there is evidence
from a meta-analysis of randomized controlled trials that vitamin C supplementation has a beneficial
effect on blood pressure [40]. Furthermore, sub-group analysis of a recent meta-analysis revealed that
vitamin C supplementation reduced LDL cholesterol in healthy participants and, triglycerides are
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reduced and HDL cholesterol is significantly increased in diabetics. Furthermore, greater effects of
vitamin C supplementation in lowering total cholesterol and triglycerides could be shown in those
with higher concentrations of these lipids at baseline and the HDL cholesterol increase was greater in
participants with lower baseline plasma concentrations of vitamin C, while the overall effects were not
significant [39].
Frei [85] argues that the scientific evidence from metabolic, pharmacokinetic, epidemiologic,
and intervention studies strongly advocates for an increase of the recommended daily intake to
≥200 mg/day to minimize the risk of negative health effects. Moreover, if the vitamin C content of
a healthy, balanced diet in line with guidelines to prevent non-communicable diseases is estimated,
it adds up to values slightly above 200 mg/day [94]. Even though these findings relate to different
functions of vitamin C, they indicate optimal intakes in a range similar to that suggested by neutrophil
motility, thereby strengthening the proposed recommendations. In addition, even though fraught with
the same problems as for the other health outcomes, there is some evidence that maintaining healthy
vitamin C levels might offer some protection against age-related cognitive decline and Alzheimer’s
disease [95]. This is not surprising, in the light of the mounting evidence for the role of CVD [96]
and oxidative stress in the development of Alzheimer’s disease [97]. Given the number of people
affected by hypertension, CVD, dementia, and cancer, defining recommendations with the highest risk
reduction for these diseases is of paramount importance.
6. Vitamin C Status in the General Population
Proposing to increase the dietary intake recommendations for vitamin C raises the question of
whether and how these can be achieved by the general population. Based on the typical food-based
dietary recommendations, even the increased intakes of ≥200 mg/day should in theory not cause
a problem: Many countries translated the WHO recommendation of ≥400 g of fruits and vegetables,
excluding potatoes, cassava, and other tubers, per day [98] into at least five daily servings of such
foods. As many of these fruits and vegetables provide significant amounts of vitamin C per average
serving (see Table 2), it is feasible to supply ≥200 mg/day of the vitamin via a balanced diet. This is
particularly the case if at least one item with high vitamin C levels (e.g., orange juice) is included
in the daily diet and preparation techniques such as steam cooking are used that reduce the loss of
vitamin C [99]. In addition, other foods also contribute important amounts: A relatively recent German
dietary survey reported that the main dietary sources for vitamin C were fruits and fruit products,
non-alcoholic beverages, and vegetables [100]. However, potatoes, meat, and meat products such as
sausages, as well as dairy products contributed to an important, but lesser, degree [100].
A study in Greece showed that adults who did not meet the recommended daily intakes for
fruits or vegetables had a higher risk of inadequate vitamin C intakes [101]. Not surprisingly, those
who complied with this specific dietary recommendation tended to have adequate amounts in their
diet [101]. In line with this, a study in Switzerland compared vitamin C intakes in omnivores,
vegetarians, and vegans, and found mean intakes of 94 mg/day, 158 mg/day, and 239 mg/day,
respectively [102]. The corresponding plasma C levels were ~55 μmol/L, ~69 μmol/L, and ~72 μmol/L,
respectively. This ties in nicely with the estimate that intakes of ≥200 mg/day achieve plasma levels in
the desirable range of >70 μmol/L [45]. Even though the data on foods consumed was not reported in
the Swiss study, it can be assumed that the increased intakes of fruits and vegetables in vegetarians
and vegans reported elsewhere [103] is reflected in this data.
However, people tend not to follow food-based dietary advice and tend to eat too much of what
they should reduce and not enough of the foods that they are encouraged to eat [104]. This is no
different in the case of fruits and vegetables, as seen in a recent study: 58% to 88% of adults around
the world did not consume the recommended five servings per day [105]. A recent survey from
Switzerland showed that only 13% consume the recommended five servings per day [106]. This is in
line with an earlier study, which reported that less than 25% of the general adult population in low-
and middle-income countries actually followed the recommendation of five portions of fruits and
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vegetables per day [107]. On the bright side, data from France shows an increase in the consumption
of fresh fruits and vegetables, accompanied by a parallel increase in vitamin C intakes, albeit from
comparatively low levels (mean intakes for adults <100 mg/day) [108].
Table 2. Composition of a range of raw fruits and vegetables (data from the U.S. Department of
Agriculture [109]).
Food Content per 100 g (mg) Unit Content per Unit (mg)
Vegetables
Red pepper 128 1 piece (119 g) 152
Green pepper 80 1 piece (119 g) 96
Broccoli 89 1 cup 1 (91 g) 81
Brussels sprouts 85 1 cup 1 (88 g) 75
Cabbage 37 1 cup 1 (89 g) 33
Cauliflower 48 1 cup 1 (107 g) 52
Tomato 14 1 piece (123 g) 17
Green peas 40 1 cup 1 (145 g) 58
Fruits
Orange 53 1 piece (96 g) 70
Kiwi 93 1 piece (69 g) 64
Mango 36 1 piece 2 (336 g) 122
Strawberry 59 1 cup 1 (144 g) 85
Cantaloupe melon 37 1 wedge (69 g) 25
Grapefruit 33 1 piece (118 g) 39
1 1 cup ≈ 2.4 dL; 2 without refuse.
This puts the French into the middle range of intakes within Europe: The European Nutrition
and Health Survey reports mean vitamin C intakes ranging from ~60 mg to ~153 mg [110]. However,
the informative value of mean intakes is limited when assessing the adequacy of intake of a population:
despite the comparatively high mean intake reported for Germany (153 mg/day for adults) [110], half
the adult population has vitamin C intake below 100 mg/day, which was the recommendation at the
time of the survey [59,111,112]. Using a lower level of 60 mg/day and 50 mg/day for men and women,
respectively, the European survey reports on 8% to 40% of adults with inadequate intakes [113], and
similar rates were reported in the U.S. [114]. Unfortunately, for many countries, only the information
on mean intakes is available. However, as the mean intakes are in a similar range as those reported
in the surveys referred to above, it can be assumed that a similar problem exists in many—also
affluent—parts of the world: In Japan, median intakes of 60 mg and 100 to 115 mg were reported for
the age group of 15 to 49 and ≥50 years, respectively [115]. Similarly, mean intakes in South Korea
were 116 mg in men and 105 mg in women [116].
Dietary supplements also play an important role in the provision of vitamin C: supplement users
across all age groups were found to have higher serum concentrations and lower risk of deficiency
than non-users [117]. In the U.S., the proportion of the general population (aged ≥2 years) with intakes
below the Estimated Average Requirement for vitamin C decreased from 46% to 25% if fortified foods
and supplements were taken into account [118]. However, supplement use in Europe is less common,
and there is a strong north-to-south gradient, with >40% and 5%, respectively, consuming some type
of dietary supplement [113]. Still, in Germany, vitamin C supplements are those used most frequently,
and around 10% reported taking them [111]. Similarly, it was among the three most commonly used
supplements in a study across Europe [119], and supplements can therefore be assumed to play an
important role as dietary sources for the vitamin.
The contribution of different foods to vitamin C intake depends on a range of factors such as
variety, maturity of the fruit or vegetable when harvested, and the climate where it grew [120–122],
but also on the processing technique involved [63,109]. This makes it difficult to extrapolate the actual
status from dietary intake data. However, serum vitamin C concentrations—a more direct marker of
vitamin C status—show a similar picture: An analysis in Canada classified 14% of adults as vitamin
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C deficient and a further 33% as having sub-optimal serum levels [123]. In the U.S., similar rates for
vitamin C deficiency were measured when serum levels were reported in the 1988 to 1994 survey [124],
but the prevalence was found to decrease to around 7% in 2003 to 2004 [2]. However, given that
persons on low incomes were at increased risk of deficiency [2], it is very likely that the economic crisis,
and the consequent increase in poverty and food insecurity [125], has reversed this trend. Moreover,
there was a trend towards lower levels for obese persons, which reached significance for women,
but not for men [2]. Given the dramatic increase in the prevalence of obesity reported [126], this is
worrying, even though it is not clear whether there is a causal link.
In summary, it can be said that the available evidence indicates that even in affluent societies,
a significant proportion of the population does not achieve adequate vitamin C status, even as defined
by the current recommendations. Increasing the recommended intake to levels more in line with our
current understanding of optimal status will further increase the gap between actual intakes and what
is regarded as being compatible with optimal health. This might increase the motivation to optimize
vitamin C intake either by food fortification or the use of supplements.
7. Conclusions
In light of the many functions that vitamin C has in the body, a range of putative biomarkers
were proposed, but they have been rejected due to shortcomings such as lack of specificity (See above).
Up to now, no functional biomarker was identified that could be used as a basis to define the dietary
intake recommendations for vitamin C. Even though scientific bodies such as IoM argued that such
an indicator is needed when they revised their recommendations, they concluded that none have
been identified yet [1]. Based on the findings of an in vitro [3] and a human intervention study [4], we
propose to investigate further neutrophil motility as such a functional marker.
Combined with the established knowledge from pharmacokinetic, observational, and intervention
studies, they indicate that current recommended intakes are set too low and that an increase to
≥200 mg/day would be beneficial for the functioning of the immune system. The importance of
vitamin C for the immune system was also recognized by the EFSA Panel on Dietetic Products,
Nutrition, and Allergies by granting the health claim that vitamin C contributes to a normal function
of the immune system [127]. Moreover, such intakes are sufficient to keep plasma vitamin C levels at
>70 μmol/L—the range which is associated with plasma saturation [45], but also with reduced risk of
CVD [74].
Further well-designed studies in humans are needed to validate neutrophil motility as a functional
marker of vitamin C sufficiency and immune function. Moreover, existing questions on the essentiality
of adequate vitamin C intakes in the prevention of a range of non-communicable diseases such as
CVD, but also cancer and dementia, need to be resolved. This requires large prospective cohort
studies, but also randomized controlled trials in participants with low baseline plasma vitamin C
levels. In addition to the general population, studies should also address sub-populations, which
might have elevated needs due to their genotype or other characteristics, such as obesity, smoking, or
increased physical activity.
Even though ≥200 mg/day vitamin C could be achieved via a balanced diet in line with the
guidelines for the prevention of non-communicable diseases, significant proportions of the population
do not achieve even the current recommendations. Consequently, methods need to be found to increase
vitamin C intake in the general population—ideally via increased intakes of fruits and vegetables,
given the benefits of such foods beyond their vitamin C content. However, as changing people’s food
habits is notoriously difficult, fortified foods or supplements might provide a more realistic solution at
least in the short term.
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